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Neuronal ceroid lipofuscinoses (NCLs; Batten disease) are a group of thirteen genetically 
heterogenous lysosomal storage diseases that, collectively, are the most common cause of 
fatal neurodegeneration in children. CLN6 Batten disease (CLN6 BD), also known as Lake-
Cavanagh disease, is a late infantile onset variant of the NCLs caused by loss-of-function 
mutations in the CLN6 gene. Mutations in both alleles of the gene result in classic NCL 
symptoms – blindness, epilepsy and progressive cognitive and motor decline – as well as 
characteristic pathophysiological features such as premature and accelerated neuronal cell 
death, chronic neuroinflammation and the intracellular accumulation of autofluorescent 
storage material in lysosomes. As a monogenic, inherited and fatal disorder, CLN6 BD is an 
excellent candidate for experimental gene therapy.  
Several preclinical and clinical trials of gene therapy have been conducted for a range 
of genetic disorders, including several NCL variants, and these have shown promising results. 
Subsequently, a clinical phase I/II CLN6 BD trial was initiated by the Gray Foundation and 
Amicus Therapeutics in 2016. This trial, which is ongoing at the time of writing, has produced 
optimistic safety and tolerance interim data. But, past experience with clinical gene therapy 
trials for several other genetic and metabolic disorders suggests that any improvements will 
not be curative. For this reason, the Gray Foundation began to investigate complementary 
treatments that might augment the therapeutic efficacy of gene therapy in CLN6 BD.  
This project used a naturally occurring murine model of CLN6 BD (the Cln6nclf mouse) 
to investigate the efficacy of two small molecule (drug) therapies – gemfibrozil and 
cannabidiol (CBD) – alone and in combination with adenovirus associated virus (AAV2/9)-
mediated gene therapy, as protection against the CLN6 behavioural phenotype. Specifically, 
Cln6nclf and C57Bl/6 (control) mice received a unilateral intracerebroventricular (i.c.v) injection 
 iv 
of gene therapy (an AAV2/9 vector expressing hCLN6 under the control of a chicken β-actin 
gene promoter) or saline (1x PBS) on post-natal days 0-2. Post-weaning, mice were dosed 
orally (every second day) with either gemfibrozil, CBD, a combination of the two drug 
therapies or a vehicle solution. Behavioural testing (ataxia phenotyping and rotarod 
performance) was conducted at 6, 9 and 12 months of age.  
Testing of over 500 animals determined that the oral administration of gemfibrozil, 
CBD, or a combination of the two drugs did not make any consistently significant 
improvements to untreated or gene-therapy treated Cln6nclf mouse behaviour. The study was 
successful, however, in reaffirming the apparent efficacy of i.c.v gene therapy in protecting 
against CLN6 BD behaviour in Cln6nclf mice (of both sexes), with no significant reduction in 
behavioural scores, when compared to healthy controls. 
This study represents the first long-term, large-scale preclinical study of this particular 
combination of therapies for CLN6 BD. It provides a solid foundation for further work 
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Note on Gene and Protein Nomenclature 
 
Human (or sheep) DNA or mRNA e.g. CLN6 
Mouse DNA or mRNA e.g. Cln6 
Human or Mouse (or sheep) protein e.g. CLN6 
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Chapter 1: Introduction 
 
1.1 Overview  
 
The neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of fatal 
neurodegenerative lysosomal storage disorders, with fourteen genetic variants identified to 
date. While each variant on its own is rare, collectively the NCLs represent the most common 
paediatric neurodegenerative disorders in the world (Williams, 2011). Almost all NCLs are 
inherited in an autosomal recessive Mendelian manner and are caused by one or more 
mutations in several different genes of known and unknown function, sometimes referred to 
as the ceroid lipofuscinosis genes (CLN1 through 14, with CLN9 predicted but not yet 
identified) (Mole & Cotman, 2015; Schulz et al., 2004). Although the NCLs are primarily 
regarded as a family of childhood disorders, age of onset ranges from congenital (‘at-birth’) 
through to early adulthood (known as ‘Kuf’s disease’)(Kufs, 1925).  
Clinical symptoms can differ between types of NCL but usually include progressive 
psychomotor degeneration, loss of vision (‘amaurosis’), myoclonic seizures, personality 
changes and dementia. Prognosis can vary from months to years, but all of the NCLs are 
currently considered incurable, chronic in nature and nearly always result in the premature 
death of the patient (Nita et al., 2016; Rider et al., 1988).  
While they vary in many aspects of pathophysiology, including genetic basis, age of 
onset, symptoms and rate of disease progression, all NCLs are characterised by three classical 
features: (1) the progressive loss of post-mitotic cells in the central nervous system (CNS), 
which leads to atrophy in the cerebral and cerebellar cortices, (2) neuroinflammation, and (3) 
the lysosomal accumulation of autofluorescent storage material within neurons (Cooper et 
al., 2015 Nelvagal et al., 2019; Palmer et al., 2013). The relationship between these features, 
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particularly as to whether one causes or is the result of the others, remains an area of ongoing 
enquiry.  
Mutations in the CLN6 gene result in a variant late infantile NCL (vLINCL) phenotype, 
sometimes referred to as Lake-Cavanagh or CLN6 Batten disease (BD). Until recently, the 
function of the CLN6 protein was essentially uncharacterised, though it was known to localise 
in the endoplasmic reticulum (ER) and to have a multi-pass transmembrane structure (Alroy 
et al., 2011; Gao et al., 2002; Wheeler et al., 2002). It is now believed to play a role in a multi-
protein complex responsible for the transportation of several lysosomal enzymes from their 
place of synthesis, within the ER, to their place of function, within the lysosome (Bajaj et al., 
2019). Children with mutations in both CLN6 alleles start presenting with vLINCL symptoms in 
early childhood, around 4 to 5 years of age, and disease progression is relatively swift, with 
death invariably occurring in early to late teens (Alroy et al., 2011).  
Monogenic, inherited, fatal disorders like CLN6 BD present as the perfect subject for 
an experimental treatment known as viral vector-mediated gene therapy (gene therapy). This 
practical compatibility, combined with the support of a parent-based charity called the Gray 
Foundation, motivated a 2016 phase 1/2 clinical trial in Nationwide Ohio’s Children’s Hospital 
(Trial No. NCT02725580, Clinicaltrials.gov 2016). The trial included 13 children, all diagnosed 
with CLN6 BD, and involved the intrathecal (‘spinal canal’) injection of a viral vector carrying a 
healthy copy of the human CLN6 gene into the lumbar (‘lower back’) spinal cord region. This 
trial, which remains ongoing, was the first of its kind and has already yielded promising interim 




 “These interim clinical data suggest that our gene therapy in CLN6 
Batten disease has the potential to halt the progression of this 
devastating fatal disease that, untreated, destroys brain function and 
kills children….It is remarkable that most children in this study appear 
to show stabilisation, particularly the younger children who were able 
to maintain high baseline motor and language scores for up to two 
years.”  
   - John Crawley from Amicus Therapeutics, 2019 
Despite this optimistic press-release, and the evidence that this experimental therapy 
was generally well tolerated by patients, the 2016 trial is unlikely to produce a cure. 
Participants who were treated post-symptom onset still appear to be declining, though 
whether this decline is slower than it would be without the treatment has yet to be 
determined. With this in mind, the Gray Foundation enlisted the Hughes lab in early 2018 to 
carry out a large-scale, pre-clinical trial in a naturally occurring mouse model of CLN6 BD to 
mirror the gene therapy used in the children in 2016 and to assess whether the use of two 
different small molecule therapies, alone and in combination with gene therapy and each 
other, had any synergistic effect on the CLN6 BD phenotype. This trial, involving over 540 mice 
and almost two years of work, forms the basis of this thesis. 
1.2 History of the Neuronal Ceroid Lipofuscinoses (NCLs; 
Batten disease) 
 
The early history of paediatric neurodegenerative diseases, including the NCLs, is that there is 
very little early history of paediatric neurodegenerative disease. Unlike other well-known 
diseases, such as cancer or tuberculosis, which have references in medical literature dating 
back to the invention of written language, the concept of neurodegeneration as a nosological 
classification, especially in children, is relatively new to medicine (Breasted, 1930; Cave & 
Demonstrator, 1939; Morse et al., 1964). Prior to the 19th century, western literature tended 
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to categorise many of the behavioural symptoms of neurodegeneration, such as dementia, 
chorea and epilepsy, as signs of broad medico-social conditions like ‘madness’, ‘simpleness’ 
and ‘feeble-mindedness’. It is also likely that the premature death of children affected by 
neurodegenerative diseases like the NCLs would have gone predominantly unnoticed due to 
generalised high infant mortality rates prior to the industrial revolution and modern medicine 
(Jennekens, 2014; Kanner, 1962; Kauffman, 1976).  
Over the past two centuries our medical, social and cultural interpretations of the NCLs 
have evolved rapidly, primarily dictated by our increasing understanding of the biological basis 
of heredity and a variety of neurodegenerative and metabolic illnesses. The narrative of the 
NCLs has been closely intertwined with other inherited neurodegenerative disorders, such as 
Tay-Sachs’ and Niemann-Pick’s disease (Sachs, 1896; Wyburn-Mason, 1943a, 1943b). This 
section briefly touches upon this evolution through three main eras, each determined by the 
technological resources available to NCL researchers at the time.  
1.2.1 The Amaurotic Familial Idiocies (AFIs): an era of clinical description 
and categorisation 
  
The earliest tools used to study the NCLs, as is the case with most diseases, were detailed 
descriptions of clinical symptoms and gross pathology at autopsy. While they are often 
referred to as ‘Batten disease’, after the British neurologist Frederick Batten who described 
one form of the disease in 1906, the first clinical description of the NCLs is actually believed to 
have been written by a rural Norwegian physician, Dr. Otto Christian Stengel, in 1826 (Batten, 
1902; Stengel, 1826). Stengel’s report describes the development of a mysterious disease in 
four siblings, born to two apparently healthy parents. In all four cases, this disease began with 
vision impairment around the age of six and quickly progressed into loss of mental and 
physical faculties, epileptic fits and “mania” (Stengel, 1826).  
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His report, written originally in Norwegian, went largely unnoticed by the International 
medical community until over a century later, when it was translated into English by A. J. 
Nissen, and the ‘singular disease’ Stengel described was recognised to be compatible with 
what is now known as CLN3 Batten disease, or classical juvenile neuronal ceroid lipofuscinosis 
(Nissen, 1954).  
Despite Stengel’s work being overlooked, the NCLs started to gain academic attention 
through other observations, namely those of British ophthalmologist Warren Tay and 
American neurologist Bernard Sachs. During his presidential address to the New York 
Neurological Society in 1896, Sachs presented the concept of ‘amaurotic familial idiocy’ (AFI) 
– a fatal disorder comprising of progressive vision loss and ‘regression’ of mental and physical 
development that he had observed in two infant siblings, four years apart. Their almost 
identical disease progressions led him to recognise the “family character” of the disease and 
during his assessments of the children he discovered both siblings to possess a rare ocular 
manifestation, a ‘brownish-red, fairly circular spot’ within a larger white disc on the retina of 
both eyes (Figure 1.1), identical to the one that had been characterised in 1881 by Tay (Sachs, 




Figure 1.1 ⎸Tay-Sachs ‘cherry red’ spot. Fundus photographs showing the characteristic ‘cherry-red spot’ 
of Tay-Sachs disease. Originally described by ophthalmologist Warren Tay in 1881 and used as 
inclusion criteria for the amaurotic familial idiocies (AFIs) by Bernard Sachs. Image taken from a case 
report by Aragão et al., 2009. 
Sach’s proposed AFI category expanded during the turn of the 20th century, thanks to 
a number of clinical descriptions of other familial cases of progressive childhood dementia and 
vision loss by British, German and Czech authors (Batten, 1902; Batten & Mayou, 1915; 
Bielschowsky, 1914; Jansky, 1909; Spielmeyer, 1905; Vogt, 1905). Similarities in post-mortem 
pathology also began to be recorded, with granular, ‘lipid-like’ material being found in neurons 
of deceased patients. The biochemical basis of these deposits wouldn’t be determined until 
much later in the century, but it was frequently referred to as ‘lipofuscin’ (meaning ‘dark fat’) 
or ‘ceroid’ (Hueck, 1912).  
Unlike the original Tay-Sachs descriptions, many of these new cases demonstrated 
later onset (post-infancy), varying symptomology and showed little consistency in terms of 
patient ethnicity (the original cases described by Sachs were from Ashkenazi Jewish 
families)(Sachs, 1896).  
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1.2.2 The Neuronal Ceroid Lipofuscinoses (NCLs): an era of 
biochemistry and ultrastructure 
By the 1950s a precarious and conflicted classification system had been developed for the 
AFIs, based primarily on clinical accounts of age of onset, and consisted, depending on who 
you asked, of five categories or variants of AFI: congenital, infantile, late infantile, juvenile and 
adult (Sandifier, 1959; Zeman & Hoffman, 1962). There was a lot of debate between 
researchers as to whether these diseases were all variants of a single genetic disease, differing 
only in intensity and age of onset, or if they were separate, albeit similar, metabolic disorders 
(Sandifier, 1959; Wyburn-Mason, 1943a, 1943b; Wolfgang, Zeman & Hoffman, 1962).  
In order to bring clarity to a field weighed down by inconsistencies and uncertainty, 
the researchers Wolfgang Zeman and Paul Dyken proposed a new classification system in 
1969, based on recent biochemical and ultrastructural observations that divided the AFIs into 
two distinct groups: Tay-Sachs disease and the NCLs (Zeman & Dyken, 1969).  
The NCLs, however, remained difficult to define – even with the help of new 
techniques and technologies - and were referred to by Zeman and Dyken as a “collection of 
heterogeneous entities” that could be “characterised by autosomal recessive inheritance, 
progressive failure of vision, intellectual faculties and motor function, and recurrent seizures,” 
as well as “more variable age of onset and the presence of retinal abnormalities other than 
the ‘cherry red spot’” (Zeman & Dyken, 1969).  
This overarching category encompassed the late infantile, juvenile and adult forms of 
the AFIs, all of which could be histologically and ultrastructurally differentiated from Tay-Sachs 
(and other gangliosidoses) due to a normal sphingolipid (aka ganglioside) profile and the 
presence of intraneural autofluorescent storage material. The biochemical character of the 
storage material still remained elusive, though it resembled the build-up of the ‘lipopigment’ 
 8 
aka ‘lipofuscin’ aka ‘ceroid’ (coloured fat) associated with natural ageing processes, from 
which the NCLs got their name (Endicott & Lillie, 1944; Lillie et al., 1941; Seehafer & Pearce, 
2006). Late infantile NCL (LINCL) cases showed characteristic ‘curvilinear’ (curved line) 
patterns of this storage material (Figure 1.2.B), when examined by electron microscope, while 
the juvenile form could be distinguished by its predominantly ‘fingerprint-like’ patterns 
(Figure 1.2.C) (Mole & Haltia, 2014). Almost five years after the establishment of the NCL 
category, a new, infantile, type of NCL was described by Haltia (1973a; 1973b) and Santavuori 
(1973), histologically characterised by the presence of storage material with a finely granular 
structure (‘granular osmophilic deposits’ or GRODs; Figure 1.2.A).  
 
Figure 1.2 ⎸The four forms of NCL intraneural storage deposits. Electron microscopy helped researchers 
elicit the ultrastructures of abnormal intraneural deposits that had been observed in nervous tissue at 
autopsy of NCL patients. Four types were identified: (A) granular osmiophilic deposits (GRODS), now 
associated with CLN1 BD, 310,000x; (B) curvilinear profiles typical of classic late infantile neuronal 
ceroid-lipofuscinosis or CLN2, 320,000x; (C) ‘fingerprint bodies’ are the primary form of intraneuronal 
inclusions in the juvenile form of NCL or CLN3, 330,000x; and (D) many inclusions in the variant forms 
of late infantile neuronal ceroid-lipofuscinosis correspond to the rectilinear complex, such as CLN5 
and CLN6, 315,000x. Image modified from Haltia, 2003.  
By the end of the 70s, there were, according to Zeman, four ‘official’ NCL variants: 
infantile (aka INCL or ‘Haltia-Santavuori disease’), late infantile (LINCL or ‘Jansky-Bielschowsky 
disease’), juvenile (JNCL or ‘Spielmeyer-Sjogren disease’) and adult (‘Kuf’s 
disease’)(Bielschowsky, 1914; Haltia, Rapola, & Santavuori, 1973; Jansky, 1909; Kufs, 1925; 
Santavuori et al., 1973; Spielmeyer, 1905; Zeman, 1976). A canine form had also been 
reported in English Setter dogs (Koppang, 1992; Koppang, 1969). Despite Zeman’s best efforts, 
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however, the NCL’s continued to defy neat categorisation, and a spectrum of ‘atypical’ cases 
began to be reported in the 80s and 90s. Some of these were named after the geological areas 
in which they were found, e.g. the ‘Finnish’, ‘Indian’ or ‘Turkish’ NCLs (Elleder et al., 1997; Lake 
& Cavanagh, 1978; Santavuori et al., 1991, 1982; Tyynelä et al., 1997; Williams et al., 1999), 
while others appeared to display an autosomal dominant inheritance pattern at odds with the 
traditionally ‘autosomal recessive’ inheritance that many had come to associate with the NCLs 
(Boehme et al., 1971; Nijssen et al., 2006; Nosková et al., 2011; Sjögren, 1931). Additionally, a 
multitude of naturally-occurring NCL animal models had been discovered, including cats 
(Green & Little, 1974), sheep (Jolly & West, 1976), cattle (Read & Bridges, 1969) and goats 
(Fiske & Storts, 1988).  
It was, ultimately, the use of a series of elegant biochemical assays that restored a little 
order to the chaotic field of NCL research when, in the late 1980s, Palmer et al., (1988) finally 
characterised the storage material found within the neurons of a South Hampshire sheep NCL 
model. Due to their ‘fatty’ appearance, previous studies had focused, unsuccessfully, on 
identifying a lipid or lipid-like substance. Palmer et al., however, found that the major 
component (two-thirds) of storage material isolated from the ovine tissue to be a low-
molecular-weight protein and, only three years later, determined this protein to be subunit C 





Figure 1.3 ⎸Subunit C of the mitochondrial ATP synthase. The major protein component of most forms 
of storage material found in the NCLs is subunit c of the mitochondrial ATP synthase. ATP synthases 
are large, transmembrane protein complexs responsible for the creation of the energy storage 
molecule adenosine triphosphate (ATP). While they can be located all over the cell, the majority are 
found embedded in the inner membranes of the cell’s mitochondria, where they act as the fifth and 
final component of the electron transport chain. Image made by author using BioRender.com.  
This mitochondrial protein turned out to be the primary component of storage 
material in most forms of human and animal NCLs, with the key exception of infantile human 
NCL (INCL) (Tyynelä et al., 1993). The storage material in this particular variant was 
determined to be a combination of sphingolipid activator proteins (saposins) A and D, and was 
later found to also be present in a few rare animal models (congenital ovine and the miniature 
schnauzer model), as well as an adult human NCL variant known as Parry disease (Nijssen et 
al., 2006; Palmer et al., 1997). Saposin storage material produced the GROD ultrastructure 
originally observed by Haltia and Santavuori in the 70s (Figure 1.2.A), while subunit C 
appeared to produce a wide variety of ultrastructures including the curvilinear and fingerprint 
patterns associated with the late infantile and juvenile forms of NCL (Mole et al., 2011).  
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1.2.3 Lysosomal genes, lysosomal storage diseases (LSDs): an era of 
genetics  
Around the same time that Zeman and Dyken first differentiated the NCLs from gangliosidoses 
like Tay-Sachs disease, another category of disease was beginning to appear in the medical 
lexicon: lysosomal storage diseases (LSDs). The lysosome, from which the LSDs get their name, 
had only been discovered by Belgian cytologist Christian de Duve ten years earlier, in the mid-
to-late 1950s. Through a series of cell fractionation studies and biochemical techniques, de 
Duve and his collaborators had come to recognise that every cell in the human body possessed 
a group of membrane-bound organelles that contained highly acidic enzymes (Appelmans & 
De Duve, 1955; Appelmans et al., 1955; Berthet & De Duve, 1951; De Duve et al., 1955; 
Gianetto & De Duve, 1955). These organelles, named ‘lysosomes’, were characterised as the 
waste management and recycling centres of the cell and it was their dysfunction, or that of 
the hydrolysing enzymes they contained, that came to be seen as the uniting feature of LSDs 
(Hers, 1965). The relationship between this newly-established group of metabolic disorders 
and the NCLs wouldn’t become clear, however, until the mid to late 90s, driven by the genetic 
revolution and the consequent genetic and functional identification of the first NCL proteins. 
The era of NCL genetics really began when, in 1989, Eiberg et al. released a study 
linking the mutated protein responsible for JNCL to the haptoglobin locus on the long arm of 
chromosome 16. This was followed, in relatively quick succession, by Vesa et al. (1995) using 
a combination of positional cloning and fluorescent in-situ hybridisation genetic techniques to 
confirm the identity of the first NCL-causing gene. They found that INCL, as described by Haltia 
and Santavuori, was caused by a mutation in the palmitoyl-protein thioesterase (PPT1) gene, 
which encodes a lysosomal hydrolase enzyme (Vesa et al., 1995). This discovery, while an 
exciting use of new genetic technologies and techniques in itself, contributed further layers of 
complexity to the study of an already exceedingly complicated group of diseases and raised 
 12 
the question of whether these disorders needed to be recategorized, again, as LSDs. The 
argument for recategorization was compounded by the further discovery, using a biochemical 
approach, of another lysosomal enzyme, tripeptidyl peptidase 1, as being responsible for the 
LINCL variant (Sleat et al., 1997).  
The following five years saw the genes underlying five different NCL variants cloned, 
with some determined to be soluble enzymes and others transmembrane in structure. The 
location and function of these newly discovered proteins wasn’t necessarily evident at the 
time, with some still remaining unidentified today, but their identification lead to the 
introduction of a new genetic classification for the NCLs – one that has remained in use for 
the past decade. At the time of this publication, human NCLs are currently classified into 
fourteen genetic forms from CLN1 through to CLN14 (with CLN9 predicted but not yet 
identified)(see Table 1.1).  
While not all of the currently identified CLN genes encode lysosomal enzymes, many (if 
not all), are associated with the larger endosomal-autophagic-lysosomal network (Bennett & 
Hofmann, 1999). The role of the lysosome and its associated pathways has proven to be more 
complex than initially realised (Walkley, 2007). Due to our ever-growing knowledge about the 
function and roles of the lysosome, the lysosomal storage disorder category has had its 
qualifying parameters expanded since its introduction in the 1960s to encompass proteins 
involved further afield than just the intraluminal lysosomal compartment itself (Hers, 1965). 
This has allowed the NCLs to be comfortably classified as LSDs and join the ranks of a 
heterogeneous group of over 50 genetically-distinct metabolic diseases (Bennet & Hofmann, 
1999).  
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Table 1.1 ⎸Summary table of human NCL variants, based on a genetic classification system. Clinical phenotype: * indicates the disease phenotype experienced by complete 
loss of function of the related gene, while bolded phenotypes are non-NCL disorders that can be caused by mutations in the same gene. Most of the information for this table 
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CLN13 NA - CLN13/CTSF 11q13.2 11 (as of 2017) 
Ceroid-lipofuscinosis 
neuronal protein 13 Soluble Lysosomal Adult (Kufs, type B) 
CLN14 NA - CLN14/KCTD7 7q11.21 1 (as of 2017) 
Potassium channel 
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SGSH NA - - - 2 (as of 2017) 
N-sulphoglucosamine 
sulphohydrolase Soluble Lysosomal 
Adult, late infantile 
MPSIIIA 
 
Table 1.1 ⎸Summary table of human NCL variants, based on a genetic classification system. Clinical phenotype: * indicates the disease phenotype experienced by complete 
loss of function of the related gene, while bolded phenotypes are non-NCL disorders that can be caused by mutations in the same gene. Most of the information for this table 
was taken from Mole & Cotman., 2015.  
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1.3 NCL genes and proteins  
 
Despite having similar, sometimes clinically indistinguishable, phenotypes, the era of genetics 
taught researchers and clinicians that the NCLs were a group of genetically distinct disorders, 
demonstrating a high degree of locus heterogeneity between variants, with 14 genes 
implicated in their pathology at time of publication. There are also currently families with NCL-
like syndromes which remain genetically undetermined (Mole & Cotman, 2015).  
All known NCL genes, often referred to as the ‘ceroid lipofuscinosis neuronal’ (CLN) 
genes, are located on autosomal chromosomes and, with two notable exceptions, are 
inherited in a Mendelian recessive manner. In 2011, Noskova et al. identified an autosomal 
dominant mutation in the DNAJ5 gene as the underlying cause of adult onset CLN4 Batten 
disease (Nosková et al., 2011). The only other example of non-recessive inheritance in the 
NCLs was an extremely rare instance of non-Mendelian uniparental disomy, in which the 
proband received only one copy of chromosome 8 from their mother, instead of a copy from 
each parent, and this chromosome replicated itself (‘complete isodisomy’) to form a 
homologous pair and, as a result, a homozygous mutation in the CLN8 gene (Vantaggiato et 
al., 2009).  
As previously mentioned, the majority of CLN genes have been found to encode 
proteins involved in the endosomal-autophagic-lysosomal compartment and secretory vesicle 
pathways – with the majority being either lysosomal enzymes involved in the intraluminal 
degradation of cellular waste (CLN1/PPT1, CLN2/TPP1, CLN5, CLN10/CTSD and CLN13/CTSF) 
or lysosomal transmembrane proteins (CLN3, CLN7, and CLN13). CLN6 and CLN8, however, 
localise to the endoplasmic reticulum (ER), while progranulin (CLN11/GRN) is found in the 
lumen of secretory vesicles. CLN4 and CLN14 are cytoplasmic proteins and are peripherally 
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associated with cellular/vesicular membranes. CLN9 has been hypothesised but not yet 
identified (Mole & Cotman, 2015; Schulz et al., 2004).  
Our understanding of the gene-protein relationship that underpins each variant of NCL 
is critically important when it comes to potential treatment strategies, as is our understanding 
of the functions and structures of NCL proteins under both physiological and pathological 
conditions. The NCL forms caused by enzyme dysfunction or deficiency, for example, are 
excellent candidates for enzyme replacement therapies (see section 1.6.1), whereas the 
variants caused by mutations in transmembrane or uncharacterised proteins prove to be less 
compatible with such approaches and thus provide unique therapeutic challenges.  
To further complicate the development of effective treatment strategies, each variant 
of the NCL appears to demonstrate some degree of allelic heterogeneity. This can result in 
varying ages of onset, in disease severity, and disease progression between patients with 
different mutations in the same gene. There are also known cases of mutations in different 
CLN genes causing clinically similar phenotypes (mutations in CLN5, CLN6, CLN7 and CLN8 have 
all been known to cause late infantile onset)(Mole & Cotman, 2015). Finally, there are also 
several instances of mutations within the CLN genes giving rise to non-NCL diseases (Table 
1.1). This non-linear and, at times, unpredictable genotype-phenotype relationship can make 
differential diagnosis difficult and may complicate potential future therapies by delaying the 
start of treatment, which may have serious consequences – as preclinical data have shown 





1.4 Animal models 
 
The study of disease mechanisms and potential therapeutics for diseases as complex as the 
NCLs wouldn’t be possible without readily available animal models. Fortunately, the NCLs lend 
themselves to model systems, with the CLN genes being highly conserved across mammalian 
species, and translational studies using both naturally occurring and genetically engineered 
forms of NCLs in animals have been at the core of NCL research for many decades (Cooper, 
2003). The use of animal models has allowed researchers to move beyond the post-mortem 
snapshot of human autopsy and given them access to any tissue, at any time-point, from early 
stages of development until death. Beyond this, behavioural assays of well-characterised 
animal models allow for efficacy studies of potential therapeutics in a controlled, closed 
system that wouldn’t be possible with human patients.  
In order to be established as a tool to study a human NCL variant, each animal model 
needs to, at a minimum, exhibit the three key pathological NCL phenotypes: (1) progressive 
neurodegeneration, (2) neuroinflammation, and (3) the presence of intraneural, 
autofluorescent storage material. Today, there are a variety of different model organisms that 
have been designed to or naturally meet these criteria for each form of NCL – including several 
non-vertebrates – and each has its own advantages and disadvantages (Phillips et al., 2006). 
This section will only cover vertebrates used for NCL research, as only these models can be 
used for the type of preclinical research that makes up the practical component of this thesis.  
1.4.1 Small animal models 
Rodents, specifically mice (Mus musculus) and rats (Rattus norvegicus domestica), have been 
the preferred animal model in many of the life sciences for over a century. Murine (mouse) 
models in particular have played a key role in translational NCL research. They have proven to 
 18 
be excellent research tools due to their availability, relatively low cost, ease of use and 
manipulation, and rapid reproductive cycle. Inbred strains of rodents are particularly useful 
when studying genetic disorders such as the NCLs, as they are bred to be genetically identical 
and this reduces variability in genotype and phenotype (Cooper, 2003; Fox et al., 2006). The 
most successful murine models used in NCL research today are those that demonstrate these 
qualities along with analogous symptoms, age of disease onset and rate of disease progression 
as their human counterparts – scaled, of course, due to the fact that healthy mice have 
considerably shorter lifespans than humans (see section 1.7.4).   
Today, there are eighteen murine strains available to researchers, summarised in Table 
1.2, which model the CLN1 (x2), CLN2 (x2), CLN3 (x4), CLN5 (x1), CLN6 (x1), CLN8 (x1), and 
CLN10 (x1) variants, along with a series of ‘NCL-like’ syndromes (x7)(Eliason et al., 2007; Gao 
et al., 2002; Glascock et al., 2011b; Gupta et al., 2001; Jalanko et al., 2005; Katz et al., 1999; 
Mitchison et al., 1999; Mole, 2018; Morgan et al., 2013; Sleat et al., 2004; Wheeler et al., 
2002). Murine models can either be genetically engineered (as is the case with the CLN1, CLN2, 
CLN3, CLN10 and NCL-like syndrome models) or be ‘naturally occurring’ (as the CLN6 and CLN8 
models are) (Bronson et al., 1999; Messer & Flaherty, 1986; Ranta et al., 1999; Wheeler et al., 
2002). Genetically engineered NCL mice have been made using a selectable marker (Gupta et 
al., 2001; Katz et al., 1999; Kopra et al., 2004) or cre-lox technology (Cotman et al., 2002). The 
majority of the NCL murine models used today have been bred or engineered from a small 
subset of mouse strains, including the Jackson Laboratory’s C57 Black 6 (C57Bl/6) mouse, 





Table 1.2 ⎸Summary table of currently available NCL mouse models. 
Form of NCL Mouse Model Creation method Reference 
CLN1 Ppt1
∆ex4 Targetted deletion via cre/lox technology Jalanko et al., 2005 




point mutation via 
cre/lox technology 




mutation via cre/lox 
and flipase-mediated 
excision of a neo 
cassette  
Geraets et al., 2017 
CLN3 
Cln3∆ex1-6 Mutation knock-in Mitchison et al., 1999 
Cln3∆ex7/8 Mutation knock-in Cotman et al., 2002 
Cln3∆ex7/8neo Neo cassette deletion Katz et al., 1999 
Cln3lacZ/lacZ lacZ knock-in Eliason et al., 2007 
CLN5 Cln5-/- Neo cassette deletion Kopra et al., 2004 
CLN6 Cln6nclf aka ‘nclf’ Naturally occurring Bronson et al., 1998 
CLN7 Msfd8(tma1) lacZ knock-in Damme et al., 2014 
CLN8 Cln8mnd aka ‘mnd’ Naturally occuring Bronson et al., 1993 and Chang et al., 1994 
CLN10 Ctsd-/- Neo cassette deletion Partanen et al., 2003 
NCL-like syndromes 
Clcn3-/- Cln3 replacement vector Dickerson et al., 2002 
Clcn6 Knockout cassette Poët et al., 2006 
Clcn7-/- Knockout cassette Kornak et al., 2001 
Grey lethal (gl) Naturally occuring Chalhoub et al., 2003 
ctsf Neo cassette deletion Tang et al., 2006. 
Ctsb/l Neo cassette deletion Roth et al., 2000. 
 
While less common in NCL research, the tropical zebrafish (Danio rerio) has also been 
known to lend itself to the study of human health and disease. Zebrafish have been utilised 
by several research groups looking into fundamental biology of the NCLs, as well as the 
potential of experimental therapeutics such as gene therapy and/or CRISPR-Cas technology 
(Russell & Mahmood, 2011; Wlodawer et al., 2003). Genetically, several zebrafish genes have 
been discovered to be homologous with all currently identified human CLN genes, though the 
fact that the zebrafish genome underwent duplication during teleost evolution (reviewed in 
Blomme et al., 2006) means that some CLN genes have more than one potential orthologue, 
such as CLN4/DNAJC5, CLN6 and CLN7/MFSD8. Whether all these candidate zebrafish genes 
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are ‘true’ orthologues, or now have an unrelated subspecialisation, is an area of ongoing 
investigation (Bond et al., 2013).  
The major advantages of zebrafish models pertain mostly to their well-characterised 
CNS and their ability to produce large numbers of offspring via external fertilization, allowing 
for manipulation to occur at any point from fertilization onwards (Bond et al., 2013; Schmid & 
Haass, 2013; Wang et al., 2007). Their young also develop in clear, external embryonic sacs – 
allowing for observation of key phases of prenatal development. These are some of the factors 
that make zebrafish excellent tools for fast, high-throughput experiments, such as drug 
discovery or toxicity assays (Kalueff et al., 2014) and an interesting candidate model organism 
for NCL work relating to prenatal pathologies.  
1.4.2 Large animal models 
While not as common in NCL studies, the use of large animals, defined as any non-rodent 
mammal used in research, offers distinct advantages over smaller animal models – primarily 
due to their closer mimicry of human NCL pathology and anatomical similarities (Casal & 
Haskins, 2006). Rodents, for example, have lissencephalic brains – that is, they lack the folds 
(gyri and sulci) present in the human cortex – and this, along with the obvious disparity in 
brain size and brain-to-body ratio, may account for many of the behavioural and 
histopathological differences observed between the mouse and human forms of NCL . Larger 
animals offer researchers a bridge between NCL studies conducted in rodents and fish and 
clinical trials in humans, due to their larger gyrencephalic brains, more complex body systems 
and ability to recapitulate a larger spectrum of the NCL symptoms experienced by human 
patients.  
The use of large animals in NCL research has also provided access to a wide range of 
naturally occurring, directly orthologous NCL variant models. This makes them a precious 
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resource considering there are only two naturally occurring murine models – Cln6nclf (CLN6 
BD) and mnd (CLN8 BD) mice – and that zebrafish models are somewhat complicated by a 
series of unique evolutionary diversification events. The use of naturally occurring NCL models 
is arguably preferable to bioengineered ones, in that they are less expensive and time-
consuming to produce, circumvent ethical issues related to the creation of transgenic 
organisms and are often less likely to display symptoms or side-effects unrelated to the human 
NCL pathology they are modelling. A variety of naturally-occurring NCL models have been 
discovered in sheep (CLN5, CLN6, and CLN10), dogs (CLN1, CLN2, CLN6, CLN8, and CLN10), 
cattle (CLN5), and non-human primates (CLN7), and several NCL-like syndromes have been 
described in cats and goats, though the genetic basis of these have yet to be identified (Awano 
et al., 2006; Cook et al., 2002; Houweling et al., 2006; Jolly & West, 1976; Katz et al., 2005; 
Koppang, 1992; Melville et al., 2005; Chalkley et al., 2014). Alongside these, a transgenic CLN3 
porcine (pig) model was characterised for the first time in mid-2019 (Johnson & Sturdevant, 










1.5 Proposed mechanism(s) of disease for the NCLs 
 
In order to determine the where, when and how of potential new NCL therapies, it is critical 
for researchers to better define disease onset and progression. The work that has done so far 
points to the fact that, despite these diseases having similar key features and phenotypes to 
each other and other LSDs, the mechanisms by which these are reached are probably quite 
different between variants (Palmer et al., 2013).  
This section contains an overview of the work that has been done across the NCLs to 
characterise their similarities and elicit their pathophysiological differences and its purpose is 
to better contextualise the therapies under investigation in this thesis’ practical component. 
It should be noted that this is by no means a comprehensive discussion of the minutiae of NCL 
pathophysiology and, due to the many outstanding questions that remain areas of ongoing 
enquiry, the features discussed below are not presented in the clean, chronological order of 
events that one would desire when discussing the natural history of a disease. It is not 
possible, at this stage, to move from mutated gene to mutated protein to affected cell 
pathway to the multitude of characteristic phenotypes associated with the NCLs, so instead 
aspects of pathophysiology will be presented as isolated vignettes, and discussion will focus 
on what we know so far, and how we know it. This approach is intended to provide a solid 
biological background for later sections on potential therapeutics for the NCLs in general and, 
more specifically, the therapies chosen for investigation in this thesis. 
1.5.1 The pronounced vulnerability of the CNS to NCL pathology  
The NCLs are, indisputably, neurological disorders. Despite the CLN proteins being 
ubiquitously expressed in of the cells in the human body, it is, invariably, the progressive, 
accelerated loss of neurons that results in the spectrum of debilitating symptoms and 
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premature deaths of NCL patients (Autti et al., 1992; Jadav et al., 2014; Mitchison et al., 2004). 
Researchers remain uncertain why this particular population of cells demonstrates such 
vulnerability to the effects of mutated CLN genes compared to somatic cells, but some suggest 
it may be due to the post-mitotic nature of neurons and their limited capacity for renewal or 
replacement (Mitchison et al., 2004). Others suggest that the protein products of CLN genes 
may possess neuron-specific roles critical for the survival of these cells (Lehtovirta, 2001; 
Luiro, 2001). The PPT1 protein, for example, which was characterised as a lysosomal hydrolase 
in the 90s, was found to be targeted to the axons in neurons and to differ in size and 
modification from PPT1 extracted from fibroblasts (Ahtiainen et al., 2003; Heinonen et al., 
2000; Lyly et al., 2007).  
It is also possible that the endosomal-lysosomal pathway protein expression profile of 
neurons leaves them more vulnerable to errors in this pathway. For instance, neurons do not 
express cathepsin C, a lysosomal protease with compensatory activity related to that of CLN 
protein TPP1. This mean that, in the absence of TPP1 (CLN2), any substrates that TPP1 would 
normally cleave for lysosomal degradation in neural cells remain intact, building up in the 
brain’s lysosomes and potentially contributing to the progression of CLN2 BD. Non-neural 
tissue, in comparison, is spared due to the somatic expression of cathepsin C which has 
extensive activity on TPP1’s substrates and can compensate (Bernardini & Warburton, 2002).  
These theories are challenged, however, by the paradoxical relative expression levels 
of CLN proteins in neural tissue compared to the rest of the body. There appears to be no 
direct relationship between the expression levels of the NCL proteins and the extent of 
degradation experienced by cells in their absence, since many tissues and organs in the body 
express far higher levels of CLN proteins than neurons and appear to experience little, if any 
negative consequences from their absence (Palmer et al., 2013). That being said, it should not 
 24 
be assumed that these non-neural tissues are completely unaffected. Many demonstrate a 
build-up of storage material similar to that seen in nervous tissue, in fact NCL diagnoses 
traditionally rely on skin and rectal biopsies, and some animal NCL models have displayed 
extra-neural pathology such as splenomegaly (Brett & Lake, 1975; Cotman et al., 2002). It is 
possible that, given enough time, these tissues would also begin to experience deleterious 
effects from CLN mutations – perhaps the slowing or cure of neurodegeneration will result in 
the uncovering of further disease complications in other organs and cell groups (Rietdorf et 
al., 2019). 
1.5.2 Selective regional and neuronal loss within the CNS 
While neurodegeneration is a common feature across all variants of human NCL, the regional 
and temporal distribution of neural atrophy is highly heterogenous. Histopathological analysis 
of patients’ brains at autopsy have demonstrated that while cerebellar, cortical and 
hippocampal regions of the brain appear to be affected across the spectrum of NCL variants, 
there are markedly graded effects on neuronal survival in different regions of the brain. 
Animal models have been critical in studying these differences, though they are complicated 
by inter-species differences and the influence of strain background and mutation type on 
comparative studies.  
While initial studies focused on the cerebral cortex as the principal pathological target 
for the NCLs, investigations in several mouse NCL models (including CLN1, CLN8 and CLN10) 
have indicated that the loss of thalamic nuclei and relay neurons proceeds any cortical 
degeneration, identifying the thalamus as having a key, if still uncharacterised, role in the 
pathology of most types of NCL (Kielar et al., 2007; Kuronen, 2012; Partanen et al., 2008). 
These studies also confirmed previous observations of the apparently targeted degeneration 
of somatosensory regions with the brain. A recent study in ctsd mice, for example, found early 
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thalamic neurodegeneration to occur only in the ventroposterior medial and ventroposterior 
lateral (VPM/VPL) nuclei and not in neighbouring thalamic structures. The VPM/VPL nuclei are 
key components of the somatosensory system, responsible for receiving somatosensory 
information from lower brain centres and relaying it to higher cortical somatosensory regions. 
The fact that these particular nuclei were found to be singularly affected early in disease 
pathogenesis complements older studies in cadaver tissue and other animal models that 
indicated neuron loss occurs earlier and is far more pronounced in somatosensory regions of 
the cortical mantle than motor areas, as it is these regions that are directly connected to the 
VPM/VPL.  
However, these findings, like most aspects of NCL pathology, are not universal – with 
a study in the CLN5 BD mouse model indicating a cortical origin for neuron loss, which only 
subsequently occurs in the thalamus (von Schantz et al., 2009). This study echoes similar work 
done in the CLN6 South Hampshire sheep model (OCLN6), where characteristic NCL changes, 
like loss of GABAergic interneurons in the thalamus, were not seen until after changes in the 
neocortex and cerebral hemispheres had occurred (Oswald et al., 2001, 2005, 2008).  
1.5.3 Glial cell activation and neuroinflammation  
Neuroinflammation refers to the complex cellular and biochemical responses of the nervous 
system to trauma, infection or neurodegeneration. This innate immune response has been 
linked to many lysosomal storage and neurodegenerative diseases including Alzheimer’s 
disease (AD), Parkinson’s disease (PD) and the NCLs, though whether this response is 
protective or a contributing factor to disease progression has yet to be determined (W. W. 
Chen et al., 2016; Heneka et al., 2015; Hirsch et al., 2012). 
Glial cells within the CNS, particularly microglia, are responsible for maintaining tissue 
homeostasis and responding to pathological stimuli. As the resident immune cells, it is the 
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microglias role to survey the microenvironment in the brain and spinal cord and produce 
chemicals that influence the activity of neighbouring astrocytes (another type of glial cell) and 
neurons.  
Under normal, healthy circumstances, microglia and astrocytes demonstrate 
deactivated phenotypes that promote cellular function through neurotropic and anti-
inflammatory factors. Under pathological conditions, however, glial cells become ‘activated’ 
and prompt an inflammatory response to help engage the immune system and/or begin 
repairs to tissue damage. This response is supposed to be transient and self-limiting, with the 
tissue eventually transitioning back to a deactivated state once the infection has been cleared 
or tissue damage has been resolved.  
Chronic inflammation of the nervous system can occur, and usually indicates the either 
some component of the immune response has failed to self-regulate or that the underlying 
inflammatory stimulus still persists. While a normal neuroinflammatory response can be 
neuroprotective, persistent, uncontrolled inflammation of the CNS can result in the build-up 
of neurotoxic materials and/or amplify neurodegenerative processes.  
Glial cell activation is a key pathophysiological feature shared by all the NCL variants, 
though the regions of the CNS in which this activation occurs, along with it’s timing during 
disease progression, varies from form to form (Cooper et al., 2015). Originally, it was assumed 
that chronic inflammation seen in the NCLs was a protective response to the pathological 
accumulation of autofluorescent storage material in cells. This hypothesis has been challenged 
in recent years by several studies in animal models that show glial activation and the 
inflammatory response are present far earlier in disease progression than first assumed, 
before storage material has even begun to accumulate, and is a far better predictor of future 
neurodegeneration than the presence of storage bodies.  
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Neuroinflammation can be identified, post-mortem, using a variety of markers 
including the upregulated expression of inflammation-associated genes, increased extra-
cellular levels of pro-inflammatory factors like chemokines or cytokines, staining for activation 
markers on microglia and astrocytes, the presence of lymphocytes in CNS tissue and/or 
increased production of auto-antibodies. Some, if not all, of these markers have been used to 
identify the presence of neuroinflammation in animal and human NCL tissue samples, firmly 
establishing it as a ubiquitous feature in all known NCL variants. 
1.5.4 Malfunction of the endosomal-lysosomal-secretory compartment 
and imparied autophagy  
It should be evident, by now, that the NCLs are the result of the dysfunction or absence of one 
or more proteins within the endosomal-lysosomal-secretory compartment. Every CLN gene 
identified to date encodes a protein or enzyme that has been associated with the lysosome, 
ER or secretory vesicles in some way – a fact that played a key role in the NCLs’ reclassification 
as LSDs. To the unitiated, it can seem strange to refer to distinct organelles such as lysosomes, 
the ER and vesicles as a pathway or ‘compartment’, but several decades of research has 
determined that these unique cellular components are closely associated due to their roles in 
a wide variety of complex , important and interlinked cellular processes. While many, if not 
all, of these processes are critical to cellular homeostasis and therefore relevant to the study 
of neurodegeneration, one pathway in particular, autophagy, has distinguished itself as 
potentially critical to the natural history of neurodegenerative storage disorders like the NCLs.  
Autophagy, meaning ‘self-eating’ (from the Greek auto- for ‘self’ and phagy for 
‘eating’), is a term used to describe several complex and strictly regulated pathways by which 
the cell degrades, recycles and removes damaged or unnecessary materials (Klionksy, 2008; 
de Duve, 1962). To date, three forms of autophagy have been described: microautophagy, 
where degradative bodies like the lysosome directly engulf cytoplasmic material via 
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membrane invagination; chaperone-mediated autophagy, where materials are tagged and 
targeted to the lysosome for degradation via intermediary chaperone-proteins, and; 
macroautophagy, the process where expendable components of the cell are isolated and 
targetted to various degradative bodies within a double-membraned vesicle called the 
autophagolysosome (Wattiaux, 1966; de Duve, 1963; Kaushik et al., 2012). Macroautophagy, 
which will hereafter be referred to simply as ‘autophagy’, is of particular relevance to the NCLs 
and other neurodegenerative disorders, as it is this process that is responsible for the majority 
of cellular waste turnover and because neurons seem to demonstrate a singular vulnerability 
to autophagic dysfunction compared to other cell populations. Why this is the case remains 
unclear, though it has been hypothesised that because of their size, extreme polarization and 
post-mitotic nature, neurons are more dependent on autophagy for survival (Tooze et al., 
2008). Whatever the reason may be, the relationship between autophagic function and 
neurodegeneration is clear, with patients with neurodegenerative diseases, such as AD or 
spinal-bulbar muscular dystrophy, having been found to possess an inordinantly high 
frequency of mutations in autophagy-related genes (ATG genes)(Nixon, 2013).  
Autophagy can be described as a series of vesicle fusion events that target, encapsulate 
and eventually degrade cytosolic materials in a repetitive process often referred to as 
autophagic flux. It can be broken down into five primary stages: (1) induction, (2) nucleation, 
(3) elongation and maturation, (4) lysosomal fusion and, (5) content degradation (Figure 1.4). 
The process is initated by a cytoplasmic protein-structure known as the ‘pre-autophagosomal 
structure’ or ‘phagophore assembly site’ (PAS). From this, a double-membraned compartment 
known as the phagophore is formed, which elongates to surround and isolate cytoplasmic 
materials targeted for degradation. Once the membrane of the phagophore fuses, creating a 
complete compartment, it forms the mature autophagosome. This structure then fuses with 
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a lysosome, forming an autolysosome, and releases its contents into the lysosome’s highly 
acidic lumen. The autophagosome and its contents are consequently broken down into their 
constitutent parts by the lysosome’s hydrolases, and these parts are then either released back 
into the cytoplasm, chaperoned to other parts of the cell for recycling, or removed from the 
cell entirely by secretory pathways (Wang, 2003).  
 
Figure 1.4 ⎸Overview of the macroautophagic pathway. Autophagy is comprised of five main stages or 
phases: (1) Initiation, where the cytosolic pre-autophagosomal structure (PAS) begins to construct a 
lipid-based membrane, usually in response to some environmental stressor/cellular signalling; (2) 
Nucleation, a double-membraned structure is formed – the phagophore - and begins to encircle 
cytoplasmic constituents tagged for degradation; (3) Elongation and maturation, Once the phagophore 
has completely sequestered the cytoplasmic constituents and both ends of the membrane have sealed, 
the structure is now known as the autophagosome; (4) Lysosomal fusion, the autophagosome fuses with 
a lysosome and releases its contents in the lysosome’s acidic lumen; (5) The cytosolic material, along 
with the autophagosome structure itself, are degraded by lysosomal hydrolases. Image made by author 
using Biorender.com.  
Autophagy alterations have been reported in several NCL in vitro and in vivo models, 
implicating its dysfunction as a shared feature of these disorders. In fact, one of the key 
hallmarks of the NCLs – the accumulation of lysosomal storage material – is itself an indication 
of some form of autophagy-related inhibition and lysosomal clearance. Further evidence of 
autophagic dysfunction in the NCLs includes the abnormally high levels of a protein closely 
associated with the formation of autophagosomal membranes, known as LC3-II, that has been 
detected in the nervous tissue of Cln3∆ex7/8, Cln6nclf and Cln10/ctsd mice, which indicates 
hyperactive autophagic function (Thelen et al., 2012). More recently, a study using CLN7-
deficient mice found a build-up of autophagosomes and other autophagy-related substrates, 
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suggesting the absence or dysfunction of the CLN7 protein might be causing a block in 
autophagic flux. Similar accumulations of autophagic components have been seen in 
fibroblasts derived from CLN6 BD patients (Brandenstein, 2015; Cannelli et al., 2009). A 
pathological increase in autophagic and lysosomal compartments, associated with defective 
autosome maturation, has also been identified in CLN2 and CLN3 patient-specific induced 
pluritpotent stem cell (iPSC)-derived neuronal cells (Vidal-Donet et al., 2013), though the 
mechanism by which these changes occur in CLN3 patients is still unknown – due primarily to 
the fact that the function of CLN3 has yet to be elicited. 
Many questions remain as to autophagy’s role in the pathophysiology of 
neurodegenerative storage diseases like the NCLs. In fact, there is still debate regarding 
whether the autophagic changes seen in neurodegeneration are the consequence of 
pathology or cellular attempts to rescue the cell from environmental stressors (Colacurcio et 
al., 2018; Tooze & Schiavo, 2008). Either way, autophagy presents as a key area of research 
for the NCLs, especially because the pathway offers several opportunities for therapeutic 
intervention. Many compounds, both naturally occuring and synthetic, have been found to 
act on different parts of the autophagic pathway, from the upregulation or inhibition of key 
autophagic genes, to the augmentation or circumvention of specific events within the 
pathway that may be affected by dysfunctional NCL proteins. While still in its infancy, 
autophagic modulation therapy is an exciting new field of research for researchers and 





1.6 NCL disease management and treatment strategies  
 
Due to their unique pathophysiology, neurodegenerative diseases such as the NCLs present 
researchers and clinicians with a wide range of therapeutic challenges and considerations. 
These include: (a) developing an effective, comprehensive and non-toxic treatment that 
addresses both the underlying pathology and symptoms of a specific NCL variant in humans, 
(b) circumnavigating any potential host immune response that might be elicited from the 
introduction of foreign or novel protein-based therapies; (c) determining the optimum 
therapeutic window for treatment, (d) establishing either long-term and/or non-invasive 
means of therapy administration and outcome measurements and, (e) overcoming the unique 
practical obstacles presented by a systemic disease that primarily targets, but is not limited 
to, the nervous system.    
There is currently no cure for any variant of NCL, and the majority of therapies available 
to date tend to focus on symptom amelioration and palliative care. Several experimental 
treatments have become available in recent years that seem to hold promise, if not as a 
complete cure then at least in terms of slowing disease progression. The clinical data regarding 
the long term efficacy of these treatments, however, is scarce – with many funded after only 
a single, short-term clinical trial – and the future of patients who take them is by no means 
secured. In light of this, it remains critical that NCL research remains focused on improving the 
therapies that are already available, investigating the potential of combination or 
complementary treatments and on generating new therapeutic technologies.  
Aside from the treatments themselves, another critical area of concern for those 
hoping to develop a cure is the timing of therapeutic intervention. With the exception of 
CLN10, where diagnosis usually occurs at birth, most NCL patients are usually only diagnosed 
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after they start presenting with symptoms, which means that a lot of neurological damage 
may have already been done before they start receiving treatment. Preclinical studies have 
shown that even the most promising of experimental therapeutics have limited efficacy when 
administered at later stages of disease progression (Cabrera-Salazar et al., 2007; Sondhi et al., 
2008). This means an optimal therapeutic window for every NCL variant needs to be identified 
and taken advantage of. Whether this is done by neonatal screening programmes or through 
the use of novel biomarker tests at specific ages will depend on the unique biology of each 
variant, as well as practical and economic factors.  
NCL variants caused by the dysfunction or absence of an integral transmembrane 
protein, such as CLN6, CLN7, CLN8 and CLN12 (Table 1.1), have been said to offer an even 
greater therapeutic challenge due to their apparent resistance to some of the more successful 
NCL therapies being developed, such as enzyme replacement therapy (ERT; section 1.6.1). 
Why this is the case is still unknown, but possibly due to the inability of exogenous proteins 
to embed themselves in the appropriate membrane without the correct post-translational 
modifications an endogenous protein would normally receive when generated within the cell. 
Additionally, these proteins are unable to be secreted and transferred in therapeutic 
concentrations to neighbouring cells, a process that is observed in soluble protein variants of 
NCL treated with ERT and is known as ‘cross-correction’. The absence of cross-correction in 
transmembrane variants of NCL means that each cell within the CNS, or at least the large 
majority, needs to be individually targetted by a potential therapy in order to achieve an 
effective amelioration of the disease phenotype (Cooper, 2008).  
1.6.1 Enzyme replacement therapy (ERT) 
 As its name suggest, enzyme replacement therapy (ERT), is a therapeutic strategy that 
replaces absent or deficient enzymes in the cell, traditionally via intravenous (IV) infusion. The 
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technique was first proposed in the mid-1960s by Christian de Duve – the same researcher 
who identified and characterised the lysosome in the mid-50s – and his collaborator Roscoe 
Brady (de Duve, 1964). In terms of treating metabolic disorders, such as LSDs, ERT has proved 
to be the most successful therapy to date. The first commercially available ERT product, 
Algucerase, received orphan drug approval from the FDA in 1991 as a treatment for Gaucher’s 
disease (Weinreb et al., 2002). It has since been successfully trialled as a therapy for Fabry 
disease (Schaefer et al., 2009) and Pompe disease (Angelini & Semplicini, 2012).  
Four NCL variants are known to be the result of lysosomal enzyme deficiencies, CLN1 
(PPT1), CLN2 (TPP1), CLN10 (CTSD) and CLN13 (CTSF), making them prime candidates for ERT. 
Preclinical ERT studies for the NCLs, to date, have focused primarily on CLN1/PPT1 and 
CLN2/TPP1. Intraveous and intrathecal delivery systems of ERT have been tested and proven 
to be well tolerated in Ppt1 knockout (Ppt1-/-) mice, with purified recombinant PPT1 causing 
significant clearance of storage material from peripheral tissues and a reduction in 
astrocytosis and glial activation (Hu et al., 2012; Lu et al., 2010, 2015). Notably, storage 
material in the brain tissue of these mice was found to be less effectively cleared by the 
therapy than in their somatic tissue – highlighting the challenge the blood brain barrier (BBB) 
presents to the development of effective therapeutic strategies for neurological disorders 
such as the NCLs. Permeabilisation of the BBB is possible, in fact several proof-of-concept 
studies have been conducted in rodent models, but it appears that currently available 
techniques risk further exacerbating neuronal damage (da Fonseca et al., 2014; Neuwelt et 
al., 1981; Rite et al., 2007; Saraiva et al., 2016; Young et al., 2004).  
Since the risks of BBB permeabilization still appear too great, researchers and clinicians 
have sought out other methods of circumventing the BBB. It is for this reason that ICV and 
intrathecal modes of delivery have become more popular than the more traditional 
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intravenous route for ERT treatment of neurological disorders. Initial safety tests of 
recombinant TPP1 (for LINCL/CLN2 BD), delivered via catheters implanted into the lateral 
ventricle (i.c.v) or subarachnoid space (intrathecal), have been conducted in mouse and dog 
models of CLN2 BD. These delivery methods appeared to be efficacious, resulting in reduced 
storage material, region-specific neuron loss and neuroinflammation (Chalkley et al., 2014; 
Chang et al., 2008; Young et al., 2004).  
Based on these promising results, the first FDA-approved recombinant enzyme 
therapeutic for Batten disease, cerliponase alfa (also known as Brinerua or BMN190) was 
developed by BioMarin Pharmaceutical and evaluated for safety in a clinical phase I/II CLN2 
BD study (Trial No. NCT01907087; Clinicaltrial.gov 2013), the results of which were published 
in 2018. The study enlisted 24 CLN2 BD patients, all between the ages of 3 and 16 years of age, 
all of whom had an intracerebroventricular reservoir and cannula surgically inserted into the 
lateral ventricle of their right hemisphere. Patients then received either 30, 100 or 300 mg of 
cerliponase alfa via a 4-hour infusion procedure every second week. Patients on lower doses 
were slowly escalated up until all participants in the study were receiving 300 mg of the drug 
each fortnight. The ERT proved a great success, with the dosage being well tolerated and 
substantially delaying motor, language and cognitive decline in participants compared to 
historical age-matched controls (Schulz et al., 2018, 2017). The success of the trial has since 
launched three more, multicentre, multi-national trials (Trial No’s. NCT02485899, 
NCT02678689, NCT02963350, Clinicaltrials.gov 2015, 2016).  
While ERT has a lot of potential as an effective therapeutic for enzyme based NCLs, it 
has a lot of obstacles to overcome before it can be considered curative. These include, as 
previously mentioned, an effective and safe means of crossing the BBB, as well as the need to 
avoid triggering undesired immunologic reactions in patients with a foreign enzyme. Finally, 
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there remains a need for a sustained delivery method that doesn’t leave patients dependant 
on fortnightly infusions – an inconvenient and expensive means of treating a chronic disorder. 
ERT’s efficacy as a treatment for the other, non-enzyme-dependent variants of NCL is also 
limited due to the fact that it can only replace soluble, free-moving enzymes such as PPT1 and 
TPP1. Many forms of the NCLs, and other LSDs, are caused by the dysfunction integral 
membrane proteins, often receptors and ligands, and these require localisation to a specific 
cellular membrane in order to carry out their function. ERT appears to have limited capacity 
to assist in treating these specific forms of protein-deficiency and so alternative therapeutic 
strategies are required. 
1.6.2 Stem cell therapy (SCT) 
Stem cell therapy (SCT), sometimes referred to as ‘regenerative medicine’, has been explored 
as a potential therapy in both humans and in several animal models of NCL. Originally, NCL 
researchers hoped that SCT would allow for the regeneration of cells lost in advanced disease, 
but it has since been determined that this isn’t currently possible in mice, which have smaller 
brains with ‘easier-to-reach’ therapeutic targets. In light of this, stem cell research has 
refocused on preserving what function remains in patients by transplanting cells that secrete 
a healthy version of the CLN gene whose absence or dysfunction underlies a NCL variant’s 
pathology (Mole et al., 2019; Tamaki et al., 2009).  
In order for SCT to be successful, cells need to be transplanted in locations where the 
enzyme they produce can reach the most affected tissues – in the case of the NCLs, this would 
be the CNS. Transplantation of enzyme-expressing haematopoietic stem cells (HSCs) has been 
trialled in several peripheral tissues, such as bone marrow and intravenously, but the success 
of those trials was limited – mostly likely due to the expressed enzyme being unable to cross 
the BBB (Lake et al., 1997; Lonnqvist et al., 2001).  
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More recently, SCT research has begun to focus on the use of a specific type of stem 
cell, known as ‘neural progenitor cells’ (NPCs; sometimes also called neural stem cells or 
NSCs). NPCs are particularly useful for the treatment of neurological disorders because they 
readily differentiate into neurons and are able to integreate with the host’s nervous system. 
Preclincial studies in the Ppt1-/- mouse model demonstrated proof of concept with successful 
integration and migration of human graft cells after transplantation into the anterior cortex 
of neonate mice. Not only did the cells integrate, grafted mice also demonstrated reduced 
autofluoroscent storage material and delayed onset of motor deficits (Tamaki et al., 2009).  
Whether such an approach would be successful in the treatment of an NCL variant 
caused by mutations in a transmembrane protein, as is the case in CLN6 BD, has yet to be 
seen, though an alternative NPC-based approach, where the cells express neuroprotective 
factors rather than the deficient enzyme itself, has been trialed in the Cln6nclf mouse model 
(Jankowiak et al., 2015). In this study, researchers transduced NPCs with a lentivirus 
expressing ciliary neurotrophic factor (CNTF), which is a cytokine that been proven to rescue 
retinal degeneration in some animal models (Wen et al., 2012). The CNTF-expressing cells 
were transplanted via intravitreal injection to one eye of Cln6nclf mice, while cells expressing 
green fluorescent protein (GFP) were injected into the other as a control. Six weeks post-
injection it was found that the NPCs had attached and formed a layer on the retina, where 
they subsequently differentiated into CNTF-expressing astrocytes. The local presence of this 
neuroprotective cytokine resulted in increased retinal thickness and upregulated 
photoreceptors in comparison to the GFP-expressing control (Jankowiak et al., 2015), proving 
that NPCs have the potential to be at least powerful treatments for some aspects of NCL 
pathology, such as retinal degeneration, if not curative.  
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Studies such as these formed the basis of a phase I SCT clinical trial for CLN1 and CLN2 
BD (Trial No. NCT00337636, Clinicaltrials.gov, 2015). In this trial, human CNS-derived stem 
cells (HuCNS-SCs) that expressed healthy PPT1 and/or TPP1 protein were transplanted into 
CLN1 or CLN2 BD via a total of six subcortical injections in both hemispheres. While the 
treatment was well tolerated and proven safe, and post-mortem PCR analysis of some 
particpants’ brains indicated successful grafting of the HuCNS-SCs, little to no clinical efficacy 
was observed in terms of slowing or halting disease progression (Selden et al., 2013).  
1.6.3 Gene therapy 
Viral-mediated gene therapy, despite having a history complicated by dramatic (and even 
fatal) side-effects in several ill-fated human trials, is emerging once more as one of the most 
exciting potential therapies for neurodegenerative diseases. Researchers are able to package 
healthy copies of a gene into a replication-deficient, recombinant virus and exploit the virus’s 
natural tendency to infect cells in order to transfer that gene into a cell or group of cells. This 
is useful when the target cell or tissues possess a single mutated gene that requires correction, 
as is the case with the neurons of NCL patients. The healthy gene in the virus can be used by 
the cell’s transcription and translational machinery to create functional, wild-type proteins 
which, in turn, can compensate for a dysfunctional or absent protein produced by the cell’s 
original, mutated gene (Figure 1.5).  
Several parameters need to be considered when designing or choosing a viral vector 
to carry a healthy gene into the CNS, these include (a) the transductive parameters of the virus 
itself, including the maximum amount of genetic material it can carry, its ability to transduce 
dividing and/or non-dividing cells, and any cell-specific tropism it might demonstrate; (b) the 
route of administration; and (c) the expression threshold required for therapeutic efficacy.  
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The most common viruses used for gene therapy are retroviruses, lentiviruses (LVs), 
adenoviruses and adeno-associated viruses (AAVs). Each species of virus has its own 
advantages and limitations, making it more or less suitable as a vector for neurodegenerative 
diseases such as the NCLs. The use of AAVs for NCL gene therapy has become popular over 
the past couple of decades due to the diverse number of AAV serotypes or pseudoserotypes 
available, with 12 serotypes identified so far, and the different properties these serotypes can 
confer, especially when experimentally recombined. 
AAVs are nonenveloped, single-stranded (ss) viruses from the Parvoviridae family. 
Unlike many viruses, AAVs are innately non-pathogenic, elicit poor responses from the host’s 
immune system and have broad cell tropism – meaning they can target and transduce a variety 
of different tissues efficiently (Naso et al., 2017). The methods by which AAV serotypes 
actually initiate transduction and penetrate the cell barrier are not well understood, though it 
is evident that it involves a series of complex interactions between glycan moieties for 
attachment to the cell surface (Pillay et al., 2017). Once inside the cell, AAVs move their 
genetic material to the nucleus and there it persists as an episome – a circular plasmid of extra-
genomic material. This feature of the AAV life cycle means that there is low risk of insertional 
mutagenesis occuring within the host genome, but also results in viral genome depletion after 
a certain number of cell divisions – making AAVs better suited for gene therapy in post-mitotic 
cell groups, such as neurons (Naso et al., 2017).  
Other limitations of AAVs include their delayed expression in transduced cells, as it can 
take up to 2 weeks for a cell to reach its expression peak post-transduction, and their small 
size – with ss AAV vectors only able to package up to 4.7 kb of DNA at a time (Ferrari et al., 
1996;. McCarty et al., 2003; McCarty, 2008). The use of self-complementary (sc) AAV vectors 
has helped address the transduction delay experienced when using ss AAVs, as it bypasses the 
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requirement for DNA synthesis to convert the ss viral DNA into an active, usable double-
stranded (ds) piece of DNA. This solution, however, exacerbates the second limitation of AAVs, 
their small size – as researchers have to package both complementary DNA strands into one 
viral particle as a single strand that can fold-in on itself once within the cell compartment. This 
halves the amount of ‘space’ available for a gene, with a maximum size of 2.3 kb (Naso et al., 
2017).  
Immunogenecity is also an important consideration when choosing an AAV serotype 
for use in gene therapy. Wildtype AAVs ‘infect’ humans regularly, meaning that most people 
have developed an arsenal of AAV antibodies which can negatively impact the success of gene 
therapy. The potential for a host immune reaction against the viral vector creates the need 
for immune screening prior to the administration of gene therapy, and in cases where the 
patient is found to have developed immunity agains the vector, alternative vectors or even 
therapies need to be considered (Johnson et al., 2019).  
There have been several preclinical trials using a specific AAV serotype derived from 
rhesus monkeys, AAVrh.10, which has potential as an alternative to the more common 
serotype used in gene therapy – AAV2 – since most people have not been in direct contact 
with rhesus monkeys and so may not have had the opportunity to develop immunity against 
AAVrh.10 (Sondhi et al., 2007, 2012).  
The majority of preclinical and clinical NCL gene therapy trials to date have focused on 
the CLN1/INCL and CLN2/LINCL variants. CLN1 BD was successfully treated via multiple 
intracranial injections of AAV2 carrying the human gene for PPT1 (hPPT1) in Ppt1-/- mice. The 
virus-mediated therapy increased PPT1 expression levels and improved some CLN1 
phenotypes – including behavioural deficits and accumulation of storage material within the 
CNS. These improvements, however, were limited – with histopathological changes only 
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observed near the injection sites, possibly due to the limited distribution of the viral vector 
(Griffey et al., 2006, 2004, 2005). Intracranial delivery of AAV2 encoding human CLN2 into 
Tpp1-/- mice yielded similar, promising yet limited, results (Sondhi et al., 2005; Passini et al., 
2006).  
Intraventricular administration of AAV2 encoding canine TPP1 (caTPP1) in a canine 
model of CLN2 BD also saw a reduction in NCL pathology, with reduced glial activation, 
improved behaviour and increased lifespan. In this study, the vector was administered into 
the circulating cerebroventricular spinal fluid (CSF), rather than directly into cortical tissue as 
it was with the Ppt1-/- and Tpp1-/- mice, which appeared to faciliate more widespread 
transduction of the virus throughout the brain. The majority, however, ended up transducing 
the ependymal lining of the third and fourth ventricles, meaning large parts of the CNS 
remained unaffected by the therapy (Vuillemenot et al., 2015).  
It became evident from studies such as these that the major limitation of the AAV2 
viral vector, a favourite for NCL gene therapy because of its neural tropism and strong levels 
of transgene expression in local tissue, was its reduced ability to transduce cells throughout 
the entire CNS from a single administration site. While injection into the CSF appeared to 
increase the range of transduction to some extent, further measures to promote adequate 
distribution of the vector throughout the host’s CNS were needed. Once such measure 
included the use of the AAV2 gene expression cassette with capsids (external shells) from 
other AAV serotypes that were known to have wider transduction distributions. To date, a 
variety of different combinations have been used experimentally in NCL animal models 
including AAV2/1, AAV2/5 and AAV2/9 (Cabrera-Salazar et al., 2007; Macauley et al., 2014; 
Shyng et al., 2017) .  
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One of these studies, by Cabrera-Salazar et al (2007), looked at the administration of 
AAV1-hTPP1 into several different brain regions of presymptomatic 4-week-old and post-
symptomatic 11-week old Tpp1-/- mice. Treatment at both ages resulted in pathological and 
behavioural improvements, though the mice that were treated presymptomatically 
performed significantly better in every parameter measured versus their post-symptomatic 
counterparts. This study, and several that have been conducted since, indicates that gene 
therapy has the potential to be a powerful therapy when applied early in disease progression, 
but will only be able to delay or prevent the NCL pathology, not reverse it (Cabrera-Salazar et 
al., 2007; Johnson et al., 2019).  
Despite the mixed results of preclinical animal studies, several NCL clinical trials in 
human patients have been completed or are currently underway. The first of these looked at 
the safety and efficacy of AAV2/9 for the treatment of CLN2 BD, and involved 10 participants 
all in the moderate-to-severe stages of CLN2 BD - according to the Steinfeld et al (2002) CLN2 
BD phenotype staging system (Trial No. NCT00151216, Clinicaltrials.gov; Steinfeld et al., 2002; 
Worgall et al., 2008). The treatment was found to be well tolerated, with no adverse events, 
and neurological decline appeared to be delayed or slowed compared to historical non-
treated controls (Worgall et al., 2008). This trial has since formed the basis for two more, 
which are currently ongoing (Trial No. NCT01161576, Clinicaltrials.gov; Trial No. 
NCT01514985, Clinicaltrials.gov). There is also a phase I/II clinical trial currently underway that 
is looking at the safety and efficacy of AAV2/9-hCLN6 in 12 CLN6 BD patients. This trial is 
known as the ‘Gray Foundation trial’ and is one of the primary motivations for the practical 




Figure 1.5 ⎸Schematic overview of the principles of viral-mediated gene therapy. Image taken from 
Johnson et al., 2019. 
1.6.4 Small molecule therapies 
Many different pharmaceutical and biological agents, referred to here as small molecule 
therapies, have been investigated as potential treatments for the NCL variants over the past 
few decades. Most of these have been compounds known to target specific aspects of NCL 
pathophysiology, such as anti-inflammatories, neuroprotective agents, autophagy and/or 
lysosome function modulators or small molecules that are known to upregulate CLN-gene 
expression (Johnson et al., 2019).  
1.6.4.a Anti-inflammatories and neuroprotective agents 
Chronic neuroinflammation has been characterised as a key component in all NCL variants and 
its reduction has shown varying levels of symptom alleviation in several in vivo models. 
Mycophenolate mofetil, an immunosuppressant commonly used to prevent organ rejection, 
was tested in Cln3-/- mice and found to significantly reduce neuroinflammation and improve 
motor performance (Seehafer et al., 2011). This work formed the basis of a clinical phase II 
safety trial in CLN3 BD patients which found that the compound, while safe and well tolerated, 
was ineffective in reducing, delaying or preventing clinical outcomes in patients 
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(NCT01399047; Clinicaltrials.gov; Augustine et al., 2019). Whether this was due to the drug 
itself having no effect, or the short time frame of the trial is an area for further investigation.  
Other anti-inflammatory compounds that have been investigated in models of NCL 
include the FDA-approved drug teriflunomide, which inhibits the proliferation of activated 
immune cells, in Cln3-/- mice, and fingolimod, which stops lymphocytes from emigrating into 
the CNS, in Ppt1-/- mice. Both were found to reduce cortical and retinal thinning, as well as 
reduce neuronal death overall (Groh et al., 2017). Steroids have also been trialled clinically as 
potential treatments, with prednisolone being found to reduce autoantibody levels and 
improve motor performance in older CLN3 BD patients (~17-18 years) but having no apparent 
effect on disease symptoms or progression in younger patients (Åberg et al., 2008). The drug’s 
benefits were significantly outweighed, however, by the adverse psychiatric effects and 
infections experienced by many of the patients in the trial. Other steroids are being explored 
in ongoing trials for other neurodegenerative disorders, such as Duchenne muscular 
dystrophy and Niemann-Pick disease, and the results of these trials may have clinical 
relevance for NCL patients.  
Finally, several neuroprotective compounds have been hypothesised as having clinical 
relevance to NCL patients due to their positive effects in a range of other neurological and 
neurodegenerative disorders. These include, but are not limited to, anti-oxidants, cytoskeletal 
stabilizers, anti-apoptic compounds, AMPA receptor agonists (which reduce excitotoxicity) 
and, most importantly for this thesis, cannabinoids.  
1.6.4.b Cannabinoids and CBD 
Cannabinoids, in particular the non-psychotropic cannabidiol (CBD), present an interesting 
area of research as potential NCL therapies due to their polymorphic neuroprotective 
qualities. To date, very little research has been conducted, either in humans or animal models, 
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with regard to the effects of cannabinoids on any variant of NCL. Despite this, many NCL 
patients are being supplemented with CBD oil by parents with and without prescription due 
to its purported analgesic (pain-relief), anxiolytic (anti-anxiety), antiepileptic (anti-seizure) and 
neuroprotective effects (Wibbeler et al., 2019; Stephanie Hughes, personal communication). 
Since patients are already receiving CBD as a supplementary treatment, it is critical we gain a 
better understanding of its potential pharmacological effects in order to better contextualise 
the data generated from the practical component of this thesis.  
Cannabinoids, also referred to as phytocannabinoids, are a group of C21 
terpenophenolic compounds generated by the decarboxylation of secondary metabolites 
produced, primarily, by plants in the Cannabis genus. It should be noted that cannabinoids 
and cannabinoid-like compounds are now beginning to be discovered in a wide range of other 
plant genii, including Echinacea and Radula, but our understanding of these is still in its infancy 
(see Kumar et al., 2019, for a comprehensive review of cannabimimetic plants)(Chicca et al., 
2009; Kumar et al., 2019; Raduner et al., 2006; Toyota et al., 1994). Cannabis indica (C. indica; 
sometimes misnamed ‘sativa’), infamous for its widespread recreational use as ‘marijuana’ or 
‘weed’, and its close, hemp-producing relative Cannabis sativa (C. sativa), produce varying 
ratios of eight acidic metabolites in their glandular trichomes which, when exposed to heat, 
oxidation or light, undergo non-enzymatic transformations into at least 144 naturally 
occurring cannabinoids. The most well-known and abundant of these are trans-9-
tetrahydrocannabinol (THC), CBD, cannabigerol (CBG), cannabinol (CBN) and 
cannabichromene (CBC)(Figure 1.6) (Hanuš et al., 2016). 
To date, the majority of research into phytocannabinoids and their potential medical 
applications has focused primarily on THC and CBD. This is due, in part, to their relative 
abundance compared to other cannabinoids, their use in the chemotaxonomic classification 
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of different species within the Cannabis genus (C. sativa, for instance, has a low THC/CBD ratio, 
making it useful for hemp production but less-favoured as a recreational drug, whereas the 
opposite is true of C. indica) and the fact that THC has been identified as the active compound 
responsible for cannabis’ psychoactive effects (Gaoni & Mechoulam, 1964; Mechoulam & 
Gaoni, 1965). Their acidic precursors, THCA and CBDA, can be found in the oil or sebum-like 
substance produced by C. indica or C.sativa’s glandular trichomes, particularly the capitate-
stalked trichomes located in and around the calyxes of female plants’ budding flowers. These 
acids are derived from a common precursor molecule, cannabigerolic acid (CBGA), which – in 
turn – is a product of the condensation of a monoterpenoid precursor, predominantly 
geranylpyrophosphate (GPP), with a phenolic precursor, olivetolic acid (OA; see Figure 1.6 for 
outline of cannabinoid biosynthesis). All these compounds are part of the plant’s secondary 
metabolism pathway and are believed to be produced to deter predators, attract pollinators 






⇐ Figure 1.6 ⎸Biosynthesis of cannabinoids within the glandular trichomes of female C. sativa flowers 
(opposite page). A. Cannabinoid biosynthesis can take place within the trichomes of both male and 
female C. sativa (or C.indica) plants, but the highest concentrations are found within glandular capitate-
stalked trichomes that cover the female flowers. B. Each capitate-stalked trichome has a stalk and cuticle 
(or head). The raw components used to make cannabinoids (sugars and hexanoic acid) are transported 
through the cells within the stalk via systems of intra- and intercellular transport, before reaching the 
resin gland disk cells (RGDC) located at the base of the trichome cuticle. A series of chemical reactions 
are carried out within the RGDC cytoplasm (detailed in C) and cannabinoid acids are released as sebum 
droplets into the cuticle’s secretory reservoir. Here cannabinoid acids can come into contact with sunlight, 
which transforms the acids into their associated cannabinoid end-products. C. A basic outline of the 
chemical reactions that are involved in the biosynthesis of cannabinoids from sugar and hexanoic acid. 
Blue arrows indicate reactions that occur within the RGDC vacuole, orange arrows indicate reactions 
that occur within the RGDC plastid. Purple and green arrows indicate reactions that occur within the 
RGDC cytoplasm, and red arrows indicate reactions that occur within the trichome cuticle’s secretory 
reservoir. Image made by author.  
While modern use of cannabis and cannabinoids like THC and CBD continues to be 
rooted in recreation and the realm of ‘alternative’ medicines, increasing clinical and public 
interest in these compounds for disease and symptom management has made way for 
research into their pharmacodynamics and pharmacokinetics (Lucas et al., 2018). However, 
there is still limited information in these areas – particularly for the less common cannabinoids 
– and further research is needed to address major gaps in the knowledge required for optimal 
production and prescription of these medicines.  
The most common route of administration for recreational cannabis (and cannabinoids) 
is via inhalation of smoke (Newmeyer et al., 2016), though cannabinoids have also been known 
to be administered orally, via oromucosal preparations, intravenously and transdermally in 
clinical and research settings (Lucas et al., 2018). The pharmacokinetics of cannabinoids 
administered via inhalation have been found to be similar to those administered 
intravenously, with both THC and CBD reaching peak plasma concentrations after 3 to 10 
minutes. THC bioavailability after inhalation has been reported to range between 10 and 35%, 
whereas inhaled CBD was found to have an average bioavailability of 31% (Grotenhermen, 
2003; Ohlsson et al., 1986).  
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Oromucosal preparations of cannabinoids (e.g. via nasal sprays) were found to produce 
lower plasma concentrations of THC and CBD than inhalation via smoking or vaporisation, but 
higher concentrations than oral administration (Therapeutic Goods Administration, 2013). 
THC and CBD have poor oral bioavailibility due to their lipophilic qualities, with some studies 
estimating it to be as low as 6% for both compounds (Agurell et al., 1981; Dinis-Oliveira, 2016; 
Eichler et al., 2012; Gaston & Friedman, 2017). Additionally, cannabinoids absorbed through 
the gastrointestinal tract have to undergo hepatic ‘first-pass’ metabolism, resulting in lower 
peak plasma levels and a longer delay before reaching that peak. While little is known about 
the metabolism of THC and CBD, it is likely that both compounds would produce interactions 
with other drugs that are also metabolised in the liver – due to their shared used of 
cytochrome P450 isozymes (Eichler, 2012; Dinis-Oliveira, 2016). For instance, both cannabis 
and tobacco smoking induce CYP1A2 activity. When the compounds are smoked together, this 
induction becomes additive. This suggests a significant drug interaction would be likely to 
occur if a patient took cannabis and a drug that is also metabolised by CYP1A2 (Anderson & 
Chan, 2016). There have also been one-off case reports of mental health episodes, such as 
mania and/or delirium, being induced by the coadministration of cannabis and certain 
medications like fluoxetine and disulfiram (Lacoursiere & Swatek, 1983; Mackie & Clark, 1994). 
None of these incidents, however, have involved the use of medical-grade, purified 
cannabinoids.  
While their lipophilic structure makes oral administration less-than-ideal, that same 
structure allows cannabinoids like THC and CBD to distribute easily throughout the body and, 
importantly for neurodegenerative diseases like the NCLs, cross the BBB (Calapai et al., 2020). 
There is some evidence to say distribution is affected by an individual’s body size and 
composition, and chronic cannabis use can result in the deposition of cannabinoids in adipose 
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tissue, resulting in the persistence of cannabinoid activity for weeks post-administration 
(Lucas et al., 2018). Many studies have shown that the elimination half-life of cannabinoids 
such as THC and CBD depend on the frequency and quantity of cannabis use which, combined 
with individual factors such as fat composition and diet, makes it difficult to estimate an exact 
half-life or rate of elimination for either compound. For instance, Smith-Kielland et al. (1999) 
found the half-life of THC in prison inmates who identified as ‘infrequent’ users of cannabis to 
be approximately 1.3 days, whereas a population model created by Heuberger et al. (2015) 
describes a ‘fast’ initial half-life of approximately 6 minutes, followed by a ‘long’ terminal half-
life of 22 hours for the same compound. An even longer elimination half-life fo THC has been 
observed in ‘heavy’ users, which has been attributed to slow-release from bodily 
compartments such as fat stores (Toennes et al., 2008). Similarly, CBD has been reported to 
have a varying half-life depending on route of administration: the average half-life following 
intravenous dosing was observed to be approximately 24 hours, while the half-life of inhaled 
CBD was found to be 31 hours (Ohlsson et al., 1986). Consroe et al. (1991) found that ‘chronic’ 
users (aka individuals who self-administered cannabis daily for a minimum of four weeks) 
elicited a CBD half-life ranging between 2 to 5 days.  
 Like all phytocannabinoids, the structure of THC and CBD give them varying affinities 
for specialised G-protein coupled receptors (GPCRs) within the human body, known as 
cannabinoid receptors (CB1 and CB2 receptors). These receptors are present on the surface 
membranes of cells throughout all the major organ systems and have roles in a series of 
physiological processes that assist with maintaining homeostasis including appetite, pain 
perception, mood and memory. Devane et al. identified the first of these endogenous 
receptors, cannabinoid receptor 1 (CB1), in rat brains in 1988 while researching the 
psychoactive effects of the cannabinoid THC, choosing to name their discovery after the class 
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of compounds that had helped them identify it (Devane et al., 1988). Cannabinoid receptor 2, 
(CB2) was discovered five years later (Munro et al., 1993). While both receptors are GPCRs and 
can be activated to varying degrees by different cannabinoids, they are distinguishable by a 
48% amino acid sequence difference in structure, varying tissue distribution, signalling 
mechanisms and sensitivity to different cannabinoids (Howlett et al., 2002). CB1 receptors, for 
example, are located primarily throughout the central and peripheral nervous systems, with 
one of their main functions being to inhibit neurotransmitter release at neural synapses. CB2 
receptors, in comparison, are found primarily in peripheral tissues and organs and are highly 
associated with the immune system (Howlett et al., 2002). THC demonstrates a high affinity 
for both CB1 and CB2 in vitro and in vivo, and it is the strong activation of these receptors and 
their associated signalling pathways that is believed to be responsible for THC’s powerful 
psychotropic qualities (Costa, 2007).  
It was originally assumed that CBD would have a similar affinity for the CB receptors, 
and that this agonism would be responsible for the plethora of neurological effects attributed 
to its use. This, however, turned out not to be the case. While CBD can bind to CB1 and CB2, it 
appears to have low to negligible agonist activity at these receptors in vivo and may even act 
in an antagonistic manner at low doses (M.-H. Rhee et al., 1997). Recent studies even suggest 
that CBD negatively modulates CB1 receptors via an allosteric mechanism (Laprairie et al., 
2015).  
CBD’s pharmacological effects are now believed to be due to activation of alternative 
receptors and pathways, as well as the cannabinoid’s innate chemical properties. It’s 
antiepileptic qualities, for instance, have been attributed to its modulation of transient 
receptor potential (TRP; vanilloid1) channels and, more recently, its role in the reduction of 
neuronal excitability through interaction with the GPR55 receptor (Kaplan et al., 2017). No 
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work has been specifically done with CBD and the myoclonic seizures experienced by NCL 
patients, but there have been several small ‘generalised seizure’ studies conducted with 
various cannabinoids, mostly THC, that have included NCL patients (Lorenz, 2002).  
Besides its antiepilpetic action, CBD has been reported to possess several other 
pharmacological attributes that would be valuable in the treatment of NCLs. For instance, 
CBD’s ability to stimulate vanilloid 1 is also associated with an analgesic effect, as stimulation 
of this receptor results in the desensitisation of sensory nociceptors (Baamonde et al., 2005; 
Iannotti et al., 2014; McCarberg & Barkin, 2007). Pain has been reported in many cases of NCL 
(Barney et al., 2015; Breau et al., 2010), though its diagnosis and management is often 
complicated by NCL patients’ compromised language and cognitive abilities (Mannerkoski et 
al., 2001). NCL patients also often experience mood disorders and anxiety, making CBD’s 
reported anxiolytic (anti-anxiety) and antidepressant qualities pertinent to treatment. These 
effects are believed to be the result of CBD’s allostoric modulation of GABAA receptors and/or 
activity at 5HT1A receptors (Bakas et al., 2017; Zanelati et al., 2010).  
Aside from addressing symptoms like seizures, pain and mood disorders, CBD also has 
the potential to address the pathology underlying NCLs. Neuroinflammation, discussed 
previously, is a key feature of all NCL variants and believed to be closely associated with – or 
even causative of – neurodegeneration. CBD has been known to reduce inflammation via the 
inhibition of [3H] adenosine uptake in murine microglia and macrophages and it has been 
found to suppress human B cell chemokine production in vitro (Carrier et al., 2006; Formukong 
et al., 1988; Watzl et al., 1991). Several studies in rodent models of AD demonstrated that CBD 
is also able to reduce neuroinflammation caused by protein toxicitiy by impairing the 
expression of nitric oxide synthase (iNOS) and interleukin 1β (IL-1β), though the signalling 
pathways by which it exerts these effects remained uncharacterised until recently (G Esposito 
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et al., 2009). There is now mounting evidence that many of the neuroprotective and anti-
inflammatory effects exerted by CBD may be the result of nuclear binding to a family of 
receptors known as the peroxisome proliferator-activated receptors (PPARs)(O’Sullivan, 
2007).  
The PPARs are a class of ligand-activated transcription factors that belong to the 
steroid/thyroid hormone superfamily of nuclear receptors (Berger & Moller, 2002). 
Traditionally regulated by lipid and steroid metabolites, they are believed to control the 
expression of a wide range of genes, many related to autophagy, lysosomal clearance, lipid 
and glucose metabolism and inflammation, among other cellular processes. They regulate 
gene expression by heterodimerizing with the retinoid X receptor (RXR) and binding to specific 
DNA sequences in the nucleus known as peroxisome proliferator response elements (PPREs), 
which are located in the enhancer regions of genes. In order to be ‘activated’, and exert its 
downstream effects on gene expression, the PPAR-RXR heterodimer must be bound by a 
ligand, such as a steroid, hormone or drug. In the absence of ligand-binding, the PPAR-RXR 
complex is bound by one of several possible co-repressor proteins, leaving it in an inactive 
state. Upon ligand binding, however, the complex undergoes a conformational change that 
allows for the release of the co-repressor protein and allows for the formation of a 
transcriptional apparatus that includes the ligand, the PPAR-RXR complex and a variety of co-
activator proteins, including p300. This apparatus allows for nucleosome remodelling and the 
assembly of a transcriptional pre-initiation complex on target gene promoters within the 
nucleus (Berger & Moller, 2002)(Figure 1.7). To date, there are currently three isoforms of 
PPAR identified: PPAR!, PPARβ (sometimes called PPARδ) and PPARɣ. Each is encoded by a 
separate gene and has a unique tissue distribution pattern, though all appear to be potentially 
relevant to the treatment of NCLs as therapeutic targets due to their polymorphic properties 
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and close relationship to several of the underlying pathological processes common across all 
NCL variants (Bookout et al., 2006; Kersten, 2008). Activation of the PPARs, either by 
endogenous or exogenous ligands, has been proven to result in a wide range of anti-
inflammatory and neuroprotective qualities both in vivo and in vitro (see more on PPAR 
signalling and PPAR! activation as a potential therapeutic target for the NCLs in section 
1.6.4.c) (Aoun et al., 2003; Drew et al., 2006; Duvanel et al., 2003; Niino, 2007; Rhee et al., 
2003; Uryu et al., 2002; Xu et al., 2005; Zander et al., 2002). 
CBD’s neuroprotective and anti-inflammatory properties have recently been directly 
linked to PPARɣ signalling in a rat model of AD, with the antagonism of the PPARɣ pathway 
resulting in a significantly reduced effect of CBD on reactive gliosis and, subsequently, 
neuronal damage (Esposito et al., 2011). Less extensive work has been done examining CBD’s 
ability to bind to and activate the other two PPAR receptors, ! and β, but there have been 
several studies linking other cannabinoid compounds to their activation and using this binding-
affinity therapeutically for neurodegenerative disorders such as AD and multiple sclerosis 
(Loría et al., 2010; Scuderi et al., 2011, 2012). 
1.6.4.c Substrate reduction therapy and autophagy modulators 
Several pharmaceutical compounds have been investigated as potential therapies for BD due 
to their ability to modulate autophagic and lysosomal biogenesis pathways within the cell 
(Gavin et al., 2013; Levin et al., 2014; Trial No. NCT00028262, Clinicaltrials.gov). Autophagic 
and lysosomal dysfunction has been linked to most of the variants of NCL to date, highlighting 
their shared importance in the pathophysiologies of this group of diseases.  
Substrate reduction therapy (SRT) is a therapeutic strategy based on the partial 
inhibition of an enzyme (or enzymes) involved in the synthesis of a pathologically 
accumulating substrate, such as the saposins or mitochondrial subunit C that are histologically 
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characteristic of the NCLs. One of the many drugs that have been evaluated for this purpose 
is cysteamine bitartrate, a lysomotropic aminothiol salt traditionally used to manage kidney 
function. In 2001, cysteamine bitartrate was found to successfully enhance lysosomal storage 
clearance in CLN 1-deficient cell cultures, and so was used in a phase IV (interventional) clinical 
trial (Gavin et al., 2013; Trial No. NCT00028262, Clinicaltrials.gov). Ten participants, all 
diagnosed with CLN 1 BD, took a daily oral dose of 60 mg/kg of cysteamine bitartrate until 
they were determined to have declined to a vegetative state or withdrew from the trial. All 
patients were found to have a complete absence of storage material in circulating 
lymphocytes by 8 months, but unfortunately this did not translate into any significant clinical 
improvement in disease progression (Levin et al., 2014).  
While SRT drugs such as cysteamine bitartrate target the enzymes and precursor 
proteins involved in the production of intracellular storage material, another similar 
therapeutic strategy approaches the problem from the opposite direction. Instead of 
preventing or reducing the production of storage material in the first place, autophagic 
modulation involves the upregulation of key enzymes involved in the autophagy pathway – 
allowing increased clearance of the unwanted storage material from the cell (Coutinho et al., 
2016). 
A group of drugs that has proven particularly promising as autophagic modulators for 
the NCLs are fibrates, which have demonstrated varying abilities to modulate lysosomal 
biogenesis and autophagic pathways both in vitro and in vivo for several neurodegenerative 
disorders (Agarwal et al., 2017; Bordet et al., 2006; Esmaeili et al., 2016).  
Fibrates are a class of known PPAR! agonists, commonly used as lipid-lowering agents 
in patients with hypercholesterolaemia. PPAR! is one of the three known peroxisomal 
proliferator-activated receptors (described in section 1.6.4.b) and, once activated, has been 
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shown to possess a wide range of neuroprotective properties via its downstream activation of 
anti-inflammatory, autophagic and lipid metabolising pathways (Esmaeili et al., 2016; Agarwel 
et al., 2017). 
Researchers and clinicians became particularly interested in fibrates as potential 
therapies for neurodegenerative diseases due to their binding and activation of the 
neuroprotective PPAR! receptor, along with the discovery and characterisation of a protein 
known as transcription factor EB (TFEB)(Napolitano & Ballabio, 2016; Settembre & Ballabio, 
2011; Settembre et al., 2011). TFEB, encoded by the TFEB gene, is sometimes referred to as 
the ‘master regulator’ of the expression of other genes involved in autophagy and lysosomal 
biogenesis, amongst many other cellular processes, and its expression is upregulated by the 
binding of the PPAR!-RXR!- transcriptional complex to TFEB PPREs (Napoliano & Ballabio, 
2016; Chen et al., 2021).  
Increased TFEB activity, which is closely associated with upregulated PPAR! activation 
and subsequent TFEB transcription, has been shown to produce a variety of anti-inflammatory 
and neuroprotective effects in several neurodegenerative (and lysosomal storage) disorder 
models. For instance, upregulation of TFEB has been seen to result in increased htt turnover 
and the elimination of protein aggregates in a mouse model of Huntington’s disease (La Spada, 
2012; Tsunemi et al., 2012). Similarly, TFEB activation has been shown to improve the folding, 
trafficking, and activity of a destabilised glucocerebrosidase in a Gaucher disease cell culture 
and has been shown to rescue activity of a β-hexosaminidase mutant in fibroblasts taken from 
Tay-Sachs disease patients (Awad et al., 2015; Song et al., 2013). 
The fact that fibrates activate the PPARs, especially PPAR!, as part of their lipid-
lowering mechanism of action (Figure 1.7), along with the fact that the PPAR!-RXR! has been 
identified as a key regulator of TFEB expression, establishes fibrates as a potential therapeutic 
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for the NCLs via their downstream autophagy modulation activity (Esmaeili et al., 2016; 
Agarwel et al., 2017). 
 
Figure 1.7 ⎸Schematic overview of PPAR# agonism within the cell. Many classes of small molecule therapy, 
such as fibrates, influence lysosomal biogenesis and autophagic processes via the activation of PPAR# 
nuclear receptors, which consequently causes the upregulation of the ‘master regulator’ of autophagic 
genes – transcription factor EB (TFEB). Image created by author using BioRender.com. 
The most commonly prescribed fibrates are fenofibrate (also known as Tricor) and 
gemfibrozil (also known as Lopid). Both were introduced as lipid-lowering agents in the mid-
1970s and are indicated for the treatment of primary hypercholesterolaemia; mixed 
dyslipidaemia; and/or hypertriglyceridaemia in adults. The lipid-modifying activity of these 
drugs has been seen in clinical practice and characterised both in vivo and in vitro, with both 
acting as PPAR! ligands and exerting their effects via PPAR!-mediated upregulation of the 
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transcription of a variety of lipid-lowering proteins, including lipoprotein lipase, and via the 
downregulation of apoprotein C-III, an inhibitor of lipoprotein lipase activity (Fazio & Linton, 
2004; Staels et al., 1998). 
Both fenofibrate and gemfibrozil, along with several other fibrates such as bezafibrate 
and clofibrate, have been investigated as potential therapies for several neurodegenerative 
diseases, including several forms of the NCLs. For example, fenofibrate, bezafibrate and 
gemfibrozil were all found to have beneficial effects on the health of lymphoblast lines derived 
from CLN3 BD patients, while fenofibrate, gemfibrozil and clofibrate were found to restore 
several lysosomal and autophagic deficits in Cln6-/- cells (Best, 2017; Hong et al., 2016). 
Furthermore, gemfibrozil has also been successfully tested in vivo in Cln2-/- and Cln6nclf mouse 
models, with drug-treated mice exhibiting improved motor performance, longevity and 
decreased intracellular storage material accumulation when compared to untreated 
counterparts (Best et al., 2017; Ghosh et al., 2012).  
As lipid-lowering agents, fenofibrate is often preferred over gemfibrozil due to its longer 
half-life (20 versus 2 hours) and higher efficacy, with fenofibrate being found to produce 
significantly greater reductions in total cholesterol, LDL and triglycerides and significantly 
increased levels of HDL (Packard et al., 2002). Additionally, gemfibrozil is a strong inhibitor of 
the metabolic enzyme CYP2C8, whose activity is key for the safe metabolism of a wide range 
of medications such as dabrafenib, loperamide, montelukast and rosiglitazone, amongst 
others, and therefore must be taken with caution in combination with other drugs. In contrast, 
fenofibrate is only a weak inhibitor of CYP2C8 and far fewer drug-drug interactions have been 
reported (Prueksaritanont et al., 2005; Schelleman et al., 2014; Tornio et al., 2017). 
Despite fenofibrate being preferred clinically as a lipid-lowering agent, the literature 
currently suggests that gemfibrozil offers more potential as an NCL therapy, particularly in the 
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treatment of CLN2 and CLN6 BD – though, to date, there have been no clinical trials run to 
investigate the effects of any fibrate in patients with any form of NCL, so it is difficult to 
ascertain whether gemfibrozil will prove to be more efficacious clinically (Best et al., 2017; 
Ghosh et al., 2012).  
Gemfibrozil, when prescribed clinically to treat lipid disorders in adults, is usually given 
as a twice-daily 600 mg oral dose, to be taken approximately 30 minutes before morning and 
evening meals. Alternatively, a single dose of 900 mg can be prescribed, to be taken 30 
minutes before evening meals (FDA.gov, 2021; “Lopid (Gemfibrozil)" Rxlist.com, 2021). In 
clinical trials, individual oral doses have ranged between 600-1600 mg without producing 
significant increases in side effects – demonstrating that the drug has a relatively wide 
therapeutic index (FDA.gov, 2021; Fereshetian et al., 1998).  
Gemfibrozil is rapidly and completely absorbed from the gastrointestinal (GI) tract and 
into enterohepatic circulation. Bioavailability of the drug is close to 100% and is highest when 
gemfibrozil is taken 30 minutes before food (Miller & Spence, 1998; Spence, 1998). Animal 
studies have shown peak plasma concentrations to occur an hour after oral administration, 
though studies in humans have demonstrated variability in this timing depending on whether 
the patient is taking one or two daily doses. A single 900 mg dose in healthy adults, for 
example, was shown to reach peak plasma concentrations of 33 ug/mL approximately 1-2 
hours after ingestion. Another study, where participants took two daily doses of 600 mg each, 
showed peak plasma concentrations of 16-23 ug/mL approximately 1-2 hours after dosing 
(Busse et al., 2009). Approximately 95% of gemfibrozil is protein (albumin) bound and its 
volume of distribution is estimated to be 0.8 L/kg. Plasma concentrations of gemfibrozil vary 
widely between individuals, but tend to increase proportionally with increasing dose, though 
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there is no established relationship between plasma concentration and therapeutic response 
(Lilja et al., 2005).  
Gemfibrozil is metabolised by liver and excreted primarily in the urine as metabolites 
(fecal elimination is about 6% in adults). Gemfibrozil’s elimination half-life has been calculated 
to be approximately 1.5 hours ("AHFS Drug Information," Bethesda, 2009). As mentioned 
previously, gemfibrozil is a strong inhibitor of the liver metabolism enzyme CYP2C8, but also 
affects CYP2C9, OATP1B1 and OATP2B1 – meaning it can increase the elimination time, 
increase the toxicity and decrease the efficacy of a wide range of other drugs (Schelleman et 
al., 2014; Tornio et al., 2017). One source lists gemfibrozil as having interactions with 131 
different medications, including common ones such as aspirin, metformin and several 
different antibiotics, so it is evident that caution must be taken when prescribing this drug 
(Lopid, RXlist.com 2021; Lopid®, FDA.gov 2021).  
A randomised, double-blind, five-year trial of gemfibrozil in adult men at risk of coronary 
heart disease, dubbed the ‘Helsinki Heart Study’, demonstrated that common side effects of 
gemfibrozil include gastrointestinal symptoms such as dyspepsia, abdominal pain and acute 
appendicitis (Frick et al., 1987; Pfizer, 2021). During the first year of the study, 11.3% of the 
subjects (n = 2051) reported “moderate to severe upper gastrointestinal symptoms”, in 
comparison to only 7% of the placebo group, though these rates decreased to 2.4% and 1.2% 
respectively over the four final years of the trial (Frick et al., 1987). Gastrointestinal side effects 
relating to the use of oral gemfibrozil in mice, particularly in disease models derived from the 
C57Bl/6 strain (such as the Cln6nclf and APP/PS1 transgenic Alzheimer’s models), is also 
suspected due to observational data collected from several of the Hughes Lab’s preliminary 
studies involving the regular oral dosing of large mouse cohorts. APP/PS1 mice, for example, 
were observed as experiencing higher rates of neophobia and, at a later stage of 
 60 
experimentation, food rejection when given jelly pellets dosed with gemfibrozil than those 
given control pellets only containing a vehicle (50:50 DMSO and Tween® 20 solution) control 
(Stephanie Hughes and Stephanie Mercer, personal communication 2019). Such observations, 
however, have not been confirmed to be linked to GI side effects and would require further 
investigation to confirm a link. Aside from gastrointestinal disturbances, other human studies 
have indicated gemfibrozil, when taken with an HMG-CoA reductase inhibitor, to be 
associated with an increased risk of rhabdomyolysis. Rhabdomyolysis is a musculoskeletal 
syndrome which manifests as the excessive release of muscle fibre contents into the blood 















1.7 CLN6 Batten disease  
 
1.7.1 Gene and protein 
The human CLN6 gene, first identified in 2002, is located on the long arm of chromosome 15 
(15q23) and is composed of seven exons spanning ~22 kb of genomic DNA. It encodes a highly-
conserved 27 kDa protein, CLN6, which is predicted to have seven transmembrane domains 
and localises in membrane of the endoplasmic reticulum (ER), as well as sub-domains of the 
ER membrane network which extend along the axons and dendrites of neural cells (Gao et al., 
2002; Heine et al., 2007; Wheeler et al., 2002).  
Until recently, very little was known about the function of the CLN6 protein, as it bears 
no homology to any other human protein and its complete structure has yet to be determined. 
In 2007, Heine et al. used differential permeabilizaton of transfected baby hamster kidney 
(BHK) cells and antibody binding assays to determine that CLN6 had a N-terminal cytoplasmic 
domain and a luminal C-terminus, and that a signalling region on the N-terminal, along with a 
dilysine motif located in the 6th and 9th transmembrane regions, dictated CLN6’s localisation 
to the ER (Heine et al., 2007). Since then, clues to CLN6’s role within the cell have come 
primarily from identifying binding partners and related signalling pathways. For instance, 
Benedict et al. (2009) determined that collapsin mediator response protein 2 (CRMP-2) 
interacts with CLN6’s N-terminus and, using the Cln6nclf mouse model and several Cln6nclf 
neuronal co-cultures, found that CRMP-2 levels were significantly downregulated in specific 
regions of the brain, particularly the thalamus, in the absence of functional CLN6 (White et al., 
2019). CRMP-2 is a protein implicated in axonal growth and development, playing several roles 
in neural microtubule dynamics, and is known to be highly expressed in the healthy, 
developing brain (Moutal et al., 2019). Aberrant Akt/GSK3 and ERK/MAPK cell signalling was 
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also identified in a Southern Hampshire sheep model (OCLN) of CLN6 BD, suggesting CLN6’s 
involvement in cellular biometal homeostasis – as both of these pathways are biometal-
regulated and increased accumulation of zinc, copper, manganese and cobalt had been 
previously identified in neural and non-neural OCLN and CLN6-/- Merino sheep tissues 
(Kanninen et al., 2013). 
The biggest advance in our understanding of the biological role of the CLN6 protein, 
however, was only published in 2019. Bajaj et al (2019) used a series of biochemical assays to 
investigate the function of CLN6 in relation to that of another NCL-related protein, CLN8. 
CLN8’s role as an ER cargo receptor had been elicited a year earlier, in 2018, by the same 
group, and the similarities between the clinical features of CLN6 BD and CLN8 BD, coupled 
with the fact that they are the only two known NCL-related proteins to be localised to the ER, 
lead the group to hypothesise that CLN6 was also involved in the ER-to-Golgi apparatus (Golgi) 
transport of lysosomal enzymes (Bajaj et al., 2018; Bajaj et al., 2019). Through the post-
mortem analysis of brain tissue taken from Cln6nclf and Cln8mnd mice, Bajaj et al (2019) 
determined that CLN6 and CLN8 work as a complex that recruits newly synthesised lysosomal 
enzymes in the ER and transports them to the Golgi. They named this complex EGRESS (ER-to-
Golgi relaying of enzymes of the lysosomal system). They determined that the complex forms 
at the ER membrane, and lysosomal enzymes are recruited via interaction with large luminal 
loops from both proteins. Absence of either protein appears to make the other unable to 
recruit the lysosomal enzymes and results in pathology. Once the enzymes have been 
recruited, they are packaged into a ‘coat-protein’ (COPI) vesicle with CLN8 and transported to 
the Golgi where they undergo further modification and packaging before being transported 
to the lysosome. CLN6, it appears, remains in the ER membrane once CLN8 has been packaged 
into a vesicle, preparing for the next round of transport (Bajaj et al., 2019).  
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While Bajaj et al’s work represents a large leap forward in our understanding of (at 
least one of) CLN6’s role(s) within the cell, there are many questions that remain unanswered. 
For example, expression levels of CLN6 mRNA transcripts have been found to differ 
significantly across the lifespan in mouse models. These studies have shown Cln6 expression 
to be amplified during prenatal development and for the first month after birth, 
demonstrating a similar murine expression profile to other NCL-related genes such as Cln1 
(Ppt1), Cln3 and Cln5, and suggesting the importance of CLN6 in neurodevelopmental 
processes such as neurogenesis and maturation (Thelen et al, 2012; Isomppi et al., 1999; 
Holmberg et al., 2004; Eliason et al., 2007). This is further supported by region-specific 
differences in Cln6 transcript expression in mice, with the highest levels of expression found 
in the dentate gyrus, the hippocampus, the Purkinje cells of the cerebrellum and cortical layers 
II-VI (Thelen et al., 2012). The dentate gyrus is one of only two brain regions found to promote 
and maintain neurogenesis in adult human brains post-development (Gage, 2002), 
highlighting the protein’s importance in this process. Why CLN6’s role is so critical to these 
neuro-developmental processes, and why its absence or dysfunction seems to confer a 
targeted vulnerability to cells within the CNS remains an area of ongoing investigation and 
speculation.  
1.7.2  Mutational spectrum  
As of 2017, which is the last time the University College London’s NCL mutation and patient 
database was updated, there were 71 unique CLN6 BD-causing mutations identified. These 
included substitutions, deletions, insertions, and duplications of both single nucleotides and 
longer sequences in all seven exons, two introns and the 5’ upstream sequence (CLN6, 
ucl.ac.uk/ncl-disease). These mutations are known not only to cause classical CLN6 BD, but are 
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also implicated in Kufs disease Type A (Arsov et al., 2011) and several non-NCL diseases (Table 
1.1) (Farqu, 2014).  
The majority of NCL-causing mutations appear to affect amino acid residues that are 
located on the ER-exposed loops of the protein. Before Bajaj et al’s (2019) paper, this 
‘clustering’ of mutations was speculated to indicate an important functional role for these 
regions within the protein, which has now been confirmed by their work (Mole et al., 2004; 
Kousi et al., 2012; Bajaj et al., 2019).  
1.7.3  Clinical presentation 
CLN6 BD was first described in several families from Costa Rica. However, CLN6 BD has since 
been identified in patients with a wide range of different ethnicities and does not appear to 
be restricted geographically to any particular part of the world (Wheeler et al., 2002).  
Symptom onset for CLN6 BD has been described as highly variable, with some cases 
reporting presentation as young as 8 months of age or as old as 8 years (Sharp et al., 2003; 
Alroy et al., 2011; Schulz et al., 2013). However, ‘classical’ CLN6 BD is traditionally seen as a 
variant of LINCL that presents between 3 and 5 years of age, with the first symptoms usually 
being vision loss and seizures (Goebel et al., 2004). Other symptoms experienced by CLN6 BD 
patients include progressive loss of speech and motor skills, developmental delays and 
intellectual decline, mood swings, personality changes and dementia. Complete loss of motor 
skills is usually observed between 4 and 10 years of age, with patients usually dying in their 
mid-to-late teens or early 20s. CT, MRI and autopsy usually reveal severe cortical and 
cerebellar atrophy (Goebel et al., 2004; Mole et al., 2004).  
In 2011, Arsov et al determined that Kufs disease Type A, originally thought to be a 
rare adult onset variant of CLN4 BD, was also caused by mutations in CLN6 (Arsov et al., 2011). 
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Disease progression and clinical presentation seems to be significantly different in Kufs 
disease patients, with most presenting with symptoms in their late 20s. Patients with Kufs also 
seem to maintain their eyesight, with their first symptoms being cognitive and/or behavioural 
changes and ataxia – all of which seem to develop several years (3-8) before myoclonic 
seizures begin. Progressive ataxia and unrelenting seizures usually leads to patients being 
wheelchair bound approximately 12 years post-diagnosis, with premature death occuring 8 to 
31 years after onset (Berkovic, 2019).  
1.7.4 The Gray Foundation (Amicus Therapeutics) CLN6 BD clinical trial 
In 2016, Amicus Therapeutics and the Gray Foundation funded the first ever clinical trial of 
AAV2/9-mediated gene therapy for CLN6 BD (Trial No. NCT02725580, Clinicaltrials.gov). 
Thirteen children, all diagnosed with CLN6 BD, received a single intrathecal dose of 
scAAV9.CB.hCLN6. While the trial is still ongoing, interim results suggest the treatment has 
been tolerated well by the participants and some of the younger children remain symptom-
free despite reaching the age at which symptoms are expected to appear (Amicus 
Therapeutics, 2019). Unfortunately, however, some of the older participants, who were 
displaying symptoms before treatment, continue to decline. Whether their rate of decline has 
been slowed by the treatment is yet to be determined, but it highlights the need for 
supplementary therapeutics to augment the effects of the gene therapy in older, symptomatic 
patients. For this reason, the Gray Foundation enlisted the help of the Hughes lab to run a 
large-scale, longitudinal combination therapy trial in Cln6nclf mice, with the hopes of designing 
a safe and effective combination treatment involving both gene and small molecule (CBD and 
gemfibrozil) treatments (Stephanie Hughes, personal communication). 
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1.7.5 Animal model – the Cln6nclf mouse  
As has been the case with all forms of NCL (see section 1.4), the use of animal models has 
been critical to understanding of the pathophysiology of CLN6 BD and to attempts to develop 
effective therapeutic strategies against it. While there are several useful CLN6 animal models 
currently available, including two CLN6-/- ovine models and one canine, the practical 
component of this thesis used the Cln6nclf murine model (Oswald et al., 2005; Katz et al., 2011; 
Best et al., 2017). The Cln6nclf murine model was selected for several reasons: 
First, the model is derived from the widely used and readily available C57 Black 6 
(C57Bl/6) inbred strain of laboratory mice. These mice are well-studied, with the line first 
established in 1921, and there is a wealth of genetic, phenotypic and genomic data available 
on the strain, including a high-quality reference genome (GRCm38.p6). From this genome, it 
has been established that mice (Mus muscularis) have a homolog of the human CLN6 gene, 
Cln6, on chromosome 9 and this homolog shares a 92% amino acid identity with its human 
counterpart (Huber et al., 2020). Originally identified in the Jackson Laboratory and described 
by Bronson et al in 1998, the Cln6nclf murine model arose from a naturally occurring insertion 
mutation of a cysteine amino acid codon into exon 4 of the C57Bl/6 Cln6 gene (Bronson et al., 
1999). Also known as the ‘nclf’ mouse, the Cln6nclf  murine model is one of only two naturally 
occurring murine models for the NCLs, the other being the Cln8mnd mouse, and lends itself – 
like most rodent models – to relatively inexpensive breeding, transportation, 
experimentation, housing and upkeep (Huber et al., 2020). The use of the Cln6nclf mouse in 
the practical component of this thesis allowed for the use and maintenance of over 540 
experimental animals, split into eighteen different experimental groups by gender, strain and 
therapy type, some of which were kept for almost two years – a feat that would be much more 
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difficult, and expensive, if one of the larger CLN6 animal models (ovine or canine) had been 
used instead. 
Second, the Cln6nclf mouse model was employed in the practical component of this 
thesis due to the fact that this work, and the overall trial it is part of, make up only one part 
of a larger international effort by several labs to investigate and improve upon the use of gene 
therapy to treat CLN6 BD. Several labs from around the world, including the Cooper and 
Weimer labs in the United States, are working on parallel projects and their data is currently 
being generated using the Cln6nclf model (Cain et al., 2019; White et al., 2021). Using the 
Cln6nclf mouse for this project ensures that any data generated will be relevant and hopefully 
translation when reported in the wider context of other labs’ work. It also means that the data 
will be able to build upon a variety of key, published CLN6 BD preclinical studies – including 
several published by current and previous members of the Hughes Lab (Neverman, 2015; Best, 
2017; Best et al., 2017; Linterman et al., 2011; Mole et al., 2019; Partridge, 2017).  
Finally, and perhaps most importantly, the Cln6nclf murine model has been 
independently validated as a reliable format for screening potential CLN6 BD therapeutics and 
found to have several key behavioural and pathological similarities to the human disease 
(Morgan et al., 2013). Early histological studies in the brains of these mice demonstrated 
progressive, selective regional and neuronal loss, as well as wide-spread astrocyte activation 
and microgliosis - both of which are considered key features of NCL pathophysiology in 
humans (see section 1.5; Bronson et al., 1999; Thelen et al., 2012).  A 2013 study conducted 
by Jeremy Morgan from the Jill Weimer Lab found the Cln6nclf mouse to demonstrate retinal 
degeneration (and blindness), motor deficits such as dysarthria and ataxia, and CLN6 BD-
characteristic cortical thinning, brain atrophy and selective loss of GABAergic inhibitory 
interneurons from the cortex and hippocampus. All these features replicate, to different 
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degrees, the disease seen in humans and other animal models of CLN6 BD (Morgan et al., 
2013). Taken together, these findings helped establish the Cln6nclf mouse as a cornerstone tool 
for studying the pathology – both behavioural and histological – of CLN6 BD.  
1.7.6 Comparing mice to ‘men’ (humans) 
The practical component of this thesis involves screening several experimental therapeutics 
for efficacy against a progressive, and therefore time-dependent, neurodegenerative 
condition. It has long been proven that interventions such as gene therapy are only effective 
when administered during their specific ‘therapeutic window’ and failure to translate this 
‘window’ from the lifespans of preclinical animal models to humans has been hypothesised as 
the reason many promising therapeutics end up failing to produce successful clinical 
outcomes, despite showing promise in the lab (Cabrera-Salazar et al., 2007; Sondhi et al., 
2008). Despite the Cln6nclf mouse having been proven to demonstrate several key features of 
human CLN6 BD, as well as sharing genes, organ systems and several aspects of systemic 
physiology with humans, it cannot be ignored that the morphometry, physiology and lifespan 
of a mouse differs significantly from that of a human (Agoston, 2017; Clancy et al., 2007; Zhao 
& Bhattacharyya, 2018). These differences should and will be taken into consideration when 
interpreting any data regarding the efficacy of a potential treatment and determining the 
optimal ‘therapeutic window’ for that treatment in humans.  
Making a direct comparison between the lifespan of a rodent, in this case the Cln6nclf 
mouse, and that of a human patient is a difficult endeavour. Various methods have been 
employed to correlate the ages of small mammals with human age. Perhaps the most 
successful, or at least most well-known, of these attempts is the standardized Carnegie staging 
system, which uses a 23-stage system to provide a unified developmental chronology of 
vertebral embryos, including those of humans and mice (DiCaglio, 2017). Unfortunately, this 
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system only extends from fertilization through to the 60th day of embryological development 
(in humans), after which the ‘embryo’ becomes known as a ‘foetus’ and the staging system 
ceases and cannot be used to compare foetal or post-natal mice to their human counterparts. 
Other methods used to compare later stages of life between humans and mice include 
determining and comparing changes in the weight of the eye lens, age and staging of 
epiphyseal closure, patterns of body weight change or tooth wear and, more recently, 
comparing the time it takes each mammal to reach ‘keystone’ stages of development: 
weaning, puberty, adulthood, reproductive senescence (menopause), and ‘old age’ (Dutta & 
Sengupta, 2016). In their 2016 paper, for example, Sulagna Dutta and Pallav Sengupta 
proposed that a precise correlation of age between mice and humans must be calculated at 
each key developmental stage over the lifespan – resulting in a changing relationship between 
‘mouse days’ and ‘human years’ over the lifespan (see Figure 1.8)(Dutta & Sengupta, 2016).  
Using Dutta and Sengupta’s model, post-natal day 0 (P0) would reflect post-natal day 
6 (P6) in human days, P28 in mice (weaning) would reflect approximately 6 human months, 
P42 in mice (puberty) would reflect 11.8 human years, P70 would reflect 27 human years and 
so on. This model is based on a simple calculation using the average lifespan of laboratory 
mice (24 months) and the average lifespan of humans (80 years): 
(80 x 365) ÷ (2 x 365) = 40 human days = 1 mouse day  
And/or 
365 ÷ 40 = 9.125 mice days = 1 human year.  
Thus, according to their calculation, one human year is equivalent to 9 mouse days 
when correlating to their entire lifespan. Recognising that this calculation is a little too 
simplistic, considering the different rates at which mice and humans develop and mature,  
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Dutta and Sengupta alter this calculation slightly for each developmental milestone, using the 
average ages at which mice and humans reach each milestone to determine a new 






Figure 1.8 ⎸Graphic abstract of Dutta and Sengupta’s comparison model for human and mouse lifespans. Dutta and Sengupta proposed a proposed that a 
precise correlation of age between mice and humans must be calculated at each key developmental stage over the lifespan – resulting in a changing 
relationship between ‘mouse days’ and ‘human years’ over the lifespan. Image taken from Dutta and Sengupta, 2016.  
 72 
 
While this model helps frame, in very simple terms, how the age of a mouse might be 
correlated to that of a human counterpart, it is flawed. For example, the model only works if 
you look at each developmental milestone in isolation: a mouse reaches puberty at P42, at 
which point you can divide 42 by 3.65 in order to calculate 11.5 human years (the approximate 
age that humans reach puberty). However, if you subtract 28 days from P42, to account for 
the fact that mice were ageing at a rate of 56.77 days = 1 human year for those first 28 days, 
you are only left with 14 days to divide by 3.65. This gives you 3.83 human years, to which you 
can add the 184 human days that mice are aged, roughly, at P28, and you have nowhere near 
the expected 11.5 human years. Therefore, it is evident that the authors intend for you to 
calculate the approximate age of your pubescent mouse, in human years, in isolation from the 
age you calculated at weaning, P28 (Dutta & Sengupta, 2016). This difference in calculation 
method could impact the way in which we interpret anatomical, physiological and behavioural 
changes that occur in a mouse between the two time points. The method used by the authors 
suggests a regular rate of development from P0 to P42, ignoring the accelerated rate you used 
to originally calculate age between P0 and P28. Using a calculation that acknowledges this 
rapid development between P0-28, however, would have to account for the mouse moving 
through the equivalent of 4013.5 days of human development over a period of just 14 days, 
and take this into account when interpreting changes in anatomy, physiology or behaviour 
between P28 and P42.  
On top of this, Dutta and Sengupta’s calculations seem to become less and less accurate 
as they progress through the lifespan of the ageing mouse, with their ‘adult stage’ equation 
correlating the age of a 6-month-old mouse (~180 days) to a 70-year-old human being. It 
becomes unclear whether they want readers to use this equation or revert to their original 
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‘entire lifespan’ equation above (in which a 180-day-old mouse would be equivalent to a 20 
year old human), but in doing so this would contradict the equation they proposed for 
‘adulthood’ (70 days in a mouse, ~25 years in a human) (Dutta & Sengupta, 2016). While Dutta 
and Sengupta’s model provides a useful framework within which to consider and compare key 
reproductive ‘milestones’ between the human and mouse species, especially around the 
period of puberty, it is evident that the model requires evidence-based modification to 
improve its accuracy and relevancy to the practical component of this thesis.  
In order to address Dutta and Sengupta’s model’s shortcomings when it comes to 
calculating later stages of life, the author of this project combined their original model with 
another, evidence-based (but far less detailed), model from the Jackson Laboratory (Flurkey 
et al., 2007). This model, shown in Figure 1.9, was developed from huge quantities of data 
using the C57Bl/6 mouse – the strain from which the Cln6nclf mouse was originally bred – and 
provides a much more reasonable estimation of ‘human age’ from animals at 6 and 12 months 
of age (both key ages for behavioural analysis in this project). The only reason this model 
wasn’t adhered to completely in the first place is due to its lack of detail surrounding birth and 
early post-natal staging, which is a key consideration because of the early stage in which this 
project’s animals were administered intracerebroventricular injections of gene therapy or a 
saline control (see Chapter 2 for more information).  
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Figure 1.9 ⎸Life history stages in C57Bl/6J mice in comparison to human beings. Data Adapted 
from Figure 20-3: Flurkey et al., 2007. “The mouse in biomedical research” in James G. Fox 
(ed.), American College of Laboratory Animal Medicine series (Elsevier, AP: Amsterdam; 
Boston). Image and abstract taken from the Jackson Laboratory’s website, “When are mice 
considered old?,”, jax.org, 2020.  
A second shortcoming of the Dutta and Sengupta model, shared by the model from the 
Jackson Laboratory, is the absence of correlation between stages of brain development in 
humans and mice, which could have significant implications for any study involving the CNS. 
The milestones chosen for calculation by Dutta and Sengupta’s model are primarily hormonal 
ones, with the criteria for each stage of life explicitly described in terms of gonadal 
development and fertility by the authors (Dutta & Sengupta, 2016). There is, of course, some 
argument to be made regarding the close relationship between endocrinological and 
neurological development, with the hypothalamic-pituitary-gonadal (HPG) axis representing 
a direct connection between the two processes, but to directly correlate hormonal and 
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neurological development risks inaccurate staging of the key processes neurological studies 
are looking to characterise. A variety of different studies show that mouse and human brain 
development differs greatly over the lifespan, especially during gestation and the first few 
weeks of life (see Figures 1.9 and 1.10)(Chini & Hanganu-Opatz, 2021; Clancy et al., 2007). For 
example, a ‘rule of thumb’ that has been applied to most rodent models is that the rat 
neurodevelopment at postnatal days 1-10 equates to the third trimester in humans, or that 
rat neurodevelopment at day P7 is equivalent to that of humans at birth (Andrews & Fitzgerald, 
1997; Clancy et al., 2007; Dobbing & Sands, 1979). The studies upon which this widely 
accepted approximation is based, however, are decades old, primarily conducted in rats, and 
several estimate neural development without empirical evidence (Dobbing & Smart, 1974; 
Dobbing, 1970, 1974; Dobbing & Sands, 1979). 
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Figure 1.10 ⎸Schematic representation of the processes guiding human and rodent brain 
(prefrontal) development. While overall brain development appears to be similar in the two 
species, individual processes occur at different relative time points and with different time 
courses. Not only are mice born at a more premature state but, even when accounting for this, 
some processes are less protracted than in humans and synaptic pruning occurs at an earlier 
stage. Image and abstract taken from Chini and Hanganu-Opatz, 2021.  
  Despite these shortcomings, the ‘third trimester’ hypothesis of brain development 
comparison is widely accepted and implemented in mouse laboratories around the world, 
including those of collaborators working on Gray Foundation preclinical and clinical trials 
running parallel with the practical component of this thesis (Best, 2017; Cain et al., 2019; 
Weimer et al., 2019; White et al., 2019). For this reason, a developmental comparison model 
used by Tseng et al. in their 2009 paper, looking at the impact of ventricular lesions on the 
 77 
development of schizophrenia-like symptoms in rats, has also been incorporated into the 
final ‘hybrid’ development model used by this thesis to compare mouse and human ages 
(Figure 1.12)(Clancy et al., Flurkey et al., 2007; Tseng et al., 2009; Dutta & Sengupta, 2016; 
Chini et al., 2021). Tseng et al.'s model (2009; Figure 1.11) takes into account the differences 
in neural development, including neurulation, synaptic pruning and gliogenesis, between 
rodents in their first seven post-natal days of life and the third trimester of the human 
foetus.  
 
Figure 1.11 ⎸Tseng et al.’s model comparing the timeline of the emergence of behavioural 
changes following the neonatal ventral hippocampal lesion in the rat and the timeline 
of the emergence of symptoms in schizophrenia in humans. While not a perfect model, 
Tseng et al’s developmental model offers some critical insight into the differences in neural 
development, including the processes of neurulation, synaptic pruning, gliogenesis and brain 
plasticity in response to trauma or disease, between rodents in their first seven post-natal days 
of life and the third trimester of the human foetus. For this reason, it has been incorporated 
into the ‘final’ model used to compare mouse and human brain development in this project. 
Image and image caption title taken from Tseng et al., 2009.  
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The final, hybridised, model used in this project to conceptualised and compare the 
lifespans of healthy and CLN6 BD-affected murine and human lifespans is depicted in Figure 
1.12. It takes into consideration the similarities and differences between the C57Bl/6 mouse, 
used in the practical component of this thesis as a healthy control and serving as the 
background strain from which the Cln6nclf mice are bred, and a healthy human’s lifespan 
(Figure 1.12.A). Despite obvous differences in length of life (with the average lifespan o a 
C57Bl/6 mouse being approximately 2 years and the average lifespan of a human being 75 
years or older, depending on the country and socioeconomic class in which they are born), 
both lifespans share several key developmental events, such as weaning and puberty, and 
both species spend the majority of their life in the post-pubescent phase known as 
‘adulthood’. From this template, one can see how different therapeutics could be given to 
mice at specific ages in order to replicate the age at which they would be given to a human 
counterpart. For instance, if you were looking to give a teenager a certain medication, you 
might consider dosing mice in a preclinical trial for that medication at some point between 
28 and 42 days of age.  
The model goes on to contrast and compare the average lifespans of athe two strains 
of mice used in the practical component of this thesis – the Cln6nclf (untreated) and C57Bl/6 
mouse strains (Figure 1.12.B). One could argue that this is a somewhat ‘easier’ or more 
direct comparison to make,  since both strains are the same species (Mus muscularis) and 
the Cln6nclf mouse was originally bred from the C57Bl/6 strain by the Jackson Laboratory 
(Bronson et al., 1999). This comparison, based on previously published literature 
surrounding the Cln6nclf mouse, is important to make as it highlights the behavioural deficits 
and truncated lifespan experienced by the Cln6nclf mouse due to its naturally occurring 
insertion mutation in the Cln6 gene. It also provides a timeline of key events over which the 
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practical component of this thesis was designed, allowing for the identification of practical 
points (6 months, 9 months and 12 months) to investigate efficacy of several small molecule 
therapies (gemfibrozil and CBD oil), alone and in combination with each other and AAV2/9-
mediated CLN6 gene therapy, in protecting Cln6nclf mice against the CLN6 BD behavioural 
phenotype (see section 1.8.1 for a summary of this project’s aims and objectives).  
Finally, the model compares the trunacted lifespan of an untreated Cln6nclf mouse and 
the average lifespan of a patient diagnosed with CLN6 BD. While this comparison 
demonstrates that both human and mice experience significant behavioural deficits and 
shortened lifespans, it also highlights some concerning differences in the timing and 
progression of the disease in each species. For instance, this model shows us that Cln6nclf 
mice tend to begin demonstrating motor deficits well into their adulthood, whereas humans 
classically start to show symptoms around 3 to 4 years of age. In fact, many human patients 
barely make it into their teenage years, the start of puberty, before reaching the end stages 
of the disease. These differences could prove problematic when trying to translate 
preclinical data into human trials – as what was successful in ameliorating or preventing 
disease in a mouse, presumably treated from birth or at least from puberty, could prove less 
efficacious when given to children who have already begun to show symptoms of motor 







⇒Figure 1.12 ⎸A three part model comparing the average lifespans of (A) C57Bl/6 mice to 
healthy humans; (B) Cln6nclf mice to C57Bl/6 mice; and (C) Cln6nclf mice to human CLN6 
BD patients (opposite page). A. Despite significantly different lengths, healthy C57Bl/6 mice 
undergo many of the same key hormonal and developmental milestones as humans. The most 
complex period of life to compare between the two species is arguably, the early 
developmental stage – with the first 7 days of life for C57Bl/6 mice often being compared to 
the third trimester in utero for humans. B. Comparing the average lifespan of C57Bl/6 mice to 
that of untreated Cln6nclf mice, as has been done in several studies prior to this project, 
highlights not only the truncated nature of the Cln6nclf lifespan but also the early emergence of 
behavioural (motor and memory/learning) deficits in the Cln6nclf strain when compared to 
C57Bl/6 controls (Poppens et al., 2019).This timeline also illustrates the observed differences 
in disease symptom onset between male and female Cln6nclf mice, although the literature finds 
that the re is no significant difference in the overall average length of life between males and 
females – suggesting males experience later onset of symptoms but more rapid disease 
progression (Poppens et al., 2019). C. Making a direct comparison between the average 
lifespan of a Cln6nclf mouse and a human patient with CLN6 BD highlights one of the biggest 
challenges to the development of efficacious therapies for CLN6 BD in humans: model 
systems, such as the Cln6nclf mouse, display markedly different disease progression. Cln6nclf 
mice, for example, don’t start showing motor deficits until approximately 6 months of age – by 
which time they are considered, developmentally, to be in ‘adulthood’. In stark comparison, 
human patients being showing motor symptoms between 3 and 4 years of age, and often don’t 
even make it t puberty, let alone adulthood. This difference in disease progression could be 
significant when translating preclinical data from a Cln6nclf model to clinical trials in humans. 
Image created by author using elements of the Flurkey et al. 2007, Tseng et al. 2009’s and 
























1.8 Summary and experimental rationale 
  
‘Batten disease’ refers to several heterogenous lysosomal-storage disorders (LSDs) of the 
nervous system known as the neuronal ceroid lipofuscinoses (NCLs). The NCLs are clinically 
characterized by debilitating neurological decline, progressive deterioration of vision and 
motor skills, personality and behavioural changes, dementia and myoclonic seizures (Haltia, 
2006; Mole et al., 2011; Rider et al., 1988; Schulz et al., 2013). Thirteen NCL variants have been 
identified to date, with a fourteenth hypothesised, and all are currently considered fatal, with 
treatments focused primarily on palliative care and symptom amelioration. Patient life 
expectancy ranges from late teens to early 30’s (Haltia, 2006; Mole & Cotman, 2015; Rider et 
al., 1988).  
Despite their overlapping clinical symptoms and pathophysiology, each form of the 
disease is genetically distinct, caused by mutations in genes encoding a range of proteins 
involved in the endosomal-lysosomal-secretory compartment (Mole & Cotman, 2015). One 
NCL-related gene, located on chromosome 15q23, encodes a non-glycosylated ER membrane 
protein, known as CLN6 (Gao et al., 2002; Wheeler et al., 2002). CLN6 has been recently 
characterised as a key component in the transport of lysosomal enzymes from the ER to the 
Golgi, and its dysfunction or absence has been associated with two types of Batten disease: a 
variant of late infantile onset NCL (vLINCL or CLN6 BD), as well as Type A Kufs disease, one of 
the few NCLs characterized by adult-onset (Kay, 2011; Kufs, 1925; Lake & Cavanagh, 1978).  
While there is currently no cure for any variant of Batten, including those caused by 
mutations in the CLN6 gene, several promising experimental therapies are being developed 
(Johnson et al., 2019; Neverman et al., 2015). These include gene therapy, which involves the 
packaging of a healthy wild-type (WT) gene (e.g. CLN6) into either lentiviral or adeno-
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associated viral (AAV) particles (Cain et al., 2019; Neverman et al., 2015; Weimer et al., 2019). 
These particles are then injected into the CNS of the CLN6 BD patient with the expectation 
that virally-transduced cells will begin to express the corrected WT gene. Gene therapy has 
been carried out, with promising results, in several preclinical trials using a variety of different 
NCL animal models (Best, 2017; Cain et al., 2019; Neverman et al., 2015). Preclinical, CLN6-
specific gene therapy has been conducted by several groups using either Cln6nclf mice or  CLN6-
/- (OCLN6) South Hampshire sheep models. These studies involved the analysis of several 
pathological parameters, including CT scans, post-mortem histopathological analysis and 
behaviour assays, to help determine if viral-mediated over-expression of the CLN6 gene will 
delay or halt disease progression in vivo (Best, 2017; Cain et al., 2019).  
Small molecule or drug compound administration is another promising field of NCL 
therapy research, one that may prove to be complementary to gene/protein-restoration 
techniques such as gene therapy or enzyme replacement therapy (Johnson et al., 2019; 
Neverman et al., 2015). Cannabidiol (CBD) and gemfibrozil are two examples of small molecule 
compounds currently being investigated as potential Batten disease therapies. CBD is a 
compound extracted from the cannabis plant, Cannabis sativa, and has been found to have 
antiepileptic, analgesic, anxiolytic, antipsychotic, antioxidative and anti-inflammatory traits, 
amongst others, in both animal and human studies (Zuardi, 2008). These traits, combined with 
CBD’s observed neuroprotective properties in Parkinson’s disease models, identify CBD as a 
potential candidate for the amelioration of several of the symptoms associated with NCLs, 
such as seizures, neuroinflammation, pain and ataxia. Madison Partridge, from the Hughes’ 
Lab, recently completed a master’s project involving the 3-month voluntary oral dosing of 
Cln6nclf mice with cannabidiol. While her results were not definitive, they did suggest that a 
longer-term administration of the drugs might result in a more statistically significant 
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difference between CBD-dosed and control groups than the one observed during her three-
month trial (Partridge, 2017). 
Aside from CBD, some preliminary small molecule work has been done with the CLN6 
BD phenotype using the lipid-lowering drug gemfibrozil (Best, 2017). Gemfibrozil is one of 
several fibrates being investigated as potential NCL therapies due to their anti-inflammatory 
and neuroprotective effect on neurons (Prahan, 2006). Preliminary data gathered from both 
in vitro and in vivo studies by the Hughes’ laboratory has been promising, warranting further 
long-term investigation into the beneficial effects of gemfibrozil for the treatment of CLN6 BD 
(Best, et al., 2017). 
To date, in vitro neural cultures and in vivo animal models have been invaluable in 
characterizing NCL disease pathologies and informing potential therapeutic strategies, such as 
those discussed above. For CLN6 BD , these have included ovine neural cultures from New 
Zealand South Hampshire sheep (OCLN6)(Best, et al., 2017; Best, 2017), mouse neural cultures 
(Cln6nclf)(Best, 2017), and in vivo ovine, murine and canine models (Best, 2017; Best et al., 
2017; Katz, et al., 2010; Morgan et al., 2013). Selecting an appropriate model with which to 
conduct further CLN6 BD research is essential. The Cln6nclf mouse was selected for the practical 
component of this thesis over larger animal models, such as sheep or dogs (which offer size 
and anatomy more similar to humans), due to the fact that this mouse, first identified by the 
Jackson Laboratory, has become recognized in the literature as an accurate, efficient and 
reliable model of human CLN6 BD and will allow for the cost-effective use of experimental 
group sizes large enough to provide statistically relevant results. The Cln6nclf model exhibits 
the key pathological features of its NCL human counterparts, including early retinal 
degeneration (~6 months of age), inflammation and associated microglial and astrocytic 
activation, the accumulation of autofluorescent cellular storage material, progressive cortical 
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atrophy and interneuron loss within the cerebral cortex and hippocampus (Morgan et al., 
2013). Finally, the use of the Cln6nclf murine model in the practical component of this thesis 
allows the work to remain consistent with past and current in vivo work being conducted by 
the Hughes lab and its collaborators (Best, 2017; Cain et al., 2019; Holthaus et al., 2019; 
Poppens et al., 2019). 
1.8.1 Aims and objectives  
The overall aim of this masters project was to investigate the efficacy of three experimental 
therapies, alone and in combination, as protection against the behavioural deficits 
experienced by untreated Cln6nclf mice. In using a well-characterised murine model of CLN6 
BD, the Cln6nclf mouse, this project will build on the results of previous, smaller, pilot studies 
investigating the therapeutic potential of AAV2/9-mediated gene therapy, gemfibrozil and 
CBD against the CLN6 BD behavioural phenotype. This project also aims to replicate many of 
the parameters of an ongoing clinical phase I/II trial of gene therapy for CLN6 BD, with the 
intention of informing potential complementary therapeutic strategies that could be used to 
augment any therapeutic effects experienced by participants. This project was also designed 
to generate novel data, as a combination therapeutic approach involving gene therapy, 
gemfibrozil and CBD has not been attempted in Cln6nclf mice, or any NCL animal model, before.  
It should also be noted that the practical component of this thesis focuses solely on 
the analysis of behavioural data and the Cln6nclf behavioural phenotype. Behavioural studies 
are only one important part of determining the efficacy of potential therapeutics and are best 
interpreted alongside post-mortem analyses. The amount of work required to conduct both 
the behavioural and post-mortem analyses would have been beyond the scope of a thesis-
only masters, and so this thesis represents only a part of a larger preclinical study being 
conducted by multiple members of the Hughes (and associated) lab(s).  
 86 
Specifically, this thesis aimed to achieve the following:  
a) To characterise an untreated Cln6nclf (UTCln6nclf) behavioural phenotype in both male 
and female animals at 6, 9 and 12 months of age, in order to distinguish a baseline UTCln6nclf 
control behavioural phenotype that could be used for comparisons when assessing the 
protective properties of gene therapy, gemfibrozil and CBD against CLN6 BD-related 
behavioural deficits.  
b) To determine whether the small molecule therapeutics, gemfibrozil and CBD, provide 
any protection against the Cln6nclf behavioural phenotype, on their own or in combination, 
without gene therapy. This will constitute the largest and most long-term study of the 
behavioural effects of either gemfibrozil or CBD in Cln6nclf mice, and the first NCL study to 
combine the two.  
c) To confirm the efficacy of AAV2/9-mediated gene therapy on its own, delivered via ICV 
injection on P0-2, in protecting against the UTCln6nclf behavioural phenotype in Cln6nclf mice.  
d) To characterise the effects of combining small molecule and gene therapies on the 
Cln6nclf behavioural phenotype and compare these effects to UTCln6nclf and healthy WT 
(C57Bl/6) mice. This will be the first study to combine gene therapy with small molecule 
therapy in the Cln6nclf mouse.  
e) To assess whether any combination of gene therapy, gemfibrozil and/or CBD offers 
any therapeutic benefit, in terms of behavioural performance, over gene therapy alone.  
f) To characterise any sex-based behavioural differences in response to the different 
therapeutic regimens.  
 
 87 
Chapter 2: Materials and Methods 
2.1 Materials  
 
For a complete list of reagents, chemicals, lab-made solutions and equipment and software 
used, see Appendix A. 
 
2.2 Project overview  
 
This project, originally designed by Stephanie Hughes and Hollie Wicky in consultation with 
the Weimer and Cooper labs and the Gray Foundation, involved the co-ordination, breeding, 
dosing, weighing and behavioural assessment of over 540 mice (see section 2.3 for more 
information on the animals and associated ethics employed) for almost two years – from 
January 2018 through until December 2019.  
The project was originally designed to have eighteen different experimental groups, 
each containing 30 animals (Table 2.1). Each experimental group was differentiated by strain 
(either C57Bl/6 or Cln6nclf), sex (male or female), whether the animals in that group received 
gene therapy or not and which oral drug they were dosed with over their lifetime (vehicle, 
gemfibrozil, cannabidiol (CBD) or a combination of gemfibrozil and cannabidiol)(Table 2.1).  
One to two days after birth (post-natal days 0-2), each mouse in every experimental 
group received an intracerebroventricular injection of either 4 µL of ‘gene therapy’ 
(scAAV9.CB.hCLN6; see section 2.4.1 for more details) or 4 µL of 1x PBS (‘no gene therapy’; 
section 2.4). Mice were then weaned at approximately 28 days and separated by their 
experimental group (Table 2.1) into enclosures that could contain up to 5 mice.  
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At approximately 30 days of age, mice began to be dosed with their allocated small molecule 
therapy via voluntary oral dosing (using strawberry flavoured jelly cubes or ‘pellets’). Mice 
were dosed every second day for the rest of their natural lives or until they reached one of 
the experimental end-points outlined in section 2.3.  
Ten mice from each experimental group (Table 2.1) were selected, at random, to 
undergo a battery of behavioural and motor skills assessments at 6 months of age (see section 
2.6 for more information on the beahvioural testing). These behavioural assays were 
conducted in a blinded manner to reduce experimenter bias. After testing, 5 of the original 10 
animals were selected randomly to be euthanised for post-mortem analyses (not included in 
this thesis).  
Similarly, 10 different mice from each experimental group (Table 2.1) were selected, 
at random, to undergo the same behavioural assays at 9 and 12 months of age (Figure 2.1). 
Further behavioural assessment was conducted on all remaining animals at 18 months of age 
but this data was not included in this thesis.  
The above outline describes the original ‘idealised’ plan for this thesis’s project. In 
reality, due to variations in litter birth timing and size, as well as the unexpected loss of some 
animals to humane end-points (see section 2.3), the number of mice that ultimately 
underwent behavioural testing in each experimental group at each time point varied 
somewhat (see Tables 2.4 and 2.5 for exact group sizes for behavioural testing). Similarly, not 
every mouse was weaned at exactly 28 days of age, started dosing at 30 days of age or began 
behavioural testing at exactly 6, 9 or 12 months of age. The Hughes Lab managed, however, 
to keep these dates within a small margin (approximately 2 days either side), and used a 
‘staggered’ approach to ensure all mice were treated and tested as close to the originally 





⇐	 Figure 2.1 ⎸Approximate timeline of the Hughes Lab’s Gray Foundation preclinical trial dosing 
regimen (previous page). Mice were divided into breeding ‘batches’ of approximately 90 animals and 
underwent neonatal i.c.v injections and began voluntary oral drug dosing (via jelly pellets) every second 
day in a staggered fashion. This allowed for all mice to receive an i.c.v injection of either 
scAAV9.CB.hCLN6 or 1x PBS at P0-2 and to be dosed every second day from 28 days of age. Similarly, 
mice were tested in a ‘staggered’ fashion to ensure all mice were 6, 9 or 12 months of age when they 
underwent testing. Image originally created by Jasmine Lock from the Hughes Lab, edited by Madeline 
McIntyre Wilson (the author). 
Table 2.1 ⎸Summary table of the different experimental groups used in the Gray Foundation trial. Each 
group had a unique combination of strain (C57Bl/6 or Cln6nclf), sex (male or female), drug treatment 
(vehicle, gemfibrozil, CBD or a combination of gemfibrozil and CBD), and gene therapy treatment 















A C57Bl/6 Yes Vehicle F 30 
B C57Bl/6 Yes Vehicle M 30 
C Cln6nclf No Vehicle  F 30 
D Cln6nclf No Vehicle M 30 
E Cln6nclf No Gemfibrozil F 30 
F Cln6nclf No Gemfibrozil M 30 
G Cln6nclf No Cannabidiol (CBD) F 30 
H Cln6nclf No CBD M 30 
I Cln6nclf No Gemfibrozil and CBD  F 30 
J Cln6nclf No Gemfibrozil and CBD M 30 
K Cln6nclf Yes Vehicle F 30 
L Cln6nclf Yes Vehicle M 30 
M Cln6nclf Yes Gemfibrozil  F 30 
N Cln6nclf Yes Gemfibrozil M 30 
O Cln6nclf Yes CBD  F 30 
P Cln6nclf Yes CBD M 30 
Q Cln6nclf Yes Gemfibrozil and CBD  F 30 
R Cln6nclf Yes Gemfibrozil and CBD M 30 
    Total 540 
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2.3 Animals  
 
All animal work was conducted in strict accordance with The Animal Welfare Act, 1999, and 
had the approval for animal husbandry, surgical procedures and use of animal tissue, granted 
by the University of Otago Animal Ethics Committee (AEC). The use of AAV in vivo in the mouse 
brain was approved by the New Zealand Environmental Protection Authority (EPA; ethics 
approval number GMD101718).  
All animals used for experimentation were either affected Cln6nclf mice or healthy wild-
type (WT) control animals from the background strain C57Bl/6. Animals were bred and 
supplied by the University of Otago’s Hercus-Taieri Research Unit (HTRU). 
After weaning at an age of ~28 days, animals were kept, in most cases, in same-sex 
group housing (2-5 mice) and monitored daily by trained HTRU staff for signs of health decline. 
Animals, when not being handled, had constant access to food, water and recreation (plastic 
cylinder and straw bedding) throughout the experiment and were kept on a strict 12-hour 
light/dark cycle. 
Animals were euthanised at one of three end-points:  
(1) at a planned, post-behavioural analysis time-point (6, 9 or 12 months) 
(2) after losing 20% of their maximum weight or 10% of their maximum weight within a 7-
day period 





2.4 Neonatal intracerebroventricular (i.c.v) injections 
 
This protocol was adapted, with consultation from the AWO veterinary team and University 
of Otago’s AEC, from the protocols used by Cain et al., 2019 and Kim et al., 2014 
2.4.1 Self-complementary (sc) adeno-associated virus (AAV) vector 
expressing human CLN6 (hCLN6) under the control of a CB promoter 
The vector used for the work presented in this thesis was cloned and packaged by the Viral 
Vector Core at the Nationwide Ohio Children’s Hospital (NWOCH) in Columbus, Ohio, USA.  
The vector was a recombinant, self-complementary (sc) adeno-associated virus 
serotype 2/9 (AAV9) vector that expressed the human gene CLN6 (hCLN6) under the control 
of the synthetic CAG (CB) promoter (scAAV9.CB.hCLN6).  
The CAG promoter consists of three parts:  
(1) the cytomegalovirus (CMV) early enhancer element  
(2) the promoter, the first exon and the first intron of a chicken beta-actin gene 
(3) the splice acceptor of the rabbit beta-globin gene (Hitoshi et al., 1991; Jun-ichi et al., 
1989).  
These elements were chosen to mirror the vector used in the 2016 Amicus Therapeutics 
CLN6 Batten disease trial (Trial No. NCT02725580, Clinicaltrials.gov). Subjects in that trial 
received a single-dose of AT-GTX-501 (scAAV9.CB.hCLN6) via intrathecal delivery.  
2.4.2 Injection apparatus  
The injection apparatus (Figure 2.2) used to deliver either AAV2/9 (NWOCH’s Viral Vector 
Core, Nationwide Ohio Children’s Hospital) or 1x PBS (Gibco™, Sigma-Aldrich NZ) was created 
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using a customised design adopted from the Weimer lab at Sanford Research, South Dakota, 
USA (Brandon Meyerink, personal communication).  
The design consisted of a 1 mL disposable slip-lock syringe (BD Luer-Lock™, Medshop 
NZ; Figure 2.2.C) with a 2 – 20 µL pipette tip (Figure 2.2.B) attached to the slip-lock nozzle and 
secured in place with fast-drying adhesive (Selleys®, Mitre10 NZ). A short (1-2 cm) piece of 
surgical silicon tubing (1 mm inner diameter; Figure 2.2.A) was attached to the cut-off tip of 
this pipette and also secured in place. Finally, custom-made glass needle tips could be inserted 
into the free end of the silicon tubing (Figure 2.2).  
After the injection protocol had taken place, the glass needle tips could be removed 
and disposed of appropriately. As the silicon tubing aged, it was either replaced or a small 
amount of fast-drying adhesive was used to secure the glass needle tips in place for each set 
of injections, to prevent the needle slipping out of the stretched tubing and to keep the 
connection air-tight.  
The glass needle tips used for all injections were made from 15.2 cm borosil glass 
capillary tubes with filament with an original outer diameter of 1 mm (World Precision 
Instruments Inc). These tubes were pulled to 1 µm outer diameter points using the University 
of Otago’s Department of Psychology’s electrophysiology micropipette puller (Sutter 
Instruments #P-97) and snapped off at the other, non-pulled, end to shorten them into 2–3 
cm lengths.  
After being inserted into the injection apparatus’s tubing and fixed into position, these 
tips were cut manually by the researchers approximately ½ cm from the point – creating a 
wider outer diameter. While the new outer diameter of the cut needle tip would vary slightly 
between needles, depending on the position at which the cut was made, the majority would 
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have been approximately 100 µm in outer diameter (Brandon Meyerink, personal 
communication). All needle tips used would have been finer than a 34 gauge (G) needle, 
hopefully reducing the amount of local tissue damage at the injection site caused by the 
insertion of the needle (Glascock et al., 2011). 
 
Figure 2.2 ⎸Weimer laboratory neonate i.c.v Injection apparatus. Consists of (A) a short (1–2 cm) piece of 
surgical silicon tubing (1 mm inner diameter), attached to (B) a 2–20 µL pipette tip with a cut-off tip, which 
is fastened to the (C) slip-lock nozzle of a disposable 1 mL slip-lock syringe. Fast-drying fixative (Selleys®, 
Mitre10), was used to keep all components firmly attached (red arrows) and a manually pulled glass 
needle tip (2–3 cm in length) would be inserted into the silicon tubing (black arrow). Photograph taken 
and edited by the author.   
2.4.3 Injection protocol  
All injections were performed with the HTRU’s Physical Containment Level 2 (PC2) biosafety 
bubble (BioBubble), with all surfaces and equipment wiped down with 10% TriGene (Merck, 
InVitro NZ) and 70% ethanol (Merck, LabSupply NZ) before and after the procedure. Personnel 
wore personal protective equipment (PPE), at all times within the BioBubble. This included 
plastic eyewear, disposable hair nets, filter masks, gloves, lab coats and shoe covers. Glass 
needle tips and any protective material that came into contact with the injection apparatus 
were disposed of in 10% TriGene after each injection session. The injection apparatus was 
cleaned thoroughly by aspiration of 70% ethanol, 10% TriGene and water after each session. 
The syringe of the injection apparatus (Figure 2.2.C) was stored with 1 mL of 3% hydrogen 
peroxide in the barrel between injection sessions.  
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Protocol training was conducted by Brandon Meyerink from the Weimer lab (Sanford 
Research, South Dakota, USA). PC2 safety training was provided by the University of Otago’s 
Department of Biochemistry Health and Safety Officer, Jackie Daniels. Viral-handling and 
safety training was provided by Hollie Wicky and Alison Clare from the Hughes lab 
(Department of Biochemistry, University of Otago, Dunedin, NZ).  
Six hundred and eighteen mouse pups, including both Cln6nclf and healthy WT controls, 
were injected on postnatal day 0-2 (P0, P1 or P2) with either 4 µL of AAV2/9 or 1x PBS. Due to 
the size of the study’s animal cohort, litters were born in groups of ~90 pups, approximately 2 
weeks apart (Figure 2.1). This ensured that all pups could be injected within the desired 2-day 
post-natal window.  
Prior to injection, pups were removed from their home cage in small groups (half a 
litter at a time). Leaving some pups with the mother while their littermates were injected 
reduced the amount of stress experienced by the mother during this procedure, as measured 
by a reduction in post-injection maternal cannibalism rates.  
Pups were originally going to be cryo-anaesthetised by being placed on a paper towel-
covered aluminium plate that had been kept in a -80℃ freezer overnight, but this method – 
recommended by Kim et al., 2014 – proved to be unsuitable as it caused the mice to fall asleep 
too quickly (under 5 minutes) and reduced their core temperatures too low. This technique 
was also found to have a high risk of freeze burn-associated tissue damage.  
For the pups welfare, this technique was modified and they were cryo-anaesthetised 
via placement on a damp paper towel in a Styrofoam box of ice. Pups were monitored closely 
and consistently throughout the anaesthesia process. This adapted method was slower than 
the original, with pups now requiring 7-10 min to reach a ‘surgical plane of general 
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anaesthesia’ (determined by an absence of the pedal withdrawal reflex), but pups revived 
quicker and the water in the towel appeared to be protective against freeze-related tissue 
damage. Post-procedural maternal cannibalism was also reduced after switching to this 
method. 
Once pups had been anaesthetised, the top of their heads were cleaned using an 
autoclaved cotton-tip applicator and 70% ethanol (Merck, LabSupply). The injection site, for 
all pups, was approximately 1 mm lateral from the sagittal suture, halfway between lambda 
and bregma, on the left hemisphere of the skull (Figure 2.3). These landmarks are visible to 
the naked eye under a good light source in murine neonates. The glass needle tips on the 
injection apparatus (Figure 2.2) were marked, either with pen or a small amount of dried super 
adhesive, at 2 mm from the tip, to ensure the injection went no deeper than 2 mm into the 
left hemisphere of the pup’s skull. This position and depth was chosen to maximise the 
chances of the AAV2/9 or 1x PBS being injected directly into the pup’s left hemisphere 
ventricle. Injection of AAV vectors into this area has been previously shown to facilitate global 
spread and transduction of the virus throughout the murine CNS, an ideal outcome for 
potential therapies of a global neurodegenerative disorder like CLN6 BD (Lock, 2018). 
 
Figure 2.3 ⎸Schematic of neonatal i.c.v injection site. Mice received a single, unilateral i.c.v injection of either 




Prior to injection, a small volume of liquid was released from the injection apparatus to 
remove any blockages and avoid the accidental injection of air bubbles. Each injection 
consisted of 4 uL of either AAV2/9 or 1x PBS, and each one was delivered to the left 
hemisphere by hand, as opposed to stereotaxic injection. The glass needle tip was left within 
the injection site for approximately 5 seconds post-delivery to reduce the amount of backflow. 
Pups were then placed on a heating pad (36.6°C, HTRU, University of Otago) with their 
littermates for 2-5 minutes in order to reverse anaesthesia.  
After being revived and returned to their home cage, animals were monitored for 5 days 
post-injection for cannibalism, pain symptoms and maternal water consumption, as per the 
University of Otago’s Animal Welfare guidelines.  
It took approximately 3-8 days to inject all ~90 pups within each litter group (Figure 2.1) 
and injections were carried out primarily by Ben Bolton (assistant research fellow, Hughes lab) 
and Madeline McIntyre Wilson (author, Hughes lab), with some done by Jasmine Lock 
(assistant research fellow, Hughes lab) and Brandon Meyerink (assistant research fellow, 








2.5 Small molecule therapy 
 
2.5.1 Weaning and jelly conditioning 
Mouse pups were weaned between 23-28 days of age. Male and female pups were separated 
into same-sex group housing (mouse ‘stock boxes’), with up to 5 mice per cage. Cln6nclf mice 
were housed with other Cln6nclf mice, and WT mice were housed with other WT mice.  
In most cases, all 2-5 mice in one group cage would be receiving the same small 
molecule therapy regimen (2.5.2 and 2.5.3 below), e.g. all mice in cage ‘x’ had been injected 
with the same treatment (AAV2/9 or 1x PBS) and would receive the same type of drug.  
After weaning, mice were given 2-3 mL of plain strawberry jelly (Champion Jelly, Trents 
Wholesaler NZ; Appendix A.2) on a ‘dosing platform’ (30 mm-diameter plastic petri dishes; 
Thermo Fisher Scientific NZ) placed in the centre of the cage. The jelly was left overnight and 
any remaining in the morning was disposed of and replaced with fresh jelly. Mice were given 
jelly every day for up to a week, until each animal in the group cage had reached the age of at 
least 28 days. This conditioning was designed to help the mice overcome any neophobia and 
accustom them to jelly as a food-source. This ‘conditioning’ step was critical for the voluntary 
oral dosing protocol. 
2.5.2 Voluntary oral dosing  
This protocol was adapted from the protocol used by Zhang & Zhang, 2011 
Each mouse began one of four small molecule therapy (drug) dosing regimens after weaning 
(approx. 1 month of age). Gemfibrozil, cannabidiol (CBD) oil, a combination of both drugs or a 
vehicle control were administered orally, suspended in a palatable, 1 mL gelatine (jelly) tablet. 
All mice were dosed every second day from weaning to their individual experimental end-
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points. Due to the staggered nature of the litter breeding for i.c.v injections (section 2.4), 
dosing was also staggered (refer to Figure 2.1).  
Table 2.2⎹ Summary table of gemfibrozil doses, based on mouse weight (in grams). Mouse weights (in 
grams) were split into 5 g ranges or ‘bins’ and all doses were calculated using the lowest weight in the 
range.  
Gemfibrozil dose rate of 120 mg/kg (0.12 mg/g; adapted from Best, 2017 and Mercer, 
unpublished thesis)  
Mouse weight ranges 
(g) 
Lowest weight in 
range (g)  Calculation 
Gemfibrozil dose 
(mg) for all mice in 
this weight range 
5 - 9 5 0.12 x 5 0.6 
10 - 14 10 0.12 x 10 1.2 
15 - 19 15 0.12 x 15 1.8 
20 - 24 20 0.12 x 20 2.4 
25 - 29 25 0.12 x 25 3 
30 - 34 30 0.12 x 30 3.6 
35-39 35 0.12 x 35 4.2 
40 - 44 40 0.12 x 40 4.8 
45-49 45 0.12 x 45 5.4 
50-54 50 0.12 x 50 6 
 
Table 2.3⎹ Summary of CBD doses, based on mouse weight (in grams). Mouse weights (in grams) were 
split into 5 g ranges or ‘bins’ and all doses were calculated using the lowest weight in the range. 
Cannabidiol dose rate of 5 mg/kg (0.005 mg/g; adapted from personal communication with 
HERBA imports)  
Mouse weight ranges 
(g) 
Lowest weight in 
range (g)  Calculation 
CBD dose (mg) for 
all mice in this 
weight range 
5 - 9 5 0.005 x 5 0.025 
10 - 14 10 0.005 x 10 0.05 
15 - 19 15 0.005 x 15 0.075 
20 - 24 20 0.005 x 20 0.1 
25 - 29 25 0.005 x 25 0.125 
30 - 34 30 0.005 x 30 0.15 
35-39 35 0.005 x 35 0.175 
40 - 44 40 0.005 x 40 0.2 
45-49 45 0.005 x 45 0.225 




In order to determine the correct dosage for each mouse, mice were weighed weekly 
from weaning, with weights rounded to the nearest gram (g). The sheer size of the study 
cohort, once all mice had been weaned, meant that it wasn’t feasible to dose mice using their 
individual, specific weights. Instead, weights were divided into a series of weight ranges, with 
each range allocated a drug-specific dose in mg (Tables 2.2 and 2.3). These doses were 
calculated using the different dose rates determined for each drug and the lightest weight in 
the weight range, producing a conservative dose for all mice with weights within that range.  
On their allocated dosing day, mice were separated from their cage-mates (up to 5 
mice per cage) by insertable dividers constructed from white corflute, a lightweight, durable 
polypropylene often used for industrial packaging. The design for these corflute dividers was 
based on a cardboard prototype created by HTRU technician Becci Gadbsy, which proved to 
be too flimsy (and edible) for long-term use. Madeline McIntyre Wilson and Ben Bolton from 
the Hughes lab, along with Peter Small, the property services manager of the University of 
Otago’s Department of Biochemistry, designed, measured, cut and constructed the corflute 
dividers specifically for the HTRU group mouse stock boxes (Figure 2.4). Approximately 150 
dividers in total were made and stored in the HTRU.  
When inserted, the corflute dividers split the stock box into five spaces which could 
comfortably fit a mouse and its ‘dosing platform’. The metal grate lid of the stock box could 
sit on top of the dividers, closing each mouse into its own enclosed space. Some stock boxes, 
due to warping and distortion caused by frequent autoclaving, required the use of bull clips 
to keep the lid firmly down on top of the divider and prevent mice climbing over the top and 
into their neighbour’s space.  
When the mice were younger and smaller, it was possible for the fifth mouse – left in 
the largest space (Figure 2.4.E) – to climb into the small space between the wall of the stock 
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box and the wall of the divider, and sometimes get stuck. To prevent this, large silicon tubing 
(2 cm-diameter; Figure 2.4) was cut into 10 cm strips and sliced vertically on one side, 
producing a circular ‘bumper’ that could be slid onto the corners of the divider, facing 
outwards into the fifth space and prevented animals moving into the small gap between the 
divider and stock box wall.  
 
 
Figure 2.4 ⎸Schematic of made-for-purpose dosing divider. Pictured in a HTRU stock box. The mae-for-
purpose divider separated stock boxes into five different areas by a dividing structure made out of corflute 
and surgical silicon tubing (blue circles). Image author’s own, created using biorender.com. 
 
Once the mice were separated and given their correct dose, they would be left to 
consume their jelly for 45-120 min. They would then be released by the removal of the dividers 
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from the stock box. Records were kept of mice who failed to consume all of their jelly within 
that time period.  
Dosing was carried out by Madeline McIntyre Wilson, Ben Bolton, Jasmine Lock, Janet 
Xu and Stephanie Hughes from the Hughes Lab, as well as by Becci, Jaye, Louise, Robyn, Fiona, 
and Matthew from the HTRU.  
2.5.3 Jelly production  
This protocol was adapted from the protocols used by Zhang & Zhang, 2011 and Mercer, 
unpublished thesis.  
Jellies were made in bulk, with the production process taking up to two days a week. An Excel 
spreadsheet was used to calculate how many individual mice were in each weight range and 
therefore how many 1 mL jelly tablets, or cubes, needed to be made up using the doses 
associated with those ranges. If a mouse was fed every second day, then at least three jelly 
tablets needed to be made, per mouse, for one week of dosing.  
If there were, for example, ten mice who all weighed between 15-19 g and were all 
receiving CBD oil only as their drug treatment regimen, then that meant that 30 jelly tablets 
needed to be made that week, with each tablet containing a CBD oil dose of 0.075 mg. This 
also meant that, for that particular group of mice, a minimum of 30 mL of jelly needed to be 
made to produce enough jelly tablets.  
This was all calculated automatically by an Excel spreadsheet for all four treatment 
regimens and across all weight ranges. The only required input was the individual weights of 
each mouse, each week. 
Jelly was made by heating one or more beakers-worth of distilled water (dH2O) to 50℃ 
using an electric kettle (Breville, Briscoes NZ), and then placing the water in beakers on a 
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magnetic stirrer hotplate (Chiltern Scientific, Thermo Fisher Scientific NZ) and adding enough 
Splenda® sweetener (Splenda®, Trents Wholesale) to create a 20% solution. A magnetic 
stirring pill was used to help dissolve the Splenda®, after which an equivalent amount of 
strawberry jelly crystals (Champion Professional, Trents Wholesale) would be added, creating 
a thick, viscous liquid. 14% gelatin and 4% methylcelluose would then be added and dissolved, 
giving the jelly a more solid consistency when it set. A hand-held immersion blender (Bodum 
Bistro, Briscoes NZ) would be used, when necessary, to help completely dissolve the gelatin 
and methylcellulose into the solution.  
Once all the components of the jelly were added and dissolved, this ‘master mix’ could 
be separated, using a measuring cylinder, into four smaller beakers: one for the gemfibrozil-
only tablets, one for the CBD oil-only tablets, one for the combination tablets and one for the 
vehicle control tablets. Each beaker would contain the correct amount of jelly required to 
make enough tablets to dose all the mice taking that drug for at least a week, so at least three 
doses per mouse. Another, smaller measuring cylinder would be used to measure out the 
amount of jelly required to make enough tablets for mice within a weight range subset for a 
given drug and that liquid jelly would be mixed, still at a temperature of 50℃, with the correct 
volume of drug stock solution to ensure that every mL of that jelly would contain the correct 
dose for mice of a certain weight.  
These sub-beakers of jelly, now each containing a specific drug at a specific 
concentration, would be poured liberally over silicon 160-well ice cube trays (12.1 cm x 23.8 
cm, Amazon). Any excess liquid jelly would be scraped off the top with a kitchen scraper. The 
trays would then be placed between two pieces of baking paper, labelled to identify the 
concentration/dosage and type of drug in the jelly, and placed in a -20℃ freezer to set 
overnight – producing trays of 160x 1 mL jelly tablets with uniform drug concentration. If the 
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amount of jelly required for that week was less than 160 mL, then several of these trays had 
been cut into half, third, quarter and even eighth sizes, allowing some flexibility in the amount 
of jelly that could be produced at one time with one drug at a specific concentration.  
All jelly was stored in containers labelled with their drug and concentration/dose at -
20℃ until needed, and could be kept frozen for up to 2 weeks.  
Twenty four-well, TC-treated, cell-culture plates (Corning® Costar®, Sigma-Aldrich NZ), 
were used and reused to distribute jelly containing the correct drug and dose to the correct 
animals (Figure 2.5). Each well in the plate was labelled with a mouse’s individual identification 
number, which contained their ear tag and an arbitrary number relating to the trial, and a 
reference sheet was used to ensure these wells received the correct jelly. Jelly was removed 
from the 24-well plates using a metal spatula and placed onto the mouse’s dosing platform 
within their divided stock box.  
 
Figure 2.5 ⎸24-well cell-culture plates for jelly storage and transportation. 24-well cell-culture plates were used to store 
and transport jelly tablets from the Biochemistry department to the individual mice in the HTRU These plates 
were washed and reused after each shipment/dosing. All wells labelled ‘NEP’ would carry jelly with the correct 
dose for the mouse in cage x with the ear-tag ‘NEP’. ‘REP’ would carry doses for the mouse with the ear-tag ‘REP’ 
etc. These plates could carry up to four doses (D1-D4) – four different days’ worth of drug treatment - over to the 
HTRU at a time, so jelly tablets could be made in bulk. Image author’s own, created using biorender.com.  
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A small subset of mice appeared to develop a jelly aversion during the study, refusing to 
eat some or – in the worst cases - any of their jelly. In order to transition these mice back into 
their planned drug therapy regimens, several alterations were made to the jelly making and 
dosing protocols: 
(1) Drug-adverse mice were returned to plain strawberry jelly (as per 2.5.1), to see if they 
were willing to eat the jelly without any drug. If they ignored the jelly, then it was 
replaced with a different flavour (e.g. lime) – also without any drug.  
(2) Once the mice were consistently eating all of their plain strawberry or plain lime jelly 
(Value, Safeway Traders NZ) tablets (minimum of three dosings), their drug was 
reintroduced at the lowest dose (e.g. the concentration they would have received if 
they still weighed ~10 g).  
(3) Once they were consistently eating this jelly (again, minimum of three dosings), then 
the dose was increased to the next weight range’s concentration. This continued until 








2.6 Behavioural Testing 
 
Due to the staggered birth of the study cohort (Figure 2.1), all behavioural assays conducted 
at 6, 9 and 12 months (12 months only for rotarod) were also staggered, with ~30 mice being 
tested every 2 weeks over a total of 2 months, per time point (Tables 2.4 and 2.5).  
The behavioural testing aspect of this study was designed to be between-subjects, 
meaning that the ~180 animals tested at each time point differed from those tested at other 
time points. ~540 animals were tested in total, across all three time points, though the mice 
and data from 12 months for ataxia is not included in this thesis due to the assessment being 
conducted by a different experimenter – Jasmine Lock. The subjective nature of the ataxia 
protocol meant that including Jasmine’s data for analysis would have meant any results might 











Table 2.4 ⎸Population table for different experimental mouse groups tested for rotarod behaviour at 6, 
9 and 12 months of age. (n)6 = number of mice tested at 6 months; (n)9 = number of mice tested at 9 
months; (n)12 = number of mice tested at 12 months; WT = wildtype; UTCln6nclf = Cln6nclf mice injected 
with 1x PBS and treated with vehicle jelly; GemfibPBS = Cln6nclf mice injected with 1x PBS and treated 
with gemfibrozil; CBDPBS = Cln6nclf mice injected with 1x PBS and treated with CBD; ComboPBS = Cln6nclf 
mice injected with 1x PBS and treated with a combination of gemfibrozil and CBD; GemfibAAV9 = Cln6nclf 
mice injected with scAAV9.CB.hCLN6 and treated with gemfibrozil; CBDAAV9 = Cln6nclf mice injected with 
scAAV9.CB.hCLN6 and treated with CBD; ComboAAV9 = Cln6nclf mice injected with scAAV9.CB.hCLN6 
and treated with a combination of gemfibrozil and CBD; No DrugAAV9 = Cln6nclf mice injected with 
scAAV9.CB.hCLN6 and treated with vehicle jelly.  
 Genotype Treatment Group Sex (n)6 (n)9 (n)12 
A WT (C57Bl/6) Vehicle (WT) M 9 9 14 
B WT (C57Bl/6) WT F 8 9 9 
C Cln6nclf 1x PBS + vehicle (UTCln6nclf) M 12 8 7 
D Cln6nclf UTCln6nclf F 9 10 8 
E Cln6nclf 1x PBS + gemfibrozil (GemfibPBS) M 10 9 7 
F Cln6nclf GemfibPBS F 10 9 8 
G Cln6nclf 1x PBS + cannabidiol (CBDPBS) M 10 15 10 
H Cln6nclf CBDPBS F 9 8 9 
I Cln6nclf 1x PBS +  
gemfibrozil and CBD (ComboPBS) 
M 10 10 10 
J Cln6nclf ComboPBS F 8 8 9 
K Cln6nclf scAAV9.CB.hCLN6 +  
vehicle (No DrugAAV9) 
M 9 10 8 
L Cln6nclf No DrugAAV9 F 10 10 10 
M Cln6nclf scAAV9.CB.hCLN6 + 
 gemfibrozil (GemfibAAV9)  
M 10 10 10 
N Cln6nclf GemfibAAV9 F 9 8 6 
O Cln6nclf scAAV9.CB.hCLN6 +  
CBD (CBDAAV9)  
M 9 8 6 
P Cln6nclf CBDAAV9 F 10 7 6 
Q Cln6nclf scAAV9.CB.hCLN6 +  
gemfibrozil and CBD (ComboAAV9) 
M 9 10 8 
R Cln6nclf ComboAAV9 F 10 9 12 










Table 2.5 ⎸Population table for different experimental mouse groups tested for ataxia behaviour at 6, 
and 9 months of age. (n)6 = number of mice tested at 6 months; (n)9 = number of mice tested at 9 
months; WT = wildtype; UTCln6nclf = Cln6nclf mice injected with 1x PBS and treated with vehicle jelly; 
GemfibPBS = Cln6nclf mice injected with 1x PBS and treated with gemfibrozil; CBDPBS = Cln6nclf mice 
injected with 1x PBS and treated with CBD; ComboPBS = Cln6nclf mice injected with 1x PBS and treated 
with a combination of gemfibrozil and CBD; GemfibAAV9 = Cln6nclf mice injected with scAAV9.CB.hCLN6 
and treated with gemfibrozil; CBDAAV9 = Cln6nclf mice injected with scAAV9.CB.hCLN6 and treated with 
CBD; ComboAAV9 = Cln6nclf mice injected with scAAV9.CB.hCLN6 and treated with a combination of 
gemfibrozil and CBD; No DrugAAV9 = Cln6nclf mice injected with scAAV9.CB.hCLN6 and treated with 
vehicle jelly.  
 Genotype Treatment Group Sex (n)6 (n)9 
A WT (C57Bl/6) Vehicle (WT) M 9 9 
B WT (C57Bl/6) WT F 8 9 
C Cln6nclf 1x PBS + vehicle (UTCln6nclf) M 12 8 
D Cln6nclf UTCln6nclf F 9 10 
E Cln6nclf 1x PBS + gemfibrozil (GemfibPBS) M 10 9 
F Cln6nclf GemfibPBS F 10 9 
G Cln6nclf 1x PBS + cannabidiol (CBDPBS) M 10 15 
H Cln6nclf CBDPBS F 9 8 
I Cln6nclf 1x PBS +  
gemfibrozil and CBD (ComboPBS) 
M 10 10 
J Cln6nclf ComboPBS F 8 8 
K Cln6nclf scAAV9.CB.hCLN6 +  
vehicle (No DrugAAV9) 
M 9 10 
L Cln6nclf No DrugAAV9 F 10 10 
M Cln6nclf scAAV9.CB.hCLN6 + 
 gemfibrozil (GemfibAAV9)  
M 10 10 
N Cln6nclf GemfibAAV9 F 9 8 
O Cln6nclf scAAV9.CB.hCLN6 +  
CBD (CBDAAV9)  
M 9 8 
P Cln6nclf CBDAAV9 F 10 7 
Q Cln6nclf scAAV9.CB.hCLN6 +  
gemfibrozil and CBD (ComboAAV9) 
M 9 10 
R Cln6nclf ComboAAV9 F 10 9 
   Totals 180 169 
 
2.6.1 Ataxia phenotyping  
This protocol was adapted from Guyenet et al’s (2011) “Simple composite scoring system for 
evaluating mouse models of cerebella ataxia”. A video explaining how scores are assigned for 
each test can be found at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121238/ 
Ataxia phenotyping is a subjective assay that allows the quantification of disease 
severity in mouse models of neurological diseases that demonstrate an ataxic phenotype (like 
CLN6 BD). Measurable tasks include a ledge test, hindlimb clasping and a gait test. Each task 
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is assigned a score on a scale of 0-3, with a combined or ‘composite’ score calculated for all 
three tasks. A score of 0 represented an absence of the diseased phenotype, while a score of 
3 represented it’s most severe manifestation (Guyenet et al., 2010).  
The experimenter conducting the behavioural tests had no prior knowledge of the 
animals’ genotypes (blinded study design).  
Animals were run through all three tasks in sequence (one after the other), before 
being returned to their home cage and given a 15 to 20 minute break. After that break, they 
would repeat the sequence again. All animals would perform three sequences or trials, 
earning a total of 9 scores between 0-3 (3 score values per task).  
2.6.1.a The ledge test 
The ledge test is a measure of motor coordination and balance, which is traditionally impaired 
in ataxic neurological disorders like CLN6 BD.  
Animals were lifted from their home cage and placed on the ledge of another, empty 
‘testing’ cage. Unaffected mice will typically grasp the ledge with all four feet and walk along 
the ledge comfortably before lowering themselves to the cage floor, landing gracefully on 
their front paws. This behaviour is assigned a score of 0.  
If an animal loses its footing briefly while walking along the edge, but otherwise seems 
coordinated, then it is assigned a score of 1. If it does not effectively use its hindlimbs, dragging 
them or clutching the sides of the cage wall with them, and/or lands on its head rather than 
its paws while lowering itself to the cage floor, then it is assigned a 2.  
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If the animal falls off the ledge completely, or almost does so, while walking or attempting to 
lower itself to the cage floor, or refuses to move along the ledge even when encouraged, then 
this warrants a score of 3. Scores were recorded on an Excel spreadsheet (Microsoft® Office). 
2.6.1.b The hindlimb clasping test 
Hindlimb clasping is a common marker of disease progression in many neurodegenerative 
disease mouse models, including Cln6nclf . Unaffected mice will typically abduct their hindlimbs 
when held upside down by the base of their tail (Figure 2.6). This abduction is, presumably, to 
help them grasp onto nearby objects and/or balance themselves while they are suspended. 
Mice who display an ataxic phenotype have difficulty keeping their hindlimbs abducted out 
from their body, and involuntarily retract them in towards their midline (Figure 2.6).  
Animals were lifted from their home cage by the base of their tail and lifted clear of 
surrounding objects (approximately 10 cm from a bench surface). The hindlimb position was 
observed by the experimenter for a total of 10 seconds, before the animal was place back in 
its cage. During that 10 second interval, if the hindlimbs were consistently abducted laterally, 
away from the abdomen, then the animal was assigned a score of 0.  
If one hindlimb was retracted towards the abdomen for more than 50% of the 10 
second window, then the animal was assigned a score of 1.  
If both hindlimbs were partially retracted towards the abdomen for more than 50% of 
the time then the animal was assigned a score of 2.  
Finally, if both hindlimbs were completely retracted in towards the abdomen or 
‘clasping’ then the animal was assigned a score of 3 (Figure 2.6). Scores were recorded in an 





Figure 2.6 ⎸Hindlimb clasping phenotype scoring system. Image adapted from Zhu et al., 2016. 
2.6.1.c The gait test 
The gait test subjectively assesses muscle co-ordination and function. In this test, the 
experimenter observes the animal’s hindlimbs as it walks around on a flat surface. Unaffected 
mice will walk normally, distributing weight on all four paws, with their belly close to – but not 
touching – the ground. Mice experiencing neurological symptoms may display limping, 
dragging, tremors, or uneven weight distribution on their hindlimbs, or may be unwilling to 
move around at all.  
Animals were removed from their home cage and placed on a clean, flat surface (a 
stainless steel bench in the University of Otago HTRU). The animals were encouraged to walk 
away from the experimenter, so that their hindlimb movements could be observed. If the 
animal walked normally, with a confident, fluid gate absent of any tremors or limping, then it 
was assigned a score of 0. If it showed a tremor or appeared to limp while walking, it was 
assigned a score of 1. If the animal had a severe tremor, severe limp, lowered pelvis or “duck 
feet” (feet pointing away from the midline of the body during movement), then it was assigned 
a score of 2. If the animal had difficulty moving forward and/or dragged its abdomen on the 
ground, it was assigned a score of 3.  
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2.6.1.d A quick note about ataxia statistical analyses 
The data collected from these three tests, as well as the subsequently calculated composite 
phenotype score that was scored between 0 and 9, are presented as averaged means with ± 
standard error of the mean (±SEM). This is a divergence from standard statistical protocol, 
which usually requires ordinal data – that is, data that is ranked or has an inherent order to it 
– to be presented using median scores as a measure of central tendency and the data set’s 
range or a confidence interval (CI) of 95% as the measure of spread.  
The decision to present our ataxia phenotyping data using the mean and ±SEM was 
based on several factors: first, the original protocol from which our behavioural assay was 
adapted, published by Guyenet et al. (2010), presents their example data using mean and 
±SEM, rather than the more traditional median and range.  
Second, our collaborators – namely the Weimer lab from Sanford Research in Sioux 
Falls, SD – used mean and ±SEM in two of their most recently published BD papers, both of 
which examined the ataxic phenotypes of Cln6nclf mice under various experimental conditions 
(Cain et al., 2019; White et al., 2019). Discrepancies in statistical methodology between our 
work and theirs would make drawing meaningful comparisons difficult, if not impossible.  
Finally, a brief foray into statistical literature revealed that the statistical community 
has not reached a consensus when it comes to the application of parametric or ‘metric’ 
analyses to ordinal data. While many of the more ‘conservative’ statisticians insist on ordinal 
data should always be analysed using either a median or mode and non-parametric testing, 
there is a growing community of statisticians who argue that many forms of ordinal data – 
such as the data presented in this thesis – have inherent ‘interval’ like qualities that lend 
themselves to accurate analyses using parametric testing and a mean measure of central 
tendency (Carifio & Perla, 2008; Norman, 2010).  
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Taking these factors into consideration, data for ataxia phenotyping in this thesis will be 
presented using mean and ± SEM and analysed via parametric testing, where normality allows.  
2.6.1.e Repeated measures 
As mentioned above, all the tasks in 2.6.1.1-3 were repeated three times on the testing 
day. These tasks were also recorded and the video was analysed at a later date by the same 
experimenter who conducted the ataxia tasks. This meant that each individual animal ended 
up having 6 repeated measures for each task, 3 taken on the day, and 3 given from the 
recording.  
Since three composite scores (0-9) were calculated by adding the triad of task scores 
(0-3) from the three trials on the day, an extra three composite scores were also produced by 
the scoring of the three trials of the three tasks via video at a later date.  
All scores for each task were averaged for analysis (Appendix A.4), including the 
composite scores. Data was then imported into GraphPad Prism (v8) for statistical analysis. 
The data presented in Chapter 3 (Results) represents the average (mean) scores for each task 
(and the composite ataxia scores) for each experimental group, ± SEM.  
2.6.2 Rotarod performance testing 
This protocol was adapted from a protocol provided by the Weimer lab at Sanford Research, 
Sioux Falls, SD, USA (personal communication). 
The rotarod performance test is a classic assay used in the psychological and 
neurosciences to assess motor co-ordination, balance and endurance in rodents. The 
parameters measured are typically ‘latency to fall’ (sometimes also referred to as ‘duration’) 
and an associated ‘rotations per minute (RPM) at fall.  
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In this study sub-cohorts of ~180 different mice (~10 from each experimental group listed in 
Table 2.4) were assessed at 6, 9 and 12 months. The protocol was split into two parts: training 
and testing. Each part consisted of three trials per animal, with the data collected from the 
testing trials used for statistical analysis. All trials were conducted using Med Associates Inc’s 
Five Lane Rota-Rod for Mice and Rota-Rod 2 Software (Appendices A.3 and A.4).  
In each trial, up to five animals were placed on the rod while it was stationary. Once 
all animals had been ‘loaded’, the rod would begin to rotate at a constant acceleration of 0.2 
rpm/s from 0 to 48 rpm. Each trial had a maximum duration of 300 seconds, meaning that 
once the rod had reached 48 rpm at 240 seconds, the rod would continue to rotate at 
maximum speed for a further 60 seconds. During the trial, each animal’s latency to fall (in 
seconds) would be recorded automatically by the Rotarod, along with the associated rpm of 
the rod at the time the animal fell.  
Three training trials would be conducted in the morning, with animals receiving an 
hour break in between trials. The three testing trials would then occur in the afternoon on the 
same day, also separated by rest intervals of an hour.  
Only the afternoon (testing) trials data and the latency to fall (in seconds) parameter 
were used for statistical analysis. Each animal had three repeated measures of latency to fall, 
which were averaged. For each trial, an individual animal could receive a continuous latency 
to fall score between 0 and 300 sec, with a higher score representing an indirect measure of 
superior motor co-ordination compared to lower scores.  
Averaged data from all mice was imported into GraphPad Prism (v.8) for statistical 
analysis, with the data presented in Chapter 3 representing the mean behavioural scores of 
each experimental group, ± SEM (Appendix A.4). 
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Chapter 3: Results 
3.1  Untreated Cln6nclf mice demonstrate expected behavioural deficits 
by 9 to 12 months of age  
Previous behavioural studies using the Cln6nclf murine model have identified a characteristic 
decline in motor co-ordination and development of hindlimb ataxia analogous to the motor 
symptoms experienced by human CLN6 BD patients (Best, 2017; Cain et al., 2019; Morgan et 
al., 2013). Since some genetic mouse models have been known to experience phenotypic 
discrepancies due to genetic drift after too many generations of inbreeding (Benavides et al., 
2019; Stevens et al., 2007; Zeldovich, 2017), it was critical to replicate and confirm the 
presence of this Cln6nclf behavioural phenotype in this study’s cohort of Cln6nclf mice. 
Characterising the untreated Cln6nclf (UTCln6nclf) behavioural phenotype in this study also lent 
itself to the development of a ‘diseased’ baseline overall, which was invaluable for further 
comparisons to the treated Cln6nclf groups and eliciting any protective effects of the various 
therapeutics being tested (sections 3.2 to 3.5).  
Four different tests were used to assess mice for motor skill and co-ordination, as well 
as screen them for ataxic behaviours, at 6, 9 and 12 months of age: the rotarod, the ledge test, 
the hindlimb clasping test and the gait test (see Chapter 2 for more info). In order to determine 
whether a diseased phenotype was present in UTCln6nclf mice (defined as Cln6nclf mice that 
received 1x PBS injection at P0-2 and were only dosed with vehicle jelly), their behavioural 
scores were compared and contrasted with those of healthy, age- and sex-matched ‘wildtype’ 
(WT; C57Bl/6s) controls at each time point.  
Sex differences in UTCln6nclf scores were also assessed, due to recent studies using the 
Cln6nclf mouse model that indicate females experience accelerated disease progression 
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compared to males (Cialone et al., 2012; Poppens et al., 2019). Identifying sex differences in 
pathology is important, and historically overlooked, when considering the translation of 
preclinical mouse studies into clinical applications (reviewed in Beery & Zucker, 2011 and Jazin 
& Cahill, 2010). 
3.1.1  The Cln6nclf disease(d) phenotype: rotarod 
The overall rate of decline in UTCln6nclf rotarod scores, and the range over which this decline 
occurred – known as the ‘elevation’ – was assessed and compared to the scores of their age-
matched WT counterparts across the 6, 9 and 12 month time points using linear regression 
(Table 3.1; Appendices B.2 and B.3). Multiple unpaired student t-tests (Appendices B.4.1-B.2) 
were also used to separately assess differences between age- and sex-matched experimental 
groups within each time point (Figures 3.1 B and C).  
Parametric testing was found to be suitable for these analyses as the data collected – 
scores measured as latency to fall (seconds) - is nominal and the experimental groups being 
assessed were found to have a normal (Gaussian) distribution at all three time points 
(D’Agostino-Pearson test; Appendix B.1.1). Data for the rotarod are presented as mean scores 
± SEM (Figure 3.1 A-C).  
The mean rotarod scores of both UTCln6nclf and WT mice – for both sexes – demonstrate 
a decline in motor co-ordination and balance over the three time points assessed, with each 
experimental group producing a negative gradient (m) in their linear equations (Appendix 
B.2.2). This was to be expected, irrespectve of genetic background or sex, due to an increase 
in age being associated with declining motor skills, even in ‘healthy’ C57Bl/6 mice (Barreto et 
al., 2010; Shoji et al., 2016).  
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While male and female UTCln6nclf mice had lower mean scores than their WT 
counterparts at every time point measured, the difference between the overall rates of 
decline in male and female UTCln6nclf mice compared to WT were found to be not significant 
(linear regression; male p = .0607; female p = .0629; Appendices B.2.1 and B.3).  
The use of multiple t-tests (Appendices B.4.1-4.2) to compare mean scores of male 
and female UTCln6nclf mice against their WT counterparts at each individual time point 
supported this non-significant result until 12 months of age, at which point the difference 
between mean Cln6nclf scores was found to be significantly lower (worse) than their WT 
counterparts for both sexes (Figure 3.1 B and C; male p = .0041; female p ≤ .001; Appendices 
B.4.1-4.2).  
Despite the overall rate of decline of UTCln6nclf mice being statistically indistinguishable 
from their WT counterparts, the overall elevations of both male and female UTCln6nclf mean 
scores were found to be significantly lower than WT (Figure 3.1; male p = .0014; female p = 
.0104; Appendices B.2.2). This could either indicate a task learning deficiency in UTCln6nclf mice 
at each individual time point, or simply reflect their inability to achieve equivalent motor co-
ordination scores to WT at any tested age due to disease-related sensorimotor deficiencies. 
Either scenario would be consistent with previously described cognitive and motor deficits in 
the UTCln6nclf mouse model (Cain et al., 2019; Gao et al., 2002; Morgan et al., 2013; Poppens et 
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⇐	Figure 3.1 Establishing the Cln6nclf disease(d) phenotype: rotarod scores (opposite page). Lower mean 
rotarod scores compared to wildtype (WT; C57Bl/6) are present across all three tested time points in the 
untreated Cln6nclf (UTCln6nclf )mouse model, for both genders, but not significant until 12 months of age. 
A. Rotarod behavioural testing was performed on female and male UTCln6nclf and WT mice at three 
different time points. Testing was conducted using Med Associates Inc’s Five-Lane RotaRod for Mice 
(Appendix A.3). Averaged means of latency to fall (in seconds; line graph) are presented for male and 
female WT (male = black squares; female = grey circles) and UTCln6nclf (male = red squares; female = 
maroon circles) animals at 6, 9 and 12 months of age, with error bars = ± SEM). Different groups of mice 
were tested at each time point (between-subjects study design). A high score (~300) indicates a high 
level of motor co-ordination as measured by the rotarod, while lower scores correlate to increasing levels 
of motor dysfunction (coloured arrow on the left). No significant differences in mean rotarod score were 
found between UTCln6nclf mice and their WT age- and sex-matched WT counterparts until 12 months of 
age. Analyses at each time point between gender-matched WT and UTCln6nclf groups were performed 
using multiple paired student t-tests (Appendices B.4.1-4.2). Linear regression analysis (solid lines; 
Appendices B.2-3) showed progressive decline in motor performance for all mice, irrespective of sex or 
strain, as summarised in Appendix B.2.2. No significant difference in overall rate of decline between 
UTCln6nclf mice and their sex-matched WT counterparts was found (male p = .0607; female p = .0629; 
Appendices B.2-3 ), but elevations for both male and female UTCln6nclf animals were determined to be 
significantly lower (male p = .0014; female p = .0104; Appendix B.2.2). n = 25-32. B. Histogram of mean 
rotarod scores (latency to fall; in seconds) of male UTCln6nclf mice (red bar on right) and their age- and 
sex-matched WT (white bar on left) controls at 12 months of age – the only time point measured where 
a significant difference was seen between the two groups’ scores. Error bars = ± SEM. Clear circles 
indicate individual animal rotarod scores (averaged from three trials). Male UTCln6nclf animals showed 
significantly reduced ability to stay on the rotarod at 12 months of age (unpaired student t-test; UTCln6nclf 
mean = 61.14 seconds; WT mean = 131.5 seconds; ** p = .0012; Appendix B.4.1). n = 7-14. C. 
Histogram of mean rotarod scores (latency to fall; in seconds) of female UTCln6nclf mice (maroon bar on 
right) and their age- and sex-matched WT (C57Bl/6; grey patterned bar on left) controls at 12 months of 
age – the only time point measured where a significant difference was seen between the two groups’ 
scores. Error bars = ± SEM. Clear circles indicate individual animal rotarod scores (averaged from three 
trials). Female UTCln6nclf animals also showed significantly reduced ability to remain on the rotarod at 12 
months of age (unpaired student t-test; Cln6nclf mean = 71.25 seconds; WT mean = 170.4 seconds; *** 
p = .002; Appendix B.4.2). n = 7-8.  
3.1.2 The Cln6nclf disease(d) phenotype: ataxia 
Three separate tasks, performed sequentially, were used to assess mice for the presence or 
absence of ataxia: the ledge test, the hindlimb clasping test, and the gait test (Figure 3.3). 
Ataxia, defined as ‘the loss of full control of bodily movements’ (from the Greek a- meaning 
‘without’ and taxis meaning ‘order’), is a commonly observed phenotype in the Cln6nclf mouse 
model and mirrors ataxic symptoms experienced by many human CLN6 BD patients (Cannelli 
et al., 2009; Morgan et al., 2013). 
In these tests, unlike the rotarod (section 3.1.1), a ‘high score’ indicates an increase in 
expression of the diseased phenotype. Each task was scored from 0 to 3, with a score of 0 
indicating an animal demonstrated no ataxic behaviour, while a score of 3 indicated a fully 
penetrant ataxic phenotype. The data collected from these three tests, as well as the 
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subsequently calculated composite phenotype score that was scored between 0 and 9 (Figure 
3.2), are presented as averaged means with ± SEM (Figures 3.2 – 3.3).  
3.1.2.a Composite ataxia phenotype scores 
Calculating a composite ataxia phenotype score for each mouse not only allows for greater 
statistical power when analysing results (Guyenet et al., 2010), but also lets researchers 
develop a more comprehensive overview of an individual animal’s or experimental group’s 
ataxic phenotype. Each assay is used to assess a different facet of ataxia and the composite 
score reduces the likelihood of a false positive or negative from one assay causing an animal 
or group to be misinterpreted as ‘healthy’ or ‘ataxic’. Twelve-month data for each 
experimental group in this study was also collected by a different experimenter (J. Lock) but 
excluded from this analysis due to the subjective nature of scoring and the inconsistencies this 
could create when looking at trends over time.  
Mean composite scores were calculated by averaging the mean scores of individual 
ataxia assays (ledge, hindlimb clasping and gait) – these scores, in turn, had been calculated 
by averaging the scores of six trials for each assay (3 conducted in-person, 3 conducted via 
watching footage of the original trials). The experimenter was blinded at the time of scoring 
for both in-person and footage assessments.  
Comparisons between mean composite scores of UTCln6nclf and WT mice were made 
using unpaired student t-tests, with separate analyses being conducted for each sex 
(Appendices B.5.1-5.2). Parametric testing was found to be suitable for these analyses as the 
despite the data collecting being ordinal (see discussion regarding ordinal data in Chapter 2), 
and the experimental groups being assessed were found to have a normal (Gaussian) 
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distribution at both time points (D’Agostino-Pearson test; Appendix B.1.2). Data are 
presented as mean composite scores ± SEM. 
No significant difference in mean composite ataxia score was observed between 
UTCln6nclf and WT controls for either sex at 6 months of age (Figure 3.2.Ai), though the mean 
score of UTCln6nclf was non-significantly higher (worse) than WT for both 6 month males and 
females.  
At 9 months, however, both male and female UTCln6nclf mice (male UTCln6nclf = 4.833 ± 
0.321; female UTCln6nclf = 5.00 ± 0.243) demonstrated significantly worse (higher) mean 
composite scores than their WT counterparts (male WT = 2.574 ± 0.222; p ≤ .0001; female WT 








Figure 3.2 ⎸ Establishing the Cln6nclf disease(d) phenotype: composite ataxia scores. Significant motor 
co-ordination deficits, as measured by composite ataxia phenotyping, are present in both male and 
female untreated Cln6nclf (UTCln6nclf ) mice by 9 months of age. Mean composite ataxia phenotype scores 
were calculated using mean scores from three trials each of ledge, hindlimb clasping and gait tests for 
male and female UTCln6nclf and wildtype (WT; C57Bl/6) mice at two different time points: 6 months (Ai-ii) 
and 9 months (Bi-ii). Different mice were tested at each time point (between-subjects study design). 
Averaged means of composite ataxia scores for WT (male = plain white bars; female = patterned grey 
bars) and UTCln6nclf (male = plain red; female = plain maroon) animals are presented in histograms for 6 
(Ai-ii) and 9 (Bi-ii) months of age. A low score (close to 0) indicates an absence of the ataxic phenotype 
as measured by the composite scoring system, while higher scores, closer to 9, indicate increasing levels 
of ataxic behaviour (coloured arrow on the left). The overall mean composite scores illustrated in Ai and 
Bi are further broken down into the average ledge (bottom), hindlimb clasping (middle) and gait (top) 
scores that comprise them in segmented bar graphs (Aii and Bii). Individual mouse composite scores 
are shown as clear circles in Ai and Bi, and error bars = ± SEM. Analyses between UTCln6nclf and their 
age- and sex-matched WT (C57Bl/6) controls were conducted via unpaired student t-tests at each time 
point for each sex (Appendices B.5.1-5.2). n(per group per time point) = 8-10. Ai-ii No significant 
difference was observed between the average composite scores of UTCln6nclf mice and their age- and 
sex-matched WT counterparts for either males or females at 6 months of age (unpaired student t-test; 
Appendices B.5.1-5.2), though UTCln6nclf animals appear to have (non-significantly) higher (worse) mean 
scores for both sexes. Bi-ii. Both male and female UTCln6nclf mice perform significantly worse than their 
age- and sex-matched WT counterparts at 9 months of age (unpaired student t-test; male WT mean 
=2.574 ; male UTCln6nclf lf mean = 4.833 ; **** male p ≤ .0001; female WT mean = 2.407 ; female UTCln6nclf 



































































































































































































































3.1.2.b Ledge test 
Mice were placed on the ledge of their home cage’s wall and were assigned a grade between 
0 and 3 based on their ability to (a) walk along the ledge, (b) lower themselves gracefully to 
the cage floor or (c) a combination of the two activities (see Chapter 2 for a more detailed 
description of the grading criteria). The ledge test is purported to assess behaviours in murine 
models that are most similar or representative of human ataxias, and is designed to measure 
co-ordination, balance and fine motor control, all of which are known to be compromised in 
human CLN6 BD patients (Cannelli et al., 2009; Guyenet et al., 2010).  
In male mice, a series of paired student t-tests† (Appendix B.6.1) revealed that UTCln6nclf 
mice performed significantly worse at the ledge test than their age-matched WT counterparts 
at both the 6 (p = .0062 ) and 9 month ( p = .0017 ) time points (Figure 3.3.A). Several previous 
studies using the Cln6nclf murine model have indicated that diseased mice should not yet be 
demonstrating significant behavioural deficits at 6 months of age, though this is by no means 
a consistent finding across all CLN6 BD animal studies and could also be assay-dependent, with 
some tests being higher resolution and/or more subjective than others.  
UTCln6nclf female mice, on the other hand, only begin to perform significantly worse 
than WT (female WT = 1.407 ± 0.204) in the ledge test at 9 months of age (female UTCln6nclf = 
2.200 ± 0.113; p = .0028; Figure 3.3.B; Appendix B.6.2). This finding is consistent with studies 
across several variants of BD that suggest females experience disease onset later than males, 
but consequently experience accelerated disease progression (Cialone et al., 2012).  
 
† All ledge, hindlimb clasping, and gait ataxia test data for the experimental groups being analysed in this section 
demonstrated normal (Gaussian) distribution (Appendices B.1.3-1.5), with three exceptions (see Appendices), so 
parametric testing was deemed appropriate in both this instance and when looking at the individual ataxic assays. The 
exceptions were treated as parametric/normal on advice of a statistician. If the majority of experimental group’s scores had 
been found to have non-normal distribution, then a non-parametric test, the Mann-Whitney test, would have been used 
instead of the unpaired student t-test.  
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3.1.2.c Hindlimb clasping test 
Aberrant clasping of the hindlimbs is a well characterised ataxic marker of disease progression 
in several neurodegenerative murine models, including Cln6nclf (Guyenet et al., 2010; Lalonde 
& Strazielle, 2011). Comparisons between experimental groups were made at different time 
points using unpaired student t-tests (Appendices B.7.1-7.2). Different mice were measured 
at each time point, making this assay between-subjects in design. Data are mean hindlimb 
clasping scores ± SEM. 
While all UTCln6nclf hindlimb clasping scores were statistically indistinguishable from 
healthy WT scores at 6 months of age, both male and female UTCln6nclf mice in this study 
demonstrated a marked hindlimb clasping phenotype, in comparison to WT controls, by 9 
months (Figure 3.3 C-D).  
At 9 months, UTCln6nclf males had an average clasping score of 1.875 ± 0.178 (Figure 
3.3.C) and females had an average of 1.950 ± 0.259 (Figure 3.3.D) . This indicated, that, on 
average, male and female UTCln6nclf mice were involuntarily retracting at least one limb in 
towards the midline of their body for over 50% of the 30 seconds they were suspended by 
their tail. Healthy WT controls, in comparison, were averaging 0.370 ± 0.196 (males) or 0.741 
± 0.206 (females) – average scores that were significantly lower than their sex-matched 
UTCln6nclf counterparts (male p = .0048; female p = .002; Appendices B.7.1-7.2). 
3.1.2.d Gait test 
In humans, gait disturbance is a common and early symptom of cerebellar ataxia in a wide 
range of neurological conditions – including BD (Cannelli et al., 2009; Schulz et al., 2013). In 
rodent models, gait is often used to assess general motor co-ordination and muscle function 
as an indirect measure of cerebellar ataxia (Guyenet et al., 2010). Comparisons between 
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experimental groups were made at different time points using unpaired student t-tests 
(Appendices B.8.1-8.2). Different mice were measured at each time point, making this assay 
between-subjects in design. Data are mean gait ataxia scores ± SEM. 
In male mice, the first significant difference in mean gait scores was seen at 9 months, 
with UTCln6nclf mice demonstrating a more obvious ataxic gait phenotype (0.875 ± 0.108) than 
WT (0.407 ± 0.118; p = .0111; Appendix B.8.1). Female UTCln6nclf mice did not demonstrate a 























































































































































































































































































































































































⇐	Figure 3.3 ⎸ Establishing the Cln6nclf disease(d) phenotype: ataxia phenotyping scores (opposite 
page). Both male and female untreated Cln6nclf (UTCln6nclf) mice demonstrate significant ataxic 
phenotypes by 9 months of age. Mice underwent three trials of a sequence three different ataxia assays 
– the ledge test, the hindlimb clasping test and the gait test (adapted from Guyenet et al., 2010) – in 
order to determine the presence or absence of an ataxic phenotype at 6 and 9 months of age. Different 
mice were assessed at each time point, making the experiment between-subjects in design. For each 
assay, a mouse could be assigned a score between 0 and 3, with 0 indicating a complete absence of 
the ataxic phenotype and 3 indicating a completely penetrant ataxic phenotype (coloured arrows on the 
left). All data (A-F) are presented as the mean of averaged (3 trials; scored from 0-3) individual mouse 
scores, with clear circles representing the individual averaged scores. Error bars = ± SEM. All analyses 
were conducted using unpaired student t-tests between sex and age matched experimental groups 
(Appendices B.6.1-8.2). A and B. Histograms of mean ledge test scores. Male (A) and female (B) 
UTCln6nclf (male = plain red bars; female = patterned maroon bars) and WT (C57Bl/6; male = plain white 
bars; females = patterned black and white bars) mice were placed on top of the wall of their home cage 
and allowed to walk along this ledge and/or lower themselves to the cage floor. Male UTCln6nclf mice 
demonstrated significantly more ataxic behaviour (higher score) compared to WT (black) at both 6 
months (WT mean = 0.7278; UTCln6nclf mean = 1.40; ** p = .0062; Appendix B.6.1) and 9 months (WT 
mean = 1.407; UTCln6nclf mean = 2.083; ** p = .0017; Appendix B.6.1) of age. Female UTCln6nclf mice, 
however, only begin to demonstrate significant deficits compared to WT at 9 months (WT mean = 1.407; 
UTCln6nclf mean = 2.200; ** p = .0028; Appendix B.6.2). n(per group per time point) = 8-12. C and D. 
Hindlimb clasping test scores. Mice were suspended for 30 seconds and their hindlimb positions 
assessed according to Guyenet et al. (2010). Both male and female UTCln6nclf only begin to show a 
significant ataxic phenotype (when compared to WT) at 9 months of age (male WT mean = 0.7407; male 
UTCln6nclf mean = 1.875; ** p = .0048; Appendix B.7.1; female WT mean = 0.3704; female UTCln6nclf mean 
=1.950; ***p = .0002; Appendix B.7.2). n(per group per time point) = 8-12. E and F. Gait test scores. 
Only 9-month-old male UTCln6nclf mice demonstrated a significantly more ataxic phenotype than their age- 
and sex-matched WT counterparts in the gait test, with a significantly higher (worse) mean score at 9 
months of age (WT mean = 0.4074; UTCln6nclf mean = 0.8750; * p = .0111; Appendix B.8.1). Female 
UTCln6nclf mice did not produce a significantly different mean score from their age- and sex-matched WT 
counterparts at either 6 (WT mean = 0.2500; UTCln6nclf mean = 0.2500; p = .9612; Appendix B.8.2) or 9 
months (WT mean = 0.6296; UTCln6nclf mean = 0.9667; p = 0.1905; Appendix B.8.2) of age. n(per group 
per time point) = 8-12                    ➢        
3.1.3  The Cln6nclf disease(d) phenotype: survival and weight 
Survival curves and median lifespan were generated from euthanasia records for each 
experimental group. Mice would be euthanised once they reached one of the three humane 
end-points stipulated by the Animal Ethics Committee (AEC; see Chapter 2 for details). Data 
are presented here up until 14 months – even though the trial continued on until past the 16 
month time point for some mice – due to the time limits of a MSc. Survival data are presented 
as percentage of the original cohort n, with curve comparisons between sex-matched Cln6nclf 
and WT conducted via separate log-rank (Mantel-Cox) tests for each sex (Appendices B.9.1-
9.2). Small ‘tick’ marks indicating planned removals of mice from the experiment for post-
mortem analysis. Weight data are presented as mean weights, in grams, ± SEM.  
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Both male and female UTCln6nclf mice had significantly shortened lifespans compared to 
their WT counterparts. This was to be expected, as a significantly shortened lifespan has 
previously been characterised as part of the Cln6nclf phenotype (Gao et al., 2002; Morgan et 
al., 2013b; Wheeler et al., 2002). Male UTCln6nclf mice had a median survival of 13.29 months, 
while their WT counterparts hadn’t even reached a median survival point at 14 months (WT 
survival was undefined at 14 months; p = 0.0005; Appendix B.9.1). Female UTCln6nclf mice had, 
on average, slightly shorter lifespans than males with a median survival of 12.50 months. 
Female WT survivals were also undefined at 14 months (p ≤ .0001).  
Body weights for all male and female UTCln6nclf and WT mice (n = 24-35) were recorded 
weekly as a means of monitoring general health. Weights taken prior to behavioural assays at 
6, 9 and 12 months of age have been averaged and used for analysis. Unpaired student t-tests 
were used to compare the weights of sex-matched UTCln6nclf and WT mice (Appendices B.10.1-
10.2). Female UTCln6nclf mice were found to be significantly lighter than WT at 6 (UTCln6nclf = 
24.11 g; WT = 27.04; p = .0041) and 9 months of age (Cln6nclf = 26.0 g; WT = 28.9 g; p = .0228). 
At 12 months, however, while still lighter (26.86 g), their mean weight was no longer 
significantly less than that of WT (30.23 g) . Male UTCln6nclf demonstrated the opposite trend – 
with non-significantly lighter weights at 6 and 9 months, followed by a significantly lighter 








Figure 3.4 ⎸ Establishing the Cln6nclf disease(d) phenotype: survival and weight. Untreated Cln6nclf 
(UTCln6nclf ) mice demonstrated variable significant differences across their lifespan but had a significantly 
decreased lifespan, overall, compared to healthy WT (C57Bl/6) controls. Survival and weights were only 
recorded up until 14 months of age due to the time limitations of a MSc thesis, however, survival and 
weights continued to be recorded for the larger Gray Foundation trial - until all animals had reached one 
of the three humane endpoints outlined in Chapter 2. Almost all male and female UTCln6nclf mice had 
reached one of these endpoints by 14 months. A. Kaplan-Meier plot of male mouse survival (%). UTCln6nclf 
mice (red lines; median survival = 13.3 months) had significantly shorter lifespans than sex-matched WT 
controls (black lines; median survival undefined at 14 months; *** p = .0005). Survival curve comparison 
conducted via log-rank (Mantel-Cox) test (Appendix B.9.1). Planned deaths (for post-behavioural post-
mortem analysis) are indicated by small ‘tick’ marks on the lines. Starting n = 28-35 per group. B. Kaplan-
Meier plot of female mouse survival (%). UTCln6nclf mice (maroon lines; median survival = 12.5 months) 
had significantly shorter lifespans than sex-matched WT controls (grey lines; median survival undefined 
at 14 months; **** p = ≤.0001). Survival curve comparison conducted via log-rank (Mantel-Cox) test 
(Appendix B.9.2). Starting n = 24-27 per group. C. Line graph of mean weights (in grams) of male 
UTCln6nclf (red squares), male WT (C57Bl/6; black squares), female UTCln6nclf (maroon circles) and female 
WT (C57Bl/6; grey circles) mice over 15 months. Female UTCln6nclf mice weighed significantly less than 
their age- and sex-matched WT counterparts at 6 (6 month female WT mean weight = 27.040 g ; 6 month 
female UTCln6nclf f mean weight = 24.11 g; ** p = .0041) and 9 (9 month female WT mean weight = 28.9 
g; 9 month female Cln6nclf mean weight = 26.0 g; * p = .0228) months of age, while male UTCln6nclf mice 
only began to show a significant difference in weight from their WT counterparts at 12 months of age (12 
month male WT mean weight = 37.76 g; 12 month male UTCln6nclf mean weight = 31.49 g; **** p ≤ .0001). 
n = 24-35. Analyses at individual time points conducted using unpaired student t-tests (Appendices 
B.10.1-10.2).  


























































3.1.4  The Cln6nclf disease(d) phenotype: sex differences 
Sex differences in disease progression is historically overlooked in the life sciences, with the 
use of a single sex (typically male) in animal model studies being a commonplace practice. This 
tradition has begun to be viewed as problematic as our understanding of how biological sex, 
and the associated physiological differences between the sex, influences a patient’s 
experience of disease – from symptoms to rate of progression – and can dictate their response 
to potential therapies. These differences could be particularly pertinent for the development 
of potential therapies for the NCLs as differences in male and female experiences of these 
diseases is underinvestigated. With this in mind, the practial component of this thesis included 
both male and female mice for every treatment combination, to ensure any sex-based 
differences in response to the three therapies being investigated (gene therapy, gemfibrozil 
and CBD) would be accounted for and characterised. Here, the mean behaviour scores of male 
and female UTCln6nclf mice are compared across the lifespan (6, 9 and 12 months for rotarod; 6 
and 9 months for ataxia and up to 14 months for survival and weight), in an effort to better 
characterise any differences in male and female experiences of untreated CLN6 BD.  
3.1.4.a Rotarod sex differences 
Male and female UTCln6nclf mice demonstrated no significant differences in mean rotarod 
scores (Figure 3.5.A) at 6, 9 or 12 months of age (unpaired t-tests; Appendix B.11), though 
females had non-significantly better (higher) scores at each time point. Similarly, there was no 
significant difference in male and female overall rate of score decline across the lifespan 
(simple linear regression; Appendix B.12).  
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3.1.4.b Composite ataxia sex differences 
Male and female UTCln6nclf mice demonstrated no significant differences in mean composite 
ataxia scores (Figure 3.5.B) at 6 or 9 months of age (unpaired t-tests; Appendix B.13), though 
females had non-significantly worse (higher) scores than their male counterparts at 6 months 
of age.  
3.1.4.c Ledge ataxia sex differences 
Male and female UTCln6nclf mice demonstrated no significant differences in mean ledge ataxia 
scores (Figure 3.5.C) at 6 or 9 months of age (unpaired t-tests; Appendix B.14). 
3.1.4.d Hindlimb clasping ataxia sex differences 
Female UTCln6nclf had significantly higher (worse) hindlimb clasping scores (Figure 3.5.D) than 
their age-matched male counterparts at 6 months of age (male mean score = 0.6; female mean 
score = 1.556; *p = .0185; Appendix B.15). 
3.1.4.e Gait ataxia sex differences 
Male and female UTCln6nclf mice demonstrated no significant differences in mean gait ataxia 
scores (Figure 3.5.E) at 6 or 9 months of age (unpaired t-tests; Appendix B.16). 
3.1.4.f Survival sex differences 
Male and female UTCln6nclf mice demonstrated no significant differences in median survival 






⇒	Figure 3.5 ⎸ Establishing the Cln6nclf disease(d) phenotype: sex differences (opposite page). No 
significant sex differences were observed in mean behavioural scores or lifespan between male and 
female untreated Cln6nclf (UTCln6nclf) mice at any age point except for mean hindlimb clasping scores at 6 
months of age. Mean behavioural scores for rotarod (A; latency to fall in seconds) at 6, 9 and 12 months 
of age, composite ataxia (B; score 0-9), the ledge ataxia test (C; score 0-3), the hindlimb clasping ataxia 
test (D; score 0-3), the gait ataxia test (E; score 0-3) at 6 and 9 months of age, and survival (F; %) up to 
14 months were compared between male and female UTCln6nclf mice. A. Female UTCln6nclf mice (maroon 
circles) appear to have, on average, higher rotarod scores than males (red squares) at all three time 
points measured. None of these differences, however, are statistically significant. Dotted lines between 
time points represent assumed trajectory of average scores between measured time points. Higher 
scores (~300) indicate a higher level of motor co-ordination and balance as measured by the rotarod 
(coloured arrow on the left). Lower scores represent increasing levels of motor dysfunction. Data are 
presented as average scores and error bars represent ± SEM. n(per group per time point) = 7-12. 
Comparisons between average scores at each time point were conducted using unpaired student t-tests 
(Appendix B.11). A simple linear regression analysis (Appendix B.12) of the overall rate of decline 
between male and female UTCln6nclf mean scores showed that there was no significant difference in slope 
(rate of decline; p = .6896) or elevation (range of time over which the decline occurred; p = .1327). B. 
Mean composite ataxia scores for male (red) and female (maroon) UTCln6nclf mice at 6 (dark) and 9 (lighter) 
months of age. Females appear to have slightly higher average composite scores at both age points, 
though this difference is not significant at either time point. Higher scores (~9) in this behavioural assay, 
unlike the rotarod, represent a more ataxic/diseased phenotype. Scores closer to 0 represent an absence 
of this disease phenotype (coloured arrow on the left). Analysis was conducted using unpaired student 
t-tests (Appendix B.11). Data are presented as average scores and error bars represent ±SEM. 
Individual averaged (3 trials) composite ataxia phenotype scores are presented as clear circles. n(per 
group per time point) = 8-10. C. Averaged ledge ataxia test scores of male (red) and female (maroon) 
UTCln6nclf mice at 6 and 9 months. No significant difference was found at either time point, although 
females demonstrated non-significantly lower ledge scores at 6 months and then ns higher at 9 months. 
Analysis was conducted using unpaired student t-tests (Appendix B.14). Data are presented as average 
scores and error bars represent ±SEM. Individual averaged (3 trials) ledge ataxia phenotype scores are 
presented as clear circles. n(per group per time point) = 8-10. D. Averaged hindlimb clasping scores of 
males (red) and females (maroon) at 6 and 9 months of age. Females demonstrated a significantly more 
ataxic (higher; coloured arrow on left) score (female mean score =1..556) at 6 months than their male 
counterparts (male mean score = 0.6; p = .0185. Analysis was conducted using unpaired student t-tests 
(Appendix B.15). This significant difference was no longer present at 9 months. Data are presented as 
average scores and error bars represent ±SEM. Individual averaged (3 trials) hindlimb clasping ataxia 
phenotype scores are presented as clear circles. n(per group per time point) = 8-10. E. Averaged gait 
scores of males (red) and females (maroon) at 6 and 9 months of age. Females appear to perform better, 
with lower scores, than males at 6 months and then have worse scores than their male counterparts at 
9 months – but neither of these differences in averaged gait score produced a statistically significant 
result. Analysis was conducted using unpaired student t-tests (Appendix B.16). Data are presented as 
average scores and error bars represent ±SEM. Individual averaged (3 trials) gait ataxia phenotype 
scores are presented as clear circles. n(per group per time point) = 8-10. F. Kaplan-Meier survival curve 
(%) of male (red) and female (maroon) UTCln6nclf mice. Small ‘tick’ marks on lines represent the planned 
removal of mice (~5 per time point, per experimental group) from the study for post-mortem analysis after 
behavioural testing at 6 and 12 months of age. No significant difference in average lifespan was observed 
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3.1.5  The Cln6nclf disease(d) phenotype: summary 
All UTCln6nclf mice, regardless of gender, had significantly shorter lifespans and demonstrated 
some form of significant behavioural deficit compared to WT by 9 months of age – though 
these deficits were not consistently present across the range of behavioural assays. Male 
UTCln6nclf mice began demonstrating significant behavioural deficits earlier than UTCln6nclf 
females, with significantly worse average composite ataxia and ledge test scores than sex-
matched WT at 6 months of age. Female UTCln6nclf behavioural scores at this age were not 
significantly different from WT but their weights were significantly lower. At 9 months, 
however, UTCln6nclf males continued to demonstrate significantly worse scores than WT only in 
the composite and ledge assays, while UTCln6nclf females performed significantly worse across 
all ataxia assays and continued to have significantly lower weights than WT.  
By 12 months of age both males and females were performing significantly worse than 
WT on the rotarod (Tables 3.1 and 3.2). No ataxia measurements were analysed at 12 months 
for this thesis, due to the fact that another reseacher, Jasmine Lock, had taken over the 
practical component of behavioural testing by this time point, and the subjective nature of 
the ataxia grading system means that the relationship between the 6 and 9 months scores and 
her 12 month scoring might be compromised by experimenter bias. Previous studies 
characterising the behavioural deficits of Cln6nclf mice up to this age point, coupled with the 
significant deficit in rotarod scores for both genders at 12 months, could lead one to 
extrapolate that any 12 month ataxia scores would be worse, if not significantly so, than WT 
at this age point. Without actually analysing the data, however, this can only remain as 
conjecture.  
Overall, the behavioural scores of UTCln6nclf mice paint a picture of progressive 
behavioural deficits in co-ordination, balance, endurance (rotarod) and motor control (ataxia) 
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over their significantly shortened lifespans. Females appear to experience later onset of 
behavioural deficits than males, but ataxic symptoms are more apparent/penetrant at this 
later time point. There were no significant differences in behavioural scores or lifespan 
between male and female UTCln6nclf, even for 6 month composite and ledge ataxia scores – 
where males were significantly worse than their sex-matched WT and females were not – with 
the exception of mean hindlimb clasping scores at 6 months. Here, UTCln6nclf females 
performed significantly worse than than UTCln6nclf males (Table 3.3). 
Table 3.1 ⎸ Establishing the Cln6nclf disease(d) phenotype: summary table of untreated Cln6nclf (UTCln6nclf) 
males. Summary table of behavioural scores (rotarod and ataxia), survival and weight comparisons 
carried out between male UTCln6nclf and age-matched male WT (C57Bl/6) mice at 6, 9 and 12 months of 
age. All behavioural score and weight comparisons were conducted using unpaired student t-tests 
(Appendices B.1.-8.2 and B.10.1), while survival curves were compared using log rank (Mantel-Cox) 
tests (Appendix B.9.1). nsd = no significant difference.  
Untreated Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod WT nsd nsd Worse (s) 
Composite WT Worse (s) Worse (s) - 
Ledge WT Worse (s) Worse (s) - 
Hindlimb WT nsd nsd - 
Gait WT nsd nsd - 
Survival WT Reduced survival (s) 













Table 3.2 ⎸ Establishing the Cln6nclf disease(d) phenotype: summary table of untreated Cln6nclf (UTCln6nclf) 
females. Summary table of behavioural scores (rotarod and ataxia), survival and weight comparisons 
carried out between female UTCln6nclf and age-matched female WT (C57Bl/6) mice at 6, 9 and 12 months 
of age. All behavioural score and weight comparisons were conducted using unpaired student t-tests 
(Appendices B.1.-B.8.2 and B.10.2), while survival curves were compared using log rank (Mantel-Cox) 
tests (Appendix B.9.2). nsd = no significant difference. 




Group 6 months 9 months 12 months 
Rotarod WT nsd nsd Worse (s) 
Composite WT nsd Worse (s) - 
Ledge WT nsd Worse (s) - 
Hindlimb WT nsd Worse (s) - 
Gait WT nsd Worse (s) - 
Survival WT Reduced survival (s) 
Weight WT Weigh less (s) Weigh less (s) nsd 
Table 3.3 ⎸ Establishing the Cln6nclf disease(d) phenotype: summary table of untreated Cln6nclf (UTCln6nclf) 
males versus females. Summary table of behavioural score (rotarod and ataxia), survival and weight 
comparisons carried out between male and female UTCln6nclf mice at 6, 9 and 12 months of age. All 
behavioural score and weight comparisons were conducted using unpaired student t-tests (Appendices 
B.11-16), while survival curves were compared using log rank (Mantel-Cox) tests (Appendix B.17). nsd 
= no significant difference. 
Untreated Cln6nclf Males vs Females 
Behavioural test 6 months 9 months 12 months 
Rotarod nsd nsd nsd 
Composite nsd nsd - 
Ledge nsd nsd - 
Hindlimb Males performed sig. better nsd - 










3.2  Sustained small molecule therapy, when administered without gene 
therapy, did not protect against motor or survival deficits in Cln6nclf 
mice  
Gemfibrozil, an FDA-approved fibrate commonly used to treat high cholesterol, and 
cannabidiol (CBD), a cannabinoid with polymorphic pharmaceutical properties that has shown 
some promising neuroprotective qualities in a wide range of neurodegenerative conditions, 
were selected for investigation due to the Gray Foundation’s interest in supplementary small 
molecule therapies and their potential to augment the efficacy of gene therapy in CLN6 BD 
patients.  
Gemfibrozil has previously shown promise in several NCL in vitro systems. It was found 
to upregulate CLN2 activity in a CLN2-/- mouse model (Ghosh et al., 2012), inhibit apoptosis of 
lymphoblast cells via autophagy recovery in CLN3-/- cell culture and has demonstrated positive 
effects on the autophagic processes and lysosomal acidity of CLN6-/- cells in vitro (Best, 2017; 
Best et al., 2017). Preliminary studies conducted by the Hughes lab have also indicated that 
gemfibrozil is well tolerated at 30 kg/mg and 120 kg/mg doses in WT (C57Bl/6) mice and 
appears to have promising effects on lysosomal clearance and autophagy markers in the 
Cln6nclf mouse brain (Stephanie Mercer, Isaiah Cheong, Cliff Abrahams and Stephanie Hughes, 
unpublished work, 2016; Best, 2017).  
CBD, in comparison, has yet to be validated as having therapeutic benefits in any form 
of BD. A preliminary investigation of it’s effect on the behaviour and post-mortem 
pathophysiology of Cln6nclf mice yielded inconclusive results, though this might be due to the 
short time frame of the study (Partridge, 2017). Despite this, CBD has been shown to have 
antiepileptic, sedative, analgesic, anti-inflammatory, anxiolytic and anti-oxidant properties in 
a wide range of healthy and pathological animal models and human clinical trials (Devinsky et 
al., 2016; Johnson et al., 2010; Russo et al., 2007; Turkanis et al., 1974; Zuardi, 2008), indicating 
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that it may offer benefits to CLN6 BD patients – though the way in which those benefits 
manifest and to what it extent has yet to be characterised. This project aims to build on the 
successful preliminary studies of gemfibrozil in vivo in a large-scale, long-term study and to 
better characterise the effects, if any exist, of CBD on the behavioural phenotype of Cln6nclf 
mice.  
Viral-mediated gene therapy has been previously established as being incredibly 
effective, both in vitro and in vivo, and has even been known to produce hyperactivity in 
Cln6nclf mice (aka higher behavioural scores than healthy controls)(Cain et al., 2019; Weimer 
et al., 2019). Such results would make interpreting the effects of complementary therapies, 
especially subtle effects, much more difficult, as they may be phenotypically masked by the 
overwhelming effects of gene therapy. Therefore, in order to properly characterise the effects 
of gemfibrozil and CBD, alone and in combination, on the Cln6nclf phenotype, they were also 
investigated here without gene therapy.  
3.2.1  Small molecule therapy in PBS-treated Cln6nclf mice: rotarod 
Ten different experimental groups were assessed with the rotarod at 6, 9 and 12 months of 
age. These included male and female (M/F) WT controls, M/F Cln6nclf mice treated with 
gemfibrozil (GemfibPBS) M/F Cln6nclf mice treated with CBD (CBDPBS), M/F Cln6nclf mice treated 
with a combination of gemfibrozil and CBD (ComboPBS) and M/F UTCln6nclf controls. All groups, 
including controls, were injected with 1x PBS at P0-2, rather than scAAV9.CB.hCLN6 (section 
2.3). GemfibPBS mice received 120 mg/kg of gemfibrozil in strawberry jelly every second day 
from weaning until individual end points of the trial. CBDPBS mice received 5 mg/kg of CBD in 
strawberry jelly every second day from weaning until the end of the trial. Finally, ComboPBS 
mice received a combination of 120 mg/kg gemfibrozil and 5 mg/kg CBD every day from 
weaning until individual end points of the trial (see sections 2.3 and 2.4 for more details 
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regarding i.c.v injections and dosing). Rotarod scores for the drug-only Cln6nclf experimental 
groups were found to have normal (Gaussian) distributions using D’Agostino & Pearson 
normality tests, so all subsequent statistical analyses were conducted using parametric testing 
(Appendix B.18).  
Linear regression was used to compare the overall rate of decline of mean rotarod 
scores over time and the associated elevation (range over which the decline occurred) of each 
drug treated group versus sex-matched WT controls and UTCln6nclf counterparts (Figure 3.6; 
Appendices B.19-21). To compare differences in rotarod score between groups at each 
individual time point, 1-way analysis of variances (ANOVAs) were used, complemented by 
Tukey’s multiple comparison post-hoc testing when significant differences were found to be 
present (Appendices B.21-22). The rotarod assay showed a steady decline in motor 
performance over time for all mice, as to be expected due to age, and this decline was 
mathematically confirmed by the negative line equations of each group (Figure 3.6; Appendix 
B.21). None of the drug treated groups (M/F GemfibPBS, M/F CBDPBS or M/F ComboPBS) overall 
rate of decline or elevation differed significantly from sex-matched UTCln6nclf mice, indicating 
that while the drugs may not be improving rotarod performances in diseased mice, they are 
at least not performing worse than the UTCln6nclf controls.  
In male mice, GemfibPBS and ComboPBS animals declined at a significantly greater rate 
than healthy male WT controls (simple linear regression; WT vs GemfibPBS adjusted p = .0033; 
WT vs ComboPBS adjusted p = .0362; Appendices B.19 and B.21), as is to be expected since 
their mean rotarod scores were not significantly different from those of male UTCln6nclf mice. 
The overall rate of decline in male CBDPBS mice, however, was not significantly different from 
that of WT (p = .1299; B.21). Male Cln6nclf mice were also the first to present with significant 
motor deficits in the rotarod task, with GemfibPBS mice scoring significantly lower (mean = 
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111.4 seconds) than WT (mean = 181.9 seconds; *p = .0358) at 9 months of age (1-way ANOVA 
with Tukey’s multiple comparisons post-hoc testing; Figure 3.7.B; Appendix B.22). By 12 
months, all three male drug-only groups were performing significantly worse than WT (Figure 
3.7.C; ****p(GemfibPBS) ≤ .0001; ****p(CBDPBS) ≤ .0001; ****p(ComboPBS) ≤ .0001; Appendix 
B.22) and their mean scores are not significantly different from those of male UTCln6nclf, 
indicating that small molecule therapy does not appear to protect male Cln6nclf mice from a 
diseased behavioural phenotype on the rotarod by 12 months of age.  
For females, mice on single-drug regimens declined at a significantly greater rate than 
WT controls (simple linear regression; **p(GemfibPBS) = .0048; *p(CBDPBS) = .0262; Figure 3.6; 
Appendices B.20-21), while female ComboPBS Cln6nclf mice appear to decline at a rate not 
significantly different from WT (p = .0629; Figure 3.6). ComboPBS female mice, while having a 
statistically similar rate of decline to WT, had a significantly different elevation (p = .0104; 
Appendix B.21)– indicating that, at every time point measured, the ComboPBS mice had a 
lower (worse) rotarod score than WT. This could indicate a learning deficit when it came to 
learning the rotarod task or be indicative of a motor deficit, either of which would indicate 
that the combined drug treatment may be influencing the slowing of decline in Cln6nclf female 
mice to a rate similar to WT, but is not eliminating the presence of a diseased phenotype 
altogether. Unlike males, where GemfibPBS mice started to show deficits at 9 months of age, 
no drug-only female group showed significant deficits until the 12 month time point. At this 
stage, all three drug treated groups performed significantly worse than WT (Figure 3.7.C; 1-
way ANOVA with Tukey’s multiple comparisons post-hoc texts; ****p(GemfibPBS) ≤ .0001 ; 
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⇐	Figure 3.6 ⎸Small molecule therapy in PBS-treated Cln6nclf mice: rotarod scores (line graphs; previous 
page). Overall rate of decline in motor skills, as determined by a rotarod assay, appears to be sexually 
dimorphic in Cln6nclf mice treated with one of the three different drug regimens (gemfibrozil, CBD and a 
combination of the two aka ‘ComboPBS’) and no gene therapy at P0-2 (1x PBS instead). Ai-iii. Mean male 
rotarod scores (square points) recorded at 6, 9 and 12 months of age. Data are presented as a line graph 
of mean scores (latency to fall, in seconds), with error bars = ± SEM. Dotted lines indicate the expected 
mean score trajectory for an experimental group between measured time points. Solid lines represent 
the regression lines of each experimental group, as calculated via simple linear regression. A high score 
(~300) indicates a high level of motor co-ordination as measured by the rotarod, while lower scores 
correlate to increasing levels of motor dysfunction (coloured arrow on the left). n(per group per time point) 
= 26-35. Ai. Male Cln6nclf mice treated with gemfibrozil only (GemfibPBS; purple lines and squares) 
declined at a significantly greater rate (simple linear regression; ** p = .0033; Appendix B.21) than 
‘healthy’ WT controls (WT C57Bl/6; black lines and squares) and showed no significant difference in 
overall rate of decline from UTCln6nclf counterparts (red lines and squares; p = .0919). n(per group per 
time point) = 26-32 Aii. Male Cln6nclf mice treated only with CBD (CBDPBS, green lines and squares) 
showed no significant (ns) difference in overall rate of decline from either the WT controls or their UTCln6nclf 
counterparts (simple linear regression, p(WT) = .1299; p(UTCln6nclf) = .1854; Appendix B.21). n(per group 
per time point) = 32-35. Aiii. Male Cln6nclf mice treated with a combination of gemfibrozil and CBD 
(ComboPBS; orange squares and lines) demonstrated a significantly greater rate of decline, overall, than 
WT controls (simple linear regression; * p = .0362; Appendix B.21). n = ranging between 30-32. Bi-iii. 
Mean female rotarod scores (circle points) recorded at 6, 9 and 12 months of age. n(per group per time 
point) = 25-27. Bi. Female Cln6nclf mice treated with gemfibrozil only (GemfibPBS; purple lines and circles) 
declined at a significantly greater rate (simple linear regression; ** p = .0048; Appendix B.21) than 
‘healthy’ WT controls (WT C57Bl/6; grey lines and circles) and showed no significant difference in overall 
rate of decline from UTCln6nclf counterparts (maroon lines and circles; p = .9984; Appendix B.21). n(per 
group per time point) = 26-27. Bii. Female Cln6nclf treated with CBD only (CBDPBS; green lines and circles) 
demonstrated a significantly greater rate of decline, overall, than WT controls (simple linear regression; 
* p = .0262; Appendix B.21). Comparison between the CBD-treated females and their UTCln6nclf 
counterparts, however, showed no significant difference in slope (simple linear regression; p = .8664; 
Appendix B.21). n = 26. Biii. Female Cln6nclf mice treated only with a combination of gemfibrozil and 
CBD (ComboPBS; orange lines and circles) showed no significant (ns) difference in overall rate of decline 
from either the WT controls or their UTCln6nclf counterparts (simple linear regression, p(WT) = .0629; 






































































































































































































































































































































































































































⇐	Figure 3.7 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: rotarod scores (histograms; previous 
page). Male and female Cln6nclf mice who received one of the three drug treatments - gemfibrozil, CBD 
or a combination of the two (‘combo’)- without gene therapy at P0-2 (were treated with 1x PBS instead; 
drug-only) were not protected against untreated Cln6nclf (UTCln6nclf) rotarod deficiencies by 12 months of 
age. Histograms presenting mean rotarod scores (latency to fall in seconds) of male (left; plain coloured 
bars) and female (right; patterned bars) Cln6nclf mice treated only with either: gemfibrozil (GemfibPBS), 
CBD (CBDPBS), or a combination of the two (ComboPBS) and their age- and gender-matched UTCln6nclf 
and WT (C57Bl/6) counterparts at 6 (A), 9 (B) and 12 (C) months of age. Data are presented as mean 
scores with error bars = ± SEM. Different mice were tested at each of the different time points, making 
the experiment between-subjects in design. All analyses were conducted using 1-way ANOVAs with 
Tukey’s post-hoc comparisons used to elicit specific significant differences between experimental groups 
(Appendix B.22-23). Individual mean mouse rotarod scores indicated by clear circles. A. Mean male 
(left; plain coloured bars) and female (right; patterned coloured bars) rotarod scores (latency to fall in 
seconds) at 6 months. No differences, for either gender, were observed between the three different drug-
only treated Cln6nclf groups (GemfibPBS, CBDPBS or ComboPBS) and ‘healthy’ WT controls or UTCln6nclf 
counterparts at 6 months of age. n(per group per time point) = 25-35. B. Mean male (left; plain coloured 
bars) and female (right; patterned, coloured bars) rotarod scores (latency to fall in seconds) at 9 months. 
Male Cln6nclf mice treated only with gemfibrozil (GemfibPBS; plain purple bar) began to show significant 
deficits (coloured arrow on the left) compared to WT controls (plain white bar; male WT mean =181.9 s; 
male GemfibPBS mean = 111.4 s; * p = .0358; Appendix B.22) n = 9. No other drug-only treated group, 
male or female, demonstrated significant differences when compared to age- and sex-matched either 
WT (male WT = plain white bar; female WT = patterned black and white bar) or UTCln6nclf (male UTCln6nclf 
= plain red bar; female UTCln6nclf = plain maroon bar) groups at 9 months. n(per group per time point) = 
8-15. C. Mean male (left; plain coloured bars) and female (right; patterned, coloured bars) rotarod scores 
(latency to fall in seconds) at 12 months. Error bars ± SEM. Individual mean mouse rotarod scores 
indicated by clear circles. Mean of male Cln6nclf mice in all three drug-only groups (GemfibPBS, CBDPBS, 
ComboPBS) were significantly worse than WT at 12 months of age (WT mean = 131.5 s; GemfibPBS mean 
= 61.14 s; CBDPBS mean = 70.33 s; ComboPBS mean = 64.60 s; **** p ≤ 0.0001; Appendix B.22). n(per 
group per time point) = 7-14. None of these three groups, however, demonstrated a significant difference 
in average score with their age matched UTCln6nclf counterparts. Significant differences in rotarod scores 
were also observed at 12 months between the female Cln6nclf mice treated only with gemfibrozil, only 
with CBD, only with a combination of both drugs and the WT control (WT mean = 170.4 s; GemfibPBS 
mean = 83.88 s; CBDPBS mean = 76.33 s; ComboPBS mean = 100.4 s; *** p ≤ 0.001; **** p ≤ 0.0001; 
Appendix B.23). None of these three female drug-only groups demonstrated a significant difference in 
mean score from their UTCln6nclf counterparts at 12 months. n(per group per time point) = 8-9.  
3.2.2  Small molecule therapy in PBS-treated Cln6nclf mice: ataxia 
In order to characterise the effects gemfibrozil, CBD or a combination of the two drugs might 
have on the Cln6nclf ataxic behavioural phenotype, without gene therapy, ten different 
experimental groups were assessed for signs of cerebellar ataxia at 6 and 9 months of age. 
Ataxia phenotyping scores for the drug-only Cln6nclf experimental groups were found to have 
normal (Gaussian) distributions using D’Agostino & Pearson normality tests, so all subsequent 
statistical analyses were conducted using parametric testing (Appendix B.18).  
3.2.2.a Composite ataxia phenotype scores 
Composite ataxia scores (0-9) for each mouse were calculated by adding together it’s mean 
ledge, hindlimb clasping and gait ataxia phenotyping scores (0-3). Individual mouse composite 
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ataxia scores were then averaged for each experimental group and presented as mean score 
(0-9) ± SEM. Comparisons between mean composite scores of age- and sex-matched 
GemfibPBS, CBDPBS, ComboPBS treated and UTCln6nclf and WT (C57Bl/6) mice were made using 1-
way ANOVAs, with Tukey’s post-hoc multiple comparisons tests conducted when significant 
differences were found to occur (Appendices B.24-25).  
No significant differences in mean composite score were detected at 6 months of age 
for male mice, regardlesss of strain or treatment group (Figure 3.8.Ai-ii; Appendix B.24). At 9 
months, however, all three male drug-only Cln6nclf treatment groups were demonstrating 
significantly higher (worse) scores than their WT counterparts (WT mean = 2.574; GemfibPBS 
mean =5.0; **** p ≤ .0001; CBDPBS mean = 4.6; **** p ≤ .0001; ComboPBS mean = 5.067; **** 
p ≤ .0001; Appendix B.24). None of these drug-only treatment groups demonstrated a 
significant difference in mean composite score from their age-matched UTCln6nclf counterparts 
(UTCln6nclf mean = 4.833), suggesting that, by 9 months of age, gemfibrozil and/or CBD small 
molecule therapy fails to protect male Cln6nclf mice from the diseased Cln6nclf ataxic 
phenotype.  
In females, however, gemfibrozil-only treated mice (GemfibPBS) demonstrated a 
significantly improved (lower) mean composite score (Figure 3.8.Bi-ii; GemfibPBS mean = 1.0 ) 
at 6 months of age compared to their age- and sex-matched UTCln6nclf counterparts (UTCln6nclf 
mean = 3.0; ** p = .0099; Appendix B.25). This score was even (non-significantly) lower than 
the mean score of 6 month female WT mice (WT mean = 2.071). No other female drug-only 
treatment group demonstrated a significant difference in mean composite score at 6 months 
of age compared to either UTCln6nclf or WT mice. At 9 months of age, female GemfibPBS treated 
Cln6nclf mice continued to do well – with the mean GemfibPBS composite score remaining 
statistically indistinguishable from age- and sex-matched WT (Figure 3.8.Bi-ii; WT mean = 
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2.407; GemfibPBS mean = 3.933; p = .075; Appendix B.25). It should be noted, however, that 
the mean composite score of the GemfibPBS treated mice was also not significantly different 
from the 9 month UTCln6nclf mean composite ataxia score (UTCln6nclf mean =5.0; p = .3215; 
Appendix B.25). In comparison, female mice treated with CBD-only (CBDPBS) or a combination 
of gemfibrozil and CBD (ComboPBS) both performed significantly worse than age- and sex-
matched WT counterparts at 9 months (Figure 3.8.Bi-ii; CBDPBS mean = 4.583; ** p = .0071; 
ComboPBS mean = 5.375; ***p = .0001 ; Appendix B.25) and were statistically indistinguishable 
from female UTCln6nclf mice at that time point. In fact, the mean composite score for ComboPBS 









Figure 3.8 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: composite ataxia scores. CBD (CBDPBS) 
and combination small molecule therapy (ComboPBS), without gene therapy, fail to protect male and 
female mice from the diseased Cln6nclf composite ataxia phenotype by 9 months of age. GemfibPBS, 
however, appears to protect female Cln6nclf mice against the diseased Cln6nclf composite ataxia 
phenotype at both 6 and 9 months of age. Mean composite ataxia phenotype scores (0 to 9) were 
calculated using averaged ataxia test individual scores (ledge, hindlimb clasping and gait) for male (Ai-
ii) and female (Bi-ii) Cln6nclf mice treated with one of three drug regimens: gemfibrozil (GemfibPBS), CBD 
(CBDPBS) or a combination of gemfibrozil and CBD (ComboPBS), and their UTCln6nclf and wildtype (WT) 
C57Bl/6 counterparts across two different time points: 6 months (left) and 9 months (right). Different mice 
were tested at each time point (between-subjects study design). A low score (close to 0) indicates an 
absence of the ataxic phenotype as measured by the composite scoring system, while higher scores, 
closer to 9, indicate increasing levels of ataxic behaviour (coloured arrow on the left). The overall mean 
composite scores illustrated in Ai and Bi are further broken down into the average ledge (bottom 
segment), hindlimb clasping (middle segment) and gait (top segment) scores in segmented bar graphs 
(Aii and Bii). Individual, averaged composite scores are shown as clear circles in Ai and Bi, error bars = 
± SEM. Analyses were conducted via 1-way ANOVAs and subsequent Tukey’s multiple comparison post-
hoc tests (Appendices B.24-25). n(per group per time point) = 8-15. Ai-ii. Histogram presenting the 
mean composite ataxia scores of male mice at 6 (left) and 9 (right) months of age. No significant 
differences were observed between the mean composite ataxia scores of any of the male drug treated 
Cln6nclf groups and their UTCln6nclf or WT counterparts at 6 months of age; (left; Appendix B.24). At 9 
months of age, however, GemfibPBS, CBDPBS and ComboPBS male mice all performed worse (higher score) 
than the WT control (WT mean = 2.574; GemfibPBS mean = 5.0; CBDPBS mean = 4.6; ComboPBS mean = 
5.067; **** p ≤ 0.0001; Appendix B.24). Bi-ii. Histogram presenting the mean composite ataxia scores 
of female mice at 6 (left) and 9 (right) months of age. Female Cln6nclf mice treated only with gemfibrozil 
(GemfibPBS) performed better (significantly lower composite ataxia score) than UTCln6nclf mice at 6 months 
of age (UTCln6nclf mean = 3.00; GemfibPBS mean = 1.0; ** p = .0099; Appendix B.25). There was no 
significant difference in the composite scores of CBDPBS or ComboPBS female mice and their UTCln6nclf 
and WT counterpoints at 6 months. At 9 months (left), female CBDPBS mice and ComboPBS mice 
performed significantly worse than WT controls (WT mean = 2.407; CBDPBS mean = 4.583; ComboPBS 














































































































































































































































































































































































































































































3.2.2.b Ledge test 
Gemfibrozil, CBD and a combination of gemfibrozil and CBD, without gene therapy, failed to 
protect Cln6nclf mice from the Cln6nclf diseased ledge ataxia phenotype by 9 months of age 
(Figure 3.9A and Figure 3.9B).  
For males, a 1-way ANOVA (Appendix B.26) indicated that there were no significant 
differences between GemfibPBS, CBDPBS, ComboPBS and WT in mean ledge scores at 6 months, 
but by 9 months all three drug-only treatment groups demonstrated a significantly higher 
(worse) score than WT (Figure 3.9A; WT mean = 1.407; GemfibPBS mean = 2.267; *** p = .0002 ; 
CBDPBS mean = 2.178; *** p = .0003 ; ComboPBS mean = 2.133; **p = .0023). No significant 
difference between the male drug-treated groups and their age-matched UTCln6nclf 
counterparts was observed at this time point, indicating the small molecule therapies did little 
to alleviate or protect against the Cln6nclf ledge phenotype established in section 3.1.2b.  
This result was mirrored by female mice (Figure 3.9B), where all three drug-only 
groups also ended up performing comparably to sex-matched UTCln6nclf mice by 9 months of 
age and demonstrating mean scores that differed significantly from healthy WT controls (WT 
mean = 1.407; GemfibPBS mean = 2.133; ** p = .0023; CBDPBS mean = 2.00; * p = .0278; 
ComboPBS = 2.167; ** p = .0026; Appendix B.27).  
3.2.2.c Hindlimb clasping test 
Mice treated with gemfibrozil, CBD or a combination of the two drugs, without gene therapy, 
had their muscle function and control assessed via the hindlimb clasping test. Different mice 
were measured at each time point, making this assay between-subjets in design. Data are 
mean hindlimb clasping scores ± SEM. 
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In male mice (Figure 3.9C), the first significant difference in hindlimb clasping scores 
was observed at 9 months, with all three drug treatment groups (GemfibPBS, CBDPBS and 
ComboPBS) retracting their limbs to the abdomen more often and more consistently than age 
and sex-matched WT controls, which was reflected in significantly higher hindlimb clasping 
scores (1-way ANOVA, WT mean = 0.7407; GemfibPBS mean = 1.800; * p = .0107 ; CBDPBS mean 
= 0.7407; ** p = .0056; ComboPBS mean = 2.200; *** p = .0002; Appendix B.28).  
Female mice (Figure 3.9.D) recapitulated the trend demonstrated by males, with no 
significant differences in mean hindlimb score observed until the 9 month time point. Here, 
female GemfibPBS, CBDPBS and ComboPBS treated mice all demonstrated significantly higher 
(worse) hindlimb clasping scores than their sex- and age-matched WT controls, but were 
statistically indistinguishable from UTCln6nclf (WT mean = 0.3704; GemfibPBS mean = 1.700; ** p 









































































































































































































































































































































































































































































































































































































































































































































































































































































































⇐	Figure 3.9 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: ataxia phenotyping scores (opposite 
page). Small molecule therapy, when administered without gene therapy, does not appear to protect 
Cln6nclf mice against the untreated Cln6nclf (UTCln6nclf) ledge and hindlimb clasping ataxia phenotypes. 
The mean gait test scores of all three drug-treated experimental groups, however, were not significantly 
different from those of healthy wildtype (WT) scores at 9 months for both sexes. Ataxia scoring criteria 
and methodology can be found in Chapter 2, adapted from Guyenet et al. 2010. Different mice were 
assessed at each time point, making the experiment between-subjects in design. For each assay, a 
mouse could be assigned a score between 0 and 3, with 0 indicating a complete absence of the ataxic 
phenotype and 3 indicating a completely penetrant ataxic phenotype (coloured arrows on the left). Data 
are presented as mean scores, with error bars representing ± SEM. Individual (averaged) mouse scores 
are presented as clear circles. All analyses were conducted using 1-way ANOVAs (Appendices B.26-
27), followed by Tukey’s multiple comparisons post-hoc tests. A. Histogram presenting mean male ledge 
scores for 6 months (left; darker coloured bars) and 9 months (right; lighter coloured bars) of age. No 
significant difference in ledge score was detected between the male drug treated Cln6nclf groups 
(GemfibPBS, purple; CBDPBS, green; ComboPBS, orange) and their UTCln6nclf (red) and WT (C57Bl/6, white) 
counterparts at 6 months of age. At 9 months, however, significant differences in ledge scores are 
observed between all three of the drug treated groups and WT (WT mean = 1.407; GemfibPBS mean = 
2.267; *** p = .0002; CBDPBS mean = 2.178; *** p = .0003; ComboPBS mean = 2.133; ** p = .0023; 
Appendix B.26), with all three drug groups performing significantly worse (higher scores; coloured arrow 
on the left) than WT. n(per group per time point) = 8-10. B. Histogram presenting mean female ledge 
scores for 6 months (left; lighter patterned bars) and 9 months (right; darker patterned bars). No 
significant difference was observed between the mean ledge scores of any of the drug treated female 
groups and WT control or UTCln6nclf at 6 months. All three drug groups (GemfibPBS, CBDPBS and 
ComboPBS), however, had significantly worse ledge scores than WT at 9 months of age (WT mean = 
1.407; GemfibPBS mean = 2.133; ** p = .0023; CBDPBS mean = 2.00; * p = .0278; ComboPBS = 2.167; ** 
p = .0026; Appendix B.27). No significant differences were found between the 9-month drug-only treated 
groups and their UTCln6nclf counterparts. n(per group per time point) = 8-12 C. Histogram presenting mean 
male hindlimb clasping scores for 6 (left; darker coloured bars) and 9 months (right; lighter coloured bars). 
No significant difference between the mean hindlimb clasping scores of drug-only treated groups and 
their age- and sex-matched WT and UTCln6nclf counterparts was detected at 6 months. All three male 
drug-only groups (GemfibPBS, CBDPBS and ComboPBS) performed significantly worse (higher mean scores) 
than WT at 9 months of age (WT mean = 0.7407; GemfibPBS mean = 1.800; * p = .0107 ; CBDPBS mean 
= 0.7407; ** p = .0056; ComboPBS mean = 2.200; *** p = .0002; Appendix B.28), but their scores were 
not significantly different from UTCln6nclf counterparts. n(per group per time point) = 8-15. D. Histogram 
presenting mean female hindlimb clasping scores for 6 (left, lighter patterned bars) and 9 months (right; 
darker patterned bars). No significant difference between the mean hindlimb clasping scores of drug-
only treated groups and their age- and sex-matched WT and UTCln6nclf counterparts was detected at 6 
months. All three female drug-only groups (GemfibPBS, CBDPBS and ComboPBS) performed significantly 
worse (higher mean scores) than WT at 9 months of age (WT mean = 0.3704; GemfibPBS mean = 1.700; 
** p = .0077; CBDPBS mean = 1.625; * p = .0217; ComboPBS mean = 1.833; ** p = .0052; Appendix B.29 ), 
but their scores were not significantly different from UTCln6nclf counterparts. n(per group per time point) = 
8-12. E. Histogram presenting mean male gait scores for 6 (left, darker coloured bars) and 9 months 
(right; lighter coloured bars). At 6 months, all three drug-only treated groups produce mean gait scores 
significantly better (lower) than their UTCln6nclf counterparts (UTCln6nclf mean = 0.4667; GemfibPBS mean = 
0.0; ** p = .0012; CBDPBS mean = 0.0; ** p = .0012; ComboPBS mean = 0.033; ** p = .0031; Appendix 
B.30). At 9 months, however, none of the male drug-only Cln6nclf show significant differences in mean 
gait score from either the healthy WT control or their UTCln6nclf counterparts. n(per group per time point) 
= 10-12. F. Histogram presenting mean female gait scores for 6 (left, lighter patterned bars) and 9 months 
(right; darker patterned bars). At 6 months of age, no significant differences in mean scores could be 
detected between any of the experimental groups. At 9 months, however, gemfibrozil-only treated female 
mice (GemfibPBS) performed significantly better (lower mean score) than their age-matched UTCln6nclf 
counterparts (UTCln6nclf mean = 0.9667; GemfibPBS mean = 0.1333; * p = .0123) while mice treated with 
a combination of gemfibrozil and CBD performed significantly worse (higher mean score) than WT 
controls (WT mean = 0.6296; ComboPBS mean =1.458 ; * p = .0261; Appendix B.31). n(per group per 
time point) = 8-12.  
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3.2.2.d Gait test 
Motor co-ordination and control, as determined by a low score in the gait test, was assessed 
in Cln6nclf mice treated with gemfibrozil, CBD or a combination of the two drugs, without gene 
therapy (Figures 3.9.E and 3.9.F). Different mice were assessed at each time point (6 and 9 
months), making the assay between subjects in design. Data are mean gait ataxia scores ± 
SEM.  
Unlike the ledge and hindlimb clasping tests, which illustrated a clear trend of motor 
skill degeneration over time, the gait test results were more varied. Male drug-only groups, 
for instance, actually demonstrated significantly better (lower) gait scores than UTCln6nclf mice 
at 6 months (UTCln6nclf mean = 0.4667; GemfibPBS mean = 0.0; ** p = .0012; CBDPBS mean = 0.0; 
** p = .0012; ComboPBS mean = 0.033; ** p = .0031; Appendix B.30). Why this is the case is 
unclear, but could either be an indication of early-acting efficacy from the drug treatments or, 
perhaps more likely, could be to do with the more subjective nature of gait assessment versus 
ledge or hindlimb (ledge and hindlimb criteria are more clearly divided into scores of 0, 1, 2 
and 3). Either way, drug only males did well at 6 months and while their scores did increase 
by 9 months, they remained statistically indistinguishable from WT controls (Appendix B.30).  
Female drug-treated mice, however, demonstrated a more linear trend – with no 
significant differences in mean gait score present for any experimental group at 6 months, 
similar to the ledge and hindlimb tests. At 9 months ComboPBS females had, on average, a 
significantly more ataxic gait phenotype than their age- and sex-matched WT controls, 
indicating that this treatment does not protect female Cln6nclf mice from the UTCln6nclf gait 
phenotype (WT mean = 0.6296; ComboPBS mean =1.458 ; * p = .0261; Appendix B.31).  
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GemPBS females, however, demonstrated significantly better (lower) gait scores than 
UTCln6nclf mice at 9 months of age (UTCln6nclf mean = 0.9667; GemfibPBS mean = 0.1333; * p = 
.0123), perhaps indicative of a sex-based difference in response to the drug, since male mice 
of the same age and treated with the same drug did not demonstrate a significantly better 
gait score than male UTCln6nclf. 
3.2.3  Small molecule therapy in PBS-treated Cln6nclf mice: survival and 
weight 
The survival curves (and median survival) of gemfibrozil, CBD and combination treated Cln6nclf 
mice were compared to WT and UTCln6nclf controls. Mice would be euthanised once they 
reached one of the three humane end-points stipulated by the Animal Ethics Committee (AEC; 
see Chapter 2 for details). Data are presented here up until 14 months – even though the trial 
continued on until past the 16 month time point for some mice – due to the time limits of a 
MSc. Survival data are presented as percentage of the original cohort n, with curve 
comparisons between sex-matched Cln6nclf and WT conducted via separate log-rank (Mantel-
Cox) tests for each sex (Appendices B.32-43).  
The median survival of male WT mice was undefined at 14 months, meaning that there 
had not been enough ‘unplanned’ deaths to determine a median survival. This meant that all 
the drug treated groups, in comparison, had significantly shorter survival curves – with 
GemfibPBS treated male mice having a median survival of 12.5 months, CBDPBS male mice 
having a median survival of 12.9 months and ComboPBS male mice having a median survival of 
12.6 months (Figure 3.10. A; WT median survival aka ‘ms’ = undefined at 14 months; GemfibPBS 
ms = 12.5 months; **** p ≤ .0001; CBDPBS ms = 12.9 months; **** p ≤ .0001 ComboPBS ms = 
12.6; * p = .0478; Appendices B.32 - 37). A dramatic drop off in population numbers around 
12 months resulted in the ComboPBS median survival being significantly shorter than UTCln6nclf 
mice as well, all ComboPBS mice met a human endpoint before 14 months of age.  
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Female survival demonstrated a similar trend (Figure 3.10.B). All drug-only treatment 
groups had significantly shorter lifespans that WT controls (WT ms = undefined at 14 months; 
GemfibPBS ms = 12.9 months; CBDPBS ms = 12.97 months; ComboPBS ms = 12 months; **** p ≤ 
.0001; Appendices B.38-40), suggesting a failure to protect against the characteristically 
shortened lifespan phenotype of Cln6nclf mice.  
Weights were also kept, as a measure of overall health, and body weight was recorded 
weekly (in grams). Average weights for each experimental group are presented in monthly 
increments, as it gives a clearer overview of weight progression throughout the lifespan. 
Simple linear regression was conducted to determine the overall rate of weight gain and/or 
loss over the first 14 months of the trial, but no differences were detected in the slopes of any 
experimental group. A series of 1-way ANOVA analyses were also used to compare the mean 
weights of gemfibrozil treated, CBD treated and combination treated Cln6nclf mice to age-
matched WT and UTCln6nclf controls at 6, 9 and 12 months – which felt appropriate, as this is 
when behavioural assessments were carried out. Data are presented here as average weights, 
in grams ± SEM (Figure 3.11).  
Male Cln6nclf mice, both treated and untreated, gain weight until approximately 7 
months of age – at which point all weights began to plateau or decline. CBDPBS males 
demonstrate significantly lower weights than WT as early as 9 months (Figure 3.11.E; CBDPBS 
mean weight = 35.4 g; WT mean weight = 38.87 g; ** p = .0067; Appendix B.44), and by 12 
months all three male drug-only groups are significantly lighter than WT controls (WT mean 
weight = 37.76 g; GemfibPBS mean weight = 33.93 g; ** p = .0055; CBDPBS mean weight = 30.83 
g; p ≤ .0001; ComboPBS mean weight = 33.86 ; p = .0273; Appendix B.44).  
Female drug-treated Cln6nclf mice, on the other hand, are significantly lighter than WT 
at 6 months (1-way ANOVA; WT mean weight = 27.04 g; GemfibPBS mean weight = 24.67 g; 
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**** p = ≤ .0001; CBDPBS mean weight = 25.29 g; * p = .0137; Combo PBS mean weight = 25.04; 
** p = .0016; Appendix B.45), and at 9 months (WT mean weight = 28.90 g; GemfibPBS mean 
weight = 25.79 g; *** p = .0007; CBDPBS mean weight = 26.44 g; * p = .0307; ComboPBS mean 
weight = 25.85 g; p = .0017; Appendix B.45). Unexpectedly, however, CBDPBS and ComboPBS 
treated females appear to either gain weight or experience a reduction in overall rate of 
weight loss by 12 months, as their average weights are no longer statistically indistinguishable 
from WT. Only GemfibPBS treated females remain significantly lighter than WT at 12 months 











Figure 3.10 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: survival curves Small molecule therapy 
alone, without gene therapy, fails to rescue Cln6nclf mice from characteristically shortened lifespans. 
Kaplan-Meier survival plots (%) comparing the survival curves of wildtype (WT; C57Bl/6; male = black 
lines; female = grey lines) and UTCln6nclf mice (male = red lines; female = maroon lines) to Cln6nclf mice 
treated with one of three small molecule therapy regimens (gemfibrozil = purple lines; CBD = green lines; 
Combo = orange lines), without gene therapy (1x PBS at P0-2). All survival curve comparisons were 
conducted using a log rank (Mantel-Cox) test in GraphPad Prism 8 (Appendices B.32-43). A. Male 
survival curves (%) from birth to 14 months of age. All three male small molecule treatment groups 
(GemfibPBS, CBDPBS and ComboPBS) had significantly shorter survival curves than WT control (WT 
median survival aka ‘ms’ = undefined at 14 months; GemfibPBS ms = 12.5 months; **** p ≤ .0001; CBDPBS 
ms = 12.9 months; **** p ≤ .0001 ComboPBS ms = 12.6; * p = .0478; Appendices B.32 - 37) with all 
ComboPBS mice reaching a humane end-point before 14 months of age. This meant that not only was 
the average survival age of male ComboPBS mice significantly younger than WT, it was also significantly 
younger than UTCln6nclf counterparts (UTCln6nclf ms =; *** p = .0005; Appendices B.34 and B.37). Starting 
n = 23-35. B. Female survival curves (%) from birth to 14 months of age. All three female small molecule 
treatment groups (GemfibPBS, CBDPBS and ComboPBS) had, on average, significantly shorter lives than 
WT controls (WT ms = undefined at 14 months; GemfibPBS ms = 12.9 months; CBDPBS ms = 12.97 months; 
ComboPBS ms = 12 months; **** p ≤ .0001; Appendices B.38-40). Their average lifespan was statistically 
indistinguishable from their UTCln6nclf counterparts (Cln6nclf ms = 12.5 months; Appendices B.41-43). n 
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⇐ Figure 3.11 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: weights (previous page). Small 
molecule therapy appears to have sexually dimorphic effects on the weights of Cln6nclf mice during the 
first fifteen months of life. Mice were weighed weekly from weaning (~28 days) to determine drug dosage 
and as a measure of general health. Weights are shown here from weaning to 15 months due to the time 
constraints of an MSc (weights continued to be tracked for the entire duration of the trial). Data are 
presented as average weights, in grams error bars = ± SEM. Analyses conducted via 1-way ANOVA with 
Tukey’s multiple comparisons post-hoc tests where applicable. A. Average male weights, in grams, over 
14 months (line graph). 1-way ANOVA analyses conducted between male WT (black squares and lines), 
GemfibPBS (purple squares and lines), CBDPBS (green squares and lines), ComboPBS (orange squares 
and lines) and UTCln6nclf (red squares and lines) mice at 6, 9 and 12 months of age. n = 24-29. B. Average 
female weights, in grams, over 15 months (line graph). 1-way ANOVA analyses conducted between 
female WT (grey circles and lines), GemfibPBS (purple circles and lines), CBDPBS (green circles and lines), 
ComboPBS (orange circles and lines) and UTCln6nclf (maroon circles and lines) mice at 6, 9 and 12 months 
of age. n = 22-33. C. Histogram of average weights (in grams) of male WT (white bar), GemfibPBS (purple 
bar), CBDPBS (green bar), ComboPBS (orange bar) and UTCln6nclf (red bar) mice at 6 months of age. Clear 
circles represent individual mouse weights at 6 months. No significant differences in average weight 
were found between any of the experimental groups at this time point (1-way ANOVA; Appendix B.44). 
There were no significant differences between the three drug treated groups and UTCln6nclf weights. n = 
21-29. D. Histogram of average weights (In grams) of female WT (black patterned bar), GemfibPBS (purple 
patterned bar), CBDPBS (green patterned bar), ComboPBS (orange patterned bar) and UTCln6nclf (maroon 
patterned bar) mice at 6 months of age. Clear circles represent individual mouse weights at 6 months. 
All three drug treated experimental groups were significantly lighter, on average, than age-matched WT 
(1-way ANOVA; WT mean weight = 27.04 g; GemfibPBS mean weight = 24.67 g; **** p = ≤ .0001; CBDPBS 
mean weight = 25.29 g; * p = .0137; Combo PBS mean weight = 25.04; ** p = .0016;Appendix B.45). 
There were no significant differences between the three drug treated groups and UTCln6nclf weights. n = 
21-27. E. Histogram of male average weights at 9 months of age. CBDPBS (green bar; mean weight = 
35.40 g) treated Cln6nclf mice demonstrate significantly lower weights, on average, than WT (WT mean 
weight = 38.87 g; ** p = .0067; Appendix B.44) at 9 months. There were no significant differences 
between the three drug treated groups and UTCln6nclf weights. n = 15-22. F. Histogram of female average 
weights at 9 months of age. All three drug treatment groups remain significantly lighter, on average, than 
WT at 9 months (WT mean weight = 28.90 g; GemfibPBS mean weight = 25.79 g; *** p = .0007; CBDPBS 
mean weight = 26.44 g; * p = .0307; ComboPBS mean weight = 25.85 g; p = .0017; Appendix B.45). 
There were no significant differences between the three drug treated groups and UTCln6nclf weights. n = 
9-24. G. Histogram of average male weights, in grams, at 12 months of age. All three drug treated groups 
demonstrated lighter weights, on average, than WT at 12 months (WT mean weight = 37.76 g; GemfibPBS 
mean weight = 33.93 g; ** p = .0055; CBDPBS mean weight = 30.83 g; p = ≤.0001; ComboPBS mean weight 
= 33.86 ; p = .0273; Appendix B.44). There were no significant differences between the three drug 
treated groups and UTCln6nclf weights. n = 8-21. H. Histogram of average female weights, in grams, at 12 
months of age. Female mice dosed only with gemfibrozil (GemfibPBS; purple patterned bar) showed 
significantly lower weights (GemfibPBS mean weight = 23.66 g) , on average, than WT (WT mean weight 
= 30.23 g; *** p = .0001; Appendix B.45). No other drug treatment group showed significant differences 
in weight from either WT or Cln6nclf and GemfibPBS weights were not statistically different from UTCln6nclf 
either. n = 4-16.  
3.2.4  Small molecule therapy in PBS-treated Cln6nclf mice: sex 
differences 
Sex differences are particularly pertinent to small molecule therapy development due to the 
well-documented differences in male and female responses to different drugs. Women have 
been determined to be more susceptible to the toxicity of many compounds, with an 
increased risk of negative side-effects such as inflammation, nausea and alopecia (Nicolson et 
al., 2010; Soldin et al., 2011). Here, the mean behaviour scores, survival data and weights of 
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male and female Cln6nclf mice treated with either gemfibrozil (GemfibPBS), CBD (CBDPBS) or a 
combination of the two drugs (ComboPBS) are compared across the lifespan in an effort to 
determine any sex-based differences in response to the small molecule therapies.  
3.2.4.a Rotarod sex differences 
Simple linear regression analyses revealed that there was no significant difference in the 
overall rate of motor skill decline, as determined by the rotarod, between male and female 
animals for any of the drug only groups (Figures 3.12.A-C). Despite this, however, a series of 
unpaired student t-test analyses at 6, 9 and 12 months detected several significant differences 
in mean rotarod score beween the sexes (Figures 3.12.E-G).  
Male and female GemfibPBS mice have comparable mean rotarod scores at 6 months 
of age (Figure 3.12.E). By 9 months, however, females are staying on the rotarod significantly 
longer than males (Figure 3.12.F; 9 month GemfibPBS male mean rotarod score = 111.4 
seconds; 9 month GemfibPBS female mean rotarod score = 160.7 seconds; **p =.0041; 
Appendix B.46) and maintain this significant difference at 12 months (Figure 3.12.G; 12 month 
male GemfibPBS mean rotarod score = 61.14 seconds; 12 month female GemfibPBS mean 
rotarod score = 83.88 seconds; * p = .0312; Appendix B.48).  
Female CBDPBS mice presented with a significantly higher rotarod score than their age-
matched male counterparts at 6 months (Figure 3.12.E; 6 month male CBDPBS mean rotarod 
score = 177 seconds; 6 month female CBDPBS mean rotarod score = 230.1 seconds; * p = .0193; 
Appendix B.47). While females continued to have a higher rotarod score at 9 months, the 
difference between scores was no longer significant and by 12 months it appears negligible 
(Figures 3.12.F and G; 12 month male CBDPBS mean rotarod score = 70.33 seconds; 12 month 
female CBDPBS mean rotarod score = 76.33 seconds; Appendix B.48).  
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Male and female ComboPBS treated mice have statistically similar scores until 12 
months of age (Figures 3.12.E-G). At 12 months, however, females perform significantly better 
than age-matched male counterparts (Figure 3.12.G; 12 month male ComboPBS mean rotarod 
score = 64.60 seconds; 12 month ComboPBS female mean rotarod score = 100.4 seconds; ** p 





































































































































































































































































































































































































































































































⇐	Figure 3.12 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: sex differences in rotarod scores 
(previous page). Male and female mice treated with either gemfibrozil (GemfibPBS), cannabidiol (CBDPBS) 
or a combination of gemfibrozil and cannabidiol (ComboPBS) demonstrated similar overall rates of decline 
in rotarod performance over time but showed statistically significant differences in average rotarod score 
at the three different time points measured. A-C. Line graphs presenting data as mean rotarod scores 
measured in latency to fall (seconds) for male (squares) and female (circle) Cln6nclf mice, treated either 
with gemfibrozil (A; male = dark purple; female = light purple), CBD (B; male = dark green; female = light 
green) or a combination of the two (C; male = orange; female = yellow). Error bars represent ± SEM. 
Dotted lines indicate the expected trajectory of rotarod scores between measured time points (6, 9 and 
12 months). Linear regression lines are represented by solid coloured lines (simple linear regression; 
Appendices B.44-45). E-G. Histograms presenting data as mean rotarod scores measured in latency 
to fall (seconds) for male (dark, solid coloured bars) and female (light, patterned bars) Cln6nclf mice 
treated with either gemfibrozil (purple), CBD (green) or a combination of the two drugs (orange) at 6 (E), 
9 (F) and 12 (G) months of age. Error bars represent ± SEM. Individual mouse scores are represented 
by clear circles. Analyses between male and female mean scores for each treatment group (GemfibPBS, 
CBDPBS and ComboPBS) were conducted using unpaired student t-tests (Appendices B.46-48). A. Both 
male (dark purple squares and lines) and female (light purple lines and circles) GemfibPBS treated Cln6nclf 
mice demonstrated a decline in ability to stay on the rotarod from 6 to 12 months of age (negative slope 
gradients in line equations for both; Appendix B.45). Simple linear regression (solid lines) revealed that 
there was no significant difference between the overall rate of decline in motor performance between 
GemfibPBS treated males and females, though elevation differed significantly (p = .0133; Appendix B.45). 
B. Both male (dark green lines and squares) and female (light green lines and circles) CBDPBS treated 
Cln6nclf mice demonstrated a decline in ability to stay on the rotarod from 6 to 12 months of age (negative 
slope gradients in line equations for both; Appendix B.45). Simple linear regression (solid lines) revealed 
that there was no significant difference between the overall rate of decline in motor performance between 
CBDPBS treated males and females, though elevation differed significantly (p = .0319; Appendix B.45).. 
C. Both male (orange lines and squares) and female (yellow lines and circles) ComboPBS treated Cln6nclf 
mice demonstrated a decline in ability to stay on the rotarod between 6 and 9 months of age (negative 
slope gradients in line equations for both; Appendix B.45). Simple linear regression (solid lines) revealed 
that there was no significant difference in the overall rate of decline in motor performance between 
ComboPBS treated males and females, though elevation differed significantly (p = .0057; Appendix B.45). 
E. Histogram presenting average rotarod scores (latency to fall in seconds) of male (dark coloured bars) 
and female (light coloured bars) drug-only treated Cln6nclf mice at 6 months of age. No significant 
difference was found between male and female GemfibPBS scores, and no significant difference was 
found between male and female ComboPBS scores. There was, however, a significant difference between 
the scores of male and female CBDPBS treated mice, with females, on average, scoring higher than their 
male counterparts (male mean score = 177 seconds; female mean score = 230.1 seconds; * p = .0193; 
Appendix B.47). n(per group) = 8-10. F. Histogram presenting average rotarod scores (latency to fall in 
seconds) of male (dark coloured bars) and female (light coloured bars) drug-only treated Cln6nclf mice at 
9 months of age. No significant differences between male and female average scores were found for 
either CBDPBS treated or ComboPBS treated mice at this age. There was, however, a significant difference 
in average score between male GemfibPBS (mean = 111.4 seconds) and GemfibPBS female (mean = 160.7 
seconds) scores (**p =.0041; Appendix B.46). n(per group) = 8-15.. G. Histogram presenting average 
rotarod scores (latency to fall in seconds) of male (dark coloured bars) and female (light coloured bars) 
drug-only treated Cln6nclf mice at 12 moths of age. No significant difference was found between male 
and female CBDPBS scores. There were, however, significant differences found between male and female 
scores for both GemfibPBS (male mean score = 61.14 seconds; female mean score = 83.88 seconds; * p 
= .0312) and ComboPBS treated mice (male mean score = 64.60 seconds; female mean score = 100.4 
seconds; ** p = .0048; Appendix B.48), with females performing better (higher score) in both cases.. 
n(per group) = 7-10.  
3.2.4.b Composite ataxia sex differences 
Male and female Cln6nclf mice demonstrated no significant difference in mean composite 
ataxia scores (Figure 3.13) at 6 or 9 months of age (unpaired t-tests; Appendices B.49-51), 
regardless of drug treatment.  
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Figure 3.13 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: sex differences in composite ataxia 
scores. Male and female mice treated with either gemfibrozil (GemfibPBS), cannabidiol (CBDPBS) or a 
combination of gemfibrozil and cannabidiol (ComboPBS) demonstrated statistically similar composite 
ataxia scores (0-9) at both 6 and 9 months of age. Histograms demonstrating mean composite ataxia 
scores for male (dark coloured bars) and female (light, patterned bars) Cln6nclf mice treated with either 
gemfibrozil (gemfibrozilPBS; purple), cannabidiol (CBD; CBDPBS; green) or a combination of gemfibrozil 
and CBD (ComboPBS), without gene therapy, at 6 (A) and 9 (B) months of age. Different mice were tested 
at each time point (between-subjects study design). A low score (close to 0) indicates an absence of the 
ataxic phenotype as measured by the composite scoring system, while higher score (close to 9) indicate 
increasing levels of ataxic behaviour (arrow on the left). Individual mouse composite scores are shown 
as clear circles and error bars = ± SEM. Analyses between male and female mean scores for each 
treatment group at each time point were conducted via unpaired student t-tests (Appendices B.49-51). 
n(per group per time point) = 8-15. A. No significant differences were observed between mean male and 
female composite ataxia scores at 6 months, regardless of drug treatment regimen (unpaired student t-
tests; Appendices B.49-51), though GemfibPBS males appear to have (non-significantly) higher (worse) 
mean scores than age-matched GemfibPBS females. B. No significant differences were observed 
between mean male and female composite ataxia scores at 9 months, regardless of drug treatment 
regimen (unpaired student t-tests; Appendices B.49-51).  
3.2.4.c Ledge ataxia sex differences 
Male and female Cln6nclf mice demonstrated no significant difference in mean ledge ataxia 
scores (Figure 3.14.A and B) at 6 or 9 months of age (unpaired t-tests; Appendices B.52-60), 
regardless of drug treatment.  
3.2.4.d Hindlimb clasping ataxia sex differences 
Male and female Cln6nclf mice demonstrated no significant difference in mean hindlimb 
clasping ataxia scores (Figure 3.14.C and D) at 6 or 9 months of age (unpaired t-tests; 
































































































































































3.2.4.e Gait ataxia sex differences 
GemfibPBS female mice performed significantly worse (higher ataxia score) in the gait ataxia 
test than age-matched male counterparts at 6 months of age (female GemfibPBS mean gait 
ataxia score = 0.1944; male GemfibPBS mean gait ataxia score = 0.0; *p = .312 ; Appendix B.58), 
though this difference was reversed at 9 months – with GemfibPBS males performing 
significantly worse (mean score of 0.9333) than females (mean score of 0.1333; ** p = .0041; 
Appendix B.58).  
Neither CBDPBS or ComboPBS treated Cln6nclf demonstrated any sex differences in mean 
gait ataxia score at 6 months of age. At 9 months, however, female ComboPBS mice 
demonstrated significantly more ataxic gaits, on average, than their age-matched male 
counterparts (12 month ComboPBS male mean gait ataxia score = 0.7333; 12 month ComboPBS 
female mean gait ataxia score = 1.458; * p = 0.233; Appendix B.60). The gait scores of M/F 



























































































































































































































































































































































































































































































⇐	 Figure 3.14 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: sex differences in ataxia 
phenotyping scores (previous page). Male and female Cln6nclf mice treated with either gemfibrozil 
(GemfibPBS), cannabidiol (CBDPBS) or a combination of gemfibrozil and cannabidiol (ComboPBS) 
demonstrated statistically similar ledge and hindlimb clasping ataxia scores at both 6 and 9 months of 
age, while mean gait ataxia scores presented with several statistically significant sex differences at both 
time points. Mice underwent three trials of a sequence three different ataxia assays – the ledge test, the 
hindlimb clasping test and the gait test (adapted from Guyenet et al., 2010) – in order to determine the 
presence or absence of an ataxic phenotype at 6 and 9 months of age. Different mice were assessed at 
each time point, making the experiment between-subjects in design. For each assay, a mouse could be 
assigned a score between 0 and 3, with 0 indicating a complete absence of the ataxic phenotype and 3 
indicating a completely penetrant ataxic phenotype (coloured arrows on the left). All data (A-F) are 
presented as the mean of averaged (3 trials; scored from 0-3) individual mouse scores, with clear circles 
representing the individual averaged scores. Error bars = ± SEM. All analyses between male and female 
mean ataxia scores were conducted using unpaired student t-tests (Appendices B.52 - 60). A and B. 
Histograms of mean ledge test scores at 6 (A) and 9 (B) months of age for male (dark coloured bars) 
and female (light coloured, patterned bars) Cln6nclf mice treated with either gemfibrozil (GemfibPBS; 
purple), CBD (CBDPBS; green) or a combination of gemfibrozil and CBD (ComboPBS; orange) without 
gene therapy. No significant differences were observed between the mean ledge scores of treatment- 
and age-matched male and female Cln6nclf mice, regardless of drug treatment regimen. C and D. 
Histograms of mean ledge hindlimb clasping scores at 6 (C) and 9 (D) months of age for male (dark 
coloured bars) and female (light coloured, patterned bars) Cln6nclf mice treated with either gemfibrozil 
(GemfibPBS; purple), CBD (CBDPBS; green) or a combination of gemfibrozil and CBD (ComboPBS; orange) 
without gene therapy. No significant differences were observed between the mean hindlimb clasping 
scores of treatment- and age-matched male and female Cln6nclf mice, regardless of drug treatment 
regimen. E and F. Histograms of mean ledge gait clasping scores at 6 (E) and 9 (F) months of age for 
male (dark coloured bars) and female (light coloured, patterned bars) Cln6nclf mice treated with either 
gemfibrozil (GemfibPBS; purple), CBD (CBDPBS; green) or a combination of gemfibrozil and CBD 
(ComboPBS; orange) without gene therapy. E. Female GemfibPBS mice demonstrated significantly higher 
(worse) gait scores than their age-matched GemfibPBS male counterparts at 6 months of age (Female 
GemfibPBS mean = 0.1944; Male GemfibPBS mean = 0.0; *p = .312 ; Appendix B.58). No other significant 
differences in mean gait scores were observed between treatment-matched male and female Cln6nclf 
drug-only groups at 6 months. F. At 9 months of age GemfibPBS treated male Cln6nclf mice were 
performing significantly worse (higher score) than their treatment- and age-matched female counterparts 
(female GemfibPBS mean = 0.1333; male GemfibPBS mean = 0.9333; ** p = .0041; Appendix B.58). A 
significant difference in mean scores was also observed between ComboPBS treated male (mean = 
0.7333) and female (mean = 1.458; * p = 0.233; Appendix B.60) Cln6nclf mice at this time point. No 
significant difference was observed between male and female CBDPBS Cln6nclf mice at 9 months.  
3.2.4.f Survival and weight gain sex differences 
Male and female Cln6nclf mice demonstrated no sex-based differences in survival, regardless 
of what small molecule therapy they received (Figure 3.15; Appendices B.61-63).  
In terms of weight gain (Figure 3.16), however, male GemfibPBS and male ComboPBS 
mice gained and lost weight at a greater rate than their female counterparts.  
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Figure 3.15 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: sex differences in survival. .Male and 
female Cln6nclf mice treated with either gemfibrozil (GemfibPBS), cannabidiol (CBDPBS) or a combination 
of gemfibrozil and cannabidiol (ComboPBS) had similar survival curves, regardless of drug treatment. 
Kaplan-Meier survival plots (%) comparing the survival curves of male and female GemfibPBS treated 
Cln6nclf mice (A), male and female CBDPBS treated Cln6nclf mice (B), and male and female ComboPBS 
treated Cln6nclf mice (C). All survival curve comparisons were conducted using log-rank (Mantel-Cox) 
tests in GraphPad Prism 8 (Appendices B.61-63). A. Male (dark purple) and female (light purple) 
GemfibPBS treated Cln6nclf survival curves from birth to 14 months of age. No significant difference was 
found between the median survival of male and female GemfibPBS treated mice (Appendix B.61). 
Starting n = 32-34. . B. Male (dark green) and female (light green) CBDPBS treated Cln6nclf survival curves 
from birth to 14 months of age. No significant difference was found between the median survival of male 
and female CBDPBS treated mice (Appendix B.62). Starting n = 27-35. C. Male (orange) and female 
(yellow) ComboPBS treated Cln6nclf survival curves from birth to 14 months of age. No significant 
difference was found between the median survival of male and female ComboPBS treated mice 





















































Figure 3.16 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: sex differences in rate of weight 
gain. .Male and female GemfibPBS- and CBDPBS- treated Cln6nclf mice gained weight (g) over their 
lifespan at similar rates, while the overall rate of weight gain in ComboPBS treated male and female Cln6nclf 
mice differed significantly. Mice were weighed weekly from weaning (~28 days) to determine drug dosage 
and as a measure of general health. Weights are shown here from weaning to 15 months due to the time 
constraints of an MSc (weights continued to be tracked for the entire duration of the trial). Data are 
presented as average weights, error bars ± SEM. Comparisons between male and female weights were 
conducted via simple linear regression only, as there is always an expected dispairty between male and 
female mice. A. Average male (dark purple) and female (light purple) GemfibPBS treated Cln6nclf weights 
(in grams) plotted every month from weaning until 14 months of age (line graph). A significant difference 
in rate of weight gain was observed between male and female GemfibPBS mice (simple linear regression; 
*p = .0219; Appendix B.67). B. Average male (dark green) and female (light green) CBDPBS treated 
Cln6nclf weights (in grams) plotted every month from weaning until 14 months of age (line graph). No 
significant difference in rate of weight gain was observed between male and female CBDPBS mice (simple 































































3.2.5  Small molecule therapy in PBS-treated Cln6nclf mice: summary 
All Cln6nclf mice, regardless of which small molecule therapy group they were in, demonstrated 
significantly shorter lifespans and some form of behavioural deficit compared to WT by either 
9 months (for ataxia) or 12 months (for rotarod). This was confirmed by the fact that these 
scores were also statistically indistinguishable from the scores of age- and sex-matched 
UTCln6nclf at each time point. The only exceptions were GemfibPBS treated female mice who did 
not demonstrate a significantly worse composite ataxia score compared to WT by 9 months 
of age and CBDPBS treated female mice who did not demonstrate a significantly worse gait 
ataxia score compared to WT by 9 months either. It can be concluded from this data that, 
overall, small molecule therapy alone does little to protect Cln6nclf mice from the diseased 
Cln6nclf phenotype established in section 3.1. 
Interestingly, however, the use of small molecule therapy, on its own without gene 
therapy, does seem to delay symptom onset in male Cln6nclf mice. As established in section 
3.1, male UTCln6nclf mice started demonstrating significant behavioural deficits compared to 
WT in the ledge and composite ataxia assays by 6 months of age. These behavioural deficits 
are absent in all three drug-only groups (Tables 3.4, 3.7 and 3.10). 
Finally, female Cln6nclf mice appear to demonstrate subtle behavioural improvements 
when treated with gemfibrozil alone – improvements which are not present in male Cln6nclf 
mice (Table 3.5). GemfibPBS treated female mice, for instance, not only maintain behavioural 
scores that are similar to WT in the 6 month composite and 9 month gait ataxia assays, but 
also demonstrate scores that are significantly better (lower) than age- and sex-matched 
UTCln6nclf. Female GemfibPBS mice also have significantly better rotarod scores than their male 
GemfibPBS counterparts at 9 and 12 months of age, indicating a sex-based difference in 
response to the drug (Table 3.6).  
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Table 3.4 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of GemfibPBS males. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between male gemfibrozil (GemfibPBS) treated Cln6nclf mice and their age- and sex-matched WT and 
untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural score and weight 
comparisons were conducted using 1-way ANOVAs (Appendices B.22, 24, 26, 28, 30 and 44), with 
Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were compared 
using log rank (Mantel-Cox) tests (Appendices B.32 and 35). nsd = no significant difference; s = 
significant. 
GemfibPBS Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd nsd 
WT nsd Worse (s) Worse (s) 
Composite 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Ledge 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Gait 
UTCln6nclf Better (s) nsd - 
WT nsd nsd - 
Survival 
UTCln6nclf nsd 
WT Reduced survival (s) 
Weight 
UTCln6nclf nsd nsd nsd 













Table 3.5 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of GemfibPBS females. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between female gemfibrozil (GemfibPBS) treated Cln6nclf mice and their age- and sex-matched WT and 
untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural score and weight 
comparisons were conducted using 1-way ANOVAs (Appendices B.23, 25, 27, 29, 31 and 45), with 
Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were compared 
using log rank (Mantel-Cox) tests (Appendix B.38 and 41). nsd = no significant difference; s = significant. 
GemfibPBS Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd nsd 
WT nsd nsd Worse (s) 
Composite 
UTCln6nclf Better (s) nsd - 
WT nsd nsd  
Ledge 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Gait 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Survival 
UTCln6nclf nsd 
WT Reduced survival (s) 
Weight 
UTCln6nclf nsd nsd nsd 
WT Weigh less (s) Weigh less (s) Weigh less (s) 
Table 3.6 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of GemfibPBS males 
versus GemfibPBS females. Summary table of behavioural score (rotarod and ataxia), survival and 
weight comparisons carried out between male and female gemfibrozil (GemfibPBS) treated Cln6nclf mice 
at 6, 9 and 12 months of age. All behavioural score and weight comparisons were conducted using 
unpaired student t-tests (Appendices B44, 46, 49, 55, 58 and 66), while survival curves were compared 
using log rank (Mantel-Cox) tests (Appendix 61). nsd = no significant difference. 
GemfibPBS Cln6nclf Males vs Females 
Behavioural 
test 6 months 9 months 12 months 
Rotarod nsd Females perform better (s) 
Females perform better 
(s) 
Composite nsd nsd - 
Ledge nsd nsd - 
Hindlimb nsd nsd - 
Gait Females perform better (s) 







Table 3.7 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of CBDPBS males. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between male CBD (CBDPBS) treated Cln6nclf mice and their age- and sex-matched WT and untreated 
Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural score and weight 
comparisons were conducted using 1-way ANOVAs (Appendices B.22, 24, 26, 28, 30 and 44), with 
Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were compared 
using log rank (Mantel-Cox) tests (Appendices B.33 and 36). nsd = no significant difference; s = 
significant. 
CBDPBS Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd nsd 
WT nsd nsd Worse (s) 
Composite 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Ledge 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Gait 
UTCln6nclf Better (s) nsd - 
WT nsd nsd - 
Survival 
UTCln6nclf nsd 
WT Reduced survival (s) 
Weight 
UTCln6nclf nsd nsd nsd 













Table 3.8 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of CBDPBS females. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between female CBD (CBDPBS) treated Cln6nclf mice and their age- and sex-matched WT and untreated 
Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural score and weight 
comparisons were conducted using 1-way ANOVAs (Appendices B.23, 25, 27, 29, 31 and 45), with 
Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were compared 
using log rank (Mantel-Cox) tests (Appendix B.39 and B.42). nsd = no significant difference; s = 
significant. 
CBDPBS Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd nsd 
WT nsd nsd Worse (s) 
Composite 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Ledge 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Gait 
UTCln6nclf nsd nsd - 
WT nsd nsd  
Survival 
UTCln6nclf nsd 
WT Reduced survival (s) 
Weight 
UTCln6nclf nsd nsd nsd 














Table 3.9 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of CBDPBS males versus 
CBDPBS females. Summary table of behavioural score (rotarod and ataxia), survival and weight 
comparisons carried out between male and female CBD (CBDPBS) treated Cln6nclf mice at 6, 9 and 12 
months of age. All behavioural score and weight comparisons were conducted using unpaired student t-
tests (Appendices B.44, 47, 50, 53, 56, 59 and 66), while survival curves were compared using log rank 
(Mantel-Cox) tests (Appendix B.62). nsd = no significant difference. 
CBDPBS Cln6nclf Males vs Females 
Behavioural test 6 months 9 months 12 months 
Rotarod Females perform better (s) nsd nsd 
Composite nsd nsd - 
Ledge nsd nsd - 
Hindlimb nsd nsd - 
Gait nsd nsd - 
Survival nsd 
Table 3.10 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of ComboPBS males. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between male combination drug (ComboPBS) treated Cln6nclf mice and their age- and sex-matched WT 
and untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural score and 
weight comparisons were conducted using 1-way ANOVAs (Appendices B.22, 24, 26, 28, 30 and 44), 
with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were 
compared using log rank (Mantel-Cox) tests (Appendix B.34 and 37). nsd = no significant difference; s 
= significant. 
ComboPBS Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd nsd 
WT nsd nsd Worse (s) 
Composite 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Ledge 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd Worse (s) - 
Gait 
UTCln6nclf Better (s) nsd - 
WT nsd nsd - 
Survival 
UTCln6nclf Reduced survival (s) 
WT Reduced survival (s) 
Weight 
UTCln6nclf nsd nsd nsd 




Table 3.11 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of ComboPBS females. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between female combination drug (ComboPBS) treated Cln6nclf mice and their age- and sex-matched WT 
and untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural score and 
weight comparisons were conducted using 1-way ANOVAs (Appendices B.23, 25, 27, 29, 31 and 45), 
with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were 
compared using log rank (Mantel-Cox) tests (Appendix B.40 and 43). nsd = no significant difference; s 
= significant. 
ComboPBS Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd nsd 
WT nsd nsd Worse (s) 
Composite 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Ledge 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Gait 
UTCln6nclf nsd nsd - 
WT nsd Worse (s)  
Survival 
UTCln6nclf nsd 
WT Reduced survival (s) 
Weight 
UTCln6nclf nsd nsd nsd 














Table 3.12 ⎸ Small molecule therapy in PBS-treated Cln6nclf mice: summary table of ComboPBS males 
versus females. Summary table of behavioural score (rotarod and ataxia), survival and weight 
comparisons carried out between male and female combination drug (ComboPBS) treated Cln6nclf mice 
at 6, 9 and 12 months of age. All behavioural score and weight comparisons were conducted using 
unpaired student t-tests (Appendices 50, 53, 56, 59, 62 and 66), while survival curves were compared 
using log rank (Mantel-Cox) tests (Appendix B.65). nsd = no significant difference. 
ComboPBS Cln6nclf Males vs Females 
Behavioural test 6 months 9 months 12 months 
Rotarod nsd nsd Females performed better (s) 
Composite nsd nsd - 
Ledge nsd nsd - 
Hindlimb nsd nsd - 


















3.3  A single i.c.v injection of scAAV9.CB.hCLN6 at P0-2 significantly 
improves behavioural scores and survival in Cln6nclf mice 
AAV2/9-mediated gene transfer of the CLN6 gene as a potential treatment for CLN6 BD has 
been investigated in several preclinical studies and is the subject of an ongoing clinical trial 
(Cain et al., 2019; Holthaus et al., 2019; Poppens et al., 2019; Trial No. NCT02725580, 
Clinicaltrials.gov 2016). However, the use of AAV2/9-mediated gene therapy for CLN6 BD is 
still very much in its infancy, and lessons from completed gene therapy trials in other 
metabolic disorders have suggested that gene therapy, as it exists right now, will not offer 
CLN6 BD patients a complete cure. For that reason, the investigtion, validation and 
improvement of gene therapy technologies must continue. This thesis aims to do that, 
primarily by combining gene therapy with several small molecule therapies and determining 
whether this combination results in improved behavioural outcomes, but also by validating 
Cln6nclf behavioural results from previous studies that used gene therapy alone. This section 
contributes to both those aims by examining the behaviour, survival and weights of Cln6nclf 
mice who received a single, unilateral i.c.v injection of scAAV9.CB.hCLN6 at P0-2 and were 
only dosed with strawberry jelly containing a vehicle solution as a control for small molecule 
therapy. In establishing a ‘No DrugAAV9’ behavioural phenotype, for male and female Cln6nclf 
mice, it is possible to not only validate and expand upon previous gene therapy studies, but 
also allow for later comparisons between a series of combined therapeutic strategies and gene 
therapy on its own. The true value of a combined therapeutic regimen can’t be fully 
understood without direct comparison to the strategy we are seeking to improve.  
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3.3.1  scAAV9.CB.hCLN6 treatment protects against the Cln6nclf 
phenotype: rotarod 
While UTCln6nclf mice began to show a decline in rotarod performance at 12 months of age 
(section 3.1), neonatal injection of scAAV9.CB.hCLN6 appears to prevent this decline in both 
male and female animals (Figure 3.17).  
Male No DrugAAV9 mice demonstrate statistically indistinguishable mean rotarod scores 
from their age- and sex-matched WT controls at 6 and 9 months, and demonstrate a 
significantly higher rotarod score than both WT and UTCln6nclf mice at 12 months (Figures 
3.17.A and C; No DrugAAV9 mean =192.9 seconds; WT mean = 131.5 seconds; ** p = .009 ; 
UTCln6nclf mean = 61.14 seconds; **** p ≤ .0001; Appendix B.72). 
Female No DrugAAV9 mice also exhibited excellent motor co-ordination and endurance 
across all three time points, and achieved a statistically significant difference in scores from 
UTCln6nclf mice by 9 months of age (Figure 3.7.D; No DrugAAV9 mean score = 257.7 seconds; 
UTCln6nclf mean score = 164.3 seconds; ** p = .005 ; Appendix B.73). At 12 months of age, 
female No DrugAAV9 mice outperformed both UTCln6nclf and WT controls (No DrugAAV9 mean 
score = 234.4 seconds; UTCln6nclf mean score = 71.25 seconds; **** p ≤ .0001; WT mean score 
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⇐	Figure 3.17 ⎸ scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: rotarod scores 
(prevous page). A single, neonatal injection of scAAV9.CB.hCLN6 significantly improves Cln6nclf rotarod 
scores at later stages of disease progression compared to untreated Cln6nclf (UTCln6nclf) mice. A and B. 
Line graphs presenting mean rotarod scores (latency to fall in seconds) of male (A) and female (B) WT 
(C57Bl/6; male = black lines and squares; female = grey lines and circles) gene therapy-treated (No 
DrugAAV9; male = blue lines and squares; female = light blue lines and circles) and UTCln6nclf (male = red 
lines and squares; females = maroon lines and squares) mice across 6, 9 and 12 months of age. Error 
bars = ± SEM. Dotted lines indicate the expected mean score trajectory for an experimental group 
between measured time points. A high score (~300) indicates a high level of motor co-ordination as 
measured by the rotarod, while lower scores correlate to increasing levels of motor dysfunction (coloured 
arrow on the left). Analyses between groups at each time point were conducted via 1-way ANOVA, with 
Tukey’s post-hoc multiple comparisons tests used when a difference was detected. C and D. Histograms 
presenting mean rotarod scores of male (C) and female (D) WT (C57Bl/6; male = white bars; female = 
black patterned bars) gene therapy-treated (No DrugAAV9; male = blue bars; female = light blue bars) and 
UTCln6nclf (male = red bars; female = maroon bars). Data are presented as mean scores ± SEM. Individual 
mouse rotarod scores (averaged from 3 trials) are represented by clear circles. All analyses conducted 
by 1-way ANOVA and Tukey’s post-hoc multiple comparisons tests. A. and C. Line graph (A) and 
histogram (B) of male rotarod scores. Male No DrugAAV9 mice demonstrate no significant difference in 
mean rotarod score from their age- and sex-matched WT and UTCln6nclf counterparts until 12 months of 
age, at which point the mean No DrugAAV9 rotarod score is significantly higher (better) than both WT and 
UTCln6nclf (No DrugAAV9 mean =192.9 seconds; WT mean = 131.5 seconds; ** p = .009 ; UTCln6nclf mean = 
61.14 seconds; **** p ≤ .0001; Appendix B.72). n(per group per time point) = 8-14. B and D. Line graph 
(B) and histogram (D) of female rotarod scores. Female No DrugAAV9 mice demonstrated a significantly 
better (higher) mean rotarod score than age- and sex-matched UTCln6nclf mice at 9 months of age (No 
DrugAAV9 mean score = 257.7 seconds; UTCln6nclf mean score = 164.3 seconds; ** p = .005 ; Appendix 
B.73). Female No DrugAAV9 mean rotarod scores reamined significantly higher than UTCln6nclf at 12 
months (No DrugAAV9 mean score = 234.4 seconds; UTCln6nclf mean score = 71.25 seconds; **** p ≤ .0001), 
but were also significantly higher than WT at this time point as well (WT mean score = 170.4 seconds; 
** p =.0058; Appendix B.73). n(per group per time point) = 8-10.  
3.3.2  scAAV9.CB.hCLN6 treatment protects against the Cln6nclf 
phenotype: ataxia 
In order to characterise the effects neonatal gene therapy might have on the Cln6nclf ataxic 
behavioural phenotype, six different experimental groups were assessed for signs of 
cerebellar ataxia at 6 and 9 months of age. These included male and female (M/F) WT 
(C57Bl/6) controls, M/F UTCln6nclf mice and M/F No DrugAAV9 mice. WT and UTCln6nclf mice were 
injected with 1x PBS at P0-2 and then given strawberry jelly with vehicle in it every second day 
from weaning as a control for small molecule therapy. No DrugAAV9 mice received a dose of 
scAAV9.CB.hCLN6 via i.c.v at P0-2 and also received vehicle jelly after weaning. Ataxia 
phenotyping scores for the drug-only Cln6nclf experimental groups, along with their UTCln6nclf 
and WT controls, were found to have normal (Gaussian) distributions using D’Agostino & 
Pearson normality tests, so all subsequent statistical analyses were conducted using 
parametric testing (Appendix B.68). 
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3.3.2.a Composite ataxia phenotype scores 
Composite ataxia scores (0-9) for each mouse were calculated by adding together it’s mean 
ledge, hindlimb clasping and gait ataxia phenotyping scores (0-3). Scores were then averaged 
for each experimental group and presented as mean score (0-9) ± SEM. Comparisons between 
mean composite scores of age- and sex-matched No DrugAAV9 treated and UTCln6nclf and WT 
(C57Bl/6) mice were made using 1-way ANOVAs, with Tukey’s post-hoc multiple comparisons 
tests conducted when significant differences were found to occur (Appendices B.74-75).  
Male No DrugAAV9 mice demonstrated significantly reduced composite scores 
compared to age- and sex-matched UTCln6nclf at both 6 (6 month male UTCln6nclf mean composite 
ataxia score = 2.467; male 6 month No DrugAAV9 mean composite ataxia score = 1.0; **p = 
.0113; Appendix B.75). and 9 months of age (male 9 month UTCln6nclf mean composite ataxia 
score = 4.833; male 9 month No DrugAAV9 mean composite ataxia score = 3.10; *** p = .0009; 
Appendix B.24). No DrugAAV9 mice demonstrated no significant difference in score from 
healthy WT controls at either time point (Figure 3.18Ai-ii).  
Female No DrugAAV9 mice also demonstrated significantly improved composite ataxia 
scores compared to UTCln6nclf counterparts at 6 (female 6 month UTCln6nclf mean composite 
ataxia score = 2.467; No DrugAAV9 mean composite ataxia score = 1.0; **p = .0113; Appendix 
B.75) and 9 months of age (Figure 3.18.Bi-ii; female 9 month UTCln6nclf mean composite ataxia 
score = 5.0; female 9 month No DrugAAV9 mean composite ataxia score = 1.633; **** p ≤ .0001; 






Figure 3.18 ⎸ scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: composite ataxia 
scores. Male and female Cln6nclf mice who received a single injection of scAAV9.CB.hCLN6 at P0-2 and 
only received a vehicle drug treatment (No DrugAAV9) have significantly improved composite ataxia scores 
compared to sex-matched untreated Cln6nclf (UTCln6nclf) mice at both 6 and 9 months of age. Mean 
composite ataxia phenotype scores (0 to 9) were calculated using averaged ataxia test individual scores 
(ledge, hindlimb clasping and gait) for male (Ai-ii) and female (Bi-ii) Cln6nclf mice treated with a single 
injection of scAAV9.CB.hCLN6 at P0-2 and vehicle drug treatment (No DrugAAV9), and their UTCln6nclf and 
wildtype (WT) C57Bl/6 counterparts across two different time points: 6 months (left) and 9 months (right). 
Different mice were tested at each time point (between-subjects study design). A low score (close to 0) 
indicates an absence of the ataxic phenotype as measured by the composite scoring system, while 
higher scores, closer to 9, indicate increasing levels of ataxic behaviour (coloured arrow on the left). The 
overall mean composite scores illustrated in Ai and Bi are further broken down into the average ledge 
(bottom segment), hindlimb clasping (middle segment) and gait (top segment) scores in segmented bar 
graphs (Aii and Bii). Individual, averaged composite scores are shown as clear circles in Ai and Bi, error 
bars = ± SEM. Analyses were conducted via 1-way ANOVAs and subsequent Tukey’s multiple 
comparison post-hoc tests (Appendices B.75-76). n(per group per time point) = 8-10. Ai-ii. Histogram 
presenting the mean composite ataxia scores of male mice at 6 (left) and 9 (right) months of age. No 
DrugAAV9 mice performed significantly better (lower score) than their age- and sex-matched UTCln6nclf 
counterparts at 6 months of age (left; UTCln6nclf mean = 2.467; No DrugAAV9 mean = 1.0; **p = .0113; 
Appendix B.75). This was also the case at 9 months of age (UTCln6nclf mean = 4.833; No DrugAAV9 mean 
= 3.10; *** p = .0009; Appendix B.24). Bi-ii. Histogram presenting the mean composite ataxia scores of 
female mice at 6 (left) and 9 (right) months of age. Female No DrugAAV9 mice performed better 
(significantly lower composite ataxia score) than UTCln6nclf at 6 months of age (UTCln6nclf mean = 3.00; No 
DrugAAV9 mean = 0.9259; ** p = .0044; Appendix B.76). There was also a significant difference in the 
composite scores of No DrugAAV9 and UTCln6nclf female mice at 9 months (left; UTCln6nclf mean = 5.0; No 

















































































































































































































































































































































































3.3.2.b Ledge test 
A single unilateral injection of scAAV9.CB.hCLN6 at P0-2 appears to protect against the 
diseased Cln6nclf ledge ataxia phenotype by 9 months of age (Figure 3.19.A and 3.19.B).  
For males, a 1-way ANOVA (Appendix B.76) indicated that there was a significant 
difference between the mean ledge score of No DrugAAV9 and UTCln6nclf mice at 6 months of age 
(Figure 3.19.A; No DrugAAV9 mean score = 0.4074; UTCln6nclf mean score = 1.4; *** p = .0003; 
Appendix B.76), with No DrugAAV9 achieving a significantly lower (better) score than their 
UTCln6nclf counterparts. This trend continued at 9 months, with male No DrugAAV9 once again 
achieving a significantly lower mean ledge ataxia score than UTCln6nclf mice (No DrugAAV9 mean 
score = 1.5; UTCln6nclf mean score = 2.083; * p = .0112; Appendix B.76). Male No DrugAAV9 mean 
scores for both time points remained statistically indistinguishable from the mean scores of 
healthy WT mice, indicating that gene therapy effectively protected male Cln6nclf mice from 
the Cln6nclf ledge phenotype established in section 3.1. 
 Female No DrugAAV9 
mice, on the other hand, do not demonstrate a significant difference in mean ledge score from 
either WT or UTCln6nclf counterparts at 6 months of age (Figure 3.19.B). It is only at 9 months 
that No DrugAAV9 begin to perform significantly better at the ledge test than age- and sex- 
matched UTCln6nclf counterparts (female 9 month No DrugAAV9 mean ledge score = 2.2; female 
9 month UTCln6nclf mean score = 2.2; **** p ≤ .0001 ; Appendix B.77). This may be due to sex 
based timing differences in response to the gene therapy, or, possibly more likely, due to the 
absence of a clear Cln6nclf phenotype at 6 months for female mice (see section 3.1). 
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3.3.2.c Hindlimb clasping test 
Cln6nclf mice treated with gene therapy alone were assessed for muscle function and control 
via the hindlimb clasping test. Different mice were measured at each time point, making this 
assay between-subjects in design. Data are mean hindlimb clasping scores ± SEM. 
Male No DrugAAV9 mice did not demonstrate any significant difference in hindlimb 
clasping score from age- and sex-matched WT controls and UTCln6nclf counterparts, at either 6 
or 9 months (Figure 3.19.C). 
Female No DrugAAV9 mice performed significantly better (lower score) at the hindlimb 
clasping ataxia assay than age- and sex-matched Cln6nclf counterparts at both 6 (Figure 3.19.D; 
female 6 month No DrugAAV9 mean score = 0.2333; female 6 month UTCln6nclf mean score = 
1.556; ** p = .0051; Appendix B.79 ) and 9 months of age (UTCln6nclf mean score = 0.9667; *** 
p = .0001; Appendix B.81).  
3.3.2.d Gait test 
Male No DrugAAV9 mice produced significantly better (lower) mean gait scores than UTCln6nclf 
mice at 6 (male 6 month No DrugAAV9 mean score = 0.0; male 6 month UTCln6nclf mean gait 
ataxia score = 0.4667; ** p = .0099; Appendix B.80) and 9 months of age (Figure 3.19.E; male 
9 month No DrugAAV9 mean score = 0.3; male 9 month UTCln6nclf mean score = 0.8750; ** p = 


































































































































































































































































































































































































































































































































































































⇐	 Figure 3.19 ⎸ scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: ataxia 
phenotyping scores (previous page). A single neonatal i.c.v injection of scAAV9.CB.hCLN6 
significantly reduces ataxic phenotype in Cln6nclf mice. A-F. Histograms presenting mean ataxia scores 
(0-3) of individual ataxia assays: ledge (A; males; B; females), hindlimb clasping (C; males; D; females), 
and gait (E; males; F; females). Scoring criteria and methodology can be found in Chapter 2, adapted 
from Guyenet et al. 2010. Different mice were assessed at each time point, making the experiment 
between-subjects in design. For each assay, a mouse could be assigned a score between 0 and 3, with 
0 indicating a complete absence of the ataxic phenotype and 3 indicating a completely penetrant ataxic 
phenotype (coloured arrows on the left). Data are presented as mean scores, with error bars representing 
± SEM. Individual (averaged) mouse scores are presented as clear circles. All analyses were conducted 
using 1-way ANOVAs (Appendices B.76-81), followed by Tukey’s multiple comparisons post-hoc tests. 
A. Histogram presenting mean male ledge ataxia scores for 6 months (left) and 9 months (right) of age. 
Male Cln6nclf mice who received a single injection of scAAV9.CB.hCLN6 at P0-2 and only received a 
vehicle drug treatment (No DrugAAV9; blue bars) performed significantly better at the ledge ataxia task 
than their age- and sex-matched UTCln6nclf counterparts (red bars) at both 6 (No DrugAAV9 mean score = 
0.4074; UTCln6nclf mean score = 1.4; *** p = .0003; Appendix B.76) and 9 months (No DrugAAV9 mean 
score = 1.5; UTCln6nclf mean score = 2.083; * p = .0112; Appendix B.76). perform significantly better at 
three different ataxia tasks, the ledge, hindlimb clasping and gait tests, than their age- and sex-matched 
UTCln6nclf counterparts by 9 months of age. n(per group per time point) = 8-12. B. Histogram presenting 
mean female ledgea ataxia scores for 6 (left) and 9 (right) months of age. Female Cln6nclf mice who 
received a single injection of scAAV9.CB.hCLN6 at P0-2 and only received a vehicle drug treatment (No 
DrugAAV9; light blue bars) showed no significant difference in mean ledge score from their age- and sex- 
matched WT (C57Bl/6; black patterned bars) and UTCln6nclf (maroon bars) counterparts at 6 months of 
age (Appendix B.77). At 9 months, however, female No DrugAAV9 mice performed significantly better 
than their age- and sex-matched UTCln6nclf counterparts (No DrugAAV9 mean score = 2.2; UTCln6nclf mean 
score = 2.2; **** p ≤ .0001 ; Appendix B.77). n(per group per time point) = 8-11. C. Histogram presenting 
mean male hindlimb clasping ataxia scores for 6 (left) and 9 (right) months of age. No significant 
difference in score was observed between No DrugAAV9 scores and those belonging to WT or UTCln6nclf 
at either time point (Appendix B.78). ). n(per group per time point) = 8-12 D. Histogram presenting mean 
female hindlimb clasping ataxia scores at 6 (left) and 9 (right) months of age. Female No DrugAAV9 
demonstrated a significantly better (lower) mean hindlimb clasping ataxia score than UTCln6nclf at both 6 
(No DrugAAV9 mean score = 0.2333; UTCln6nclf mean score = 1.556; ** p = .0051; Appendix B.79) and 9 
months of age (No DrugAAV9 mean score = 0.5; UTCln6nclf mean score = 1.95 ; *** p = .0003; Appendix 
B.79). ). n(per group per time point) = 8-11. E. Histogram presenting mean male gait scores at 6 (left) 
and 9 (right) months of age. No DrugAAV9 mean scores were significantly better (lower) than UTCln6nclf 
scores at both 6 (No DrugAAV9 mean score = 0.0; UTCln6nclf mean score = 0.4667; ** p = .0099; Appendix 
B.80) and 9 months of age (No DrugAAV9 mean score = 0.3; UTCln6nclf mean score = 0.8750; ** p = .0035; 
Appendix B.80). n(per group per time point) = 8-12. F. Histogram presenting mean female gait scores 
at 6 (left) and 9 (right) months of age. No DrugAAV9 mean scores were statistically indistinguishable from 
age- and sex-matched UTCln6nclf and WT counterparts at 6 months of age (Appendix B.81). At 9 months, 
however, female No DrugAAV9 demonstrated a significantly better (lower; No DrugAAV9 mean score = 0.0) 
mean score than both WT (WT mean score = 0.6296; * p = .0110) and UTCln6nclf mice (UTCln6nclf mean 
score = 0.9667; *** p = .0001; Appendix B.81). ). n(per group per time point) = 8-11.  
3.3.3  scAAV9.CB.hCLN6 treatment protects against the Cln6nclf 
phenotype: survival and weight 
A single injection of scAAV9.CB.hCLN6 at P0-2, without any drug therapy, rescues Cln6nclf mice, 
of both sexes, from characteristically shortened lifespans and improves survival significantly 
compared to untreated Cln6nclf (UTCln6nclf) mice. Survival and weights were only recorded up 
until 14 months of age due to the time limitations of a MSc thesis, however, survival and 
weights continued to be recorded for the larger Gray Foundation trial - until all animals had 
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reached one of the three humane endpoints outlined in Chapter 2. Survival curve comparisons 
were conducted using a series of log-rank (Mantel-cox) tests (Appendices B.82-85) and 
weights were compared using simple linear regression (Appendices B.86-87 and B.89-90) and 
1-way ANOVAs (Appendices B.88 and B.91). 
⇒	Figure 3.20 ⎸ scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: survival and 
weight (following page). A single injection of scAAV9.CB.hCLN6 at P0-2, without any drug therapy, 
rescues Cln6nclf mice, of both sexes, from characteristically shortened lifespans and improves survival 
significantly compared to untreated Cln6nclf (UTCln6nclf) mice. Survival and weights were only recorded up 
until 14 months of age due to the time limitations of a MSc thesis, however, survival and weights 
continued to be recorded for the larger Gray Foundation trial - until all animals had reached one of the 
three humane endpoints outlined in Chapter 2. Survival curve comparisons were conducted using a 
series of log-rank (Mantel-cox) tests (Appendices B.82-85) and weights were compared using simple 
linear regression (Appendices B.86-87 and B.89-90) and 1-way ANOVAs (Appendices B.88 and B.91) 
A. Kaplan-Meier plot of male mouse survival (%). Male mice treated with a single dose of 
scAAV9.CB.hCLN6 at P0-2 and vehicle drug (No DrugAAV9; blue lines; median survival = undefined at 14 
months) had significantly longer lifespans than UTCln6nclf mice (red lines; median survival = 13.3 months; 
**** p ≤ .0001; Appendix B.83). No significant difference in median survival could be detected between 
mal No DrugAAV9 and WT by 14 months. Starting n =28-35. B. Kaplan-Meier plot of female mouse survival 
(%). Female mice treated with a single dose of scAAV9.CB.hCLN6 at P0-2 and vehicle drug (No DrugAAV9; 
light blue lines; median survival = undefined at 14 months) had significantly longer lifespans than UTCln6nclf 
mice (maroon lines; median survival =12.50 months; **** p ≤ .0001; Appendix B.85). No significant 
difference in median survival could be detected between female No DrugAAV9 and WT mice by 14 months. 
Starting n =24-27. C. Line graph of mean weights (in grams) of male No DrugAAV9 (blue lines and squares), 
UTCln6nclf (red lines and squares) and WT (C57Bl/6; black lines and squares) mice over a period of 15 
months. Simple linear regression analysis (solid lines)revealed that there was a significant difference in 
the overall rate of weight gain and loss over the 15 month period between male No DrugAAV9 and UTCln6nclf 
mice ( *** p = .0008; Appendix B.87) and between No DrugAAV9 and WT (**** p ≤ .0001; Appendix B.86). 
1-way ANOVA analyses conducted on data from at 6, 9 and 12 months revealed that at 9 months No 
DrugAAV9 mice weighed, on average, significantly less than WT (No DrugAAV9 mean weight = 35.95 g; WT 
mean weight = 38.87 g; ** p = .0093; Appendix B.88). At 12 months, however, the difference in mean 
weight between No DrugAAV9 and WT was no longer significant (Appendix B.88). No DrugAAV9 mice 
weighed significantly more, on average, than UTCln6nclf mice at 12 months of age (No DrugAAV9 mean 
weight = g; UTCln6nclf mean weight =; ** p = .0012; Appendix B.88). n(per group per time point) =14-28. 
D. Line graph of mean weights (in grams) of female No DrugAAV9 (light blue lines and circles), UTCln6nclf 
(maroon lines and circles) and WT (C57Bl/6; grey lines andcircles) mice over a period of 15 months. 
Simple linear regression analysis (solid lines)revealed that there was a significant difference in the overall 
rate of weight gain and loss over the 15 month period between female No DrugAAV9 and UTCln6nclf mice 
( *** p = .0066; Appendix B.90) and between No DrugAAV9 and WT (*** p = .0026; Appendix B.89). No 
significant differences in mean weight were detected between No DrugAAV9, UTCln6nclf and WT weights at 
6, 9 or 12 months of age via 1-way ANOVA (Appendix B.91).   
  
 188 






















































ale Untr ated Cln6nclf

















ale Untreated C n6nclf
 189 
3.3.4  scAAV9.CB.hCLN6 treatment protects against the Cln6nclf 
phenotype: sex differences 
Many host factors can help determine the success or failure of gene therapy. These include, 
but are not limited to, the innate immune reaction generated by administration of the 
therapy, differing gene expression profiles between tissues, organs and individuals, and 
hormonal attenuation or exacerbation of downstream symptoms (Amur et al., 2012; Duffy et 
al., 2012). It is now well understood that biological sex can play a huge role in all of these 
areas, with an individual’s sex dictating what hormones are secreted and when, the speed, 
size and specificity of an immune response to foreign material and the ability of viral vectors 
to transduce specific tissues (Calcedo & Wilson, 2013; Dane et al., 2013; Dodge et al., 2005; 
Wells & Goldspink, 1992; Yan et al., 2005). CLN6 BD, like all variants of NCL, is not a sex-specific 
disease. For this reason it is critical to assess the efficacy and safety of every potential therapy 
in both male and female animal models and to compare results to identify and characterise 
any sex-dependent differences in response. For these reasons, this section compares the 
behaviour scores, survival data and weights of both male and female Cln6nclf mice treated with 
gene therapy alone (No DrugAAV9).  
3.3.4.a Rotarod sex differences 
No DrugAAV9 male and female Cln6nclf mice experienced statistically similar rates of decline in 
rotarod score over 6, 9 and 12 months (simple linear regression; Appendices B.92-93). Despite 
this, however, a series of unpaired student t-test analyses at 6, 9 and 12 months revealed a 
significant difference in mean rotarod score beween the sexes at 9 months of age (Figures 
3.21.A; Appendix B.94). At 9 months, female No DrugAAV9 mice demonstrated significantly 
higher levels of motor co-ordination, balance and endurance (as measured by the rotarod) 
compared to their age-matched male counterparts (9 month male mean score = 165.4 
seconds; 9 month female male mean score = 257.7; ** p = .0014; Appendix B.94). This 
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disparity appears to be transient, however, with male and female scores becoming statistically 









Figure 3.21 ⎸scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: sex differences in 
rotarod scores. Male and female Cln6nclf mice treated with a single injection of scAAV9.CB.hCLN6 at 
P0-2 and a vehicle drug (No DrugAAV9) demonstrated similar overall rates of decline in rotarod 
performance over time but showed statistically significant differences in average rotarod score at 9 
months of age. A. Line graph presenting data as mean rotarod scores measured in latency to fall 
(seconds) for male (dark blue squares) and female (light blue circles) Cln6nclf mice who received a single, 
neonatal i.c.v injection of scAAV9.CB.hCLN6 at P0-2 (No DrugAAV9). Error bars represent ± SEM. Dotted 
lines indicate the expected trajectory of rotarod scores between measured time points (6, 9 and 12 
months). Linear regression lines are represented by solid coloured lines (simple linear regression; 
Appendices B.92-93). No significant difference in overall rate of motor decline, as measured by the 
rotarod, was detected between male and female No DrugAAV9 mice. B. Histogram presenting data as 
mean rotarod scores (latency to fall in seconds) for male (dark blue bars) and female (light blue bars) No 
DrugAAV9 mice at 6, 9 and 12 months of age. A series of unpaired student t-tests were used to assess 
differences in scores between male and female mice at each time point (Appendix B.94). No significant 
difference in mean rotarod scores were detected between male and female scores at 6 and 12 months 
of age. At 9 months, however, female No DrugAAV9 demonstrated a significantly higher (better) score 
than males (9 month male mean score = 165.4 seconds; 9 month female male mean score = 257.7; ** p 




























































































3.3.4.b Composite ataxia sex differences 
Male and female No DrugAAV9 mice demonstrated no significant difference in mean composite 
ataxia scores (Figure 3.22) at 6 or 9 months of age (unpaired t-tests; Appendix B.95). 
 
Figure 3.22 ⎸scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: sex differences in 
composite ataxia scores. Male and female Cln6nclf mice who received a single injection of 
scAAV9.CB.hCLN6 at P0-2 and only received a vehicle drug treatment (No DrugAAV9) have significantly 
improved composite ataxia scores compared to sex-matched untreated Cln6nclf (UTCln6nclf) mice at both 
6 and 9 months of age. Mean composite ataxia phenotype scores (0 to 9) were calculated using averaged 
ataxia test individual scores (ledge, hindlimb clasping and gait) for male (Ai-ii) and female (Bi-ii) Cln6nclf 
mice treated with a single injection of scAAV9.CB.hCLN6 at P0-2 and vehicle drug treatment (No 
DrugAAV9), and their UTCln6nclf and wildtype (WT) C57Bl/6 counterparts across two different time points: 6 
months (left) and 9 months (right). Different mice were tested at each time point (between-subjects study 
design). A low score (close to 0) indicates an absence of the ataxic phenotype as measured by the 
composite scoring system, while higher scores, closer to 9, indicate increasing levels of ataxic behaviour 
(coloured arrow on the left). The overall mean composite scores illustrated in Ai and Bi are further broken 
down into the average ledge (bottom segment), hindlimb clasping (middle segment) and gait (top 
segment) scores in segmented bar graphs (Aii and Bii). Individual, averaged composite scores are 
shown as clear circles in Ai and Bi, error bars = ± SEM. Analyses were conducted via 1-way ANOVAs 
and subsequent Tukey’s multiple comparison post-hoc tests (Appendices B.75-76). n(per group per 
time point) = 8-10. Ai-ii. Histogram presenting the mean composite ataxia scores of male mice at 6 (left) 
and 9 (right) months of age. No DrugAAV9 mice performed significantly better (lower score) than their age- 
and sex-matched UTCln6nclf counterparts at 6 months of age (left; UTCln6nclf mean = 2.467; No DrugAAV9 
mean = 1.0; **p = .0113; Appendix B.75). This was also the case at 9 months of age (UTCln6nclf mean = 
4.833; No DrugAAV9 mean = 3.10; *** p = .0009; Appendix B.24). Bi-ii. Histogram presenting the mean 
composite ataxia scores of female mice at 6 (left) and 9 (right) months of age. Female No DrugAAV9 mice 
performed better (significantly lower composite ataxia score) than UTCln6nclf at 6 months of age (UTCln6nclf 
mean = 3.00; No DrugAAV9 mean = 0.9259; ** p = .0044; Appendix B.76). There was also a significant 
difference in the composite scores of No DrugAAV9 and UTCln6nclf female mice at 9 months (left; UTCln6nclf 



























































3.3.4.c Ledge ataxia sex differences 
Female No DrugAAV9 mice demonstrate a significantly higher ledge ataxia score than age-
matched males at 6 months of age (Figure 3.23.A; unpaired student t-test; 6 month male 
mean score = 0.4074; 6 month female mean score = 0.9667; * p = .0201; Appendix B.96). This 
difference is only temporary, however, as there was no significant difference observed 
between the mean ledge ataxia score of male and female No DrugAAV9 mice at 9 months of age 
(Figure 3.2.A). 
3.3.4.d Hindlimb clasping ataxia sex differences 
In the hindlimb clasping ataxia assay, no differences were observed between male and female 
No DrugAAV9 mice until 9 months of age – at which point males demonstrated a significantly 
higher hindlimb clasping score (Figure 3.23.B; 9 month male mean score = 1.3; 9 month female 
mean score = 0.5; * p = .0137; Appendix B.97).  
3.3.4.e Gait ataxia sex differences 
Sex-specific differences in AAV2/9-mediated gene therapy’s effect on the Cln6nclf gait 
phenotype seems to be somewhat age-dependent, as No DrugAAV9 females peform poorly 
compared to male mice at 6 months of age (Figure 3.23.C; 6 month male mean score = 0.0; 6 
month meanataxia score = 0.333; ** p = .0019; Appendix B.98) but then appear to recover at 
9 months, producing a very low hindlimb score. No DrugAAV9 males decline in a more 
traditional manner, performing well at 6 months, and then becoming significantly worse than 
females by 9 months (Figure 3.23.C; 9 month male mean score = 0.3; 9 month female mean 
score = 0.0; * p = .0104; Appendix B.98). It is difficult to intrepret these trends, however, due 
to the fact that separate groups of mice were assessed at each time point – leaving open the 


























































































































































































⇐	Figure 3.23 ⎸scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: sex differences in 
ataxia phenotyping scores (opposite page). Female mice who received a single scAAV9.CB.hCLN6 
injection at P0-2 and vehicle drug (No DrugAAV9) appear to perform better across three different ataxia 
behavioural assays (the ledge, hindlimb clasping and gait tests)than their male No DrugAAV9 counterparts 
during early stages of disease progression. This trend, however, is completely reversed by 9 months, 
with male No DrugAAV9 mice achieving consistently better ataxia scores than females in all three tests. 
Mice underwent three trials of a sequence three different ataxia assays – the ledge test, the hindlimb 
clasping test and the gait test (adapted from Guyenet et al., 2010) – in order to determine the presence 
or absence of an ataxic phenotype at 6 and 9 months of age. Different mice were assessed at each time 
point, making the experiment between-subjects in design. For each assay, a mouse could be assigned 
a score between 0 and 3, with 0 indicating a complete absence of the ataxic phenotype and 3 indicating 
a completely penetrant ataxic phenotype (coloured arrows on the left). All data (A-C) are presented as 
the mean of averaged (3 trials; scored from 0-3) individual mouse scores, with clear circles representing 
the individual averaged scores. Error bars = ± SEM. All analyses between male and female mean ataxia 
scores were conducted using unpaired student t-tests (Appendices B.96 -98) A. Histogram of mean 
ledge ataxia scores for male (dark blue bars) and female (light blue bars) No DrugAAV9 treated Cln6nclf 
mice at 6 (left) and 9 (right) months of age. Data are presented as mean scores ± SEM. Clear circles 
represent individual averaged mouse scores (3x trials per mouse). At 6 months of age females 
demonstrated a significantly higher (worse) ledge score than their male counterparts (6 month male 
mean ledge ataxia score = 0.4074; 6 month female mean ledge ataxia score = 0.9667; * p = .0201; 
Appendix B.96). This significant difference, however, in mean ledge scores no longer present at 9 
months. n(per group, per time point) = 9-11. B. Histogram of mean hindlimb clasping scores for male 
(dark blue bars) and female (light blue bars) No DrugAAV9 treated Cln6nclf mice at 6 (left) and 9 (right) 
months of age. Data are presented as mean scores ± SEM. Clear circles represent individual averaged 
mouse scores (3x trials per mouse). No significant difference was detected between male and female 
scores at 6 months of age. At 9 months, however, male No DrugAAV9 were performing significantly worse 
than females (9 month male hindlimb clasping ataxia score = 1.3; 9 month female hindlimb clasping 
ataxia score = 0.5; * p = .0137; Appendix B.97) n (per group, per time point) = 9-10. C. Histogram of 
mean gait ataxia scores for male (dark blue bars) and female (light blue bars) No DrugAAV9 treated Cln6nclf 
mice at 6 (left) and 9 (right) months of age. Data are presented as mean scores ± SEM. Clear circles 
represent individual averaged mouse scores (3x trials per mouse). At 6 months, female No DrugAAV9 
mice performed significantly worse than male counterparts (6 month male gait ataxia score = 0.0; 6 
month female gait ataxia score = 0.333; ** p = .0019; Appendix B.98). At 9 months, however, this trend 
reverses and male mice perform significantly worse than female (9 month male gait ataxia score = 0.3; 
9 month female gait ataxia score = 0.0; * p = .0104; Appendix B.98). n (per group, per time point) = 9-
10.  
3.3.4.f Survival and weight sex differences 
Male and female No DrugAAV9 mice demonstrated no significant difference in median survival 




Figure 3.24 ⎸ scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: sex differences in 
survival and weight. Male and female Cln6nclf mice treated with a single injection of scAAV9.CB.hCLN6 
at P0-2 and vehicle drug (No DrugAAV9) show statistically similar survival curves (A) and rates of weight 
gain over fourteen months (B). A. Kaplan-Meier survival plot (%) comparing the survival curves of male 
(dark blue) and female (light blue) No DrugAAV9 mice over a period of 14 months. No significant difference 
in median survival was detected by 14 months (Appendix B.99). Starting n = 29. B. Line graph 
presenting the mean weights of male (dark blue squares) and female (light blue circles) No DrugAAV9 
mice over a 14 month period – from weaning until 15 months of age. Simple linear analysis revealed no 
significant difference in overall rate of weight gain and loss during this period (Appendix B.100). No 
analyses were conducted directly between mean weights at 6, 9 and 12 months as there is an expected 
difference in male and female weights for mice due to sex-based differences in morphology. Starting n 
= 29.  
 

































3.3.5  scAAV9.CB.hCLN6 treatment protects against the Cln6nclf 
phenotype: summary 
Analysis of No DrugAAV9 behavioural scores, survival and weights indicates that a single, 
unilateral i.c.v injection of scAAV9.CB.hCLN6 at P0-2 potentially protects Cln6nclf mice from the 
several key deficits associated with the Cln6nclf behavioural phenotype.  
Male No DrugAAV9 performed significantly better than UTCln6nclf mice at 6 months for 
both the composite and ledge ataxia assays, which were the two assays and time point at 
which the Cln6nclf diseased behaviour phenotype was first observed in UTCln6nclf mice (section 
3.1). This, coupled with the fact that their 6 month composite and ledge ataxia scores were 
also statistically indistinguishable from WT, indicates a potential protection against the Cln6nclf 
phenotype at this time point. Male No DrugAAV9 also demonstrated significantly improved 
behavioural scores for all other assays, except 6 and 9 month rotarod and gait, and 
significantly improved survival by 15 months of age, compared to UTCln6nclf mice (Table 3.13).  
Females treated with AAV2/9-mediated therapy also did well, with significantly 
improved behavioural scores seen at at least one time point per behavioural test when 
compared to age and sex-matched UTCln6nclf (Table 3.14). 
Direct comparison between the sexes revealed that females, overall, seem to have 
higher scores in behaviour, possibly indicating a sex-based predisposition to AAV2/9-mediated 
gene therapy - though there were no significant sex differences observed in survival or rate of 








Table 3.13 ⎸ scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: summary table of No 
Drug
AAV9
 males. Summary table of behavioural score (rotarod and ataxia), survival and weight 
comparisons carried out between male Cln6nclf treated only with gene therapy (a single injection of 
scAAV9.CB.hCLN6 at P0-2) and vehicle drug (No DrugAAV9) and their age- and sex-matched WT and 
untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural score and weight 
comparisons were conducted using 1-way ANOVAs (Appendices B.72, 74, 76, 78, 80 and B.88), with 
Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were compared 
using log rank (Mantel-Cox) tests (Appendices B.82 and 83). nsd = no significant difference; s = 
significant. 
No DrugAAV9 Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd Better (s) 
WT nsd nsd Better (s) 
Composite 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd - 
Ledge 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd - 
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd nsd - 
Gait 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd - 
Survival 
UTCln6nclf Increased survival (s) 
WT nsd 
Weight 
UTCln6nclf nsd nsd Weigh more (s) 













Table 3.14 ⎸ scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: summary table of No 
Drug
AAV9
 females. Summary table of behavioural score (rotarod and ataxia), survival and weight 
comparisons carried out between female Cln6nclf treated only with gene therapy (a single injection of 
scAAV9.CB.hCLN6 at P0-2) and vehicle drug (No DrugAAV9) and their age- and sex-matched WT and 
untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural score and weight 
comparisons were conducted using 1-way analysis of variances ANOVAs (Appendices B.73, 75, 77, 
79, 81 and B.91), with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival 
curves were compared using log rank (Mantel-Cox) tests (Appendices B.84 and B.85). nsd = no 
significant difference; s = significant. 
No DrugAAV9 Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd Better (s) Better (s) 
WT nsd nsd Better (s) 
Composite 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd  
Ledge 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Hindlimb Clasping 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd  
Gait 
UTCln6nclf nsd Better (s) - 
WT nsd Better (s)  
Survival 
UTCln6nclf Increased survival (s) 
WT nsd 
Weight 
UTCln6nclf nsd nsd nsd 
WT nsd nsd nsd 
Table 3.15 ⎸ scAAV9.CB.hCLN6 treatment protects against the Cln6nclf phenotype: summary table of No 
Drug
AAV9
 males versus No Drug
AAV9
 females. Summary table of behavioural score (rotarod and ataxia), 
survival and weight comparisons carried out between male and female Cln6nclf mice treated only with 
gene therapy (a single injection of scAAV9.CB.hCLN6 at P0-2) and vehicle drug (No DrugAAV9) at 6, 9 
and 12 months of age. All behavioural score and weight comparisons were conducted using unpaired 
student t-tests (Appendices B.94, 95, 96, 97 and 98), while survival curves were compared using log 
rank (Mantel-Cox) tests (Appendix B.99). nsd = no significant difference. 
No DrugAAV9 Cln6nclf Males vs Females 
Behavioural test 6 months 9 months 12 months 
Rotarod nsd Females perform better (s) nsd 
Composite nsd Females perform better (s) - 
Ledge nsd nsd - 
Hindlimb nsd Females perform better (s) - 





3.4  Combined gene and small molecule therapy protects against the 
CLN6 BD behavioural phenotype in Cln6nclf mice 
It has become commonplace in the medical and research community to target several aspects 
of a disease’s pathology in order to maximise therapeutic outcome. In diseases such as CLN6 
BD, which are of genetic origin and therefore affect a wide range of cell and tissue types, a 
single treatment – even one as promising as AAV2/9-mediated gene therapy – is unlikely to 
address all clinical presentations or endure throughout a patient’s lifetime. Several 
combination therapies have been trialled in the NCLs, including ibuprofen with lamotrigene in 
Cln3-/- mice and gene therapy coupled with a bone marrow transplant in Ppt1-/- mice, with 
varying levels of success (Cooper et al., 2018; Macauley et al., 2012). So far the most successful 
studies have involved multiple injections of AAV-mediated gene therapy (PPT1 in Ppt1-/- mice), 
administered at several different sites throughout the CNS . While promising, multiple 
injections into the brain and spine of children is not what most would consider an ‘ideal’ 
therapeutic strategy – so the search continues for treatment combinations that can improve 
therapeutic outcomes without sacrificing quality of life or creating unjustifiable risk to the 
patient. Here, the effects of several different combined gene and small molecule therapies on 
the Cln6nclf behavioural phenotype are investigated, in the hopes of identifying a synergystic 
combination that can inform future therapeutic strategies and maximise clinical outcomes.  
3.4.1  Functional improvements in combination therapy mice: rotarod 
Ten different experimental groups were assessed with the rotarod at 6, 9 and 12 months of 
age. Six of these groups represented three unique combinations of gene and small molecule 
therapy. GemfibAAV9 mice (separated into male and female cohorts) received a single i.c.v 
injection of scAAV9.CB.hCLN6 at P0-2 and were dosed with 120 mg/kg of gemfibrozil every 
second day from weaning until individual end points of the trial. CBDAAV9 mice (M/F) also 
received a neonatal i.c.v injection of AAV2/9-mediated gene therapy and were dosed with 5 
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mg/kg of CBD every second day from weaning until individual end points of the trial. Finally, 
ComboAAV9 mice (M/F) received AAV2/9-mediated gene therapy shortly after birth via 
unilateral i.c.v injection and were dosed with a combination of 120 mg/kg and 5 mg/kg CBD 
every second day from weaning until individual end points of the trial (see sections 2.3 and 
2.4 for more details regarding i.c.v injections and dosing). Rotarod scores for the combination 
therapy Cln6nclf experimental groups were found to have normal (Gaussian) distributions using 
D’Agostino & Pearson normality tests, so all subsequent statistical analyses were conducted 
using parametric testing (Appendix B.102).  
Linear regression was used to compare the overall rate of decline in mean rotarod 
scores over time and the associated elevation (range over which the decline occurred) of each 
combination therapy treated group versus sex-matched WT controls and UTCln6nclf mice 
(Appendices B.104-107). To compare differences in rotarod score between groups at each 
individual time point, 1-way ANOVAs were used, complemented by Tukey’s multiple 
comparison post-hoc testing when significant differences were found to be present 
(Appendices B.108-109). The rotarod assay showed a steady decline in motor performance 
over time for all mice, as to be expected due to age, and this decline was mathematically 
confirmed by the negative line equations of each group (Figure 3.25; Appendix B.106). 
In male mice, all three combination therapy (GemfibAAV9, CBDAAV9 and ComboAAV9) 
groups declined at a significantly slower rate than male UTCln6nclf animals, an all three declined 
at a rate statistically indistinguishable from healthy WT controls (Figures 3.25.A, C and E; 
Appendices 103 and 107). Male CBDAAV9 and ComboAAV9 treated mice were the first male 
combination treatment groups to demonstrate a significant difference in mean rotarod score, 
with both performing significantly better (higher score) than UTCln6nclf counterparts at 9 
months of age (Figure 3.26.B; male 9 month UTCln6nclf mean score = 144.4 seconds; male 9 
  
 202 
month CBDAAV9 mean score = 249.2 seconds; * p = .0105; male 9 month ComboAAV9 mean score 
= 228.5 seconds; * p = .0418; Appendix B.108). At this time point the mean scores of 
GemfibAAV9 and healthy WT controls remained statistically indistinguishable from UTCln6nclf – 
suggesting hyperactivity or over performance on the behalf of male CBDAAV9 and ComboAAV9 
mice. By 12 months of age, however, all male combination treatment groups were 
demonstrating significantly higher rotarod scores than age- and sex-matched UTCln6nclf 
counterparts, indicating all three combination therapies potentially offer protection against 
the Cln6nclf rotarod behavioural phenotype at this age point in male mice (Figure 32.6.C; male 
12 month UTCln6nclf mean rotarod score = 61.14 seconds; male 12 month GemfibAAV9 mean 
score = 190.4 seconds; **** p ≤ .0005; male 12 month CBDAAV9 mean score = 193.6 seconds; 
**** p ≤ .0001; male 12 month ComboAAV9 mean score = 170.7 seconds; *** p = .0001, 
Appendix B.108).  
In terms of linear regression, female combination therapy groups demonstrated a 
similar trend to males, with female GemfibAAV9, CBDAAV9 and ComboAAV9 animals declining at a 
significantly slower rate than female UTCln6nclf animals (Figures 3.25.B, D and F; Appendices 
104 and 107). ComboAAV9 females were the first to demonstrate a significant difference from 
UTCln6nclf mice, with a significantly increased mean rotarod score at 9 months (Figure 3.26.B; 
female 9 month UTCln6nclf mean score = seconds; female 9 month ComboAAV9 mean score = 
seconds; * p = ; Appendix B.109). By 12 months of age, however, all three treatment groups 
were demonstrating significantly better mean rotarod scores than UTCln6nclf (female 12 month 
UTCln6nclf mean score = 71.25 seconds; female 12 month GemfibAAV9 mean score = 230.4 
seconds; **** p ≤ .0001; female 12 month CBDAAV9 mean score = 209.2 seconds; **** p ≤ 
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⇐	Figure 3.25 ⎸ Functional improvements in combination therapy mice: rotarod scores (line graphs; 
previous page). Cln6nclf mice treated with a combination of gene and small molecule therapy 
(GemfibAAV9, CBDAAV9, and ComboAAV9) demonstrated significantly slower rates of motor co-ordination 
decline, as determined by rotarod scores, over a 12 month period than their age-matched untreated 
Cln6nclf (UTCln6nclf ) counterparts at 6, 9 and 12 months of age, regardless of gender and which type of 
small molecule therapy they received. Female GemfibAAV9 and ComboAAV9 treatment groups even 
declined at a significantly slower rate than the age- and sex-matched WT (C57Bl/6) controls. Data are 
presented as a line graph of mean scores (latency to fall, in seconds), with error bars = ± SEM. Different 
mice were tested at different time points, making this experiment between-subjects in design. Dotted 
lines indicate the expected mean score trajectory for an experimental group between measured time 
points. Solid lines represent the regression lines of each experimental group, as calculated via simple 
linear regression (Appendices B.105-107). A high score (~300) indicates a high level of motor co-
ordination as measured by the rotarod, while lower scores correlate to increasing levels of motor 
dysfunction (coloured arrow on the left). A. Line graph presenting male mean GemfibAAV9 (purple), 
UTCln6nclf (red) and WT (C67Bl/6; black) rotarod scores over 6, 9 and 12 months of age. Male mice treated 
with a combination of gene therapy and gemfibrozil had a significantly reduced rate of motor decline 
compared to UTCln6nclf counterparts (*** p =.0007; Appendix B.107). Starting n (per group) = 27-30. B. 
Line graph presenting female mean GemfibAAV9 (purple), UTCln6nclf (maroon) and WT (C57Bl/6; black) 
rotarod scores over 6, 9 and 12 months of age. Female mice treated with a combination of gene therapy 
and gemfibrozil had a significantly reduced rate of motor decline compared to UTCln6nclf counterparts (*** 
p =.0002; Appendix B.107). Starting n (per group) = 23-32. C. Line graph presenting male mean 
CBDAAV9 (green), UTCln6nclf and WT rotarod scores over 6, 9 and 12 months of age. Male mice treated 
with gene therapy and CBD had a significantly reduced rate of motor decline compared to UTCln6nclf 
counterparts (** p = .0035; Appendix B.107). Starting n (per group) = 24-32. D. Line graph presenting 
female mean CBDAAV9 (green), UTCln6nclf and WT rotarod scores over 6, 9 and 12 months of age. Female 
mice treated with gene therapy and CBD had a significantly reduced rate of motor decline compared to 
UTCln6nclf counterparts (*** p = .0003; Appendix B.107). Starting n (per group) = 23-31. E. Line graph 
presenting male mean ComboAAV9 (orange), UTCln6nclf and WT rotarod scores over 6, 9 and 12 months of 
age. Male mice treated with gene therapy and a combination of gemfibrozil and CBD had a significantly 
reduced rate of motor decline compared to UTCln6nclf counterparts (** p = .0096; Appendix B.107). 
Starting n (per group) = 27-32. F. Line graph presenting female mean ComboAAV9 (orange), UTCln6nclf and 
WT rotarod scores over 6, 9 and 12 months of age. Feale mice treated with gene therapy and a 
combination of gemfibrozil and CBD had a significantly reduced rate of motor decline compared to 



















































































































































































































































































































































































































































⇐	Figure 3.26 ⎸ Functional improvements in combination therapy mice: rotarod scores (histograms; 
previous page). All three combinations of gene and small molecule therapy (GemfibAAV9, CBDAAV9 and 
ComboAAV9) appear to protect both male and female Cln6nclf mice from the diseased Cln6nclf rotarod 
behavioural phenotype by 12 months of age. Histograms presenting mean rotarod scores (latency to fall 
in seconds) of male (left; plain coloured bars) and female (right; patterned bars) Cln6nclf mice treated a 
combination of gene therapy and either: gemfibrozil (GemfibAAV9), CBD (CBDAAV9), or a combination of 
the two (ComboAAV9) and their age- and gender-matched UTCln6nclf and WT (C57Bl/6) counterparts at 6 
(A), 9 (B) and 12 (C) months of age. Data are presented as mean scores with error bars = ± SEM. 
Different mice were tested at each of the different time points, making the experiment between-subjects 
in design. All analyses were conducted using 1-way ANOVAs with Tukey’s post-hoc comparisons used 
to elicit specific significant differences between experimental groups (Appendix B.108-109).Clear circles 
represent averaged individual mouse scores (3x trials per mouse). A. Mean male (left; plain coloured 
bars) and female (right; patterned coloured bars) rotarod scores (latency to fall in seconds) at 6 months. 
No differences, for either gender, were observed between the three different combination therapy Cln6nclf 
groups (GemfibAAV9, CBDAAV9 or ComboAAV9) and ‘healthy’ WT controls or UTCln6nclf counterparts at 6 
months of age. n(per group per time point)= 6-12. B. Histogram presenting mean male (left; plain 
coloured bars) and female (right; patterned coloured bars) rotarod scores (latency to fall in seconds) at 
9 months. Male CBDAAV9 and ComboAAV9 mice demonstrated significantly better rotarod scores than 
UTCln6nclf (male UTCln6nclf mean rotarod score = 144.4 seconds; male CBDAAV9 mean rotarod score = 249.2 
seconds; * p = .0105; male ComboAAV9 mean rotarod score = 228.5 seconds; * p = .0418; Appendix 
108). Female ComboAAV9 mice also demonstrated significantly better rotarod scores than UTCln6nclf at 9 
months (female UTCln6nclf mean rotarod score = seconds; female ComboAAV9 mean rotarod score = 
seconds; * p = ; Appendix B.109). No other significant differences were present between groups at 9 
months. n(per group) = 7-10. C. Histogram presenting mean male (left; plain coloured bars) and female 
(right; patterned coloured bars) rotarod scores (latency to fall in seconds) at 12 months. All three 
combination therapy experimental groups were demonstrating significantly higher rotarod scores than 
UTCln6nclf mice, regardless of gender, by 12 months (male UTCln6nclf mean rotarod score = 61.14 seconds; 
male GemfibAAV9 mean rotarod score = 190.4 seconds; **** p ≤ .0005; male CBDAAV9 mean rotarod score 
= 193.6 seconds; **** p ≤ .0001; male ComboAAV9 mean rotarod score = 170.7 seconds; *** p = .0001, 
Appendix B.108; female UTCln6nclf mean rotarod score = 71.25 seconds; female GemfibAAV9 mean 
rotarod score = 230.4 seconds; **** p ≤ .0001; female CBDAAV9 mean rotarod score = 209.2 seconds; 
**** p ≤ .0001; female ComboAAV9 mean rotarod score = 251.4 seconds; **** p ≤ .0001, Appendix B.109). 












3.4.2  Functional improvements in combination therapy mice: ataxia 
In order to characterise the effects combined gene and small molecule therapy might have on 
the Cln6nclf ataxic behavioural phenotype, ten different experimental groups were assessed 
for signs of cerebellar ataxia at 6 and 9 months of age. Ataxia phenotyping scores for the 
combination therapy Cln6nclf experimental groups were found to have normal (Gaussian) 
distributions using D’Agostino & Pearson normality tests, so all subsequent statistical analyses 
were conducted using parametric testing (Appendix B.102). 
3.4.2.a Composite ataxia phenotype scores 
Composite ataxia scores (0-9) for each mouse were calculated by adding together it’s mean 
ledge, hindlimb clasping and gait ataxia phenotyping scores (0-3). Individual mouse composite 
ataxia scores were then averaged for each experimental group and presented as mean score 
(0-9) ± SEM. Comparisons between mean composite scores of age- and sex-matched 
GemfibAAV9, CBDAAV9, ComboAAV9 treated and UTCln6nclf and WT mice were made using 1-way 
ANOVAs, with Tukey’s post-hoc multiple comparisons tests conducted when significant 
differences were found to occur (Appendices B.110-111). 
Male ComboAAV9 and CBDAAV9 treated mice demonstrated significantly improved 
(lower) composite ataxia scores than age- and sex-matched UTCln6nclf mice as early as 6 months 
of age (Figure 3.27.Ai-ii; . male 6 month UTCln6nclf mean score = 2.467; male 6 month CBDAAV9 
mean score = 1.074; * p = .0431; Appendix B.110). The only female combination treatment 
group to demonstrate a significant difference in mean composite ataxia score at this time 
point was ComboAAV9, which demonstrated a significantly lower score than UTCln6nclf mice 
(Figure 3.27.Bi-ii; female 6 month UTCln6nclf mean score= 3.00; female 6 month GemfibPBS mean 
score = 1.0; ** p = .0099; Appendix B.111).  
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By 12 months of age all combination treatments, male and female, demonstrated 
significantly lower (better) scores than age- and sex-matched UTCln6nclf mice, indicating that all 
three treatments (GemfibAAV9, ComboAAV9 and CBDAAV9) could protentially confer some 
protection to Cln6nclf mice from the diseased Cln6nclf composite ataxia phenotype at this late 
stage in disease progression (Figures 3.27.Ai-ii and 3.27.Bi-ii; male 12 month UTCln6nclf mean 
score = 4.833; male 12 month GemfibAAV9 mean score = 2.433; **** p = .0008; male 12 month 
CBDAAV9 mean score = 2.708; ** p = .0059; male 12 month ComboAAV9 mean score = 2.667; ** 
p = .0027; Appendix B.110; female 12 month UTCln6nclf mean score = 5.0; female 12 month 
GemfibAAV9 mean score = 2.250; **** p ≤ .0001; female 12 month CBDAAV9 mean score = 2.0; 














































































































































































































































































































































































































































































































































































⇐	 Figure 3.27 ⎸ Functional improvements in combination therapy mice: composite ataxia scores 
(previous page). All three combinations of gene and small molecule therapy (GemfibAAV9, CBDAAV9 and 
ComboAAV9) appear to protect both male and female Cln6nclf mice from the diseased Cln6nclf composite 
ataxia behavioural phenotype by 9 months of age. Mean composite ataxia phenotype scores (0 to 9) 
were calculated using averaged ataxia test individual scores (ledge, hindlimb clasping and gait) for male 
(Ai-ii) and female (Bi-ii) Cln6nclf mice treated with gene therapy and one of three drug regimens: 
gemfibrozil (GemfibAAV9), CBD (CBDAAV9) or a combination of gemfibrozil and CBD (ComboAAV9), and 
their untreated Cln6nclf (UTCln6nclf) and wildtype (WT) C57Bl/6 counterparts across two different time 
points: 6 months (left) and 9 months (right). Different mice were tested at each time point (between-
subjects study design). A low score (close to 0) indicates an absence of the ataxic phenotype as 
measured by the composite scoring system, while higher scores, closer to 9, indicate increasing levels 
of ataxic behaviour (coloured arrow on the left). The overall mean composite scores illustrated in Ai and 
Bi are further broken down into the average ledge (bottom segment), hindlimb clasping (middle segment) 
and gait (top segment) scores in segmented bar graphs (Aii and Bii). Individual, averaged composite 
scores are shown as clear circles in Ai and Bi, error bars = ± SEM. Analyses were conducted via 1-way 
ANOVAs and subsequent Tukey’s multiple comparison post-hoc tests (Appendices B.24-25). n(per 
group per time point) = 7-14. Ai-ii. Histogram presenting the mean composite ataxia scores of male mice 
at 6 (left) and 9 (right) months of age. Male CBDAAV9 mice demonstrated a significantly better (lower) 
composite ataxia score than age- and sex-matched UTCln6nclf counterparts at 6 months of age (UTCln6nclf 
mean score = 2.467; CBDAAV9 mean score = 1.074; * p = .0431; Appendix B.110). Similarly, ComboAAV9 
mice also performed significantly better than UTCln6nclf at 6 months (ComboAAV9 mean score = 0.9259; * 
p = 0.0196; Appendix B.110). At 9 months of age all three gene therapy and drug treated groups were 
performing significantly better than UTCln6nclf mice (UTCln6nclf mean score = 4.833; GemfibAAV9 mean score 
= 2.433; **** p = .0008; CBDAAV9 mean score = 2.708; ** p = .0059; ComboAAV9 mean score = 2.667; ** 
p = .0027; Appendix B.110). n (per group, per time point) = 8-12 Bi-ii. Histogram presenting the mean 
composite ataxia scores of female mice at 6 (left) and 9 (right) months of age. Female ComboAAV9 Cln6nclf 
mice performed better (significantly lower composite ataxia score) than UTCln6nclf at 6 months of age 
(UTCln6nclf mean score= 3.00; GemfibPBS mean score = 1.0; ** p = .0099; Appendix B.111). There was 
no significant difference in the composite scores of GemfibAAV9 or CBDAAV9 female mice and their 
UTCln6nclf and WT counterpoints at 6 months. At 9 months (left), all three gene therapy and drug treatment 
groups (GemfibAAV9, CBDAAV9 and ComboAAV9) were performing significantly better than UTCln6nclf mice 
(UTCln6nclf mean score = 5.0; GemfibAAV9 mean score = 2.250; **** p ≤ .0001; CBDAAV9 mean score = 2.0; 
** **** p ≤ .0001; ComboAAV9 mean score = 1.963; **** p ≤ .0001; Appendix B.111). n (per group, per 
time point) = 7-14. 
3.4.2.b Ledge test 
ComboAAV9 treated male mice demonstrated a significantly lower (better) ledge score than 
age- and sex-matched UTCln6nclf counterparts as early as 6 months of age (Figure 3.28.A; male 
6 month ComboAAV9 mean score = 0.4074; male 6 month UTCln6nclf mean score = 1.400; ** p = 
.0032; Appendix B.112). At 9 months, ComboAAV9 treated mice continue to maintain a 
significantly lower ledge score than UTCln6nclf (Figure 3.28.A; 9 month male UTCln6nclf mean score 
= 2.083; male 9 month ComboAAV9 mean ledge ataxia score = 1.233; * p = .0233; Appendix 
B.112). At this time point, male GemfibAAV9 mice also begin to demonstrate a significantly 
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improved mean score when compared to UTCln6nclf (Figure 3.28.A; male 9 month GemfibAAV9 
mean score = 1.2; * p = .0161; Appendix B.112).  
GemfibAAV9 females peform well in the ledge ataxia task at 6 months of age, 
demonstrating a mean ledge score that was significantly lower (better) than both UTCln6nclf and 
WT controls (Figure 3.28.B; female 6 month GemfibAAV9 mean score = 0.5185; female 6 month 
WT mean score = 1.204; * p = .0325; female 6 month UTCln6nclf mean score = 1.185; * p = .0320; 
Appendix B.113).  
3.4.2.c Hindlimb clasping test 
Mice treated with both gene therapy and either gemfibrozil, CBD or a combination of the two 
drugs, had their muscle function and control assessed via the hindlimb clasping test. Different 
mice were measured at each time point, making this assay between-subjets in design. Data 
are mean hindlimb clasping scores ± SEM. 
In male mice (Figure 3.28.C), the first and only significant difference in mean hindlimb 
clasping score was observed at 9 months, with GemfibAAV9 mice retracting their limbs to the 
abdomen more often and more consistently than age- and sex-matched UTCln6nclf counterparts 
(1-way ANOVA; male 12 month GemfibAAV9 mean score = 0.7667;male 12 month UTCln6nclf 
mean score = 1.875; * p = .0258; Appendix B.114).  
Female mice treated with a combination of gene and small molecule therapy (Figure 
3.28.D) also failed to demonstrate a significant difference in mean hindlimb clasping score 
until 9 months of age. At 9 months, however, all three treatment groups performed 
significantly better (lower score) that age- and sex-matched UTCln6nclf mice (female 12 month 
UTCln6nclf mean score = 1.950; female 12 month GemfibAAV9 mean score = 0.2917; **** p ≤ 
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.0001; female 12 month CBDAAV9 mean score = 0.4286; *** p = .0003; female 12 month 
ComboAAV9 mean score = 0.5926; **** p = .0006; Appendix B.115).  
3.4.2.d Gait test 
Motor co-ordination and muscle function, as determined by a low score in the gait test, was 
assessed in Cln6nclf mice treated with both gene therapy and either gemfibrozil, CBD or a 
combination of the two drugs, (Figures 3.28.E and 3.28.F). Different mice were assessed at 
each time point (6 and 9 months), making the assay between subjects in design. Data are mean 
gait ataxia scores ± SEM.  
All three male combination therapy groups (GemfibAAV9, CBDAAV9 and ComboAAV9) 
performed significantly better at the gait ataxia test than age- and sex-matched UTCln6nclf 
controls at 6 months of age (Figure 3.28.E; male 6 month UTCln6nclf mean score = 0.4667; male 
6 month GemfibAAV9 mean score = 0.06667; * p = .0168; male 6 month CBDAAV9 mean score = 
0.0370; * p = .0112; male 6 month ComboAAV9 mean score = 0.0; ** p = .0049 ; Appendix B.116). 
At 9 months, however, only ComboAAV9 and CBDAAV9 treated male animals continued to 
perform significantly better than UTCln6nclf mice (Figure 3.28.E; male 9 month UTCln6nclf mean 
score = 0.8750; male 9 month CBDAAV9 mean score = 0.2083; * p = .0105; male 9 month 
ComboAAV9 mean score = 0.3333; * p = 0.0380; Appendix B.116). For females, only ComboAAV9 
mice at 9 months of age demonstrated an improved gait ataxic phenotype compared to 
UTCln6nclf counterparts (Figure 3.28.F; female 9 month ComboAAV9 mean score = 0.2222; female 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































⇐	Figure 3.28 ⎸ Functional improvements in combination therapy mice: ataxia phenotyping scores 
(previous page). Female Cln6nclf mice treated with both gene therapy and combination small molecule 
therapy (ComboAAV9) appear to be consistently protected from the diseased Cln6nclf ataxia phenotype 
across all three ataxia assays (the ledge, hindlimb clasping and gait tests) by 9 months of age, while the 
other combined gene and small molecule therapy treatment groups (male ComboAAV9, plus both male 
and female GemfibAAV9 and CBDAAV9) show varied differences in score from untreated Cln6nclf (UTCln6nclf) 
mice across the different tests and time points (6 and 9 months). Histograms presenting mean ataxia 
scores (0-3) for individual ataxia assays: ledge (A; males; B; females), hindlimb clasping (C; males; D; 
females), and gait (E; males; F; females). Scoring criteria and methodology can be found in Chapter 2, 
adapted from Guyenet et al. 2010. Different mice were assessed at each time point, making the 
experiment between-subjects in design. For each assay, a mouse could be assigned a score between 0 
and 3, with 0 indicating a complete absence of the ataxic phenotype and 3 indicating a completely 
penetrant ataxic phenotype (coloured arrows on the left). Data are presented as mean scores, with error 
bars representing ± SEM. Individual (averaged) mouse scores are presented as clear circles. All 
analyses were conducted using 1-way ANOVAs (Appendices B.112-117), followed by Tukey’s multiple 
comparisons post-hoc tests A. Histogram presenting mean male ledge scores for 6 months (left; darker 
coloured bars) and 9 months (right; lighter coloured bars) of age. No significant difference in ledge score 
was detected between male drug GemfibAAV9 or CBDAAV9 mean ledge scores and their UTCln6nclf (red) 
and WT (C57Bl/6, white) counterparts at 6 months of age. Male ComboAAV9 treated mice, however, 
demonstrated a significantly better (lower) mean ledge ataxia score than UTCln6nclf mice at this time point 
(ComboAAV9 mean score = 0.4074; UTCln6nclf mean score = 1.400; ** p = .0032; Appendix B.112). At 9 
months of age, CBDAAV9’s mean ledge ataxia score remained statistically indistinguishable from both 
UTCln6nclf or WT mice. In comparison, male GemfibAAV9 and ComboAAV9 treated mice demonstrate 
significantly better (lower) mean ledge scores at 9 months than UTCln6nclf mice (UTCln6nclf mean score = 
2.083; GemfibAAV9 mean score = 1.2; * p = .0161; ComboAAV9 mean score = 1.233; * p = .0233; Appendix 
B.112). n(per group per time point) = 8-12. B. Histogram presenting mean female ledge scores for 6 
months (left; lighter coloured bars) and 9 months (right; darker coloured bars) of age. At 6 months the 
only significant difference in mean scores was between GemfibAAV9 (mean score = 0.5185) and WT (WT 
mean score = 1.204); * p = .0325) and UTCln6nclf (UTCln6nclf mean score = 1.185; * p = .0320; Appendix 
B.113) scores. At 9 months, however, all three female gene therapy and drug-treated groups (GemfibAAV9, 
CBDAAV9 and ComboAAV9) were performing significantly better than age- and sex-matched UTCln6nclf 
counterparts (UTCln6nclf mean score = 2.200; GemfibAAV9 mean score = 1.250; ** p = .0018; CBDAAV9 
mean score = 1.143; *** p = .0007; ComboAAV9 mean score = 1.148 *** p = .0003; Appendix B.113). 
n(per group per time point) = 7-10. C. Histogram presenting mean male hindlimb clasping ataxia scores 
for 6 (left; dark coloured bars) and 9 months of age (right; light coloured bars). No significant differences 
were found between any male experimental groups at 6 months of age (Appendix B.114). At 9 months, 
however, male GemfibAAV9 treated mice were performing significantly better (lower score) than their age- 
and sex-matched UTCln6nclf counterparts (GemfibAAV9 mean score = 0.7667; UTCln6nclf mean score = 1.875; 
* p = .0258; Appendix B.114). No other differences between gene therapy and drug treated groups and 
healthy or diseased controls was found at this time point. n(per group per time point) = 8-12. D. Histogram 
presenting mean female hindlimb clasping ataxia scores for 6 (left; dark coloured bars) and 9 (right; light 
coloured bars) of age. No significant differences in mean hindlimb clasping ataxia scores were detected 
between the mean scores of AAV and drug treated groups (GemfibAAV9, CBDAAV9 and ComboAAV9) and 
age- and sex-matched WT or UTCln6nclf at 6 months of age (Appendix B.115). At 9 months, however, all 
three female AAV and drug treated groups were demonstrating significantly better (lower) hindlimb 
clasping scores than their age- and sex- matched UTCln6nclf counterparts (UTCln6nclf mean score = 1.950; 
GemfibAAV9 mean score = 0.2917; **** p ≤ .0001; CBDAAV9 mean score = 0.4286; *** p = .0003; 
ComboAAV9 mean score = 0.5926; **** p = .0006; Appendix B.115). n(per group per time point) = 7-10. 
E. Histogram presenting mean male gait ataxia scores at 6 (left; dark coloured bars) and 9 (right; light 
coloured bars) of age. All three male AAV and drug treated groups (GemfibAAV9, CBDAAV9 and ComboAAV9) 
performed significantly better (lower scores) than UTCln6nclf counterparts at 6 months of age (UTCln6nclf 
mean score = 0.4667; GemfibAAV9 mean score = 0.06667; * p = .0168; CBDAAV9 mean score = 0.0370; * 
p = .0112; ComboAAV9 mean score = 0.0; ** p = .0049 ; Appendix B.116). At 9 months, however, only 
male CBDAAV9 and ComboAAV9 groups presented significantly better (lower) scores than UTCln6nclf mice 
(UTCln6nclf mean score = 0.8750; CBDAAV9 mean score = 0.2083; * p = .0105; ComboAAV9 mean score = 
0.3333; * p = 0.0380; Appendix B.116). n(per group per time point) = 8-12. F. Histogram presenting 
mean female gait ataxia scores at 6 (left; light coloured bars) and 9 months (right; dark coloured bars) of 
age. No significant differences in mean gait ataxia scores were detected between any female treatment 
groups at 6 months of age (Appendix B.117). At 9 months female ComboAAV9 treated mice performed 
significantly better than their age- and sex-matched UTCln6nclf counterparts (ComboAAV9 mean score = 
0.2222; UTCln6nclf mean score = 0.9667; * p = .0189; Appendix B.117). No other significant differences 
were detected between treatment groups at this time point. n(per group per time point) = 7-10. 
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3.4.3  Functional improvements in combination therapy mice: survival 
and weight 
The survival curves (and median survival) of mice treated with gene therapy and either 
gemfibrozil, CBD and a combination of the two drugs were compared to WT and UTCln6nclf 
controls. Survival data are presented as percentage of the original cohort n, with curve 
comparisons between sex-matched Cln6nclf and WT conducted via separate log-rank (Mantel-
Cox) tests for each sex (Appendices B.118-129).  
All male combination treated groups had significantly improved survival in comparison 
to UTCln6nclf mice (Figure 3.29.A) – with all three groups having ‘undefined’ median survivals at 
14 months of age – meaning there had not been enough ‘unplanned’ deaths within the 
experimental group to determine a median survial by that time point (male UTCln6nclf median 
survival = 13.3 months; male GemfibAAV9 median survival = undefined at 14 months; **** p ≤ 
.0001; male CBDAAV9 median survival = undefined at 14 months; *** p = .0013; male ComboAAV9 
median survival = undefined at 14 months; **** p ≤ .0001; Appendices B.118-123).  
Female survival demonstrated a similar trend (Figure 3.29.B). All combination 
treatment groups had significantly longer lifespans than UTCln6nclf mice (UTCln6nclf median 
survival = 12.5 months; GemfibAAV9 median survival = undefined at 14 months; **** p ≤ .0001; 
CBDAAV9 median survival = undefined at 14 months; ** p = .0040; ComboAAV9 median survival 
= undefined at 14 months; **** p ≤ .0001; Appendices B.124- 129), indicating that all three 
combination treatments are potentially effective in protecting Cln6nclf mice against the 
characteristically shortened Cln6nclf lifespan phenotype.  
Weights were also kept, as a measure of overall health, and body weight was recorded 
weekly (in grams). Average weights for each experimental group are presented here, however, 
monthly as it gives a clearer overview of weight progression throughout the lifespan. Simple 
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linear regression was conducted to determine the overall rate of weight change over the first 
14 months of the trial. In males, GemfibAAV9 and ComboAAV9 treated mice gained and lost 
weight in a fluctuating manner, resulting in significant differences in overall rate of weight gain 
and loss from both UTCln6nclf and WT mice (Figure 3.30.A; Appendix B.130). The only significant 
difference in mean male weights observed via 1-way ANOVA at 6, 9 or 12 months, however, 
was at 9 months, where CBDAAV9 and ComboAAV9 both demonstrated significantly lower 
weights, on average, than WT controls (Figure 3.30.E; male 9 month WT mean weight = 38.57 
g; male 9 month CBDAAV9 mean weight = 36 g; * p = .0290; male 9 month ComboAAV9 mean 
weight = 34.53 g; *** p = .0001; Appendix B.132). At every other time point there were no 
significant differences detected between the mean weights of any of the male combined 
treatment groups and either WT or UTCln6nclf mice.  
Females receiving GemfibAAV9 or ComboAAV9 also appear to have gained and loss weight 
in a fluctuating manner, with their linear regression lines differing significantly from both 
UTCln6nclf mice and WT (Figure 3.30.B; Appendix B.131). All three female combination 
treatment groups demonstrated significantly lighter weights than age- and sex-matched WT 
controls at 6 months (Figure 3.30.D; Appendix B.133), but only GemfibAAV9 and ComboAAV9 
maintained significantly lighter mean weights by 9 months of age (Figure 3.30.F; female 9 
month WT mean weight = 28.90 g; female 9 month GemfibAAV9 mean weight = 26.05g; ** p = 
.0059; female 9 month ComboAAV9 mean weight = 26.32 g; * p = .0126; Appendix B.133). There 





Figure 3.29 ⎸ Functional improvements in combination therapy mice: survival. When given with 
scAAV9.CB.hCLN6 gene therapy, CBD (CBDAAV9), gemfibrozil (GemfibAAV9), and combination 
(ComboAAV9) small molecule therapies rescue Cln6nclf mice from characteristically shortened lifespans. 
Kaplan-Meier survival plots (%) comparing the survival curves of wildtype (WT; C57Bl/6; male = black 
lines; female = grey lines) and untreated Cln6nclf mice (UTCln6nclf ; male = red lines; female = maroon lines) 
to Cln6nclf mice treated with both gene therapy and one of three small molecule therapy regimens 
(GemfibAAV9 = purple lines; CBDAAV9 = green lines; ComboAAV9 = orange lines). All survival curve 
comparisons were conducted using a log rank (Mantel-Cox) test in GraphPad Prism 8 (Appendices 
B.118-129). A. Male survival curves (%) from birth to 14 months of age. All three gene therapy and drug 
treatment groups (GemfibAAV9, CBDAAV9 and ComboAAV9) demonstrated significantly improved survival 
compared to UTCln6nclf mice (UTCln6nclf median survival = 13.3 months; GemfibAAV9 median survival = 
undefined at 14 months; **** p ≤ .0001; CBDAAV9 median survival = undefined at 14 months; *** p = .0013; 
ComboAAV9 median survival = undefined at 14 months; **** p ≤ .0001; Appendices B.118-123) Starting 
n = 27-35. B. Female survival curves (%) from birth to 14 months of age. All three gene therapy and drug 
treatment groups (GemfibAAV9, CBDAAV9 and ComboAAV9) demonstrated significantly improved survival 
compared to UTCln6nclf mice (UTCln6nclf median survival = 12.5 months; GemfibAAV9 median survival = 
undefined at 14 months; **** p ≤ .0001; CBDAAV9 median survival = undefined at 14 months; ** p = .0040; 
ComboAAV9 median survival = undefined at 14 months; **** p ≤ .0001; Appendices B.124- 129). Starting 
n = 22-28.  
 
 



































































































































































































































































































⇐	Figure 3.30 ⎸ Functional improvements in combination therapy mice: weights (opposite page). Small 
molecule therapy, given in combination with sc.AAV9.CB.hCLN6 gene therapy, appears to have sexually 
dimorphic effects on the weights of Cln6nclf mice during the first fourteen months of life. Mice were 
weighed weekly from weaning (~28 days) to determine drug dosage and as a measure of general health. 
Weights are shown here from weaning to 15 months due to the time constraints of an MSc (weights 
continued to be tracked for the entire duration of the trial). Data are presented as average weights, error 
bars ± SEM. Analyses conducted via 1-way ANOVA with Tukey’s multiple comparisons post-hoc tests 
where applicable. A. Average male weights, in grams, over 14 months (line graph). Linear regression 
lines are represented by solid coloured lines. Simple linear regression revealed that the overall rate of 
weight gain between WT mice and GemfibAAV9 differed significantly during this 14 month period (* p 
= .0146; Appendix B.130), with male GemfibAAV9 taking longer to gain weight than their WT counterparts 
and consistently weighing less at each time point measured. Similarly, the overall rate of weight gain in 
male ComboAAV9 mice was found to be less than that of WT via simple linear regression (*** p = .0007; 
Appendix B.130). Finally, both male GemfibAAV9 and male ComboAAV9 mice gained weight significantly 
faster and maintained that weight longer than untreated Cln6nclf (UTCln6nclf) mice (GemfibAAV9 * p = .0340; 
ComboAAV9 ** p =.0018; Appendix B.130). Starting n for all groups = 25-31. B. Average female weights, 
in grams, over 14 months (line graph). Linear regression lines are represented by solid coloured lines. 
Simple linear regression revealed that the overall rate of weight gain between WT mice and GemfibAAV9 
differed significantly during this 14 month period (**** p ≤ .0001; Appendix B.131), with female 
GemfibAAV9 taking longer to gain weight than their WT counterparts and consistently weighing less at 
each time point measured. Similarly, the overall rate of weight gain in female ComboAAV9 mice was found 
to be less than that of WT via simple linear regression (**** p ≤ .0001; Appendix B.131). Finally, both 
female GemfibAAV9 and female ComboAAV9 mice gained weight significantly faster and maintained that 
weight longer than UTCln6nclf mice (GemfibAAV9 *** p = .0003; ComboAAV9 **** p ≤ .0001; Appendix B.131). 
Starting n for all groups = 25-33. C. Histogram of mean male weights (in grams) at 6 months of age. No 
significant differences were detected between the mean weights of the different treatment groups 
(Appendix B. 132). n(per group) = 24-31 D. Histogram of mean female weights (in grams) at 6 months 
of age. 1-way ANOVA analysis revealed that all three treatment groups (GemfibAAV9, CBDAAV9 and 
ComboAAV9) weighed, on average, significantly less than age- and sex-matched WT controls at 6 months 
of age (WT mean weight = g; GemfibAAV9 mean weight = g; **** p =; CBDAAV9 mean weight = g; *** p = ; 
ComboAAV9 mean weight = g; **** p ≤ .0001; Appendix B.133). n (per group) = 25-28. E. Histogram of 
mean male weights (in grams) a 9 months of age. Both CBDAAV9 and ComboAAV9 mice demonstrated 
significantly lower weights than WT controls (WT mean weight = 38.57 g; CBDAAV9 mean weight = 36 g; 
* p = .0290; ComboAAV9 mean weight = 34.53 g; *** p = .0001; Appendix B.132). n (per group) = 18-26. 
F. Histogram of mean female weights (in grams) at 9 months of age. Both GemfibAAV9 and ComboAAV9 
mice demonstrated significantly lower weights than WT controls (WT mean weight = 28.90 g; GemfibAAV9 
mean weight = 26.05g; ** p = .0059; ComboAAV9 mean weight = 26.32 g; * p = .0126; Appendix B.133). 
n(per group) = 20-25. G. Histogram of mean male weights (in grams) at 12 months of age. No significant 
differences were detected between the mean weights of the different treatment groups (Appendix B. 
132). n(per group) = 12-25. H. Histogram of mean female weights (in grams) at 12 months of age. No 
significant differences were detected between the mean weights of the different treatment groups 
(Appendix B. 133). n(per group) = 5-19. 
3.4.4  Functional improvements in combination therapy mice: sex 
differences 
While the consideration of sex differences has been important throughout the practical 
component of this project, the investigation of sex-based differences in response to the three 
potential combination therapies (GemfibAAV9, CBDAAV9 and ComboAAV9) is particularly pertinent 
in terms of informing potential complementary therapeutic strategies for CLN6 BD patients 
from the Gray Foundation’s 2016 clinical trial. Patients involved in the trial were of both sexes, 
and may have sex-determined responses to the additional use of gemfibrozil, CBD or both 
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drugs in conjunction with the gene therapy they have already received. With this in mind, sex 
based differences in behavioural outcomes as experienced by Cln6nclf mice are examined here 
– as a limited proxy for sex-based differences that may or may not be experienced by children 
from the trial.  
3.4.4.a Rotarod sex differences 
Male and female GemfibAAV9 Cln6nclf mice experienced statistically similar rates of decline in 
rotarod score over 6, 9 and 12 months of age (Figure 3.31.A; simple linear regression; 
Appendix B.135). They also demonstrate no significant differences in mean rotarod score at 
6, 9 or 12 months of age, as determined by a series of unpaired student t-tests (Figures 3.31.E-
G; Appendix B.136). Similarly, no significant differences in overall rate of decline (simple linear 
regression) and mean rotarod scores at 6, 9 and 12 months of age were detected between 
male and female CBDAAV9 treated mice (Figures 3.31.B, E-G; Appendices B.135 and B.137). 
ComboAAV9 treated animals, however, demonstrated a significant difference in overall rate of 
rotarod score decline, with females experiencing a significantly slower decline in score 
compared to males (simple linear regression; Figure 3.31.C; Appendix B.135). Male and 
female ComboAAV9 mean rotarod scores are statistically indistinguishable until 12 months of 
age, at which point females perform significantly better than their age-matched male 
counterparts (Figure 3.31.G; male ComboAAV9 mean score = seconds; female ComboAAV9 mean 
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⇐	Figure 3.31 ⎸ Functional improvements in combination therapy mice: sex differences in rotarod scores 
(previous page). No significant sex-based differences were detected in the rotarod scores and overall 
rate of decline of those scores for Cln6nclf mice treated with a single dose of scAAV9.CB.hCLN6 at P0-2 
in combination with either the gemfibrozil (GemfibAAV9) or CBD (CBDAAV9) small molecule regimens. 
Female Cln6nclf mice, however, demonstrated significantly better (higher) rotarod scores than their male 
counterparts at 12 months of age when treated with both scAAV9.CB.hCLN6 and combined small 
molecule therapy (ComboAAV9). A-C. Line graphs presenting data as mean rotarod scores measured in 
latency to fall (seconds) for male (squares) and female (circle) Cln6nclf mice, treated with gene therapy 
and either gemfibrozil (A; male = dark purple; female = light purple), CBD (B; male = dark green; female 
= light green) or a combination of the two (C; male = orange; female = yellow). Error bars represent ± 
SEM. Dotted lines indicate the expected trajectory of rotarod scores between measured time points (6, 
9 and 12 months). Linear regression lines are represented by solid coloured lines (simple linear 
regression; Appendices B.134 and B.135). E-G. Histograms presenting data as mean rotarod scores 
measured in latency to fall (seconds) for male (dark, solid coloured bars) and female (light, patterned 
bars) Cln6nclf mice treated with gene therapy and either gemfibrozil (purple), CBD (green) or a 
combination of the two drugs (orange) at 6 (E), 9 (F) and 12 (G) months of age. Error bars represent ± 
SEM. Individual mouse scores are represented by clear circles. Analyses between male and female 
mean scores for each treatment group (GemfibAAV9, CBDAAV9 and ComboAAV9) were conducted using 
unpaired student t-tests (Appendices B.136-138). A. Both male (dark purple squares and lines) and 
female (light purple lines and circles) GemfibAAV9 treated Cln6nclf mice demonstrated a decline in ability 
to stay on the rotarod from 6 to 12 months of age (negative slope gradients in line equations for both; 
Appendix B.135). Simple linear regression (solid lines) revealed that there was no significant difference 
between the overall rate of decline or elevation of decline in motor performance between GemfibAAV9 
treated males and females. n(per group, per time point) = 6-10. B. Both male (dark green lines and 
squares) and female (light green lines and circles) CBDAAV9 treated Cln6nclf mice demonstrated a decline 
in ability to stay on the rotarod from 6 to 12 months of age (negative slope gradients in line equations for 
both; Appendix B.135). Simple linear regression (solid lines) revealed that there was no significant 
difference between the overall rate of decline or elevation of decline in motor performance between 
CBDAAV9 treated males and females, (Appendix B.135). n (per group, per time point) = 6-10. C. Both 
male (orange lines and squares) and female (yellow lines and circles) ComboAAV9 treated Cln6nclf mice 
demonstrated a decline in ability to stay on the rotarod from 6 to 12 months of age (negative slope 
gradients in line equations for both; Appendix B.135). Simple linear regression (solid lines) revealed 
that there was a significant difference between the overall rate of decline in motor performance between 
CBDAAV9 treated males and females, with males declining at a greater rate than females (** p = .0067; 
Appendix B.134). n(per group, per time point) = 8-12. D. Histogram presenting average rotarod scores 
(latency to fall in seconds) of male (dark coloured bars) and female (light coloured bars) drug-only treated 
Cln6nclf mice at 6 months of age. No significant difference was found between male and female scores 
for any drug treatment at 6 months (Appendices B.136-138). n(per group) = 9-10. E. Histogram 
presenting average rotarod scores (latency to fall in seconds) of male (dark coloured bars) and female 
(light coloured bars) drug-only treated Cln6nclf mice at 9 months of age. No significant difference was 
found between male and female scores for any drug treatment at 9 months (Appendices B.136-138). 
n(per group) = 7-10. F. Histogram presenting average rotarod scores (latency to fall in seconds) of male 
(dark coloured bars) and female (light coloured bars) drug-only treated Cln6nclf mice at 12 moths of age. 
No significant difference was found between male and female GemfibAAV9 or male and female CBDAAV9 
scores. There was, however, a significant difference between male and female scores for ComboAAV9 
treated mice (male ComboAAV9 mean score = seconds; female ComboAAV9 mean score = seconds; *** p 
= .0001; Appendix B.136-138). n(per group) = 6-12.  
3.4.4.b Composite ataxia sex differences 
No significant differences in mean composite ataxia score were detected between male and 




Figure 3.32 ⎸ Functional improvements in combination therapy mice: sex differences in composite 
ataxia scores. Male and female Cln6nclf mice treated with both scAAV9.CB.hCLN6 gene therapy and 
either gemfibrozil (GemfibAAV9), cannabidiol (CBDAAV9), or a combination of the two small molecule 
therapies (ComboAAV9), demonstrated statistically similar composite ataxia scores (0-9) at both 6 and 9 
months of age. Histograms demonstrating mean composite ataxia scores for male (dark coloured bars) 
and female (light, patterned bars) Cln6nclf mice treated with gene therapy and either gemfibrozil 
(gemfibrozilAAV9; purple), cannabidiol (CBD; CBDAAV9; green) or a combination of gemfibrozil and CBD 
(ComboAAV9), at 6 (A) and 9 (B) months of age. Different mice were tested at each time point (between-
subjects study design). A low score (close to 0) indicates an absence of the ataxic phenotype as 
measured by the composite scoring system, while higher score (close to 9) indicate increasing levels of 
ataxic behaviour (arrow on the left). Individual mouse composite scores are shown as clear circles and 
error bars = ± SEM. Analyses between male and female mean scores for each treatment group at each 
time point were conducted via unpaired student t-tests (Appendices B.139-141). n(per group per time 
point) = 7-14. A. No significant differences were observed between mean male and female composite 
ataxia scores at 6 months, regardless of drug treatment regimen (unpaired student t-tests; Appendices 
B.139-141), though GemfibAAV9 females appear to have (non-significantly) higher (worse) mean scores 
than age-matched GemfibAAV9 males. B. No significant differences were observed between mean male 
and female composite ataxia scores at 9 months, regardless of drug treatment regimen (unpaired student 
t-tests; Appendices B.139-141), though ComboAAV9 males appear to have (non-significantly) higher 
(worse) mean score than age-matched ComboAAV9 females.  
3.4.4.c Ledge ataxia sex differences 
Male and female Cln6nclf mice demonstrated no significant difference in mean ledge ataxia 
scores (Figure 3.33.A and B) at 6 or 9 months of age (unpaired t-tests; Appendices B.142-144), 
































































































































































3.4.4.d Hindlimb clasping ataxia sex differences 
Male and female Cln6nclf mice demonstrated no significant difference in mean hindlimb 
clasping ataxia scores (Figure 3.33.C and D) at 6 or 9 months of age (unpaired t-tests; 
Appendices B.145-147), regardless of treatment group.  
3.4.4.e Gait ataxia sex differences 
GemfibAAV9 female mice performed significantly worse (higher ataxia score) in the gait ataxia 
test than age-matched male counterparts at 6 months of age (GemfibAAV9 female mean score 
= ; GemfibAAV9 male mean score = ; * p = .0248 ; Appendix B.148), though this difference did 
not continue to 9 months, with no significant difference detected between male and female 
GemfibAAV9 at this time point. In comparison, neither CBDPBS or ComboPBS treated Cln6nclf 
demonstrated any sex differences in mean gait ataxia score at 6 or 9 months of age (Appendix 














































































































































































































































































































































































































































































































































⇐	 Figure 3.33 ⎸ Functional improvements in combination therapy mice: sex differences in ataxia 
phenotyping scores (previous page). Male and female Cln6nclf mice treated with both 
sc.AAV9.CB.hCLN6 gene therapy and either gemfibrozil (GemfibAAV9), CBD (CBDAAV9), or a combination 
of gemfibrozil and cannabidiol (ComboAAV9), demonstrated statistically similar ledge and hindlimb 
clasping ataxia scores at both 6 and 9 months of age, while GemfibAAV9 females performed significantly 
worse than males in the gait ataxia assay at 6 months of age. Mice underwent three trials of a sequence 
three different ataxia assays – the ledge test, the hindlimb clasping test and the gait test (adapted from 
Guyenet et al., 2010) – in order to determine the presence or absence of an ataxic phenotype at 6 and 
9 months of age. Different mice were assessed at each time point, making the experiment between-
subjects in design. For each assay, a mouse could be assigned a score between 0 and 3, with 0 indicating 
a complete absence of the ataxic phenotype and 3 indicating a completely penetrant ataxic phenotype 
(coloured arrows on the left). All data (A-F) are presented as the mean of averaged (3 trials; scored from 
0-3) individual mouse scores, with clear circles representing the individual averaged scores. Error bars 
= ± SEM. All analyses between male and female mean ataxia scores were conducted using unpaired 
student t-tests (Appendices B.142 -150). A and B. Histograms of mean ledge test scores at 6 (A) and 
9 (B) months of age for male (dark coloured bars) and female (light coloured, patterned bars) Cln6nclf 
mice treated with gene therapy and either gemfibrozil (GemfibAAV9; purple), CBD (CBDAAV9; green) or a 
combination of gemfibrozil and CBD (ComboAAV9; orange) without. No significant differences were 
observed between the mean ledge scores of treatment- and age-matched male and female Cln6nclf mice, 
regardless of drug treatment regimen. n(per group, per time point) = 7-10. C and D. Histograms of mean 
hindlimb clasping test scores at 6 (C) and 9 (D) months of age for male (dark coloured bars) and female 
(light coloured, patterned bars) Cln6nclf mice treated with gene therapy and either gemfibrozil (GemfibAAV9; 
purple), CBD (CBDAAV9; green) or a combination of gemfibrozil and CBD (ComboAAV9; orange). No 
significant differences were observed between the mean hindlimb clasping scores of treatment- and age-
matched male and female Cln6nclf mice, regardless of drug treatment regimen. n(per group, per time 
point) = 7-10. E. Histogram of mean gait ataxia test scores at 6 months of age for male (dark coloured 
bars) and female (light coloured, patterned bars) Cln6nclf mice treated with gene therapy and either 
gemfibrozil (GemfibAAV9; purple), CBD (CBDAAV9; green) or a combination of gemfibrozil and CBD 
(ComboAAV9; orange). GemfibAAV9 treated female mice performed significantly worse than their age-
matched male counterparts at 6 months (GemfibAAV9 female mean score = ; GemfibAAV9 male mean score 
= ; * p = .0248 ; Appendix B.148). n (per group) = 10. F. Histogram of mean gait ataxia scores at 9 
months of age for male (dark coloured bars) and female (light coloured, patterned bars) Cln6nclf mice 
treated with gene therapy and either gemfibrozil (GemfibAAV9; purple), CBD (CBDAAV9; green) or a 
combination of gemfibrozil and CBD (ComboAAV9; orange). No significant differences were observed 
between the mean gait ataxia scores of treatment- and age-matched male and female Cln6nclf mice, 
regardless of drug treatment regimen. n (per group) = 7-10.  
3.4.4.f Survival and weight sex differences 
Male and female Cln6nclf mice demonstrated no sex-based differences in survival, regardless 
of what composite therapy regimen they were on (Figure 3.34; Appendices B.151-153).  
In terms of weight gain (Figure 3.35), however, male Cln6nclf mice demonstrated significantly 
greater rates of weight change over 14 months compared to females for every combination 




Figure 3.34 ⎸ Functional improvements in combination therapy mice: sex differences in survival. Male 
and female Cln6nclf mice treated with a combination of gene and small molecule therapy (GemfibAAV9, 
CBDAAV9 and ComboAAV9) showed statistically similar survival curves, regardless of which small molecule 
therapy treatment they received. Kaplan-Meier survival plots (%) comparing the survival curves of male 
and female GemfibAAV9 treated Cln6nclf mice (A), male and female CBDAAV9 treated Cln6nclf mice (B), and 
male and female ComboAAV9 treated Cln6nclf mice (C). All survival curve comparisons were conducted 
using log-rank (Mantel-Cox) tests in GraphPad Prism 8 (Appendices B.151-153). A. Male (dark purple) 
and female (light purple) GemfibAAV9 treated Cln6nclf survival curves from birth to 14 months of age. No 
significant difference was found between the median survival of male and female Gemfibaav9 treated mice 
(Appendix B.151). Starting n = 27-31. B. Male (dark green) and female (light green) CBDAAV9 treated 
Cln6nclf survival curves from birth to 14 months of age. No significant difference was found between the 
median survival of male and female CBDAAV9 treated mice (Appendix B.152). Starting n = 28-29. C. Male 
(orange) and female (yellow) ComboAAV9 treated Cln6nclf survival curves from birth to 14 months of age. 
No significant difference was found between the median survival of male and female ComboAAV9 treated 





















































Figure 3.35 ⎸ Functional improvements in combination therapy mice: sex differences in weights. Male 
and female Cln6nclf mice treated with a combination of gene and small molecule therapy (GemfibAAV9, 
CBDAAV9 and ComboAAV9) showed sex-based differences in their overall rate of weight gain over fourteen 
months – with males gaining more weight, more quickly, than females for all three combination therapy 
treatment groups. Mice were weighed weekly from weaning (~28 days) to determine drug dosage and 
as a measure of general health. Weights are shown here from weaning to 15 months due to the time 
constraints of an MSc (weights continued to be tracked for the entire duration of the trial). Data are 
presented as average weights, error bars ± SEM. Comparisons between male and female weights were 
conducted via simple linear regression only, as there is always an expected dispairty between male and 
female mice. A. Average male (dark purple) and female (light purple) GemfibAAV9 treated Cln6nclf weights 
(in grams) plotted every month from weaning until 14 months of age (line graph). A significant difference 
in rate of weight gain was observed between male and female GemfibAAV9 mice (simple linear regression; 
*p = .0397). Starting n = 27-31 B. Average male (dark green) and female (light green) CBDAAV9 treated 
Cln6nclf weights (in grams) plotted every month from weaning until 14 months of age (line graph). A 
significant difference in rate of weight gain was observed between male and female CBDAAV9 mice 
(simple linear regression; *p = .0279). Starting n =28-29. C. Average male (orange) and female (yellow) 
ComboAAV9 treated Cln6nclf weights (in grams) plotted every month from weaning until 14 months of age 
(line graph). A significant difference in rate of weight gain was observed between male and female 






























































3.4.5  Functional improvements in combination therapy mice: summary 
Analysis of the behavioural, and survival data generated by male and female Cln6nclf mice 
treated with a combination of gene therapy and either gemfibrozil (GemfibAAV9), CBD (CBDAAV9) 
or both drugs (ComboAAV9) indicates that all three combination therapies potentially offer 
protection against the several key deficits associated with the Cln6nclf behavioural phenotype. 
Interestingly, however, no combination therapy was able to completely restore mean Cln6nclf 
weights to those of healthy WT controls, with combination treatment mice showing no 
significant difference in mean weights from UTCln6nclf at every time point measured (6, 9 and 
12 months) and often weighing significantly less than WT at one or more time points (Figure 
3.30).  
The median survival of male and female GemfibAAV9, CBDAAV9 and ComboAAV9 mice were 
all significantly increased compared to UTCln6nclf mice and statistically indistinguishable from 
the median survival of sex-matched WT groups by 15 months of age (Figure 3.29; Tables 3.16 
to 3.24).  
There were two isolated instances in which combination treatment mice achieved 
behavioural scores higher than those of age- and sex-matched WT controls: GemfibAAV9 males 
performed significantly better than WT males on the rotarod at 12 months of age and 
GemfibAAV9 females performed significantly better than WT females at the ledge ataxia test at 
6 months of age (Tables 3.16 and 3.17).  
Finally, there appeared to be no significant sex-based differences in behavioural scores 
or survival in response to any of the three combination therapies, with the exception of 




Table 3.16 ⎸ Functional improvements in combination therapy mice: summary table of GemfibAAV9 males. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between male gene therapy and gemfibrozil (GemfibAAV9) treated Cln6nclf mice and their age- and sex-
matched WT and untreated Cln6nclf (UTCln6nclf ) counterparts at 6, 9 and 12 months of age. All behavioural 
score and weight comparisons were conducted using 1-way ANOVAs (Appendices B.108, 110, 112, 
114, 116 and B.132), with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival 
curves were compared using log rank (Mantel-Cox) tests (Appendices B.118 and B.121). nsd = no 
significant difference; s = significant. 
GemfibAAV9 Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd Better (s) 
WT nsd nsd Better (s) 
Composite 
UTCln6nclf nsd Better (s) - 
WT nsd nsd - 
Ledge 
UTCln6nclf nsd Better (s) - 
WT nsd nsd - 
Hindlimb Clasping 
UTCln6nclf nsd Better (s) - 
WT nsd nsd - 
Gait 
UTCln6nclf Better (s) nsd - 
WT nsd nsd - 
Survival 
UTCln6nclf Increased survival (s) 
WT nsd 
Weight 
UTCln6nclf nsd nsd nsd 













Table 3.17 ⎸ Functional improvements in combination therapy mice: summary table of GemfibAAV9 
females. Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons 
carried out between female gene therapy and gemfibrozil (GemfibAAV9) treated Cln6nclf mice and their 
age- and sex-matched WT and untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. 
All behavioural score and weight comparisons were conducted using 1-way ANOVAs (Appendices 
B.109, 111, 113, 115, 117 and B.133), with Tukey’s post-hoc multiple comparisons tests where 
appropriate, while survival curves were compared using log rank (Mantel-Cox) tests (Appendices B.124 
and 127). nsd = no significant difference; s = significant. 
GemfibAAV9 Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd Better (s) 
WT nsd nsd nsd 
Composite 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Ledge 
UTCln6nclf Better (s) Better (s) - 
WT Better (s) nsd  
Hindlimb Clasping 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Gait 
UTCln6nclf nsd nsd - 
WT nsd nsd  
Survival 
UTCln6nclf Increased survival (s) 
WT nsd 
Weight 
UTCln6nclf nsd nsd nsd 
WT Weigh less (s) Weigh less (s) nsd 
Table 3.18 ⎸ Functional improvements in combination therapy mice: summary table of GemfibAAV9 males 
versus GemfibAAV9 females. Summary table of behavioural score (rotarod and ataxia), survival and 
weight comparisons carried out between male and female gene therapy and gemfibrozil (GemfibAAV9) 
treated Cln6nclf mice at 6, 9 and 12 months of age. All behavioural score and weight comparisons were 
conducted using unpaired student t-tests (Appendices B.136, 139, 142, 145 and B.148), while survival 
curves were compared using log rank (Mantel-Cox) tests (Appendix B.151). nsd = no significant 
difference. 
GemfibAAV9 Cln6nclf Males vs Females 
Behavioural test 6 months 9 months 12 months 
Rotarod nsd nsd nsd 
Composite nsd nsd - 
Ledge nsd nsd - 
Hindlimb nsd nsd - 






Table 3.19 ⎸ Functional improvements in combination therapy mice: summary table of CBDAAV9 males. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between male gene therapy and cannabidiol (CBDAAV9) treated Cln6nclf mice and their age- and sex-
matched WT and untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural 
score and weight comparisons were conducted using 1-way ANOVAs (Appendices B.108, 110, 112, 
114, 116 and 133), with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival 
curves were compared using log rank (Mantel-Cox) tests (Appendices B.125 and B.128). nsd = no 
significant difference; s = significant. 
CBDAAV9 Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd Better (s) Better (s) 
WT nsd nsd nsd 
Composite 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd - 
Ledge 
UTCln6nclf nsd Better (s) - 
WT nsd nsd - 
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd nsd - 
Gait 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd - 
Survival 
UTCln6nclf Increased survival (s) 
WT nsd 
Weight 
UTCln6nclf nsd nsd nsd 













Table 3.20 ⎸ Functional improvements in combination therapy mice: summary table of CBDAAV9 females. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between female gene therapy and cannabidiol (CBDAAV9) treated Cln6nclf mice and their age- and sex-
matched WT and untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months of age. All behavioural 
score and weight comparisons were conducted using 1-way ANOVAs (Appendices B. 109, 111, 113, 
115, 117 and B.133), with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival 
curves were compared using log rank (Mantel-Cox) tests (Appendices B125 and B.123). nsd = no 
significant difference; s = significant. 
CBDAAV9 Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd nsd Better (s) 
WT nsd nsd nsd 
Composite 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Ledge 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Hindlimb Clasping 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Gait 
UTCln6nclf nsd nsd - 
WT nsd nsd  
Survival 
UTCln6nclf Increased survival (s) 
WT nsd 
Weight 
UTCln6nclf nsd nsd nsd 
WT Weigh less (s) nsd nsd 
Table 3.21 ⎸ Functional improvements in combination therapy mice: summary table of CBDAAV9 males 
versus CBDAAV9 females. Summary table of behavioural score (rotarod and ataxia), survival and weight 
comparisons carried out between male and female gene therapy and cannabidiol (CBDAAV9) treated 
Cln6nclf mice at 6, 9 and 12 months of age. All behavioural score and weight comparisons were conducted 
using unpaired student t-tests (Appendices B.137, 140, 143, 146 and B.149), while survival curves were 
compared using log rank (Mantel-Cox) tests (Appendix B.152). nsd = no significant difference. 
CBDAAV9 Cln6nclf Males vs Females 
Behavioural test 6 months 9 months 12 months 
Rotarod nsd nsd nsd 
Composite nsd nsd - 
Ledge nsd nsd - 
Hindlimb nsd nsd - 






Table 3.22 ⎸ Functional improvements in combination therapy mice: summary table of ComboAAV9 males. 
Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons carried out 
between male gene therapy and combination small molecule therapy (ComboAAV9) treated Cln6nclf mice 
and their age- and sex-matched WT and untreated Cln6nclf (UTCln6nclf) counterparts at 6, 9 and 12 months 
of age. All behavioural score and weight comparisons were conducted using 1-way ANOVAs 
(Appendices B.108, 110, 112, 114, 116 and B.132), with Tukey’s post-hoc multiple comparisons tests 
where appropriate, while survival curves were compared using log rank (Mantel-Cox) tests (Appendices 
B.120 and 123). nsd = no significant difference; s = significant. 
ComboAAV9 Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd Better (s) Better (s) 
WT nsd nsd nsd 
Composite 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd - 
Ledge 
UTCln6nclf Better (s) nsd - 
WT nsd nsd - 
Hindlimb Clasping 
UTCln6nclf nsd nsd - 
WT nsd nsd - 
Gait 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd - 
Survival 
UTCln6nclf Increased survival (s) 
WT nsd 
Weight 
UTCln6nclf nsd nsd nsd 













Table 3.23 ⎸ Functional improvements in combination therapy mice: summary table of ComboAAV9 
females. Summary table of behavioural score (rotarod and ataxia), survival and weight comparisons 
carried out between female gene therapy and combination small molecule therarpy (ComboAAV9) treated 
Cln6nclf mice and their age- and sex-matched WT and UTCln6nclf Cln6nclf (UTCln6nclf) counterparts at 6, 9 
and 12 months of age. All behavioural score and weight comparisons were conducted using 1-way 
ANOVAs (Appendices B.109, 111, 113, 115, 117 and 113), with Tukey’s post-hoc multiple comparisons 
tests where appropriate, while survival curves were compared using log rank (Mantel-Cox) tests 
(Appendices B.126 and 129). nsd = no significant difference; s = significant. 
ComboAAV9 Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod 
UTCln6nclf nsd Better (s) Better (s) 
WT nsd nsd nsd 
Composite 
UTCln6nclf Better (s) Better (s) - 
WT nsd nsd  
Ledge 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Hindlimb Clasping 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Gait 
UTCln6nclf nsd Better (s) - 
WT nsd nsd  
Survival 
UTCln6nclf Increased survival (s) 
WT nsd 
Weight 
UTCln6nclf nsd nsd nsd 
WT Weigh less (s) Weigh less (s) nsd 
Table 3.24 ⎸ Functional improvements in combination therapy mice: summary table of ComboAAV9 males 
versus ComboAAV9 females. Summary table of behavioural score (rotarod and ataxia), survival and 
weight comparisons carried out between male and female gene therapy and combination small molecule 
therapy (ComboAAV9) treated Cln6nclf mice at 6, 9 and 12 months of age. All behavioural score and weight 
comparisons were conducted using unpaired student t-tests (Appendices B.138, 141, 144, 147 and 
B.150), while survival curves were compared using log rank (Mantel-Cox) tests (Appendix B.153). nsd 
= no significant difference. 
ComboAAV9 Cln6nclf Males vs Females 
Behavioural 
test 6 months 9 months 12 months 
Rotarod nsd nsd Females performed better (s) 
Composite nsd nsd - 
Ledge nsd nsd - 
Hindlimb nsd nsd - 





3.5  Combination therapy offers no overt behavioural benefits to Cln6nclf 
mice when compared to gene therapy alone  
It is now apparent that AAV2/9-mediated gene therapy, alone or in combination with either 
gemfibrozil and/or CBD, may confer varying levels of protection to male and female Cln6nclf 
mice against a range of CLN6 BD phenotypes. These results, in themselves, are optimistic – 
especially for parents of the participants of the Gray Foundation’s 2016 gene therapy trial, as 
there are reports that several have been supplementing the gene therapy their children 
received with CBD based on anecdotal evidence (Wibbeler et al., 2019; Stephanie Hughes, 
personal communication).  
Despite this, it is worth investigating whether any of the combination therapies 
(GemfibAAV9, CBDAAV9 or ComboAAV9) result in significantly better or worse behavioural scores 
and survival than gene therapy on its own. This is for two main reasons: first, and perhaps 
most importantly, it is critical to ensure that efficacy of the gene therapy treatment is not 
being attenuated, even subtly, by the addition of small molecule therapy. There have been 
several instances recorded where the combination of two or more therapies has resulted in 
antagonism and a reduction in overall therapeutic efficacy, as was the case with attempts to 
combine ERT and AAV2/9-mediated gene therapy in Ppt1-/- mice (Pearse, 2015).  
Secondly, because combination therapies, by their very nature, require additional 
resources to be administered, it is worth determining whether they are worth the investment 
of those additional resources. Regular dosing with small molecule therapy, for instance, will 
require an ongoing cost – either to the funding body or to the family of the patient – and in 
countries such as the United States of America, where there is no universal healthcare or 
pharmaceutical subsidies available without personal health insurance, this cost may end up 
being significant over the patient’s lifetime. Additionally, regular dosing requires foresight and 
planning to ensure strict adherance to the dosing regimen, which can be taxing for the patient 
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and their family. In light of these practical considerations, it is important to determine whether 
the small molecule therapies investigated in this thesis are producing behavioural outcomes 
that outweigh the resources that will be required to use them in combination with gene 
therapy. 
3.5.1 Combination therapy versus gene therapy alone: rotarod 
In an effort to elicit whether combination therapy offers any behavioural benefits over gene 
therapy alone, at least in terms of motor co-ordination or balance preservation as measured 
by the rotarod, eight different experimental groups were assessed with the rotarod at 6, 9 and 
12 months of age. Six of these groups represented three unique combinations of gene and 
small molecule therapy: M/F GemfibAAV9, M/F CBDAAV9 and ComboAAV9 (treatment regimens as 
described in section 3.4.1), while the last two groups consisted of No DrugAAV9 mice (treatment 
regimen as described in section 3.3.1).  
Linear regression was used to compare the overall rate of decline in mean rotarod 
scores over time and the associated elevation (range over which the decline occurred) of each 
combination therapy treated group versus sex-matched No DrugAAV9 mice (Appendices B.154-
156). No significant differences were detected between any of the combination therapy 
groups and the groups treated with gene therapy alone, regardless of gender (Figure 3.36). 
This similarity was recapitulated by statistically indistinguishable mean rotarod scores at 6, 9 


























⇒	Figure 3.36 ⎸ Combination therapy versus gene therapy alone: rotarod scores (line graphs; opposite 
page). Cln6nclf mice treated with a combination of gene and small molecule therapy experience a decline 
in motor co-ordination, as measured by the rotarod, statistically similar to that experienced by sex-
matched Cln6nclf mice treated with gene therapy alone, regardless of sex or the type of small molecule 
therapy they were treated with. Data are presented as a line graph of mean scores (latency to fall, in 
seconds), with error bars = ± SEM. Different mice were tested at different time points, making this 
experiment between-subjects in design. Dotted lines indicate the expected mean score trajectory for an 
experimental group between measured time points. Solid lines represent the regression lines of each 
experimental group, as calculated via simple linear regression (Appendices B.154-156). A high score 
(~300) indicates a high level of motor co-ordination as measured by the rotarod, while lower scores 
correlate to increasing levels of motor dysfunction (coloured arrow on the left). A.-F. No significant 
differences in overall rate of motor decline, as measured by the rotarod, can be detected between mice 
treated with gene therapy alone and those treated with gene and small molecule therapy, regardless of 
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⇐	Figure 3.37 ⎸ Combination therapy versus gene therapy alone: rotarod scores (histograms; opposite 
page). No statistical differences were seen between mean rotarod scores at 6, 9 and 12 months for 
Cln6nclf mice treated with gene therapy alone or in combination with one of three different small molecule 
therapies: gemfibrozil (GemfibAAV9), cannabidiol (CBDAAV9) or both gemfibrozil and CBD (ComboAAV9). 
Histograms presenting mean rotarod scores (latency to fall in seconds) of male (left; plain coloured bars) 
and female (right; patterned bars) Cln6nclf mice treated with gene therapy and either: vehicle (No 
DrugAAV9), gemfibrozil (GemfibAAV9), CBD (CBDAAV9), or a combination of the two (ComboAAV9) and their 
age- and gender-matched untreated (UTCln6nclf) and WT (C57Bl/6) counterparts at 6 (A), 9 (B) and 12 (C) 
months of age. Data are presented as mean scores with error bars = ± SEM. Different mice were tested 
at each of the different time points, making the experiment between-subjects in design. All analyses were 
conducted using 1-way analysis of variances (ANOVAs) with Tukey’s post-hoc comparisons used to elicit 
specific significant differences between experimental groups (Appendix B.154-156). Individual mean 
mouse rotarod scores indicated by clear circles. (A-C). No significant differences were seen in the mean 
scores of mice treated with gene therapy alone (No DrugAAV9) and those of mice treated with gene therapy 
and small molecule therapy (GemfibAAV9, CBDAAV9 and ComboAAV9), for either gender, at any time point. 
n(per group, per time point) = 6-12.  
3.5.2  Combination therapy versus gene therapy alone: ataxia 
In order to determine wheether combined gene and small molecule therapy is more effective 
at protecting against the Cln6nclf ataxic phenotype than gene therapy alone, eight different 
experimental groups were assessed for signs of cerebellar ataxia at 6 and 9 months of age. 
These included male and female (M/F) No DrugAAV9 , M/F GemfibAAV9, M/F CBDAAV9 and M/F 
ComboAAV9 mice. All mice received a dose of scAAV9.CB.hCLN6 via i.c.v at P0-2. No DrugAAV9 
mice received vehicle jelly after weaning, while the different combination therapy groups 
received their respective small molecule therapy (gemfibrozil, CBD or a combination of the 
two) in strawberry jelly after weaning.  
3.5.2.a Composite ataxia phenotype scores 
Composite ataxia scores (0-9) for each mouse were calculated by adding together mean ledge, 
hindlimb clasping and gait ataxia phenotyping scores (0-3). Scores were then averaged for 
each experimental group and presented as mean score (0-9) ± SEM. Comparisons between 
mean composite scores of age- and sex-matched No DrugAAV9 treated and combination 
therapy treated (GemfibAAV9, CBDAAV9 and ComboAAV9) mice were made using 1-way ANOVAs, 
with Tukey’s post-hoc multiple comparisons tests conducted when significant differences 
were found to occur (Appendices B.159-160).  
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No significant differences in mean composite ataxia scores were detected between the 
combination therapy groups (GemfibAAV9, CBDAAV9 and ComboAAV9) and No DrugAAV9 mice at 










Figure 3.38 ⎸ Combination therapy versus gene therapy alone: composite ataxia scores. No statistical 
differences were seen between mean composite ataxia scores at 6, 9 and 12 months for Cln6nclf mice 
treated with gene therapy alone or in combination with one of three different small molecule therapies: 
gemfibrozil (GemfibAAV9), cannabidiol (CBDAAV9) or both gemfibrozil and CBD (ComboAAV9). Mean 
composite ataxia phenotype scores (0 to 9) were calculated using averaged ataxia test individual scores 
(ledge, hindlimb clasping and gait) for male (Ai-ii) and female (Bi-ii) Cln6nclf mice treated with gene 
therapy and one of three drug regimens: gemfibrozil (GemfibAAV9), CBD (CBDAAV9) or a combination of 
gemfibrozil and CBD (ComboAAV9), and Cln6nclf mice treated with gene therapy alone (No DrugAAV9). 
C57Bl/6 counterparts across two different time points: 6 months (left) and 9 months (right). Different mice 
were tested at each time point (between-subjects study design). A low score (close to 0) indicates an 
absence of the ataxic phenotype as measured by the composite scoring system, while higher scores, 
closer to 9, indicate increasing levels of ataxic behaviour (coloured arrow on the left). The overall mean 
composite scores illustrated in Ai and Bi are further broken down into the average ledge (bottom 
segment), hindlimb clasping (middle segment) and gait (top segment) scores in segmented bar graphs 
(Aii and Bii). Individual, averaged composite scores are shown as clear circles in Ai and Bi, error bars = 
± SEM. Analyses were conducted via 1-way analysis of variances (ANOVAs) and subsequent Tukey’s 
multiple comparison post-hoc tests (Appendices B.159-160). n(per group per time point) = 8-14. Ai-ii 
and Bi-ii No significant differences were found between any experimental groups mean composite ataxia 







































































































































































































































































































































































































































































3.5.2.b Ledge test 
No significant differences were observed in mean ledge ataxia scores between combination 
treatment and gene therapy-only treated groups (Figure 3.39.A and B; Appendices B.161 and 
B.162).  
3.5.2.c Hindlimb clasping test 
No significant differences were observed in mean hindlimb clasping ataxia scores between 
combination treatment and gene therapy-only treated groups (Figure 3.39.C and D; 
Appendices B.163 and B.164).  
3.5.2.d Gait test 
While no significant differences were observed in male mean gait test scores between 
combination treatment and gene therapy-only treated groups at 6 or 9 months (Figure 3.39.E; 
Appendix B.165), several significant differences were detected between female scores at both 
time points (Figure 3.39.F). Female CBDAAV9 and ComboAAV9 performed significantly better at 
the gait test than age- and sex-matched No DrugAAV9 counterparts at 6 months of age (No 
DrugAAV9 mean score = 0.333; CBDAAV9 mean score = 0.0333; * p = .0128 ; ComboAAV9 mean 
score = 0.0333; * p = .0128; Appendix B.166). At 9 months, however, these significant 
differences have disappeared and the only difference observed was between the mean score 
of GemfibAAV9 treated female mice and No DrugAAV9 mice, with GemfibAAV9 performing 
significantly worse (higher score) at this time point (No DrugAAV9 mean score = 0.0; ** p = .0029; 




































































































































































































































































































































































































































































































































































































































































































































































































































⇐	Figure 3.39 ⎸ Combination therapy versus gene therapy alone: ataxia phenotyping scores (previous 
page). Only a few statistically significant differences were observed in mean ataxia assay scores 
between Cln6nclf mice treated with a combination of gene and small molecule therapy (GemfibAAV9, 
CBDAAV9 and ComboAAV9) and Cln6nclf mice treated with gene therapy alone (No DrugAAV9) Histograms 
presenting mean ataxia scores (0-3) for individual ataxia assays: ledge (A; males; B; females), hindlimb 
clasping (C; males; D; females), and gait (E; males; F; females). Scoring criteria and methodology can 
be found in Chapter 2, adapted from Guyenet et al. 2010. Different mice were assessed at each time 
point, making the experiment between-subjects in design. For each assay, a mouse could be assigned 
a score between 0 and 3, with 0 indicating a complete absence of the ataxic phenotype and 3 indicating 
a completely penetrant ataxic phenotype (coloured arrows on the left). Data are presented as mean 
scores, with error bars representing ± SEM. Individual (averaged) mouse scores are presented as clear 
circles. All analyses were conducted using 1-way ANOVAs (Appendices B.161-166), followed by 
Tukey’s multiple comparisons post-hoc tests A. and B. Histograms presenting the mean ledge ataxia 
scores of male (A) and female (B) mice. No significant differences were detected between GemfibAAV9 
(purple), CBDAAV9 (green) and ComboAAV9 (orange) mean ledge ataxia scores and the mean scores of 
No DrugAAV9 mice at 6 (left hand side of histograms) or 9 months of age (right hand side of histograms) 
for either male (A) or female (B) mice (Appendices B.161 and B.162). n(per group per time point) = 7-
10 C. and D. Histograms presenting the mean hindlimb clasping ataxia scores of male (C) and female 
(D) mice. No significant differences were detected between GemfibAAV9 (purple), CBDAAV9 (green) and 
ComboAAV9 (orange) mean hindlimb clasping ataxia scores and the mean scores of No DrugAAV9 mice at 
6 (left hand side of histograms) or 9 months of age (right hand side of histograms) for either male (C) or 
female (D) mice (Appendices B.163 and B.164). n(per group per time point) = 7-10 E. Histogram 
presenting mean gait ataxia scores for male mice at 6 (left; dark coloured bars) and 9 months of age 
(right; light coloured bars). No significant diffferences were detected between any of the experimental 
treatment groups at either time point (Appendix B.165). n(per group per time point) = 8-10. F. Histogram 
presenting mean gait ataxia scores for female mice at 6 (left; light coloured bars) and 9 months of age 
(right; dark coloured bars). At 6 months, female CBDAAV9 (green bars) and ComboAAV9 (orange bars) 
treatment groups demonstrated significantly lower (better) mean gait ataxia scores than age- and sex-
matched No DrugAAV9 (light blue bars) mice (No DrugAAV9 mean score = 0.333; CBDAAV9 mean score = 
0.0333; * p = .0128 ; ComboAAV9 mean score = 0.0333; * p = .0128; Appendix B.166). At 9 months, 
however, the only significant difference between mean scores is between the mean gait ataxia score of 
GemfibAAV9 mice (0.7083) and that belonging to No DrugAAV9 mice (No DrugAAV9 mean score = 0.0; ** p 
= .0029; Appendix B.166). GemfibAAV9 mice perform significantly worse (higher score) than No DrugAAV9 











3.5.3  Combination therapy versus gene therapy alone: survival and 
weight 
The survival curves (and median survival) of Cln6nclf mice treateed with both gene therapy and 
gemfibrozil, CBD and combination were compared to Cln6nclf mice who received gene therapy 
alone. Survival data are presented as percentage of the original cohort n, with curve 
comparisons between sex-matched Cln6nclf conducted via separate log-rank (Mantel-Cox) 
tests for each sex (Appendices B.167-172).  
All experimental groups, for both male and female mice, had ‘undefined’ median 
survivals by 15 months – due to the fact that less than half of each group’s cohort had passed 
away from unplanned deaths. Despite this, one significant difference in survival curve was 
detected for male mice, with CBDAAV9 mice having a significantly reduced survival curve 
compared to No DrugAAV9 mice (Figure 3.40; Appendices B.170-172).  
Weights were also kept, as a measure of overall health, and body weight was recorded 
weekly (in grams). Average weights for each experimental group are presented here, however, 
monthly as it gives a clearer overview of weight progression throughout the lifespan. Simple 
linear regression was conducted to determine the overall rate of weight gain and/or loss over 
the first 14 months of the trial, but no differences were detected in the slopes of any 
experimental group. A series of 1-way ANOVA analyses were also used to compare the mean 
weights of combination therapy treated Cln6nclf mice to age-matched No DrugAAV9 mice at 6, 9 
and 12 months – which felt appropriate, as this is when behavioural assessments were carried 
out. Data are presented here as average weights, in grams ± SEM (Figure 3.41). 
Male mean weights were found to be statistically indistinguishable at 6, 9 and 12 
months of age (Figure 3.41.A, C, E and G; Appendix B.173). Females, however, did 
demonstrate so significant differences in mean weights at 6 and 12 months of age (Figures 
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3.41.B, D, and H). GemfibAAV9 and ComboAAV9 treated female mice demonstrated significantly 
lower mean weights than No DrugAAV9 treated mice at 6 months of age (Figures 3.41.D; female 
6 month No DrugAAV9 mean weight = 26.17 g; female 6 month GemfibAAV9 mean weight = 24.44 
g; * p = .0117; female 6 month ComboAAV9 mean weight = 24.04 g; ** p =.0014 ; Appendix 
B.174). Similarly, GemfibAAV9 treated female mice were, on average, significantly lighter than 
No DrugAAV9 counterparts at 12 months of age (GemfibAAV9 mean weight = 26.95 g; No DrugAAV9 












Figure 3.40 ⎸ Combination therapy versus gene therapy alone: survival. While male Cln6nclf mice that were 
treated with a combination of gene therapy and CBD small molecule therapy (CBDAAV9) demonstrated 
reduced survival in comparison to sex-matched Cln6nclf who received gene therapy alone (No DrugAAV9), 
the rest of the Cln6nclf mice, both male and female, who received both gene therapy and one of three 
small molecule therapy regimens demonstrated no significant difference in survival from that of No 
DrugAAV9. Kaplan-Meier survival plots (%) comparing the survival curves of No DrugAAV9 (male = blue 
lines; female = light blue lines) ) to Cln6nclf mice treated with one of three combination therapy regimens 
(gemfibrozil and gene therapy = purple lines; CBD and gene therapy = green lines; combination of 
gemfibrozil, CBD and gene therapy = orange lines). All survival curve comparisons were conducted using 
a log rank (Mantel-Cox) test in GraphPad Prism 8 (Appendices B.167-172). A. Male survival curves (%) 
from birth to 14 months of age. Only CBDAAV9 mice had a significantly shorter median survival rate than 
No DrugAAV9 (male No DrugAAV9 median survival aka ‘ms’ = undefined at 14 months; CBDAAV9 ms = 
undefined at 14 months; * p = .00373; Appendix B.168). While both experimental groups had not yet 
reached a median survival of 14 months, CBDAAV9’s cohort had experienced several more unplanned 
deaths than No DrugAAV9(6 deaths vs 1). Starting n(per group) = 27-31. B. No significant difference was 
detected between the survival curves of female No DrugAAV9, GemfibAAV9, CBDAAV9 and ComboAAV9 mice 
(Appendices B.170-172). Starting n(per group) = 22-29. 
 




























































































































































































































































































⇐	Figure 3.41 ⎸ Combination therapy versus gene therapy alone: weights (opposite page). Weights of 
male Cln6nclf mice treated with combined gene and small molecule therapy do not differ significantly from 
those of male Cln6nclf mice treated with gene therapy alone, while female Cln6nclf who receive both 
gemfibrozil and gene therapy (GemfibAAV9) appear to have significantly lower weights than gene therapy 
only female Cln6nclf mice by 12 months of age. Mice were weighed weekly from weaning (~28 days) to 
determine drug dosage and as a measure of general health. Weights are shown here from weaning to 
15 months due to the time constraints of an MSc (weights continued to be tracked for the entire duration 
of the trial). Data are presented as average weights, error bars ± SEM. Analyses conducted via 1-way 
ANOVA with Tukey’s multiple comparisons post-hoc tests where applicable.A. Line graph of average 
male weights (in grams) over 14 months (from weaning to ~15 months). 1-way ANOVA analyses 
conducted between male No DrugAAV9 (blue squares and lines), GemfibAAV9 (purple squares and lines) , 
CBDAAV9 (green squares and lines) and ComboAAV9 (orange squares and lines). Starting n(per group) = 
23-31 B. Line graph of average female weights (in grams) over 14 months (from weaning to ~15 months). 
1-way ANOVA analyses conducted between female No DrugAAV9 (light blue circles and lines), GemfibAAV9 
(purple circles and lines) , CBDAAV9 (green circles and lines) and ComboAAV9 (orange circles and lines). 
Starting n(per group) = 22-29. . C. Histogram of mean male No DrugAAV9 (blue bar) GemfibAAV9 (purple 
bar), CBDAAV9 (green bar) and ComboAAV9 (orange bar) mice at 6 months of age. No significant 
differences in average weight were found between any of the experimental groups at this time point (1-
way ANOVA; Appendix B.173). n (per group) = 23-31. D. Histogram of mean female No DrugAAV9 (light 
blue bar) GemfibAAV9 (purple bar), CBDAAV9 (green bar) and ComboAAV9 (orange bar) mice at 6 months 
of age. ComboAAV9 and GemfibAAV9 treated female mice weighed significantly less, on average, than No 
DrugAAV9 mice at this time point (female 6 month No DrugAAV9 mean weight = 26.17 g; female 6 month 
GemfibAAV9 mean weight = 24.44 g; * p = .0117; female 6 month ComboAAV9 mean weight = 24.04 g; ** 
p =.0014 ; Appendix B.174). n (per group) = 24-28. E. Histogram of mean male No DrugAAV9, GemfibAAV9 
CBDAAV9 and ComboAAV9 mice at 9 months of age. No significant differences in average weight were 
found between any of the experimental groups at this time point (1-way ANOVA; Appendix B.173). n(per 
group) = 19-26. F. Histogram presenting mean female No DrugAAV9, GemfibAAV9 CBDAAV9 and ComboAAV9 
mice at 9 months of age. No significant differences in average weight were found between any of the 
experimental groups at this time point (1-way ANOVA; Appendix B.174). n(per group) = -25. G. 
Histogram of mean male No DrugAAV9, GemfibAAV9 CBDAAV9 and ComboAAV9 mice at 12 months of age. 
No significant differences in average weight were found between any of the experimental groups at this 
time point (1-way ANOVA; Appendix B.173). n(per group) = 12-25. F. Histogram presenting mean 
female No DrugAAV9, GemfibAAV9 CBDAAV9 and ComboAAV9 mice at 9 months of age. Female GemfibAAV9 
mice demonstrated a significantly lower mean weight (in grams) than their age- and sex-matched No 
DrugAAV9 counterparts (GemfibAAV9 mean weight = 26.95 g; No DrugAAV9 mean weight = 30.22 g; * p = ; 
Appendix B.174). n(per group) = 17-19. 
3.5.4  Combination therapy versus gene therapy alone: summary 
The behavioural scores, survival and weights of Cln6nclf mice treated with gene therapy and 
one of three possible small molecule therapy regimens (gemfibrozil, CBD or a combination of 
both gemfibrozil and CBD) were directly compared to age- and sex- matched No DrugAAV9 
Cln6nclf counterparts, who had only received gene therapy and a vehicle instead of small 
molecule therapy. This was done to determine if the use of a combination treatment offered 
any additional therapeutic benefit against the Cln6nclf compared to gene therapy alone, with 




Overall, it appears that there were very few significant differences in behavioural, 
survival and weight outcomes between the different treatment groups – regardless of gender. 
There were only four instances in which a combination therapy group out performed No 
DrugAAV9 mice. Male CBDAAV9 and ComboAAV9 mice achieved a higher mean hindlimb clasping 
score than male No DrugAAV9 mice and female CBDAAV9 and ComboAAV9 mice achieved a higher 
gait ataxia score than female No DrugAAV9 mice, all differences occurring at 6 months of age. 
Unfortunately there were also two instances in which a combination therapy 
treatment group performed significantly worse than No DrugAAV9 mice: CBDAAV9 male mice had 
a significantly reduced survival curve compared to male No DrugAAV9 mice and female 
GemfibAAV9 mice performed significantly worse in the gait ataxia test than female No DrugAAV9 
mice at 9 months. 
This data, taken together, suggests that the overall effects of different combined 
therapeutic strategies on key Cln6nclf phenotypes offer negligible benefit over the use of gene 
therapy alone, and in one or two cases even seem to antagonise the positive effects elicited 










Table 3.25 ⎸ Combination therapy versus gene therapy alone: summary table of male GemfibAAV9 scores 
versus No DrugAAV9 scores. Summary table of behavioural score (rotarod and ataxia), survival and 
weight comparisons carried out between male gene therapy and gemfibrozil (GemfibAAV9) treated Cln6nclf 
mice and their age- and sex-matched gene therapy-only Cln6nclf (No DrugAAV9) counterparts at 6, 9 and 
12 months of age. All behavioural score and weight comparisons were conducted using 1-way ANOVAs 
(Appendices B.157, 159, 161, 163 and B.165), with Tukey’s post-hoc multiple comparisons tests where 
appropriate, while survival curves were compared using log rank (Mantel-Cox) tests (Appendices B.167). 
nsd = no significant difference; s = significant. 
GemfibAAV9 Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod No DrugAAV9 nsd nsd nsd 
Composite No DrugAAV9 nsd nsd - 
Ledge No DrugAAV9 nsd nsd - 
Hindlimb Clasping No DrugAAV9 nsd nsd - 
Gait No DrugAAV9 nsd nsd - 
Survival No DrugAAV9 nsd 
Weight No DrugAAV9 nsd nsd nsd 
Table 3.26 ⎸ Combination therapy versus gene therapy alone: summary table of female GemfibAAV9 
scores versus No DrugAAV9 scores. Summary table of behavioural score (rotarod and ataxia), survival 
and weight comparisons carried out between female gene therapy and gemfibrozil (GemfibAAV9) treated 
Cln6nclf mice and their age- and sex-matched gene therapy-only Cln6nclf (No DrugAAV9) counterparts at 6, 
9 and 12 months of age. All behavioural score and weight comparisons were conducted using 1-way 
ANOVAs with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were 
compared using log rank (Mantel-Cox) tests (Appendices B.170). nsd = no significant difference; s = 
significant. 
GemfibAAV9 Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod No DrugAAV9 nsd nsd nsd 
Composite No DrugAAV9 nsd nsd - 
Ledge No DrugAAV9 nsd nsd - 
Hindlimb Clasping No DrugAAV9 nsd nsd - 
Gait No DrugAAV9 nsd Worse (s) - 
Survival No DrugAAV9 nsd 








Table 3.27 ⎸ Combination therapy versus gene therapy alone: summary table of male CBDAAV9 scores 
versus No DrugAAV9 scores. Summary table of behavioural score (rotarod and ataxia), survival and 
weight comparisons carried out between male gene therapy and cannabidiol (CBDAAV9) treated Cln6nclf 
mice and their age- and sex-matched gene therapy-only Cln6nclf (No DrugAAV9) counterparts at 6, 9 and 
12 months of age. All behavioural score and weight comparisons were conducted using 1-way ANOVAs 
(Appendices B.157, 159, 161, 163 and B.165), with Tukey’s post-hoc multiple comparisons tests where 
appropriate, while survival curves were compared using log rank (Mantel-Cox) tests (Appendices B.168). 
nsd = no significant difference; s = significant. 
CBDAAV9 Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod No DrugAAV9 nsd nsd nsd 
Composite No DrugAAV9 nsd nsd - 
Ledge No DrugAAV9 nsd nsd - 
Hindlimb Clasping No DrugAAV9 Better (s) nsd - 
Gait No DrugAAV9 nsd nsd - 
Survival No DrugAAV9 Reduced survival (s) 
Weight No DrugAAV9 nsd nsd nsd 
Table 3.28 ⎸ Combination therapy versus gene therapy alone: summary table of female CBDAAV9 scores 
versus No DrugAAV9 scores. Summary table of behavioural score (rotarod and ataxia), survival and 
weight comparisons carried out between female gene therapy and cannabidiol (CBDAAV9) treated Cln6nclf 
mice and their age- and sex-matched gene therapy-only Cln6nclf (No DrugAAV9) counterparts at 6, 9 and 
12 months of age. All behavioural score and weight comparisons were conducted using 1-way ANOVAs, 
with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were 
compared using log rank (Mantel-Cox) tests (Appendices B.171). nsd = no significant difference; s = 
significant. 
CBDAAV9 Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod No DrugAAV9 nsd nsd nsd 
Composite No DrugAAV9 nsd nsd - 
Ledge No DrugAAV9 nsd nsd - 
Hindlimb Clasping No DrugAAV9 nsd nsd - 
Gait No DrugAAV9 Better (s) nsd - 
Survival No DrugAAV9 nsd 







Table 3.29 ⎸ Combination therapy versus gene therapy alone: summary table of male ComboAAV9 scores 
versus No DrugAAV9 scores. Summary table of behavioural score (rotarod and ataxia), survival and 
weight comparisons carried out between male gene therapy and combination small therapy (ComboAAV9) 
treated Cln6nclf mice and their age- and sex-matched gene therapy-only Cln6nclf (No DrugAAV9) 
counterparts at 6, 9 and 12 months of age. All behavioural score and weight comparisons were 
conducted using 1-way analysis of variances (ANOVAs; Appendices B.157, 159, 161, 163 and B.165), 
with Tukey’s post-hoc multiple comparisons tests where appropriate, while survival curves were 
compared using log rank (Mantel-Cox) tests (Appendices B.169). nsd = no significant difference; s = 
significant. 
ComboAAV9 Cln6nclf Males 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod No DrugAAV9 nsd nsd nsd 
Composite No DrugAAV9 nsd nsd - 
Ledge No DrugAAV9 nsd nsd - 
Hindlimb Clasping No DrugAAV9 Better (s) nsd - 
Gait No DrugAAV9 nsd nsd - 
Survival No DrugAAV9 nsd 
Weight No DrugAAV9 nsd nsd nsd 
Table 3.30 ⎸ Combination therapy versus gene therapy alone: summary table of female ComboAAV9 
scores versus No DrugAAV9 scores. Summary table of behavioural score (rotarod and ataxia), survival 
and weight comparisons carried out between male gene therapy and combination small therapy 
(ComboAAV9) treated Cln6nclf mice and their age- and sex-matched gene therapy-only Cln6nclf (No 
DrugAAV9) counterparts at 6, 9 and 12 months of age. All behavioural score and weight comparisons were 
conducted using 1-way ANOVAs, with Tukey’s post-hoc multiple comparisons tests where appropriate, 
while survival curves were compared using log rank (Mantel-Cox) tests (Appendices B.172). nsd = no 
significant difference; s = significant. 
ComboAAV9 Cln6nclf Females 
Behavioural Test Comparison Group 6 months 9 months 12 months 
Rotarod No DrugAAV9 nsd nsd nsd 
Composite No DrugAAV9 nsd nsd - 
Ledge No DrugAAV9 nsd nsd - 
Hindlimb Clasping No DrugAAV9 nsd nsd - 
Gait No DrugAAV9 Better (s) nsd - 
Survival No DrugAAV9 nsd 










Chapter 4: Discussion 
4.1 Thesis summary and significance  
The practical component of this thesis was designed to contribute to a larger pre-clinical trial, 
funded by the Gray Foundation and run by the Hughes Lab, to assess the efficacy of gene 
therapy when complemented by two different experimental small molecule therapeutics, 
alone and in combination, on the CLN6 BD phenotype. This thesis focuses solely on 
behavioural assessment, with plans being made by the Hughes Lab to conduct post-mortem 
biochemical analyses in the near future. Here, a naturally-occurring CLN6 BD animal model, 
the Cln6nclf mouse, was used to investigate whether the use of gemfibrozil, an FDA-approved 
fibrate, and/or cannabidiol (CBD), a cannabinoid with purported neuroprotective properties, 
would amplify or attenuate the efficacy of AAV2/9-mediated gene therapy in protecting 
against behavioural deficits typical of UTCln6nclf mice. Sex differences in behavioural response 
to the different treatment regimens were also investigated, due to the mounting preclinical 
and clinical evidence that male and female experiences of the NCLs vary in terms of symptom 
onset and severity, as well as speed of progression (Cialone et al., 2012; Poppens et al., 2019). 
In order to make meaningful observations regarding the efficacy of gemfibrozil and/or 
CBD as complementary therapies, it was first important to establish and characterise an 
UTCln6nclf behavioural phenotype for each of the behavioural assays used, with which the 
behavioural scores of different treatment groups could later be compared. Here, the UTCln6nclf 
mice were found to recapitulate previously described motor deficits in rotarod and ataxia 
tests. A significant ataxic phenotype could be detected as early as 6 months for males and 9 
months for females, and all mice were performing significantly worse than WT on the rotarod 
by 12 months of age – indicating a reduction in motor co-ordination and balance.  
 258 
Once healthy WT control and diseased Cln6nclf behavioural baselines had been 
established, the effects of gemfibrozil and CBD, alone and in combination with each other, 
were investigated without gene therapy. These ‘drug-only’ Cln6nclf experimental groups were 
included in the trial (and the practical component of this thesis) to better characterise any 
subtle therapeutic effects gemfibrozil and CBD might have on the Cln6nclf behavioural 
phenotype. Little in vivo work has been conducted previously on the therapeutic efficacy of 
gemfibrozil and/or CBD in Cln6nclf mice, and no published studies to date have specifically 
looked at their protective properties against the Cln6nclf diseased behavioural phenotype. By 
investigating and characterising the effects of these two small molecule therapies on the 
behavioural phenotype of Cln6nclf mice, this thesis represents the first publication to address 
this specific gap in the literature. At first glance, the data seemed to indicate that neither 
gemfibrozil nor CBD had any kind of effect on the Cln6nclf behavioural phenotype – mice were 
still declining significantly by 9 months of age and had characteristically short lifespans. On 
closer examination, however, subtle effects became evident – with male mice who received 
any form of small molecule therapy appearing to have delayed disease onset in comparison 
to UTCln6nclf mice. Female mice also seemed to do a little better on gemfibrozil in the composite 
and gait ataxia assays, in comparison to UTCln6nclf counterparts, though this improvement was 
not present across all behavioural tests and would warrant further investigation.  
While the primary aim of this work was to explore the possibility of combined gene 
and small molecule therapy, experimental groups of mice treated with gene therapy alone 
(No DrugAAV9) were also assessed for behavioural performance in comparison to healthy WT 
controls and UTCln6nclf mice. This was done to validate and expand upon a series of published 
preclinical studies looking at AAV2/9-mediated gene transfer in the Cln6nclf mouse and to 
recapitulate, to a certain extent, the therapeutic parameters of the 2016 Gray Foundation 
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CLN6 BD clinical trial (Cain et al., 2019; Trial No. NCT02725580, Clinicaltrials.gov). Here, it was 
found that a single neonatal i.c.v injection of scAAV9.CB.hCLN6 appeared to protect Cln6nclf 
mice, of both sexes, from a wide swathe of characteristic behavioural deficits. Compared to 
sex-matched UTCln6nclf counterparts, male and female No DrugAAV9 mice experienced 
significantly extended survival, significantly higher 12 month rotarod scores, as well as better 
6 and 9 month composite and hindlimb clasping ataxia scores. Male No DrugAAV9 mice also 
performed significantly better than male UTCln6nclf mice at the ledge test at both 6 and 9 
months, a significant improvement considering it was the 6 month ledge and composite ataxia 
tests where male UTCln6nclf mice first began to demonstrate deficits compared to WT controls 
(section 3.1). There were also several instances where No DrugAAV9 mice outperformed even 
the healthy WT controls, with both male and female No DrugAAV9 achieving significantly higher 
mean rotarod scores than WT at 12 months of age, and females outperforming WT in the gait 
ataxia test at 9 months of age. Females, overall, appear to have responded better to the gene 
therapy than males – with females producing significantly higher scores than males in four out 
of five behavioural assays. This data, taken together, confirms the efficacy of AAV2/9-
mediated gene therapy as protection against the Cln6nclf mouse and may even have produced 
a novel observation regarding a sex-based difference in response to CLN6 gene therapy.  
Perhaps the most important aspect of this work was the investigation of the effects of 
combined gene and small molecule therapy on the Cln6nclf behavioural phenotype. Here, 
Cln6nclf treated with both AAV2/9-mediated gene therapy and either gemfibrozil, CBD or a 
combination of the two drugs were assessed in the hopes of finding a synergystic combination 
that could augment the protective qualities of gene therapy alone and potentially inform 
future therapeutic strategies for CLN6 BD children who have already received gene therapy. 
All three combination therapies (GemfibAAV9, CBDAAV9 and ComboAAV9) showed promise by 
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protecting Cln6nclf mice, of both genders, against the UTCln6nclf behavioural and survival 
phenotypes. Male Cln6nclf mice treated with both gene therapy and gemfibrozil even 
outperformed healthy WT controls on the rotarod assay at 12 months, while female 
GemfibAAV9 mice outperformed WT at 6 months in the ledge ataxia test – perhaps indicating a 
synergystic quality to the combination of gene therapy with gemfibrozil in this mouse model. 
Considering, again, however that these results were only for one assay out of five, further 
investigation into the effects of gemfibrozil in combination with gene therapy is warranted. It 
should also be noted that no combination of gene therapy and drug resulted in a rescue of 
mean weights to WT at 6, 9 or 12 months.  
Finally, the behavioural, survival and weight data of combination therapy treated mice 
was compared to that of mice treated with gene therapy alone (No DrugAAV9). This was to 
determine whether there is any added benefit to using combination therapy over gene 
therapy alone. The results were mixed, as is discussed below, and ultimately there were not 
enough significant improvements in behaviour produced by any combination therapy group 
to warrant concluding the superiority of their treatment regimen over gene therapy alone, 
especially in light of the risks, side-effects and additional costs associated with the combined 
use of a second therapeutic. Despite this, the work presented in this thesis represents a novel 
investigation into the treatment of CLN6 BD with combined therapeutic strategies and has 
produced several important and interesting observations that will require future research. 
This thesis also represents the first long term, in-depth investigation into the effects of CBD in 
an animal model of any NCL variant and builds on preliminary in vivo gemfibrozil studies for 
the NCLs by providing a detailed account of behavioural responses to long term treatment 
with this compound.  
 261 
4.2 In mouse: the use of small molecule therapeutics for CLN6 
BD (gemfibrozil) 
Gemfibrozil is an FDA-approved, cholesterol-lowering drug and a member of a class of 
amphipathic carboxylic acids called ‘fibrates’. Its potential as a complementary therapy to 
AAV2/9-mediated gene therapy in Cln6nclf mice was investigated here because of its known 
ability to modulate autophagic and lysosomal processes via PPAR𝛼 activation and subsequent 
TFEB upregulation. Gemfibrozil has also shown considerable promise in several in vitro and in 
vivo NCL models, including the a Cln2-/- mouse model (Ghosh et al., 2017) and a sheep CLN6 
neural culture model (OCLN)(Best et al., 2017), and preliminary work conducted by other 
members of the Hughes lab has indicated both its safety and potential efficacy in Cln6nclf mice 
(Best, 2017; Stephanie Mercer, Isaiah Cheong, Cliff Abrahams and Stephanie Hughes, 
unpublished work).  
Here, the effects of gemfibrozil, alone and in combination with another small molecule 
therapy (cannabidiol; CBD), were examined – with and without gene therapy – on the Cln6nclf 
behavioural phenotype. Ultimately, it was determined that the effects of gemfibrozil alone 
(section 3.2), in this study at least, were limited, with negligible protection conferred to either 
male or female Cln6nclf mice who were dosed regularly with gemfibrozil alone from weaning 
and had received a neonatal 1x PBS i.c.v injection at P0-2. Despite this, subtle sex-based 
differences in response to gemfibrozil were observed – with female mice appearing to 
experience protection against the 6 month composite ataxia and 9 month gait ataxia Cln6nclf 
phenotypes and having better behavioural scores than Cln6nclf males overall. Interestingly, 
these sex-based differences appeared to be all but erased, even reversed, when gemfibrozil 
was used in conjunction with AAV2/9-mediated gene therapy (section 3.4). While one could 
attribute the majority of the behavioural improvements experienced by both sexes treated 
with this combination therapy to the gene therapy, rather than gemfibrozil, it is odd that the 
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difference in male and female GemfibAAV9 behavioural scores becomes non-significant, across 
the battery of behavioural tests and tested time points, when females had been previously 
observed to have significantly improved scores compared to their male counterparts across 
many of the tested parameters, when treated with gemfibrozil and gene therapy separately. 
This discrepancy certainly warrants further investigation, as it could indicate a synergystic 
effect of gemfibrozil and gene therapy in male animals or alternatively an antagonistic effect 
in females.  
  It is possible that the dose used in this study (120 mg/kg) was not optimal for 
protecting against behavioural deficits in Cln6nclf mice – though if the dose was to be increased 
there would have to be preliminary work conducted regarding tolerance and toxicity. It is also 
important that any behavioural data reported here is ultimately complemented by post 
mortem analyses, as the full therapeutic effect of gemfibrozil on Cln6nclf pathology can’t be 
understood without these. While, ultimately, it is the effect of therapeutic intervention on the 
disease state that is most important when treating patients, post mortem analysis might offer 
critical insights into the mode of action of gemfibrozil, in vivo, and even help answer basic 
biological questions regarding CLN6 BD pathology in general. At a minimum, post mortem 
analysis may help confirm whether gemfibrozil was managing to have any effect whatsoever 
on the nervous tissue of the tested mice – a critical question, as the bioavailability of any 
potential small molecule therapy, and its ability to cross the BBB, is paramount to treating any 
neurological disease like CLN6 BD.  
Due to the voluntary nature of dosing (described in section 2.5.2 and discussed in 
further detail below, in section 4.7.4), it is possible that the mice in this study were not 
receiving the full 120 mg/kg dose regularly – with many mice failing to eat all or some of their 
jelly tablets on occasion. It was observed, in fact, that the majority of mice who appeared to 
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develop taste aversion to the jelly tablets were being dosed with either gemfibrozil or a 
combination of gemfibrozil and CBD, so it is possible that the drug either had an unpalatable 
taste or smell, or resulted in unobserved side effects such as gastrointestinal irritation or 
nausea in the mice. While the cohort of mice who developed taste aversion was small, and 
most were reintroduced quite quickly to the correct dose via strategies described in section 
2.5.3, the possibility that gemfibrozil dosed mice were not, in fact, receiving the full dose 
expected and the consequences this might have on behavioural outcomes needs to be 
considered. Detailed notes were taken of which animals developed taste aversion, so it would 
be worth cross-referencing the data collected and analysed here with these notes and perhaps 
eliminating or separating data produced by animals known to experience dosing difficulties. It 
may also be worth running a long-term in vivo trial in which Cln6nclf mice are dosed by oral 
gavage or intraperitoneal injection, two methods that have been commonly used to 
administer gemfibrozil in other trials, as this will ensure accurate dosing – though a smaller 
cohort would have to be used, due to the time consuming nature of these dosing strategies 







4.3 In mouse: the use of small molecule therapeutics for CLN6 
BD (CBD) 
Cannabidiol (CBD) is a non-psychoactive, natural compound produced by the C. sativa plant. 
It has been proven to possess a host of neuroprotective properties in both preclinical and 
clinical studies and its polymorphic modes of action have made it an appealing therapeutic 
candidate for a range of neurodegenerative disorders including Alzheimers, Parkinson’s and 
Huntingtons. In vivo and in vitro preclinical studies specifically focusing on CBDs use in any 
variant of NCL, however, are limited. Despite this gap in the literature, the parents of many 
NCL patients have been reported as administering CBD to their children based on anecdotal 
evidence of its broad range of neuroprotective action (Wibbeler et al., 2019). For this reason, 
it is critical that more preclinical data is generated regarding its use in NCL variants. This thesis 
represents the first long-term, comprehensive study to examine the effects of CBD, alone and 
in combination with gemfibrozil and/or gene therapy, on the behavioural phenotype of an 
NCL animal model – the Cln6nclf mouse.  
Overall, the oral administration of CBD on its own was determined to have no 
significant effect on the UTCln6nclf behavioural phenotype and was unable to rescue Cln6nclf 
shortened lifespans (section 3.2). While this outcome is disappointing, it is encouraging to see 
that no CBD-treated mice performed significantly worse than UTCln6nclf counterparts, indicating 
that while the treatment may not be protective, at least it doesn’t appear to have a negative 
effect on behaviour.  
An important observation made in this thesis, however, was the significantly reduced 
survival of male Cln6nclf mice treated with both CBD and AAV2/9-mediated gene therapy 
(CBDAAV9), compared to the survival of No DrugAAV9 counterparts (section 3.4). While this is, at 
first glance, an alarming result, several factors need to be taken into consideration: first, the 
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survival data generated for this thesis encompassed only the first 15 months of the trial being 
run by the Hughes Lab. This meant that the majority of all AAV2/9-treated mice, regardless of 
whether they were concommitantly receiving small molecule therapy, were still alive by the 
time the data was generated and analysed, giving an incomplete picture of the ‘true’ survival 
curves of these experimental groups. It is possible that after 15 months of age one or more 
groups suddenly experienced an increase in unplanned deaths, or that CBDAAV9 treated male 
mice maintained a steady survival rate that eventually became non-significant from that of 
the No DrugAAV9 mice. More information and further analysis is required to confirm that male 
CBDAAV9 mice really do have a significantly decreased lifespan compared to No DrugAAV9 mice. 
Secondly, the survival plots generated for this thesis included all unplanned deaths – this 
means that it included the deaths of animals who were euthanised for non-disease related 
welfare reasons. The nature of group housing rodents for long periods of time means that 
many animals can end up injuring each other, through fighting or simply through close 
proximity, and while every effort was made to identify and ameliorate these scenarios with 
the mice used in this study, several animals did have to be euthanised due to bite wounds or 
injuries that wouldn’t respond to veterinary intervention. There was also a spate of 
hydrocephalus-related euthanisations that occurred early on in the trial, which are now 
believed to be the result of inaccurate or too deep needle placement during the neonatal i.c.v 
protocol. It is possible that, due to pure chance, a large number of these non-NCL-related 
deaths occurred within the male CBDAAV9 cohort. In order to determine whether or not this is 
the case, the data reported here would need to be cross-referenced with the meticulous notes 
kept regarding unplanned animal deaths.  
Finally, while the results presented in this thesis indicate that CBD, on its own or in 
combination with gemfibrozil, does not protect against the rotarod performance deficits, 
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ataxic phenotype, shortened lifespan and reduced weights that are characteristic of UTCln6nclf 
mice, this does not exclude its usefulness as a therapeutic compound for other CLN6 BD 
symptoms. It would be useful to conduct an in-depth, long-term study of regular CBD dosing 
in Cln6nclf mice which examines its analgesic effects, using a pain response assay, its 
antiepileptic effects, via measurement of seizure activity and hyperexcitability in the brain, its 
anxiolytic effects, via an anxiety assay such as marble burying, and/or its effect on disordered 
sleep and social activity. Anxiety, muscle pain, personality changes and mood and sleep 
disorders are all symptoms experiened by CLN6 BD patients, and a small molecule therapeutic, 
such as CBD, that could address one or more of these symptoms would be useful in elevating 
therapeutic outcomes – especially when used in conjunction with one or more other therapies 
that might be better suited for addressing underlying pathology and motor dysfunction, such 











4.4 In (hu)man: the use of small molecule therapeutics for 
CLN6 BD  
There are several potential advantages to the use of small molecule therapeutics, such as 
gemfibrozil and CBD, in children with lysosomal storage diseases like the NCLs, and in 
particular CLN6 BD. Both are oral medications that do not require invasive administration and 
have been previously proven to be well tolerated and have low toxicity in humans. Both 
medications have multiple modes of action, with many of CBDs properties still not fully 
understood or explored, and most of these mechanisms are known to promote neuronal 
health via autophagic upregulation, lysosomal clearance and reduction of inflammation.  
Despite these advantages, however, the long term use of gemfibrozil and CBD as 
potential therapeutics for CLN6 BD would not be without risk. Chronic use of gemfibrozil has 
been known to cause deleterious side effects, including dizziness and nausea, as well as mood 
and gastrointestinal disturbances. There have even been some reported cases of patients 
developing rhabdomyolysis, which causes kidney dysfunction and muscle weakness (Roy & 
Pahan, 2009). While CBD appears to have less reported side effects than gemfibrozil, a recent 
publication implicated the role of 2-arachidonoylglycerol (2-AG), the most abundant 
endocannabinoid found in the brain, in promoting cerebellar inflammation (Martinez-Torres 
et al., 2019). While 2-AG is not CBD, and it’s inflammatory action is purported to occur via CB2 
receptor signalling – while CBD’s neuroprotective effects are believed to be conducted via a 
range of alternative signalling pathways - this paper highlights how much is still unknown 
regarding the use of cannabinoids as therapeutics, especially in the CNS, and the potential for 
a cannabinoid to exacerbate neuroinflammation should not be taken lightly.  
In light of these risks and the inconclusive nature of the behavioural data reported 
here, as well as the limitations of this study (discussed below), the use of gemfibrozil and/or 
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CBD cannot yet be recommended with any certainty for use in human CLN6 BD patients. This 
is not to say that they won’t be beneficial, but further investigation is critical in order to 















4.5 In mouse: the use of viral-mediated gene therapy to treat 
CLN6 BD 
The survival, weight and behavioural data presented in this thesis demonstrates that a single 
neonatal i.c.v injection of scAAV9.CB.hCLN6 offers significant protection against the diseased 
Cln6nclf behavioural phenotype. Cln6nclf mice treated with gene therapy alone demonstrated 
significantly increased lifespans, as well as improved rotarod and ataxia scores compared to 
UTCln6nclf counterparts. These results support a growing catalogue of preclinical literature that 
indicates gene therapy can ameliorate neurodegenerative processes in animal models of CLN6 
BD. They also suggest that not only does neonatal gene transfer of the CLN6 gene increase the 
lifespan of treated Cln6nclf mice, but it is capable of increasing their quality of life – in so far as 
they retain functional mobility and motor skills over the first fourteen months of life. Mice 
from this study undertook a Morris Water Maze (MWM) test concurrently with the 
behavioural assays described in this thesis, though the MWM results were omitted due to 
time constraints. It would be valuable to include and compare the MWM results, once they 
have been analysed, with the rotarod and ataxia results described here, as MWM data will 
give an indication of cognitive and memory function in treated and UTCln6nclf mice. If CLN6 gene 
therapy is found to improve Cln6nclf cognition, as it has been in previously published CLN6 BD 
gene therapy studies, then this will be further evidence of an improved ‘quality of life’ for 
these mice – a conclusion that is of great importance when considering transition from the lab 
to clinical application (Holthaus et al., 2019; Poppens et al., 2019; Weimer et al., 2019).  
While the data from this thesis suggests that AAV2/9-mediated gene therapys is 
effective in treating some of the major features of CLN6 BD in mice, namely the deterioration 
of motor skills as the disease progresses, it has also produced some observations that merit 
further investigation. Primarily, the rotarod data collected for this thesis (section 3.3.1) 
indicates that gene therapy-treated Cln6nclf mice, of both sexes, produce significantly higher 
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(‘better’) rotarod scores than both UTCln6nclf and healthy WT controls at 9 (females only) and 
12 months of age (males and females). This phenomenon of gene therapy-treated Cln6nclf 
behavioural scores that supersedes even those of healthy controls has been observed and 
commented on elsewhere, for instance Holthaus et al (2019) noticed a similar trend in their 
open field test data. It has been suggested that this hyperactivity may be a previously 
uncharacterised cognitive phenotype belonging to the Cln6nclf mouse, or CLN6 BD in general, 
that was uncovered by the preservation of mobility in Cln6nclf animals at later stages of disease 
progression – or the result, perhaps, of overexpression of the human CLN6 transcript in the 
brain (Holthaus et al., 2019).  
 The full effect of gene therapy treatment may have been obscured in the results 
published here, due to the fact that the UTCln6nclf experimental group’s phenotype did not 
become fully evident until later time points in the behavioural assays used – with significant 
differences between healthy WT control scores and the UTCln6nclf cohort not becoming 
significant until 9 (for ataxia) and 12 months (for rotarod) of age. Certainly, previously 
published CLN6 gene therapy studies involving behavioural assays seem to produce more 
consistently significant differences in scores between gene therapy-treated and UTCln6nclf 
cohorts at earlier time points than are seen in the results published here. Without further post 
mortem analysis to confirm both the genotype of the UTCln6nclf animals and the presence of 
viral-mediated CLN6 expression in the CNS of No DrugAAV9 animals, the reason(s) as to why the 
results published here differ from previously published studies involving AAV2/9-mediated 
gene therapy can only be hypothesised.  
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4.6 In (hu)man: the use of viral-mediated gene therapy to treat 
CLN6 BD 
Interim clinical trial data, released in 2019 from Amicus Therapeutics, indicates that AAV2/9-
mediated gene transfer of the CLN6 gene via intrathecal injection was well tolerated in human 
CLN6 BD patients and has resulted in negligible side effects or toxicity (Amicus Therapeutics, 
2019). This data also indicated that several younger patients, often siblings of patients who 
had already begun to show symptoms at the time of the trial, remain asymptomatic – despite 
reaching the ages that their older siblings were when they began to demonstrate disease 
onset (Amicus Therapeutics, 2019). This information is promising, but the trial is not yet 
considered complete and won’t be until 2021. Additionally, these data were released by 
Amicus Therapeutics for an Amicus Therapeutics drug trial, which is an important 
consideration when drawing conclusions as the data could be subject to bias towads the 
interests of the company and its stakeholders. Previous, completed clinical trials involving 
AAV2/9-mediated gene therapy in a range of metabolic and genetic disorders, including 
another variant of NCL, suggest that while this trial may be successful in reducing or delaying 
symptoms, it is unlikely to be curative (Trial No. NCT00151216, Clinicaltrials.gov; Steinfeld et 
al., 2002; Worgall et al., 2008). In preparation for this outcome, ongoing research into the 
optimisation and/or augmentation of AAV2/9-mediated gene therapy for NCLs, and CLN6 BD 





4.7 Combination therapy for CLN6 BD  
While all three combined therapies (GemfibAAV9, CBDAAV9 and ComboAAV9) tested in this trial 
demonstrated significant success in protecting against several Cln6nclf behavioural phenotypes 
in both male and female mice (section 3.4), direct comparison of these results with those of 
mice treated with gene therapy alone (No DrugAAV9) makes it difficult to justify the use of such 
combinations without further investigation.  
Only a few positive significant differences were elicited between the behavioural 
scores, survival and weights of combination treated and gene therapy-only treated mice, with 
CBDAAV9 and ComboAAV9 male mice achieving better hindlimb clasping ataxia scores at 6 and 9 
months of age, respectively, and female CBDAAV9 and ComboAAV9 mice achieving better gait 
scores at 6 months of age. Considering all four groups who demonstrated a significantly 
improved score received a regular dose of CBD, in some form, it is very possible that these 
improvements were due to one of CBD’s many neurological effects, such as analgesia or 
muscle relaxation. Mice who experience less pain are more likely to walk comfortably, while 
mice with relaxed muscles are less likely to experience involuntary hindlimb contractions. At 
this stage, however, these hypotheses are untested and would require further investigation 
to determine what is causing these improved phenotypes and why gait is specifically improved 
in females while hindlimb clasping is specifically improved in males. 
While promising, and the segregation of higher female scores to the gait assay and 
male scores to the hindlimb clasping assay is interesting in itself, these improvements 
represent only one significant improvement on gene therapy alone, per combination 
treatment group, out of five behavioural assays. It should also be taken into consideration that 
male CBDAAV9 treated mice experienced significantly reduced survival compared to No 
DrugAAV9 counterparts, and this could be a serious problem with the concomittant use of CBD 
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with gene therapy. Euthanasia records will need to be cross-referenced with the data 
presented here to determine whether the effect observed is the result of a response to the 
combined treatment, or simply coincidental loss of animals to a variety of non-disease related 















4.8 Limitations  
4.8.1 Use of the Cln6nclf mouse model to study therapeutic efficacy  
The use of animal models, large and small, to model and study disease has always been at the 
core of the biomedical sciences. They have offered and continue to offer researchers and 
clinicians insights into the anatomy, physiology, behaviour and biochemistry of health and 
disease that wouldn’t be possible if they were limited to the use of cadavers or human 
patients. The use of the naturally occurring Cln6nclf model as a proxy for CLN6 BD in children 
follows in this tradition and was a critical component of this thesis. The availability of such a 
model allowed for the cost-effective breeding of experimental cohorts (~30 mice per 
experimental group; 18 groups) that were large enough to provide significant statistical power 
to any results eludicated and the use of the Cln6nclf mouse lent itself to rigorous, systematic 
assessment of diseased behaviour at different time points across the lifespan - all of which 
would not have been feasible with larger animal models or human patients.  
Despite this, the use of such a model is not without it’s limitations. The anatomy and 
physiology of mice, particularly their CNS, differs greatly from that of humans and this can 
often complicate the transition from preclinical animal studies to human trials. Recently, 
mouse models have been criticised for failing to predict the efficacy of clinical trials in several 
neurodegenerative diseases, including Alzheimer’s disease (AD) and Amyotrophic Lateral 
Sclerosis (ALS)(Turner & Talbot, 2008; Zahs & Ashe, 2010), and so any study of 
neurodegenerative disease that depends on the interpretation of mouse behaviour needs to 
take into account the shortcomings and limitations of using such a model. These include the 
fact that rodents are lissencephalic, with small, smooth brains, compared to the large, 
gyrencephalic brains of the CLN6 BD patients they are being used to emulate. There are also 
significant differences between mouse and man in a variety of other body systems that would 
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play an important role in dictating the efficacy of a potential therapeutic, such as the immune 
and endocrine systems.  
Aside from physiological disparities, using mouse behaviour as an absolute measure of 
therapeutic efficacy, as is done here, without accompanying post-mortem analyses, is risky as 
it involves several key assumptions, such as the assumption that gene therapy was correctly 
administered to the left ventricle at birth. A range of things may have gone wrong and resulted 
in an absence of viral-mediated CLN6 expression in the brains of animals tested here, 
compromising any results published. While the Hughes lab took every measure to ameliorate 
human error, and many of the observed behavioural effects are too large and too obvious to 
allow for ambiguity, this trial will only really be complete once post-mortem analysis has 
confirmed that the mice assessed under the assumption of having received gene therapy 
actually did receive that therapeutic intervention.  
Finally, behavioural performance in rodents can be influenced by a wide range of 
genetic and environmental factors, some of which can’t be controlled for, despite best efforts 
on behalf of the researcher. These include differences in behaviour based on whether they 
are group housed, the presence or absence of recreation, the proximity of other rodents of 
the opposite gender and the time of day when they are assessed for behaviour. Mice in this 
trial were assessed during the day, and were kept on a 12 hour light cycle that mirrored the 
one outside. Since rodents are nocturnal, mice were essentially being tested at a time of day 
when they would normally be asleep or less active – this may have had some impact on their 
behavioural performances. Unfortunately, due the sheer size of the study, this scheduling 
could not be avoided.  
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4.8.2 Voluntary oral dosing as a mode of therapeutic administration 
Zhang’s (2011) voluntary oral administration protocol was adapted to purpose for the 
practical component of this thesis and, overall, provided a convenient way of administering a 
variety of small molecule therapies (gemfibrozil, CBD and a combination of the two drugs) to 
a large number of animals on a regular basis (every second day for almost 2 years). Zhang’s 
protocol offered an alternative to the more traditional form of oral administration – the 
intragastric gavage (oral gavage) technique. Oral gavage, while effective, would have been 
extremely time consuming to perform on ~500 animals and could have resulted in a significant 
number of injuries to both the researcher and animals due to need to handle and restrain 
individual animals in order to perform the technique correctly. Moreover, there is some 
evidence to suggest that regular restraint of research animals can induce short and long-term 
stress responses which may have ultimately influenced behavioural outcomes and 
compromised the study’s results (Zhang et al., 2011; Balcombe et al., 2004). 
Despite being safer, faster and less stressful than oral gavage, the use of voluntary oral 
dosing via fruit-flavoured gelatin (jelly) tablets in this study presented and created its own 
limitations. The sheer number of experimental animals involved in the study meant that, at its 
peak, the study required the production of ~1500x 1 mL gelatin tablets a week, divided into 
different drug types and concentrations. Administration and production of these could require 
upwards of 20 hours a week, before dosing even occurred. Dosing itself could take up to four 
hours a day, every day (the mice were split into two cohorts – with each dosed on alternating 
days). It is difficult to acertain whether this protocol could have been automated further, as 
many adaptations and alterations were made to the original to make the study do-able within 
these timeframes, but if it could have been, the skills required to do so would, no doubt, have 
lain outside a MSc Neuroscience student’s skillset.  
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A second, significant jelly-related problem that developed during the study was the 
propensity of certain mice to develop taste aversion to the jelly tablets and refuse to eat parts, 
or even the entire tablet during the allocated dosing period (up to 2 hours). Previous studies, 
including several pilot studies conducted within the Hughes Lab, had indicated that this might 
be an issue and several tactics were enlisted to avoid, mitigate and correct such behaviour 
when it occurred. These included the introduction of ‘drug-free’ jelly to mice for 
approximately a week post-weaning and pre-dosing, to try and overcome the natural 
neophobia most mice exhibit towards new foods. Once mice were consistently eating the 
plain, drug-free jelly, they began their dosing regimen. Despite this, several mice still 
developed taste aversion. When this occurred, mice would be reintroduced to drug-free jelly 
for a short period of time. The concentration of the drug would then slowly be introduced and 
built up over time, until mice were once again receiving the full dose based on their weight. If 
they continued to show no interest in the jelly, the flavour would be switched – from 
strawberry to lime. Most animals would regain an interest in the jelly tablet once flavours had 
been switched, but some required multiple rounds of reducing the drug concentration and 
building it back before they began to consistently consume the correct dose of drug. Zhang et 
al. (2011) recommended ‘fasting’ animals who demonstrated an aversion to the tablets, but 
this technique was avoided in this study due to the fact that a starved state can induce 
autophagy in cells, and therefore has the potential to compromise any data collected from the 
study. Detailed notes were taken of the mice who experienced taste aversion, and it would be 
interesting to separate their behavioural data from the rest of their treatment group and 
compare them, to see if the difference in dosing had any meaningful impact on behavioural 
or post-mortem outcomes. Interestingly, it was observed that the vast majority of mice that 
did experience taste aversion were given jelly with gemfibrozil or a combination of gemfibrozil 
and CBD in it. Most vehicle or CBD treated mice ate t most or all of their jelly throughout the 
 278 
duration of the study. This may be due to the flavour of the gemfibrozil, which is known to be 
strong and bitter, or perhaps due to some gemfibrozil-related side effect such as 
gastrointestinal disturbance or nausea. Further testing would need to be done to determine 
whether either of these scenarios are the case.  
4.8.3 Disparities between this study and the Gray Foundation’s clinical 
trial  
In order to better inform possible complementary therapeutic strategies for CLN6 BD patients, 
this preclinical study was designed, in part, to recapitulate many of the parameters of the Gray 
Foundation’s 2016 clinical phase I/II trial. The same viral vector, for instance, was used in both 
the clinical trial’s CLN6 BD patients and the Cln6nclf mice treated for this study. Mice even 
received a human copy of CLN6 via AAV2/9-mediate gene therapy, though this was not only 
to recapitulate the trial’s vector but also because there are few readily available, effective 
mouse Cln6 antibodies available and post-mortem analysis will require the use of antibodies 
to determine the level of CLN6 expression in mouse tissues. Human CLN6 will be easier to 
identify post-mortem (Stephanie Hughes, personal communication). Despite many 
similarities, however, there were several key differences, the most significant, perhaps, being 
the time of intervention.  
It is now well-established in NCL literature that therapeutic efficacy is contingent on 
early intervention (Cabrera-Salazar et al., 2007). The efficacy of early treatment with viral-
mediated gene therapy has been demonstrated in several animal models of lysosomal storage 
disorders, including a Cln2-/- mouse model, and the success of treating such diseases before 
symptom onset appears to be profound – even more so when performed during the neonatal 
period (Cabrera-Salazar et al., 2007; Consiglio et al., 2001; Sevin et al., 2007; Sevin et al., 2006; 
Waddington et al., 2004). This is problematic when considering the treatment of rare 
childhood disorders such as the NCLs for a variety of reasons, most significant being the fact 
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that most patients are identified via symptom onset. This was the case with the majority of 
patients involved in the 2016 Gray Foundation clinical trial, with only a few patients being 
presymptomatic due to their identification via genetic screening after having an older sibling 
diagnosed with the disease. This means that, by the time the majority of these patients 
received gene therapy intervention, they would have surpassed the optimal therapeutic 
window identified in preclinical studies. In fact, the neonatal murine brain represents a similar 
developmental stage to the human foetus, meaning an equivalent treatment period would 
require in utero administration of gene therapy in humans. In this study we elected to 
administer gene therapy at P0-2 (the neonatal period), despite it not accurately representing 
the developmental stage most of the patients in the 2016 clinical trial would have been at 
when receiving treatment. This was primarily due to the fact that administering gene therapy 
to mice at a later stage would have require stereotaxic surgery, a time consuming protocol 
with great risk to the mice, and would have made running a trial with over 500 mice impossible 
due to time constraints. It would be beneficial for future studies to look at the possibility of 
optimising gene therapy when administered at a later stage in disease progression, to better 
recapitulate the way in which gene therapy is currently administered to patients – post-
symptom onset – and to produce results that may be a more relevant indication of potential 
success in children.  
This disparity between the optimal therapeutic window for gene therapy and the way 
in which therapeutic need is currently identified in NCL patients, however, is an area of 
concern that will need to be addressed, especially if gene therapy becomes more 
commonplace. It also justifies the need for broader, more comprehensive prenatal and 
congenital genetic screening programs in humans, though these are associated with a variety 
of ethical considerations of their own. 
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4.8.4 Disparities between this study and the work of collaborators  
The data in this thesis closely recapitulates Bronson et al’s original findings which reported 
rear-limb paralysis starting at approximately 10 months of age, as male Cln6nclf mice only 
demonstrated significantly reduced scores in two (ledge and composite ataxia) out of five 
(rotarod, as well as composite, ledge, hindlimb and gait ataxia) behavioural assessments 
conducted at 6 months (Bronson et al., 1999). At 9 months, however, males continued to 
demonstrate these significantly lower ledge and composite ataxia scores and females had 
significantly worse ataxia scores than age- and sex-matched WT controls in all four ataxia 
assays, suggesting the presence of stronger diseased phenotype across all Cln6nclf mice at this 
later time point. Additionally, male and female Cln6nclf rotarod scores collected for this thesis 
indicate that rotarod-specific motor deficits are not present until at least after 9 months of 
age, which also supports Bronson et al’s behavioural observations (Bronson et al., 1999).  
Morgan et al., however, were able to detect rotarod performance deficiencies as early 
as 3 months in their UTCln6nclf cohort (Morgan et al., 2013). It is difficult to determine what 
might cause this discrepancy between the data gathered here and their study, but there are 
several study design differences that need to be taken into account. Primarily, this thesis did 
not include behavioural testing at any age point before 6 months, nor did Morgan et al. choose 
to publish their day 270 (~9 months) rotarod results, so direct comparison of these results to 
those in Morgan et al.’s paper is impossible. We cannot, with the information given, eliminate 
the possibility that the Cln6nclf mice in this study may have performed significantly worse than 
WT at 3 months of age, though when one considers the linear way in which neurodegenerative 
diseases progress this seems unlikely. One can also raise the question as to why Morgan et al 
didn’t publish the 9 month rotarod data they collected, as it may have served to strengthen 
their characterisation of behavioural deficits in the Cln6nclf mouse. However, it is possible that, 
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due to publication-related space and word limits, they simply chose to leave this information 



















4.9 Future directions 
While the behavioural analyses outlined in this thesis represent a critical part of the larger 
Gray Foundation preclinical trial being conducted by the Hughes lab, a significant amount of 
work remains to be done before the trial can be considered complete. This will include post-
mortem processing, imaging and analysis of the tissues removed from posthumously via 
transcardial perfusion, as well as the statistical analysis of over 300 hours of Morris Water 
Maze (MWM) behaviour recordings taken at 6, 9, 12 and 16 months. Some of the behavioural 
analyses reported here may also have to be reassessed in order to incorporate 12 and 16 
month behavioural data that was, due to time restrictions, left out of this thesis.  
Mice who reached one of the three humane endpoints outlined in Chapter 2 were 
euthanised via transcardial perfusion and had their brains, spines, eyes, livers, kidneys, hearts 
and spleens removed, as well as a blood sample and tail tip taken. These materials are 
currently stored in a -80℃ freezer and will require a large amount of resources to process, 
image and analyse. Despite the amount of money and man-hours this will require, post-
mortem analysis is well worth doing. First, post-mortem results will help better confirm the 
results produced for this thesis. Blood samples and tail tips can be used to genotype the mice 
that were assessed for behaviour and confirm that they were the correct genotype (either 
Cln6nclf or C57Bl/6) and that the Cln6nclf colony kept by the Hughes lab had not undergone 
genotypic drift over the years it has been maintained in Dunedin, New Zealand – a 
phenomenon that is not unheard of in mouse models of genetic disease (Benavides et al., 
2019; Stevens et al., 2007; Zeldovich, 2017). This will validate any results and analyses 
reported in this thesis. Second, analysis of the brains of mice belonging to the AAV2/9-treated 
experimental groups (M/F No DrugAAV9, M/F GemfibAAV9, M/F CBDAAV9 and M/F ComboAAV9) 
will help confirm whether the AAV2/9-mediated gene therapy was administered correctly, via 
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direct injection into the left hemisphere cerebroventricular space. If CLN6 expression is 
localised to the cerebral or meningeal layers surrounding the injection site, this will suggest 
that the needle was inserted incorrectly – either too shallowly, or too far to the left or right. 
Direct injection into the cerebroventricular space is critical for effective gene therapy, as this 
method takes advantage of the circulating cerebroventricular spinal fluid (CSF) and allows the 
vector to be carried throughout the central nervous system via this circulation. While AAV 
vectors demonstrate extremely effective local cellular transduction, a feature that made them 
attractive as a gene therapy vector in the first place, diseases that effect the entire nervous 
system – like CLN6 BD – require transduction throughout the brain and spinal cord.  
Analysis of the spinal cord and visceral organs will also give a better understanding of 
how far the gene therapy spread outside the CNS, which may inform future decisions 
regarding vector choice. It is now becoming clear that, while the primary objective of NCL 
therapy development is to cease neurodegeneration, there may well be visceral pathologies 
that become problematic once the neurodegeneration has been dealt with. This could mean 
that efforts to develop a successful, CNS-restricted, gene therapy would only produce a short 
term solution, with patients dying at a later age from related pathologies in somatic tissues 
like the heart, liver or kidneys. An effective gene therapy would be one that focuses on the 
CNS, but also successfully transduces other critical tissues like cardiac muscle or hepatocytes. 
Despite the fact that there is a large amount of work yet to be done in terms of MWM 
and post-mortem analysis, this project represents the first large-scale, longitudinal (>12 
months) preclinical combination therapy trial of AAV2/9-mediated hCLN6 gene therapy, 
gemfibrozil and cannabidiol (CBD) in the naturally-occurring Cln6nclf mouse model of CLN6 BD. 
It utilized and refined a series of novel techniques, including the use of cryotherapy and drawn 
glass needles to deliver gene therapy via i.c.v injection to newborn (P0-P2) mice and the 
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efficient mass production and delivery of small molecule jelly ‘tablets’, which allowed for 
ongoing voluntary oral dosing of around 500 mice for almost two years.  
Furthermore, the project reinforced the findings of several other key preclinical CLN6 
BD studies by documenting AAV2/9-mediated hCLN6 gene therapy as successfully protecting 
Cln6nclf mice, of both sexes, against several of the characteristic behavioural and motor deficits 
seen in untreated controls. Similarly, the project’s findings reiterated the significant impact a 
single neonatal i.c.v injection of scAAV9.CB.hCLN6 can have in terms of extending and 
restoring the lifespans of Cln6nclf mice.  
While neither gemfibrozil, CBD, or a combination of the two drugs appeared to make 
any consistently significant improvements to either untreated or gene-therapy treated Cln6nclf 
mouse behavior, the project still represents the first attempt to characterize the impact of 
these particular small molecule therapies, alone and in combination, on the Cln6nclf phenotype 
and raised some interesting questions regarding dosage, mode of therapeutic delivery and 
sex-based differences in response to each therapeutic modality that was trialed.  
The work and results documented here do not, by any means, rule out the potential 
benefits of either gemfibrozil or CBD as complementary therapeutics for patients with CLN6 
BD. Instead, they simply lay the foundation for further investigation and raise novel questions 
regarding other, still untested, benefits (such as analgesia or emotional modulation) that may 
be elicited from the use of either, or both, therapies, alone and in combination with AAV2/9-
mediated hCLN6 gene therapy.    
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Appendix A: supplementary information for Chapter 2  
Appendix. A.1 Reagents and chemicals 
Listed in alphabetical order.  




Adeno-associated virus (AAV) serotype 2/9 with human CLN6 (hCLN6) DNA (solution) 
Manufacturer: Nationwide Ohio Children’s Hospital Viral Vector Core 
Supplier: Nationwide Ohio Children’s Hospital Viral Vector Core 




Cannabidiol oil (Cannabis sativa; solution; 5.25%; 6x 30 mL bottles) 
Manufacturer: Medropharm Health Science  
Supplier: Herba Healthcare Australia 
(D+) sucrose for molecular biology (powder; C12H22O11) 
Manufacturer: Neofroxx 
Ref: 1104KG001 
Supplier: Lab Supply Ltd.  
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Dimethyl sulfoxide (solution; DMSO; C2H6OS; ≥99.9%) 
Manufacturer: Sigma-Aldrich (Merck) 
Ref: D2650-100 mL 
Supplier: Sigma-Aldrich New Zealand 
Di-sodium hydrogen phosphate (powder; disodium phosphate; Na2HPO4) 
Manufacturer: Emsure® (Merck) 
Ref: F2026086838 
Supplier: Sigma-Aldrich New Zealand 
Emla® needle anaesthetic (cream; 5%; 30 mg/ml)  
Manufacturer: Astra Zeneca  
Ref: #TA6856 
Supplier: University of Otago Animal Welfare Office (AWO) 
Gemfibrozil (powder; C15H22O3) 
Manufacturer: Pfizer 
Ref: G9518-25 G 
Supplier: Sigma-Aldrich New Zealand 
Hydrogen peroxide (solution; H2O2; 3%) 
Manufacturer: PSM Healthcare Ltd trading as API 
Ref: 11053253 




Instant adhesive (gel)  
Manufacturer: Selleys® 
Ref: 371419 
Supplier: Mitre10 New Zealand, South Dunedin  
Isopropyl alcohol (solution; 2-propanol; (CH3)2CHOH; ≥99.7%) 
Manufacturer: AnalaR NORMAPURE® 
Ref: 20842.312 
Supplier: VWR™ Chemicals international  
Jelly (crystals; lime; 80 g) 
Manufacturer: Value (Safeway Traders NZ) 
Supplier: Centre City New World, Dunedin, NZ 
Jelly (crystals; strawberry; 2.5 kg) 
Manufacturer: Champion Professional  
Ref: 4187991 
Supplier: Trents Wholesale 
Methylcellulose (powder; viscosity: 4,000 cP)  
Manufacturer: Sigma-Aldrich (Merck) 
Ref: M0512-100 G 




Paraformaldehyde (powder; OH(CH2O)nH (n = 8-100)) 
Manufacturer: Sigma-Aldrich (Merck) 
Ref: P6148 
Supplier: Sigma-Aldrich New Zealand 
Phosphate buffer saline (solution; 1x; pH 7.4)  
Manufacturer: Gibco™ 
Ref: 1001000-49 
Supplier: Life Technologies New Zealand Pty Ltd (ThermoFisher Scientific) 
Sodium azide (solution; NaN3; ≥99.5%) 
Manufacturer: Fluka™ (Honeywell Research Chemicals)  
Ref: 71289 
Sodium chloride (powder; NaCl) 
Manufacturer: Emsure® (Merck) 
Ref: K49451104832 
Supplier: Sigma-Aldrich New Zealand  
Sodium pentobarbital (solution; C11H18N2O3; 30 mg/ml) 
Diluted from 300 mg/ml by University of Otago’s Drug Control Officer (DCO) 
Manufacturer: Provet NZ Pty Ltd.  




Sodium phosphate monobasic (powder; monosodium phosphate; NaH2PO4) 
Manufacturer: Sigma-Aldrich (Merck) 
Ref: SO751-500 G 
Supplier: Sigma-Aldrich New Zealand 
Splenda® sweetener (powder; 120 g) 
Manufacturer: Splenda® 
Ref: 3076946 
Supplier: Trents Wholesale 
TriGene (concentrate) 
Manufacturer: TriGene Advance 
Ref: EATTRIG36  
Supplier: InVitro Technologies 
Trypan blue (solution; 0.05%) 
Diluted from 0.4% in lab 
Manufacturer: Logos Biosystems  
Ref: #T13001 
Supplier: Logos Biosystems 
Tween® 20 (solution; polysorbate 20; C58H114O26; ≥40.0%) 
Manufacturer: Sigma-Aldrich (Merck) 
Ref: P2287-500 mL 
Supplier: Sigma-Aldrich New Zealand 
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Unflavoured gelatin (crystals; 2.5 kg) 
Manufacturer: Davis (Gelita) 
Ref: 3055956 






















Appendix.A.2 Lab-made solutions and buffers 
Listed in alphabetical order.  
CBD stock solution (solution; dosage of 120 mg per kg) 
1. Follow all steps outlined below in Gemfibrozil stock solution except:  
CBD used in this thesis had a stock solution concentration of 50 mg per mL, therefore 
use 50 mg per mL for C2 in C1V1 = C2V2. 
Despite the CBD already coming in a liquid form, the CBD jelly tablets must also have 
vehicle in them, to control for any possible side effects of Tween20 and DMSO. This 
ratio is 1:1. Therefore, if you put 100 uL of CBD oil in the jelly, then also put in 100 uL 
of vehicle (50 uL of Tween20 and 50 uL of DMSO). 
CBD and gemfibrozil stock solution (solution; gemfibrozil dosage of 120 mg per kg + CBD 
dosage 120 mg per kg) 
1. Follow all steps outlined below in Gemfibrozil stock solution except:  
You should calculate how much gemfibrozil and CBD to put into the jelly separately, 
even though they both end up in the same amount of jelly. You do not need to double 
the amount of jelly for two drugs. Also, because you are putting Tween20 and DMSO 
in the jelly as the vehicle for gemfibrozil, you do not need to put in extra vehicle for 
CBD. This would double the amount of vehicle each mouse gets compared to other 
mice in other treatment groups.  
Gemfibrozil stock solution (solution; dosage of 120 mg per kg) 
1. Convert the gemfibrozil dosage (120 mg per kg) from mg per kg to mg per g by dividing 
by 1000: 120/1000 = 0.12 mg/g 
2. Work out how much of gemfibrozil (in mg) you need per dose (per 1 mL of jelly) for 
each mouse within each weight ‘range’ (see Table 2.2). This will give you the 
concentration for all the jelly you need to make all the doses for the mice in that weight 
range overall.  
E.G. 0.12 mg/g + a 24 g mouse (treated as a 20 g mouse per Table 2.2) = 0.12 x 
20 = 2.4 mg gemfibrozil required for that mouse’s dose.  
If you have ten mice who all fall within the 20g – 24g weight range (Table 2.2), 
they will all receive 1 mL doses of jelly with a concentration of 2.4 mg/mL. 
3. Now work out the total number of doses you need to make up for the week. This will 
give you the total volume of jelly you want to make up for all mice within a particular 
weight range that will receive 1 mL jelly tablets every second day with this particular 
gemfibrozil concentration.  
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# of doses = # of mice in weight range x # of days you want to dose those mice before 
making more jelly (approx 4 for one week). 
E.G. 10 x 4 = 40 doses total, each dose is a 1 mL jelly tablet, therefore you want 
to make 40 mLs of jelly overall.  
4. Jelly is difficult to manipulate because it is very viscous. Therefore, you want to make 
up more jelly than you actuall need – to leave room for measurement error. We used 
20% error margin.  
E.G. Total volume of jelly needed (in mL) x 0.2 (20%) = Total volume of jelly to 
make, including error.  
E.G.2 40 mL x 0.2 = 48 mL 
5. Now calculate how much gemfibrozil stock solution to add to your jelly (stock solution 
is always 1200 mg/mL). This means if you had one mL of solution (liquid – in this case, 
DMSO and Tween 20), you would have 1200 mg of powdered gemfibrozil dissolved in 
it.  
6. You can either choose to make a 1 mL aliquot of stock solution, simply by adding 500 
uL of Tween20, 500 uL of DMSO and 1200 mg of gemfibrozil, or you can calculate how 
much stock solution you are going to need for every weight range in gemfibrozil and 
then make up enough stock solution to supply all the different weight ranges (you 
might end up needing more or less than 1 mL of stock solution). 
7. Use the following equation to calculate how much stock solution you need to dissolve 
in the liquid jelly given to a certain number of mice in a certain weight range:  
C1V1 = C2V2 
C1 (concentration 1 or initial concentration; concentration of gemfibrozil for each 1 
mL jelly tablet made, as calculated in step 2) x V1 (volume 1 or initial volume; volume 
of jelly calculated in step 4) = C2 (concentration 2 or final concentration; 
concentration of gemfibrozil stock solution) x V2 (volume 2 or final volume; volume 
of gemfibrozil stock solution required to make C1 in V1) 
Rearrange this equation to get V2, the volume of stock solution required. 
E.G 2.4 mg/mL (concentration 1 – concentration of the jelly) x 48 mL (volume 1 - 
volume of jelly needed) / 1200 mg/mL (concentration 2 – concentration of stock 
solution) = 0.096 mL (volume 2 – the volume of stock solution required, in mLs). 
The answer is given in mL. To convert to µL (for pipetting), simply x 1000.  




Modified Davidson’s fixative (solution; makes 1 L) 
200 mL formalin (37%)  
300 mL bulk ethanol 
100 mL acetic acid 
300 mL dH2O 
TriGene (solution; 10%; makes 100 mL) 
10 mL TriGene concentrate 
90 mL dH2O 
Paraformaldehyde (PFA; solution; 4%; makes 1 L) 
40 g paraformaldehyde (PFA) 
500 mL 0.1 M phosphate buffer (PB) or 500 mL dH2O 
Heat to 60℃ with stirring until PFA has dissolved 
Make up to 1 L with 0.1 M PB or dH2O 
Filter and pH to 7.4 
Phosphate buffer (PB; solution; 0.1 M; makes 2 L)  
Solution A: 27.6 g sodium phosphate monobasic (NaH2PO4H2O) 
Solution B: 53.6 g sodium phosphate dibasic (Na2HPO47H2O) 
Mix 280 mL of solution A with 720 mL solution B 
Adjust pH to 7.2 




Phosphate buffer saline (PBS; solution; 10x; makes 1 L) 
80 g NaCl 
11.5 g Na2HPO4 
2 g KH2PO4 
2 g KCl 
800 mL dH2O 
Stir to dissolve and make up to 1 L with ddH2O 
PBS (1x) (solution; makes 1 L) 
100 mL 10x PBS 
900 mL ddH2O 
PBS-sodium azide (solution; 0.02%; makes 500 mL) 
50 L PBS (1x) 
0.1 mg sodium azide powder (0.02% w/v) 
Make up to 500 mL with dH2O 
Sucrose (solution; 30%) 
30 g sucrose 
Made to 100 mL with 0.1 M PB or dH2O 
Vehicle (solution; makes 10 mL) 
5 mL dimethyl sulfoxide (DMSO) 




Appendix.A.3 Instruments and equipment 
Listed in alphabetical order.  
0.6 mL microcentrifuge tubes 
Manufacturer : Corning® Axygen® 
Ref: MCT-060-C-S 
Supplier: Sigma-Aldrich New Zealand 
1 mL disposable slip-lock syringes  
Manufacturer: BD Luer-Lock™ (Becton, Dickinson and Company) 
Ref: 309628 
Supplier: Medshop NZ  
1.5 mL microcentrifuge tubes 
Manufacturer : Corning® Axygen® 
Ref: MCT-150-C-S 
Supplier: Sigma-Aldrich New Zealand 
15 mL plastic centrifuge tubes 
Manufacturer: Corning® 
Ref: CLS430791-500 





160 grid mini silicon ice cube trays (12.1 cm x 23.8 cm; 1 cm x 1 cm wells) 




2 mL microcentrifuge tubes 
Manufacturer: Corning ® Axygen® 
Ref: MCT-200-C 
Supplier: Sigma-Aldrich New Zealand 
20 mL syringe with a slip lock  
Manufacturer: Basik 
Ref: 217418 
Manufacturer: Shoof Vet  




25 gauge (G) x 5/8” disposable needle (0.50 x 16 mm)  
Manufacturer: Terumo Europe 





Manufacturer: Terumo Europe 
Ref: 211 663 
Supplier: Shoof Vet 
5-Lane RotaRod for Mice 
Manufacturer: Med Associates Inc 
Ref: ENV-574M 
Supplier: Med Associates Inc 
50 mL plastic centrifuge tubes 
Manufacturer: Corning® 
Ref: CLS4558-300 




Supplier: Ted Pella Inc 
Cotton-tipped, non-sterile applicators 
Sterilised via autoclaving 
Manufacturer: Nanjing Lustre Medical + Healthcare 
Ref: 40059030063 






Supplier: Briscoes NZ  
Heating pads and re-chargable batteries 
Supplier: University of Otago’s Hercus-Taieri Resource Unit (HTRU) 
Immersion blender 
Manufacture: Bodum Bistro 
Ref: ZIP473 
Supplier: Briscoes NZ 
Magnetic stirrer hotplate (500 V) 
Manufacturer: Chiltern Scientific 
Ref: C128 
Supplier: Hughes Lab 
Portable lab balance scales (0.001-60 g) 
Manufacturer : Denvern Instrument (Sartorius) 
Ref : S1-68 





Portable scientific scales (0.01 g - 610 g)  
Manufacturer: Denver Instrument (Sartorius) 
Ref: MXX-612 
Supplier: Biostrategy Sales and Services Ltd  
Pulled glass needles (1 µm point) 
Originally 6-inch Borosilicate Glass Capillaries with 1.0 mm outer diameter 
Manufacturer: World Precision Instruments  
Ref: 1B100-f6 
Supplier: Fisher Scientific  
Serrated hemostat kelly forceps 
Manufacturer: Fisherbrand™ 
Ref: 08-907 
Supplier: Hughes Lab 
Silicon surgical tubing (1 mm inner-diameter)  
Supplier: Weimer Lab, Sanford Research  
Single-edge, blue carbon steel blades 
Manufacturer: Pal® 
Ref: 121-20 




Sharp-pointed dissection scissors (4.12”) 
Manufacturer: Fisherbrand™ 
Ref: 08-935 
Supplier: Hughes Lab  
Spinbar® magnetic stirring fleas (assorted sizes)  
Manufacturer: Spinbar® 
Ref: Z283886-3EA 
Supplier: Sigma-Aldrich New Zealand  
Stainless steel, sterile surgical blades 
Manufacturer: Swann-Morton ® 
Ref: 0310 
Supplier: University of Otago’s Department of Biochemistry  
Standard dissection scissors (5.12”) 
Manufacturer: Fisherbrand™ 
Ref: 08-951-25 
Supplier: Hughes Lab 






Straight blunt/sharp dissection scissors (14 cm) 
Manufacturer: Thermo Scientific™ Shandon™ 
Ref: 28252 
Supplier: Hughes Lab 
TC-treated multiple (24) well plates 
Manufacturer: Corning® Costar® 
Ref: CLS3527-100 
Supplier: Sigma-Aldrich New Zealand 
Universal, flat bottom container with screw cap (30 mL) 
Ref: S8027SU 
Supplier: MediRay 
Waterbath (0-100℃; 3 L) 
Manufacturer: Grant Instruments (Cambridge) Ltd  
Ref: OE9528010 (Equivalent = T100) 
Supplier: Biolab Scientific Ltd 
Winged infusion set with protector 
Manufacturer: Terumo Europe 
Ref: SV*S21NL09 




Xtracare VSS fume cupboard 
Manufacturer: Thermoplastic Engineering Ltd  
Ref: 208B 



























Listed in alphabetical order.  
GraphPad Prism (version 8) for Mac 
Manufacturer: GraphPad Software, San Diego, California, USA 
Ref: Version 8  
Supplier: University of Otago’s Department of Biochemistry 
IBM SPSS Statistics (version 25) 
Manufacturer: IBM Corp, Armonk, NY, USA 
Ref: 17918 
Supplier: University of Otago’s Student Information Technology Services  
Microsoft® Excel for Mac (version 16.30) 
Manufacturer: Microsoft Office 
Ref: 19100300 
Supplier: University of Otago’s Student Information Technology Services  
RotaRod 2 
Manufacture: Med Associates Inc 
Ref: SOF-571 



















Statistical supplementary material available at:  
https://drive.google.com/file/d/1StAQ4n41HjkFFCdC7bfHogfOLs67H4Zi/view?usp=sharing 
 
